	Query	Target	Query-Cov	Align-From	Align-To	DrugBank ID	Reg.Status	Mol.Name	SMILES
0	sp|Q8I566|GLYA_PLA	Q53ET4	102.26	46.0	498.0	DB00114	approved; investigational; nutraceutical	Pyridoxal phosphate	Cc1ncc(c(C=O)c1O)COP(=O)(O)O
1	sp|Q8I566|GLYA_PLA	Q53ET4	102.26	46.0	498.0	DB00116	nutraceutical	Tetrahydrofolic acid	Nc([nH]1)nc(=O)c(c12)NC(CN2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O
2	sp|Q8I566|GLYA_PLA	Q53ET4	102.26	46.0	498.0	DB00145	approved; nutraceutical; vet_approved	Glycine	NCC(=O)O
3	sp|Q8I566|GLYA_PLA	P34897	102.26	46.0	498.0	DB00114	approved; investigational; nutraceutical	Pyridoxal phosphate	Cc1ncc(c(C=O)c1O)COP(=O)(O)O
4	sp|Q8I566|GLYA_PLA	P34897	102.26	46.0	498.0	DB00116	nutraceutical	Tetrahydrofolic acid	Nc([nH]1)nc(=O)c(c12)NC(CN2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O
5	sp|Q8I566|GLYA_PLA	P34897	102.26	46.0	498.0	DB00145	approved; nutraceutical; vet_approved	Glycine	NCC(=O)O
6	sp|Q8I566|GLYA_PLA	P34897	102.26	46.0	498.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
7	sp|Q8I566|GLYA_PLA	P34896	102.71	23.0	477.0	DB00114	approved; investigational; nutraceutical	Pyridoxal phosphate	Cc1ncc(c(C=O)c1O)COP(=O)(O)O
8	sp|Q8I566|GLYA_PLA	P34896	102.71	23.0	477.0	DB00116	nutraceutical	Tetrahydrofolic acid	Nc([nH]1)nc(=O)c(c12)NC(CN2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O
9	sp|Q8I566|GLYA_PLA	P34896	102.71	23.0	477.0	DB00145	approved; nutraceutical; vet_approved	Glycine	NCC(=O)O
10	sp|Q8I566|GLYA_PLA	P34896	102.71	23.0	477.0	DB01055	experimental	Mimosine	OC(=O)[C@@H](N)Cn1ccc(=O)c(O)c1
11	sp|Q8I566|GLYA_PLA	P34896	102.71	23.0	477.0	DB02067	experimental	Triglu-5-formyl-tetrahydrofolate	Nc([nH]1)nc(=O)c(c12)N(C=O)[C@H](CN2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)N[C@H](C(=O)O)CCC(=O)N[C@H](C(=O)O)CCC(=O)O
12	sp|Q8I566|GLYA_PLA	P34896	102.71	23.0	477.0	DB02800	experimental	5-hydroxymethyl-5,6-dihydrofolic acid	O=c1[nH]c(N)nc(c12)N=C[C@@H](N2CO)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O
13	sp|Q8I566|GLYA_PLA	P34896	102.71	23.0	477.0	DB02824	experimental	N-Pyridoxyl-Glycine-5-Monophosphate	Cc1ncc(COP(=O)(O)O)c(c1O)CNCC(=O)O
14	sp|Q8I566|GLYA_PLA	P0A827	87.1	6.0	391.0	DB02824	experimental	N-Pyridoxyl-Glycine-5-Monophosphate	Cc1ncc(COP(=O)(O)O)c(c1O)CNCC(=O)O
15	sp|Q8I566|GLYA_PLA	P0A827	87.1	6.0	391.0	DB11596	approved; investigational	Levoleucovorin	Nc([nH]1)nc(=O)c(c12)N(C=O)[C@H](CN2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O
16	sp|Q8I566|GLYA_PLA	Q5KUI2	87.1	2.0	387.0	DB03256	experimental	(6R)-Folinic acid	Nc([nH]1)nc(=O)c(c12)N(C=O)[C@@H](CN2)CNc3ccc(cc3)C(=O)N[C@H](C(=O)O)CCC(=O)O
17	sp|C6KT50|PDX1_PLA	C6KT50	99.67	1.0	301.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
18	sp|Q8IE47|SIR5_PLA	Q9NXA8	94.51	30.0	288.0	DB02059	experimental	Adenosine-5-Diphosphoribose	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)CO[P@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H](O)[C@H](O)[C@@H]4O
19	sp|Q8IE47|SIR5_PLA	Q9NXA8	94.51	30.0	288.0	DB02701	approved; investigational	Nicotinamide	NC(=O)c1cccnc1
20	sp|Q8IE47|SIR5_PLA	Q9NXA8	94.51	30.0	288.0	DB03478	experimental	2'-O-Acetyl Adenosine-5-Diphosphoribose	CC(=O)O[C@@H]1[C@H](O)[C@H](O[C@@H]1O)COP(=O)(O)OP(=O)(O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n3cnc(c34)c(N)ncn4
21	sp|Q8IE47|SIR5_PLA	Q9NXA8	94.51	30.0	288.0	DB04786	investigational	Suramin	O=S(=O)(O)c(c1)cc(S(=O)(=O)O)c(c12)c(ccc2S(=O)(=O)O)NC(=O)c3ccc(C)c(c3)NC(=O)c4cc(ccc4)NC(=O)Nc5cccc(c5)C(=O)Nc6c(C)ccc(c6)C(=O)Nc(ccc7S(=O)(=O)O)c(c78)c(S(=O)(=O)O)cc(c8)S(=O)(=O)O
22	sp|Q8IE47|SIR5_PLA	Q9NXA8	94.51	30.0	288.0	DB15493	experimental	Cambinol	c1cccc(c12)c(c(O)cc2)Cc3c([nH]c(=S)[nH]c3=O)-c4ccccc4
23	sp|Q8IE47|SIR5_PLA	Q96EB6	84.98	235.0	467.0	DB02709	investigational	Resveratrol	Oc1ccc(cc1)/C=C/c2cc(O)cc(O)c2
24	sp|Q8IE47|SIR5_PLA	Q96EB6	84.98	235.0	467.0	DB13978	experimental	Selisistat	O=C(N)C1CCCc(c12)c3c([nH]2)ccc(Cl)c3
25	sp|Q8IE47|SIR5_PLA	Q96EB6	84.98	235.0	467.0	DB15493	experimental	Cambinol	c1cccc(c12)c(c(O)cc2)Cc3c([nH]c(=S)[nH]c3=O)-c4ccccc4
26	sp|Q8IE47|SIR5_PLA	Q8IXJ6	83.88	60.0	289.0	DB15493	experimental	Cambinol	c1cccc(c12)c(c(O)cc2)Cc3c([nH]c(=S)[nH]c3=O)-c4ccccc4
27	sp|Q8IE47|SIR5_PLA	Q9NTG7	80.95	118.0	339.0	DB02059	experimental	Adenosine-5-Diphosphoribose	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)CO[P@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H](O)[C@H](O)[C@@H]4O
28									
29	sp|P62344|CDPK1_PL	P62344	99.81	1.0	524.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
30	sp|P62344|CDPK1_PL	Q8IBS5	97.14	18.0	527.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
31	sp|P62344|CDPK1_PL	Q9Y2H1	73.28	40.0	424.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
32	sp|P62344|CDPK1_PL	Q15208	74.62	36.0	427.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
33	sp|P62344|CDPK1_PL	Q9H422	75.95	187.0	585.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
35	sp|P62344|CDPK1_PL	Q13873	70.04	191.0	558.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
36	sp|Q8IBS5|CDPK4_PL	Q8IBS5	99.81	1.0	528.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
37	sp|Q8IBS5|CDPK4_PL	P62344	96.97	8.0	520.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
38	sp|Q8IBS5|CDPK4_PL	Q13557	75.76	8.0	408.0	DB07853	experimental	2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile	N#CCC1C=CC(C=C1)=Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
39	sp|Q8IBS5|CDPK4_PL	Q13557	75.76	8.0	408.0	DB08039	experimental	(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE	CN(C)S(=O)(=O)c(c1)ccc(c12)NC(=O)C\2=C/c([nH]3)cc(c34)CCCC4
40	sp|Q8IBS5|CDPK4_PL	Q13557	75.76	8.0	408.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
41	sp|Q8IBS5|CDPK4_PL	Q9UQM7	71.78	8.0	387.0	DB04119	experimental	Hexatantalum Dodecabromide	[Br]
42	sp|Q8IBS5|CDPK4_PL	Q9UQM7	71.78	8.0	387.0	DB04447	experimental	1,4-Dithiothreitol	SC[C@H](O)[C@@H](O)CS
43	sp|Q8IBS5|CDPK4_PL	Q9UQM7	71.78	8.0	387.0	DB07766	experimental	(2Z,3E)-2,3'-biindole-2',3(1H,1'H)-dione 3-{O-[(3R)-3,4-dihydroxybutyl]oxime}	c1cccc(c12)/C(C(=O)N2)=C(/Nc(c34)cccc4)\C3=N\OCC[C@@H](O)CO
44	sp|Q8IBS5|CDPK4_PL	Q9UQM7	71.78	8.0	387.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
45	sp|Q8IBS5|CDPK4_PL	Q9Y2H1	71.4	41.0	418.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
46	sp|Q8IBS5|CDPK4_PL	Q15208	72.92	36.0	421.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
47	sp|Q8IBS5|CDPK4_PL	O95835	71.02	654.0	1029.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
48	sp|Q8IBS5|CDPK4_PL	Q9BUB5	72.16	23.0	404.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
49	sp|Q8IBS5|CDPK4_PL	Q9HAZ1	70.45	105.0	477.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
50	sp|Q8IBS5|CDPK4_PL	P49760	72.35	103.0	485.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
52	sp|Q8IBS5|CDPK4_PL	Q13873	71.02	198.0	573.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
53	sp|Q8IJN7|ENO_PLAF	Q8IJN7	99.78	1.0	446.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
54	sp|Q8IJN7|ENO_PLAF	P09104	96.19	2.0	431.0	DB02726	experimental	2-Phosphoglycolic Acid	OC(=O)COP(=O)(O)O
55	sp|Q8IJN7|ENO_PLAF	P06733	96.19	3.0	432.0	DB01593	approved; investigational	Zinc	[Zn]
56	sp|Q8IJN7|ENO_PLAF	P06733	96.19	3.0	432.0	DB09130	approved; investigational	Copper	[Cu]
57	sp|Q8IJN7|ENO_PLAF	P06733	96.19	3.0	432.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
58	sp|Q8IJN7|ENO_PLAF	P06733	96.19	3.0	432.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
59	sp|Q8IJN7|ENO_PLAF	P06733	96.19	3.0	432.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
60	sp|Q8IJN7|ENO_PLAF	P06733	96.19	3.0	432.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
61	sp|Q8IJN7|ENO_PLAF	P13929	96.19	2.0	431.0	DB01709	experimental	2-phospho-D-glyceric acid	OC[C@H](C(=O)O)OP(=O)(O)O
62	sp|Q8IJN7|ENO_PLAF	P13929	96.19	2.0	431.0	DB01819	experimental	Phosphoenolpyruvate	OC(=O)C(=C)OP(=O)(O)O
63	sp|Q8IJN7|ENO_PLAF	P13929	96.19	2.0	431.0	DB02726	experimental	2-Phosphoglycolic Acid	OC(=O)COP(=O)(O)O
64	sp|Q8IJN7|ENO_PLAF	P13929	96.19	2.0	431.0	DB03645	experimental	Phosphonoacetohydroxamic Acid	ONC(=O)CP(=O)(O)O
65	sp|Q8IJN7|ENO_PLAF	Q27655	95.96	2.0	430.0	DB12245	approved; investigational	Triclabendazole	CSc([nH]1)nc(c12)cc(c(Cl)c2)Oc3cccc(Cl)c3Cl
66	sp|P50250|SAHH_PLA	P50250	99.79	1.0	479.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
67	sp|P50250|SAHH_PLA	P9WGV3	99.16	20.0	495.0	DB07052	experimental	5'-S-ethyl-5'-thioadenosine	CCSC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
68	sp|Q8ICR0|CDPK2_PL	Q8IBS5	100.59	5.0	517.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
69	sp|Q8ICR0|CDPK2_PL	P62344	97.45	13.0	509.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
70	sp|Q8ICR0|CDPK2_PL	Q9BYT3	73.67	52.0	427.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
71	sp|Q8ICR0|CDPK2_PL	Q9HBH9	70.14	61.0	418.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
72	sp|Q8ICR0|CDPK2_PL	Q13627	81.53	95.0	510.0	DB07608	experimental	N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide	Clc1cccc(c1)[C@H](CCN)C(=O)Nc(c2)ccc(c23)[nH]nc3NC(=O)c4ccccc4
73	sp|Q8ICR0|CDPK2_PL	Q13627	81.53	95.0	510.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
74	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
75	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB15624	experimental	Halicin	Nc1nnc(s1)Sc2ncc(s2)[N+]([O-])=O
76	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB01782	experimental	Pyrazolanthrone	c1cccc(c12)c3c4c([nH]n3)cccc4C2=O
77	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB02388	experimental	Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	C1CNCCC1c2n(CCC)c(c(n2)-c3ccc(Cl)c(Cl)c3)-c4ccnc(n4)NC5CCCCC5
78	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB03084	experimental	Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	CN1CCC(CC1)c2n(CCC)c(c(n2)-c3ccc(Cl)c(Cl)c3)-c4ccnc(n4)NC5CC5
79	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB03623	experimental	9-(4-Hydroxyphenyl)-2,7-Phenanthroline	Oc1ccc(cc1)-c(cn2)cc(c23)c4c(cc3)ccnc4
80	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
81	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB06933	experimental	N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide	CC(C)(C)NS(=O)(=O)c1ccc(cc1)-c(c2)cnc(c23)cccc3Nc4ccccn4
82	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB07010	experimental	N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE	Clc1cc(ccc1)-c2c[nH]nc2-c3c[nH]c(c3)C(=O)NCc4ccccc4
83	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB07217	experimental	N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide	Fc1ccccc1C(=O)Nc(s2)c(C#N)c(c23)CCCC3
84	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08005	experimental	4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide	CCNC(=O)N1CCC(CC1)Nc2nc(c(Cl)cn2)-c3c[nH]c(c34)cccc4
85	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08010	experimental	(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime	c1ccccc1/C=C/c2cccc(c23)N(C(=O)C\3=N/O)Cc(cc(F)c4)c(c45)OCOC5
86	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08011	experimental	(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime	Fc(c1)ccc(c12)N(C(=O)C\2=N\O)Cc3cc(F)cc(c34)COCO4
87	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08015	experimental	(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime	c1ccccc1-c2cccc(c23)N(C(=O)C\3=N/O)Cc4cc(F)cc(c45)COCO5
88	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08021	experimental	5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide	C#CCN1CCN(CC1)c2c(Cl)cccc2NC(=O)c3ccc(Br)o3
89	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08023	experimental	N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine	C1CCCCC1N(C)c2nc(ccn2)-c3cnc(n34)cccc4
90	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08025	experimental	N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE	CO[C@H]1CC[C@@H](CC1)C(=O)Nc2cc(ccn2)-c3cc(ncc3)Nc4ccc(F)cc4
91	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08026	experimental	2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide	CNC(=O)CN1CCC(CC1)Nc2nc(ccn2)-c3cnc(n34)cccc4
92	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB08555	experimental	1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline	COc(c(Cl)c1)cc(c12)CCN=C2c3cccc(Br)c3
93	sp|Q8ICR0|CDPK2_PL	P53779	70.14	29.0	386.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
94	sp|Q8ICR0|CDPK2_PL	Q9BUB5	77.41	27.0	421.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
95	sp|Q8ICR0|CDPK2_PL	Q9Y463	77.41	47.0	441.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
96	sp|Q8ICR0|CDPK2_PL	O95835	75.05	650.0	1032.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
97	sp|Q8ICR0|CDPK2_PL	Q9HAZ1	73.87	102.0	478.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
98	sp|Q8ICR0|CDPK2_PL	P49759	74.26	103.0	481.0	DB04367	experimental	Debromohymenialdisine	NC1=NC(=O)/C(N1)=C2\CCNC(=O)c(c23)[nH]cc3
99	sp|Q8ICR0|CDPK2_PL	P49759	74.26	103.0	481.0	DB06376	investigational	CHGN111	 
100	sp|Q8ICR0|CDPK2_PL	P49759	74.26	103.0	481.0	DB08691	experimental	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate	CCOC(=O)c(n1C)c(/C(C#N)=C\N)c(c12)ccc(Cl)c2Cl
101	sp|Q8ICR0|CDPK2_PL	P49759	74.26	103.0	481.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
102	sp|Q8ICR0|CDPK2_PL	Q9H422	81.14	182.0	595.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
103	sp|Q8ICR0|CDPK2_PL	Q9H2X6	82.51	165.0	585.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
104	sp|Q8ICR0|CDPK2_PL	P49760	75.44	102.0	486.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
105	sp|Q8ICR0|CDPK2_PL	P49761	74.66	253.0	633.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
106	sp|Q8ICR0|CDPK2_PL	P49761	74.66	253.0	633.0	DB08691	experimental	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate	CCOC(=O)c(n1C)c(/C(C#N)=C\N)c(c12)ccc(Cl)c2Cl
107	sp|Q8ICR0|CDPK2_PL	P49761	74.66	253.0	633.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
108	sp|Q8IDR3|MYOA_PLA	P35579	89.36	80.0	811.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
109	sp|Q8IDR3|MYOA_PLA	P35749	89.85	84.0	819.0	DB04444	experimental	Tetrafluoroaluminate Ion	F[Al-](F)(F)F
110	sp|Q8IDR3|MYOA_PLA	Q7Z406	89.61	106.0	839.0	DB01944	experimental	(S)-blebbistatin	c1cc(C)cc(C2=O)c1N=C([C@]23O)N(CC3)c4ccccc4
111	sp|Q8IDR3|MYOA_PLA	Q7Z406	89.61	106.0	839.0	DB03126	experimental	Mant-Adp	n1cnc(N)c(c12)ncn2[C@H]3C[C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)OC(=O)c4ccccc4NC
112	sp|Q8IDR3|MYOA_PLA	Q7Z406	89.61	106.0	839.0	DB04444	experimental	Tetrafluoroaluminate Ion	F[Al-](F)(F)F
113	sp|Q8IDR3|MYOA_PLA	Q7Z406	89.61	106.0	839.0	DB07468	experimental	(3aS)-3a-hydroxy-5-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one	c1ccc(C)c(C2=O)c1N=C([C@]23O)N(CC3)c4ccccc4
114	sp|Q8IDR3|MYOA_PLA	Q7Z406	89.61	106.0	839.0	DB07469	experimental	(3aS)-3a-hydroxy-7-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one	Cc(c1)ccc(C2=O)c1N=C([C@]23O)N(CC3)c4ccccc4
115	sp|Q8IDR3|MYOA_PLA	Q7Z406	89.61	106.0	839.0	DB07470	experimental	(3aS)-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one	c1ccccc1N(CC2)C([C@@]23O)=Nc4c(C3=O)cccc4
116	sp|Q8IDR3|MYOA_PLA	Q7Z406	89.61	106.0	839.0	DB08276	experimental	trifluoro-[hydroxy-[hydroxy-[2-(N-methyl-2-nitro-anilino)ethoxy]phosphoryl]oxy-phosphoryl]oxy-beryllium(1-)	CN(CCO[P@](O)(=O)O[P@@](O)(=O)O[Be-](F)(F)F)c1ccccc1[N+]([O-])=O
117	sp|Q8IDR3|MYOA_PLA	P12883	90.1	86.0	823.0	DB08378	experimental	4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID	OC(=O)CC[C@H](O)Nc1ccc(cc1)N2C(=O)CCC2=O
118	sp|Q8IDR3|MYOA_PLA	Q12965	87.41	14.0	729.0	DB03366	experimental; investigational	Imidazole	[nH]1ccnc1
119	sp|Q8IDR3|MYOA_PLA	Q8NEV4	93.03	337.0	1098.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
120	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00477	approved; investigational; vet_approved	Chlorpromazine	CN(C)CCCN1c(cccc2)c2Sc(c13)ccc(Cl)c3
121	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00527	approved; vet_approved	Cinchocaine	c1cccc(c12)nc(OCCCC)cc2C(=O)NCCN(CC)CC
122	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00622	approved; investigational	Nicardipine	COC(=O)C1=C(C)NC(C)=C(C1c2cc([N+]([O-])=O)ccc2)C(=O)OCCN(C)Cc3ccccc3
123	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00623	approved	Fluphenazine	OCCN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F
124	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00753	approved; vet_approved	Isoflurane	FC(F)OC(Cl)C(F)(F)F
125	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00831	approved; investigational	Trifluoperazine	CN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F
126	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00836	approved	Loperamide	c1ccccc1C(C(=O)N(C)C)(c2ccccc2)CCN(CC3)CCC3(O)c4ccc(Cl)cc4
127	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00850	approved	Perphenazine	OCCN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(Cl)c4
128	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00925	approved	Phenoxybenzamine	c1ccccc1CN(CCCl)C(C)COc2ccccc2
129	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01023	approved; investigational	Felodipine	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2c(Cl)c(Cl)ccc2
130	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01065	approved; nutraceutical; vet_approved	Melatonin	COc(cc1)cc(c12)c(c[nH]2)CCNC(=O)C
131	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01069	approved; investigational	Promethazine	CN(C)C(C)CN1c(cccc2)c2Sc(c13)cccc3
132	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01100	approved	Pimozide	c1cc(F)ccc1C(c(cc2)ccc2F)CCCN3CCC(CC3)n4c(=O)[nH]c(c45)cccc5
133	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01115	approved	Nifedipine	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2ccccc2[N+]([O-])=O
134	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01244	approved; withdrawn	Bepridil	CC(C)COCC(N1CCCC1)CN(c2ccccc2)Cc3ccccc3
135	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01373	nutraceutical	Calcium	[Ca]
136	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01429	experimental	Aprindine	CCN(CC)CCCN(c1ccccc1)C(C2)Cc(c23)cccc3
137	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB02868	experimental	Deacetoxyvinzolidine	CC[C@@]1(C2)C=CCN(CC3)[C@@H]1[C@]3([C@@H]4[C@]25OC(=O)N(C5=O)CCCl)c6c(N4C)cc(OC)c(c6)[C@](C[C@@H]78)(C(=O)OC)c9c(c1c([nH]9)cccc1)CCN(C7)C[C@@](O)(C8)CC
138	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB03900	experimental	tert-butanol	CC(C)(C)O
139	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB03977	experimental	Trimethyllysine	C[N+](C)(C)CCCC[C@H](N)C(=O)O
140	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB04513	experimental	N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide	NCCCCCCNS(=O)(=O)c1cccc(c12)c(Cl)ccc2
141	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB04825	approved; withdrawn	Prenylamine	c1ccccc1CC(C)NCCC(c2ccccc2)c3ccccc3
142	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB04841	approved	Flunarizine	c1cc(F)ccc1C(c(cc2)ccc2F)N3CCN(CC3)C/C=C/c4ccccc4
143	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB08039	experimental	(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE	CN(C)S(=O)(=O)c(c1)ccc(c12)NC(=O)C\2=C/c([nH]3)cc(c34)CCCC4
144	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
145	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
146	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
147	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB13800	approved; experimental	Calcium levulinate	CC(=O)CCC([O-])=O
148	sp|P62203|CALM_PLA	P0DP23	99.33	1.0	149.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
149	sp|P62203|CALM_PLA	P0DP24	99.33	1.0	149.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
150	sp|P62203|CALM_PLA	P0DP24	99.33	1.0	149.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
151	sp|P62203|CALM_PLA	P0DP24	99.33	1.0	149.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
152	sp|P62203|CALM_PLA	P0DP25	99.33	1.0	149.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
153	sp|P62203|CALM_PLA	P0DP25	99.33	1.0	149.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
154	sp|P62203|CALM_PLA	P0DP25	99.33	1.0	149.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
155	sp|P62203|CALM_PLA	P02585	96.64	12.0	156.0	DB01023	approved; investigational	Felodipine	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2c(Cl)c(Cl)ccc2
156	sp|P62203|CALM_PLA	P02585	96.64	12.0	156.0	DB01373	nutraceutical	Calcium	[Ca]
157	sp|P62203|CALM_PLA	P02585	96.64	12.0	156.0	DB04682	experimental	Octylphenoxy polyethoxyethanol	CC(C)(C)CC(C)(C)c1ccc(cc1)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
158	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB00831	approved; investigational	Trifluoperazine	CN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F
159	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB00922	approved; investigational	Levosimendan	C[C@@H]1CC(=O)NN=C1c2ccc(cc2)NN=C(C#N)C#N
160	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB01023	approved; investigational	Felodipine	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2c(Cl)c(Cl)ccc2
161	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB01244	approved; withdrawn	Bepridil	CC(C)COCC(N1CCCC1)CN(c2ccccc2)Cc3ccccc3
162	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB01373	nutraceutical	Calcium	[Ca]
163	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB01375	experimental	Aluminium monostearate	CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O
164	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB03944	experimental	5-[1-(3,4-Dimethoxy-Benzoyl)-1,2,3,4-Tetrahydro-Quinolin-6-Yl]-6-Methyl-3,6-Dihydro-[1,3,4]Thiadiazin-2-One	C[C@H]1SC(=O)NN=C1c(cc2)cc(c23)CCCN3C(=O)c4cc(OC)c(OC)cc4
165	sp|P62203|CALM_PLA	P63316	98.66	10.0	157.0	DB04513	experimental	N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide	NCCCCCCNS(=O)(=O)c1cccc(c12)c(Cl)ccc2
166	sp|P62203|CALM_PLA	P63098	97.99	11.0	157.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
167	sp|P62203|CALM_PLA	P63098	97.99	11.0	157.0	DB11693	investigational	Voclosporin	C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
168	sp|P62203|CALM_PLA	Q96LZ3	97.99	11.0	157.0	DB00091	approved; investigational; vet_approved	Cyclosporine	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
169	sp|P62203|CALM_PLA	Q96LZ3	97.99	11.0	157.0	DB11693	investigational	Voclosporin	C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
170	sp|P62203|CALM_PLA	P19105	92.62	24.0	162.0	DB08378	experimental	4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID	OC(=O)CC[C@H](O)Nc1ccc(cc1)N2C(=O)CCC2=O
171	sp|P62203|CALM_PLA	P22676	112.75	12.0	180.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
172	sp|P62203|CALM_PLA	P22676	112.75	12.0	180.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
173	sp|P62203|CALM_PLA	P22676	112.75	12.0	180.0	DB13800	approved; experimental	Calcium levulinate	CC(=O)CCC([O-])=O
174	sp|P62203|CALM_PLA	P22676	112.75	12.0	180.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
175	sp|P62203|CALM_PLA	O75340	83.22	30.0	154.0	DB01373	nutraceutical	Calcium	[Ca]
176	sp|P62203|CALM_PLA	O75340	83.22	30.0	154.0	DB01593	approved; investigational	Zinc	[Zn]
177	sp|P62203|CALM_PLA	O75340	83.22	30.0	154.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
178	sp|P62203|CALM_PLA	O75340	83.22	30.0	154.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
179	sp|P62203|CALM_PLA	O75340	83.22	30.0	154.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
180	sp|P62203|CALM_PLA	O75340	83.22	30.0	154.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
181	sp|P62203|CALM_PLA	P43080	100.0	11.0	160.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
182	sp|P62203|CALM_PLA	P62344	97.32	370.0	515.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
183	sp|P62203|CALM_PLA	P62166	100.67	21.0	171.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
184	sp|P62203|CALM_PLA	P62166	100.67	21.0	171.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
185	sp|P62203|CALM_PLA	P62166	100.67	21.0	171.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
186	sp|P62203|CALM_PLA	P14649	97.99	60.0	206.0	DB08378	experimental	4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID	OC(=O)CC[C@H](O)Nc1ccc(cc1)N2C(=O)CCC2=O
187	sp|P62203|CALM_PLA	P35243	103.36	21.0	175.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
188	sp|P62203|CALM_PLA	Q8IBS5	100.0	374.0	523.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
189	sp|P62203|CALM_PLA	Q99653	106.04	22.0	180.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
190	sp|P62203|CALM_PLA	Q99653	106.04	22.0	180.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
191	sp|P62203|CALM_PLA	Q99653	106.04	22.0	180.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
192	sp|P62203|CALM_PLA	Q9UBV8	85.23	120.0	247.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
193	sp|P62203|CALM_PLA	Q9UBV8	85.23	120.0	247.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
194	sp|P62203|CALM_PLA	Q9UBV8	85.23	120.0	247.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
195	sp|P62203|CALM_PLA	P30626	86.58	35.0	164.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
196	sp|P62203|CALM_PLA	P30626	86.58	35.0	164.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
197	sp|P62203|CALM_PLA	P30626	86.58	35.0	164.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
198	sp|P62203|CALM_PLA	O75746	85.23	91.0	218.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
199	sp|P62203|CALM_PLA	Q13938	94.63	23.0	164.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
200	sp|P62203|CALM_PLA	Q13938	94.63	23.0	164.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
201	sp|P62203|CALM_PLA	Q13938	94.63	23.0	164.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
202	sp|P62203|CALM_PLA	P07384	95.3	538.0	680.0	DB04276	experimental	4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium	OC(=O)C[C@H](O)C(=O)N[C@@H](CC(C)C)C(=O)NCCCC[NH+]=C(N)N
203	sp|P62203|CALM_PLA	P07384	95.3	538.0	680.0	DB04653	experimental	N-[(benzyloxy)carbonyl]-L-leucyl-N-[(1S)-3-fluoro-1-(4-hydroxybenzyl)-2-oxopropyl]-L-leucinamide	c1ccccc1COC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)CF)Cc2ccc(O)cc2
204	sp|P62203|CALM_PLA	P07384	95.3	538.0	680.0	DB07627	experimental	(2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE	O[C@@H]1C[C@@H](CO1)NC(=O)[C@H](CC(C)C)NC(=S)Nc2ccccc2
205	sp|P62203|CALM_PLA	P28676	83.89	57.0	182.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
206	sp|P62203|CALM_PLA	P28676	83.89	57.0	182.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
207	sp|P62203|CALM_PLA	P28676	83.89	57.0	182.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
208	sp|P62203|CALM_PLA	Q9UJS0	88.59	24.0	156.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
209	sp|P62203|CALM_PLA	Q9UJS0	80.54	159.0	279.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
210	sp|P62203|CALM_PLA	O75838	74.5	62.0	173.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
211	sp|P62203|CALM_PLA	O75838	74.5	62.0	173.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
212	sp|P62203|CALM_PLA	O75838	74.5	62.0	173.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
214	sp|P62203|CALM_PLA	P12814	73.83	740.0	850.0	DB09130	approved; investigational	Copper	[Cu]
215	sp|P62203|CALM_PLA	Q99828	77.85	61.0	177.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
216	sp|P62203|CALM_PLA	Q99828	77.85	61.0	177.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
217	sp|P62203|CALM_PLA	Q99828	77.85	61.0	177.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
218	sp|P62203|CALM_PLA	Q9NXG6	84.56	126.0	252.0	DB00126	approved; nutraceutical	Ascorbic acid	OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
219	sp|P62203|CALM_PLA	P80303	93.29	182.0	321.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
220	sp|P62203|CALM_PLA	P80303	93.29	182.0	321.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
221	sp|P62203|CALM_PLA	P80303	93.29	182.0	321.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
222	sp|P62203|CALM_PLA	Q02818	92.62	181.0	319.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
223	sp|P62203|CALM_PLA	Q02818	92.62	181.0	319.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
224	sp|P62203|CALM_PLA	Q02818	92.62	181.0	319.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
225	sp|P62203|CALM_PLA	P42971	74.5	41.0	152.0	DB00355	approved	Aztreonam	[O-]S(=O)(=O)N1C(=O)[C@H]([C@@H]1C)NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(n2)[NH3+]
226	sp|P62203|CALM_PLA	P42971	74.5	41.0	152.0	DB00493	approved	Cefotaxime	CC(=O)OCC(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\OC)c3csc(n3)N
227	sp|P62203|CALM_PLA	P42971	74.5	41.0	152.0	DB01598	approved	Imipenem	C[C@@H](O)[C@@H](C1=O)[C@H](N12)CC(=C2C(=O)O)SCC/N=C/N
228	sp|P62203|CALM_PLA	P42971	74.5	41.0	152.0	DB04570	approved; investigational	Latamoxef	Cn1nnnc1SCC(=C2C(=O)O)CO[C@@H](N23)[C@](C3=O)(OC)NC(=O)C(C(=O)O)c4ccc(O)cc4
229	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00477	approved; investigational; vet_approved	Chlorpromazine	CN(C)CCCN1c(cccc2)c2Sc(c13)ccc(Cl)c3
230	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00527	approved; vet_approved	Cinchocaine	c1cccc(c12)nc(OCCCC)cc2C(=O)NCCN(CC)CC
231	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00622	approved; investigational	Nicardipine	COC(=O)C1=C(C)NC(C)=C(C1c2cc([N+]([O-])=O)ccc2)C(=O)OCCN(C)Cc3ccccc3
232	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00623	approved	Fluphenazine	OCCN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F
233	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00753	approved; vet_approved	Isoflurane	FC(F)OC(Cl)C(F)(F)F
234	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00831	approved; investigational	Trifluoperazine	CN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F
235	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00836	approved	Loperamide	c1ccccc1C(C(=O)N(C)C)(c2ccccc2)CCN(CC3)CCC3(O)c4ccc(Cl)cc4
236	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00850	approved	Perphenazine	OCCN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(Cl)c4
237	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB00925	approved	Phenoxybenzamine	c1ccccc1CN(CCCl)C(C)COc2ccccc2
238	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01023	approved; investigational	Felodipine	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2c(Cl)c(Cl)ccc2
239	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01065	approved; nutraceutical; vet_approved	Melatonin	COc(cc1)cc(c12)c(c[nH]2)CCNC(=O)C
240	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01069	approved; investigational	Promethazine	CN(C)C(C)CN1c(cccc2)c2Sc(c13)cccc3
241	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01100	approved	Pimozide	c1cc(F)ccc1C(c(cc2)ccc2F)CCCN3CCC(CC3)n4c(=O)[nH]c(c45)cccc5
242	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01115	approved	Nifedipine	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2ccccc2[N+]([O-])=O
243	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01244	approved; withdrawn	Bepridil	CC(C)COCC(N1CCCC1)CN(c2ccccc2)Cc3ccccc3
244	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01373	nutraceutical	Calcium	[Ca]
245	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB01429	experimental	Aprindine	CCN(CC)CCCN(c1ccccc1)C(C2)Cc(c23)cccc3
246	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB02868	experimental	Deacetoxyvinzolidine	CC[C@@]1(C2)C=CCN(CC3)[C@@H]1[C@]3([C@@H]4[C@]25OC(=O)N(C5=O)CCCl)c6c(N4C)cc(OC)c(c6)[C@](C[C@@H]78)(C(=O)OC)c9c(c1c([nH]9)cccc1)CCN(C7)C[C@@](O)(C8)CC
247	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB03900	experimental	tert-butanol	CC(C)(C)O
248	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB03977	experimental	Trimethyllysine	C[N+](C)(C)CCCC[C@H](N)C(=O)O
249	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB04513	experimental	N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide	NCCCCCCNS(=O)(=O)c1cccc(c12)c(Cl)ccc2
250	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB04825	approved; withdrawn	Prenylamine	c1ccccc1CC(C)NCCC(c2ccccc2)c3ccccc3
251	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB04841	approved	Flunarizine	c1cc(F)ccc1C(c(cc2)ccc2F)N3CCN(CC3)C/C=C/c4ccccc4
252	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB08039	experimental	(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE	CN(C)S(=O)(=O)c(c1)ccc(c12)NC(=O)C\2=C/c([nH]3)cc(c34)CCCC4
253	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
254	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
255	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
256	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB13800	approved; experimental	Calcium levulinate	CC(=O)CCC([O-])=O
257	sp|P24044|CALM_PLA	P0DP23	99.33	1.0	149.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
258	sp|P24044|CALM_PLA	P0DP24	99.33	1.0	149.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
259	sp|P24044|CALM_PLA	P0DP24	99.33	1.0	149.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
260	sp|P24044|CALM_PLA	P0DP24	99.33	1.0	149.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
261	sp|P24044|CALM_PLA	P0DP25	99.33	1.0	149.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
262	sp|P24044|CALM_PLA	P0DP25	99.33	1.0	149.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
263	sp|P24044|CALM_PLA	P0DP25	99.33	1.0	149.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
264	sp|P24044|CALM_PLA	P02585	96.64	12.0	156.0	DB01023	approved; investigational	Felodipine	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2c(Cl)c(Cl)ccc2
265	sp|P24044|CALM_PLA	P02585	96.64	12.0	156.0	DB01373	nutraceutical	Calcium	[Ca]
266	sp|P24044|CALM_PLA	P02585	96.64	12.0	156.0	DB04682	experimental	Octylphenoxy polyethoxyethanol	CC(C)(C)CC(C)(C)c1ccc(cc1)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
267	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB00831	approved; investigational	Trifluoperazine	CN1CCN(CC1)CCCN2c(cccc3)c3Sc(c24)ccc(c4)C(F)(F)F
268	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB00922	approved; investigational	Levosimendan	C[C@@H]1CC(=O)NN=C1c2ccc(cc2)NN=C(C#N)C#N
269	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB01023	approved; investigational	Felodipine	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c2c(Cl)c(Cl)ccc2
270	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB01244	approved; withdrawn	Bepridil	CC(C)COCC(N1CCCC1)CN(c2ccccc2)Cc3ccccc3
271	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB01373	nutraceutical	Calcium	[Ca]
272	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB01375	experimental	Aluminium monostearate	CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O
273	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB03944	experimental	5-[1-(3,4-Dimethoxy-Benzoyl)-1,2,3,4-Tetrahydro-Quinolin-6-Yl]-6-Methyl-3,6-Dihydro-[1,3,4]Thiadiazin-2-One	C[C@H]1SC(=O)NN=C1c(cc2)cc(c23)CCCN3C(=O)c4cc(OC)c(OC)cc4
274	sp|P24044|CALM_PLA	P63316	98.66	10.0	157.0	DB04513	experimental	N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide	NCCCCCCNS(=O)(=O)c1cccc(c12)c(Cl)ccc2
275	sp|P24044|CALM_PLA	P63098	97.99	11.0	157.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
276	sp|P24044|CALM_PLA	P63098	97.99	11.0	157.0	DB11693	investigational	Voclosporin	C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
277	sp|P24044|CALM_PLA	Q96LZ3	97.99	11.0	157.0	DB00091	approved; investigational; vet_approved	Cyclosporine	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
278	sp|P24044|CALM_PLA	Q96LZ3	97.99	11.0	157.0	DB11693	investigational	Voclosporin	C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
279	sp|P24044|CALM_PLA	P19105	92.62	24.0	162.0	DB08378	experimental	4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID	OC(=O)CC[C@H](O)Nc1ccc(cc1)N2C(=O)CCC2=O
280	sp|P24044|CALM_PLA	P22676	112.75	12.0	180.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
281	sp|P24044|CALM_PLA	P22676	112.75	12.0	180.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
282	sp|P24044|CALM_PLA	P22676	112.75	12.0	180.0	DB13800	approved; experimental	Calcium levulinate	CC(=O)CCC([O-])=O
283	sp|P24044|CALM_PLA	P22676	112.75	12.0	180.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
284	sp|P24044|CALM_PLA	O75340	83.22	30.0	154.0	DB01373	nutraceutical	Calcium	[Ca]
285	sp|P24044|CALM_PLA	O75340	83.22	30.0	154.0	DB01593	approved; investigational	Zinc	[Zn]
286	sp|P24044|CALM_PLA	O75340	83.22	30.0	154.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
287	sp|P24044|CALM_PLA	O75340	83.22	30.0	154.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
288	sp|P24044|CALM_PLA	O75340	83.22	30.0	154.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
289	sp|P24044|CALM_PLA	O75340	83.22	30.0	154.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
290	sp|P24044|CALM_PLA	P43080	100.0	11.0	160.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
291	sp|P24044|CALM_PLA	P62344	97.32	370.0	515.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
292	sp|P24044|CALM_PLA	P62166	100.67	21.0	171.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
293	sp|P24044|CALM_PLA	P62166	100.67	21.0	171.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
294	sp|P24044|CALM_PLA	P62166	100.67	21.0	171.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
295	sp|P24044|CALM_PLA	P14649	97.99	60.0	206.0	DB08378	experimental	4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID	OC(=O)CC[C@H](O)Nc1ccc(cc1)N2C(=O)CCC2=O
296	sp|P24044|CALM_PLA	P35243	103.36	21.0	175.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
297	sp|P24044|CALM_PLA	Q8IBS5	100.0	374.0	523.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
298	sp|P24044|CALM_PLA	Q99653	106.04	22.0	180.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
299	sp|P24044|CALM_PLA	Q99653	106.04	22.0	180.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
300	sp|P24044|CALM_PLA	Q99653	106.04	22.0	180.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
301	sp|P24044|CALM_PLA	Q9UBV8	85.23	120.0	247.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
302	sp|P24044|CALM_PLA	Q9UBV8	85.23	120.0	247.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
303	sp|P24044|CALM_PLA	Q9UBV8	85.23	120.0	247.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
304	sp|P24044|CALM_PLA	P30626	86.58	35.0	164.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
305	sp|P24044|CALM_PLA	P30626	86.58	35.0	164.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
306	sp|P24044|CALM_PLA	P30626	86.58	35.0	164.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
307	sp|P24044|CALM_PLA	O75746	85.23	91.0	218.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
308	sp|P24044|CALM_PLA	Q13938	94.63	23.0	164.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
309	sp|P24044|CALM_PLA	Q13938	94.63	23.0	164.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
310	sp|P24044|CALM_PLA	Q13938	94.63	23.0	164.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
311	sp|P24044|CALM_PLA	P07384	95.3	538.0	680.0	DB04276	experimental	4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium	OC(=O)C[C@H](O)C(=O)N[C@@H](CC(C)C)C(=O)NCCCC[NH+]=C(N)N
312	sp|P24044|CALM_PLA	P07384	95.3	538.0	680.0	DB04653	experimental	N-[(benzyloxy)carbonyl]-L-leucyl-N-[(1S)-3-fluoro-1-(4-hydroxybenzyl)-2-oxopropyl]-L-leucinamide	c1ccccc1COC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)CF)Cc2ccc(O)cc2
313	sp|P24044|CALM_PLA	P07384	95.3	538.0	680.0	DB07627	experimental	(2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE	O[C@@H]1C[C@@H](CO1)NC(=O)[C@H](CC(C)C)NC(=S)Nc2ccccc2
314	sp|P24044|CALM_PLA	P28676	83.89	57.0	182.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
315	sp|P24044|CALM_PLA	P28676	83.89	57.0	182.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
316	sp|P24044|CALM_PLA	P28676	83.89	57.0	182.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
317	sp|P24044|CALM_PLA	Q9UJS0	88.59	24.0	156.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
318	sp|P24044|CALM_PLA	Q9UJS0	80.54	159.0	279.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
319	sp|P24044|CALM_PLA	O75838	74.5	62.0	173.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
320	sp|P24044|CALM_PLA	O75838	74.5	62.0	173.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
321	sp|P24044|CALM_PLA	O75838	74.5	62.0	173.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
323	sp|P24044|CALM_PLA	P12814	73.83	740.0	850.0	DB09130	approved; investigational	Copper	[Cu]
324	sp|P24044|CALM_PLA	Q99828	77.85	61.0	177.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
325	sp|P24044|CALM_PLA	Q99828	77.85	61.0	177.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
326	sp|P24044|CALM_PLA	Q99828	77.85	61.0	177.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
327	sp|P24044|CALM_PLA	Q9NXG6	84.56	126.0	252.0	DB00126	approved; nutraceutical	Ascorbic acid	OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
328	sp|P24044|CALM_PLA	P80303	93.29	182.0	321.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
329	sp|P24044|CALM_PLA	P80303	93.29	182.0	321.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
330	sp|P24044|CALM_PLA	P80303	93.29	182.0	321.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
331	sp|P24044|CALM_PLA	Q02818	92.62	181.0	319.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
332	sp|P24044|CALM_PLA	Q02818	92.62	181.0	319.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
333	sp|P24044|CALM_PLA	Q02818	92.62	181.0	319.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
334	sp|P24044|CALM_PLA	P42971	74.5	41.0	152.0	DB00355	approved	Aztreonam	[O-]S(=O)(=O)N1C(=O)[C@H]([C@@H]1C)NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(n2)[NH3+]
335	sp|P24044|CALM_PLA	P42971	74.5	41.0	152.0	DB00493	approved	Cefotaxime	CC(=O)OCC(=C1C(=O)O)CS[C@@H](N12)[C@@H](C2=O)NC(=O)/C(=N\OC)c3csc(n3)N
336	sp|P24044|CALM_PLA	P42971	74.5	41.0	152.0	DB01598	approved	Imipenem	C[C@@H](O)[C@@H](C1=O)[C@H](N12)CC(=C2C(=O)O)SCC/N=C/N
337	sp|P24044|CALM_PLA	P42971	74.5	41.0	152.0	DB04570	approved; investigational	Latamoxef	Cn1nnnc1SCC(=C2C(=O)O)CO[C@@H](N23)[C@](C3=O)(OC)NC(=O)C(C(=O)O)c4ccc(O)cc4
338	sp|P61075|CDC2H_PL	Q15418	75.35	61.0	278.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
339	sp|P61075|CDC2H_PL	Q15418	75.35	61.0	278.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
340	sp|P61075|CDC2H_PL	Q15418	72.22	417.0	625.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
341	sp|P61075|CDC2H_PL	Q15418	72.22	417.0	625.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
342	sp|P61075|CDC2H_PL	P51812	75.35	67.0	284.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
343	sp|P61075|CDC2H_PL	P51812	75.35	67.0	284.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
344	sp|P61075|CDC2H_PL	P51812	72.22	421.0	629.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
345	sp|P61075|CDC2H_PL	P51812	72.22	421.0	629.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
346	sp|P61075|CDC2H_PL	Q9UK32	75.35	72.0	289.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
347	sp|P61075|CDC2H_PL	Q9UK32	70.14	425.0	627.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
348	sp|P61075|CDC2H_PL	O75676	78.47	31.0	257.0	DB03247	approved; investigational	Flavin mononucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
349	sp|P61075|CDC2H_PL	O75676	90.28	416.0	676.0	DB03247	approved; investigational	Flavin mononucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
350	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
351	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB05243	investigational	XL019	 
352	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB07161	experimental	5-phenyl-1H-indazol-3-amine	Nc1n[nH]c(c12)ccc(c2)-c3ccccc3
353	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB07162	experimental	4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide	CC(C)(C)NS(=O)(=O)c1ccc(cc1)-c(cc2)cc(c23)c(N)n[nH]3
354	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB08067	experimental	4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM	C1CC1NC(=O)Nc2c[nH]nc2-c([nH]3)nc(c34)ccc(c4)C[NH+]5CCOCC5
355	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB08877	approved	Ruxolitinib	C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
356	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
357	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
358	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
359	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
360	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB12500	approved; investigational	Fedratinib	CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4
361	sp|P61075|CDC2H_PL	O60674	86.81	547.0	797.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
362	sp|P61075|CDC2H_PL	Q07785	99.65	1.0	288.0	DB02519	experimental	Indirubin-5-sulphonate	OS(=O)(=O)c(cc1)cc(c12)/C(C(=O)N2)=C(C3=O)/Nc(c34)cccc4
363	sp|P61075|CDC2H_PL	Q07785	99.65	1.0	288.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
364	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB02375	experimental	Myricetin	Oc(c1)cc(O)c(c12)c(=O)c(O)c(o2)-c3cc(O)c(O)c(O)c3
365	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
366	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB08877	approved	Ruxolitinib	C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
367	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
368	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
369	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
370	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB12500	approved; investigational	Fedratinib	CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4
371	sp|P61075|CDC2H_PL	P23458	94.44	584.0	856.0	DB15091	approved; investigational	Upadacitinib	FC(F)(F)CNC(=O)N1C[C@@H](CC)[C@H](C1)c2cnc(n23)cnc4c3cc[nH]4
372	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB02375	experimental	Myricetin	Oc(c1)cc(O)c(c12)c(=O)c(O)c(o2)-c3cc(O)c(O)c(O)c3
373	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
374	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB08877	approved	Ruxolitinib	C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
375	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
376	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
377	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
378	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB12500	approved; investigational	Fedratinib	CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4
379	sp|P61075|CDC2H_PL	P23458	93.4	876.0	1145.0	DB15091	approved; investigational	Upadacitinib	FC(F)(F)CNC(=O)N1C[C@@H](CC)[C@H](C1)c2cnc(n23)cnc4c3cc[nH]4
380	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB01888	experimental	4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide	CN(C)S(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)c(cn3)C(C)C)N[C@H]4CC[C@H](N)CC4
381	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
382	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
383	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02091	experimental	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine	Cc1nc(C)c(s1)-c2nc(N)ncc2
384	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
385	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02197	experimental	4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide	NS(=O)(=O)c1ccc(cc1)Nc2nc(ccn2)-c3cnc(n34)cccc4
386	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02297	experimental	2-Amino-6-Chloropyrazine	Nc1cncc(Cl)n1
387	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02407	experimental	6-O-Cyclohexylmethyl Guanine	[nH]1cnc(c12)c(nc(n2)N)OCC3CCCCC3
388	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02538	experimental	N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide	CC(=O)Nc1nc(ccn1)-c2c(C)nc(n23)cccc3
389	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02603	experimental	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	[nH]1cnc(c12)c(nc(c2)N)OCC3CCCCC3
390	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02647	experimental	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	c1ccccc1C(=O)Nc2cc(n[nH]2)C3CC3
391	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
392	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02833	experimental	[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine	Nc1nc(C)c(s1)-c2nc(ncc2)Nc3cccc(c3)[N+]([O-])=O
393	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02898	experimental	(5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone	n1c[nH]c(c12)nc(N)nc2OC[C@H]3CCC(=O)N3
394	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02915	experimental	4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine	Cc1nc(C)c(s1)-c2ccnc(n2)Nc3ccc(C(F)(F)F)cc3
395	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02950	experimental	Hymenialdisine	O=C1NCC[C@@H]([C@@H](C12)C=C(Br)N=2)C3=NC(N)=NC3=O
396	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02963	experimental	(5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine	CS(=O)(=O)c1ccc(cc1)Nc2cc(Cl)nc(n23)ccn3
397	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB02973	experimental	4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide	NS(=O)(=O)c1ccc(cc1)/N=N/C(C(=O)N=2)=c(c23)cc(Br)cc3
398	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03019	experimental	4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine	Nc1nccc(n1)-c2c(Cl)sc(Cl)c2
399	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03307	experimental	4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide	Nc1ncnc(c1)Nc2ccc(cc2)S(=O)(=O)N
400	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03365	experimental	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	COc(c1)c(OC)cc(c12)ncnc2Nc3cc(O)ccc3
401	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03428	experimental	SU9516	COc(c1)ccc(c12)NC(=O)C\2=C/c3cnc[nH]3
402	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03490	experimental	3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole	c1cccc(c12)Cc3c2n[nH]c3-c4ccncc4
403	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
404	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03583	experimental	(2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one	c1cccc(c12)NC(\[C@@]2(C)O)=C(/C(=O)N3)c(c34)cc(cc4)S(=O)(=O)N5CCC(O)CC5
405	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03663	experimental	1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol	CC(C)C(=O)COc1nc(N)nc(c12)nc[nH]2
406	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03737	experimental	4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One	C[C@@H](O)[C@H](N)[C@H](O)C#Cc1c(F)ccc(c12)NC(=O)C\2=C/c3c(OC)cc[nH]3
407	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB03801	experimental	Lysine Nz-Carboxylic Acid	OC(=O)[C@@H](N)CCCCNC(=O)O
408	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04006	experimental	[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone	c1ccccc1C(=O)c(c(n2)N)n(c23)cc(cc3)C(=O)c4c(F)cccc4F
409	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04101	experimental	N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide	Cc1nc(C)c(s1)-c2nc(ncc2)/N=C/NO
410	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04186	experimental	N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea	C1CC[C@@H](N12)c3c(C2=O)cccc3NC(=O)Nc4ccccn4
411	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04288	experimental	2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine	C1CCCC1n2cnc(c23)c(NCc4ccccc4)nc(n3)N[C@@H]5CC[C@@H](N)CC5
412	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04407	experimental	4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol	CNc1nc(C)c(s1)-c2ccnc(n2)Nc3ccc(O)cc3
413	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04518	experimental	3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol	Cc1nc(C)c(s1)-c2nc(ncc2)Nc3cccc(O)c3
414	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04607	experimental	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE	NS(=O)(=O)c1ccc(cc1)Nc(n2)cn(c23)cc(cc3)C(=O)c4c(Cl)cccc4Cl
415	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04662	experimental	OLOMOUCINE II	n1cn(C(C)C)c(c12)nc(N[C@H](CC)CO)nc2NCc3ccccc3O
416	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB04669	experimental	TRIAZOLOPYRIMIDINE	Brc1cccc(c1)-c(nc([n+]23)nc[nH]3)cc2NCc4ccncc4
417	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
418	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
419	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06844	experimental	4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE	n1csc(c12)c=3c(cc2)=NC(=O)C3CNc4ccc(cc4)S(=O)(=O)Nc5ccccn5
420	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06888	experimental	(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE	[C@@H]12CN([C@H](C)C1)CCn3[nH]c4c(cccc4c3=O)c5nc6c([nH]c5=O)cccc6O2
421	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06944	experimental	N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide	C1CC1c2n[nH]c(c2)NC(=O)Cc(cc3)cc(c34)cccc4
422	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06948	experimental	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	C1CCCCC1COc(c(c23)[nH]cn3)nc(n2)Nc4ccccc4
423	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06976	experimental	1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA	C1CCN[C@@H]1c2cc(n[nH]2)NC(=O)Nc3cccc(c34)C(=O)N5[C@H]4CCC5
424	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB06983	experimental	(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol	c1ccccc1-c(nc(n23)c(cn3)CO)cc2NCc4cnccc4
425	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07024	experimental	2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE	O=S1(=O)CCCN1c(cc(C)c2)c(c23)oc(c(c3=O)O)-c4ccc(O)c(O)c4
426	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07054	experimental	(2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2ncnc(c2)Nc3c(F)ccc(c3)C(F)(F)F
427	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07065	experimental	5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine	N#CSc(cn1)c(n12)nc(-c3c(Cl)c(Cl)ccc3)cc2NCc4ccncc4
428	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07126	experimental	O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE	NS(=O)(=O)c1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
429	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07137	experimental	(2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide	C1CC1C2=CC(\N=N2)=N/C(=O)[C@@H](C)c3ccc(cc3)N4CCNC4=O
430	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07163	experimental	5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE	NCCNc1cc(-c2[nH]ccc2)c3C(=O)Nc(c3c14)ccc4F
431	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07164	experimental	N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	C1CC1Nc2nc(ccn2)-c(cn3)c(n34)cccn4
432	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07179	experimental	3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide	Cc1ccccc1-c(nc(n23)c(Br)cn3)cc2NCc4c[n+]([O-])ccc4
433	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07203	experimental	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	Clc1cccc(c1)Nc(n2)nc(c(c23)[nH]cn3)OCC4CCCCC4
434	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07210	experimental	3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	c1ccccc1-c(nc(n23)c(Br)cn3)cc2NCc4ccncc4
435	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07220	experimental	N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE	O=S1(=O)CCCN1c(c2)ccc(c23)[nH]nc3NC(=O)Cc4ccc(cc4)N5CCCCC5
436	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07431	experimental	(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one	O=C1N[C@H](CN)CNc(c12)c3c(s2)ccc(c3)OC
437	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07471	experimental	5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE	Clc1ccccc1[C@@H](C)Oc2c(C(=O)N)sc(c2)-n3cnc(c34)cc(OC)c(c4)OC
438	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07493	experimental	5-Bromoindirubin	c1cc(Br)cc(c12)/C(C(=O)N2)=C(C3=O)/Nc(c34)cccc4
439	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07501	experimental	(2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2ncc(Br)c(n2)Nc3ccccc3
440	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07504	experimental	(2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2ncc(Br)c(n2)Nc3ccccc3
441	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07529	experimental	(5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one	N=C1NC(=O)/C(S1)=C\c2ccccn2
442	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07531	experimental	4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=O)NC3=O
443	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07533	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE	CNS(=O)(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=N)NC3=O
444	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07534	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=N)NC3=O
445	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07538	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1C(F)(F)F)-c2ccc(o2)/C=C3\SC(=N)NC3=O
446	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07539	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID	OC(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=N)NC3=O
447	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07540	experimental	4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE	O=C1NC(=N)SC\1=C(\C)c2ccc(o2)-c3ccc(cc3)S(=O)(=O)N
448	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07562	experimental	N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE	CN(C)c1ccc(cc1)Nc2nc(ccn2)-c3c(C)nc(s3)C
449	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07595	experimental	(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE	Brc1cccc(c1)-c(nc([n+]23)cc[nH]3)cc2NCc4ccncc4
450	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07606	experimental	6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE	Clc1cc(Cl)cc(Cl)c1-n(nc2CC)c(c23)nc([nH]c3=O)Cc4cc(O)c(O)cc4
451	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07612	experimental	6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE	CC(C)(C)Nc1nc(C(F)(F)F)nc(c12)ccc(c2)-c3cccc(N)c3
452	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07618	experimental	2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE	NCC1CCN(CC1)CC(=O)Nc2cccc(c23)c4c(C3=O)c([nH]n4)C5CCCCC5
453	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07622	experimental	1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA	CN1CCN(CC1)NC(=O)Nc2cccc(c23)c4c(C3=O)c([nH]n4)-c5c(C)nc(s5)C
454	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07685	experimental	4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)ncn3)OCC4CCCCC4
455	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07686	experimental	4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)ncn3)NC4CCCCC4
456	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07687	experimental	4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE	N[C@H]1CC[C@@H](CC1)Nc(nc(n23)ncn3)cc2Nc4ccc(cc4)S(=O)(=O)N
457	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07688	experimental	4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)ncn3)OC4CCCCC4
458	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07731	experimental	CAN-508	Nc1n[nH]c(N)c1/N=N/c2ccc(O)cc2
459	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07750	experimental	(2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2nccc(n2)Nc3c(Cl)ccc(Cl)c3
460	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07751	experimental	(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2cc(ncn2)Nc3c(F)cccc3F
461	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07755	experimental	(2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2nccc(n2)Nc3c(Cl)ccc(Cl)c3
462	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07761	experimental	(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2cc(ncn2)Nc3c(F)cccc3F
463	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07790	experimental	N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE	COCCNS(=O)(=O)c1ccc(cc1)Nc2nc(ccn2)-c3cnc(C)n3C(C)C
464	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07791	experimental	4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE	CNS(=O)(=O)c1ccc(cc1)Nc2nc(ccn2)-c3cnc(C)n3C4CC4
465	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07852	experimental	1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID	Cc1nc(C(=O)O)nn1-c2cc(Cl)cc(Cl)c2
466	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07889	experimental	(2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2nccc(n2)-c3c(C)nc(n34)cccc4
467	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07936	experimental	N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine	CN(C)[C@H]1CCN(C1)C(=O)c2ccc(cc2)Nc3nc(c(F)cn3)-c4cnc(C)n4C(C)C
468	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB07982	experimental	2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol	CC(C)n1c(C)ncc1-c2nc(ncc2)Nc3ccc(cc3)N4CCN(CC4)C(=O)CO
469	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08066	experimental	N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE	c1ccccc1C(=O)Nc2c[nH]nc2-c([nH]3)nc(c34)cccc4
470	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08094	investigational	RO-4584820	COc1ccc(F)c(F)c1C(=O)c2cnc(nc2N)NC3CCN(CC3)S(=O)(=O)C
471	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08122	experimental	N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide	c1cccc(c12)NC(=O)C\2=C/Nc3ccc(cc3)S(=O)(=O)NC
472	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08123	experimental	N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide	CNS(=O)(=O)Cc1ccc(cc1)N/N=C2\C(=O)Nc(c23)ccc4c3scn4
473	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08124	experimental	3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one	c1ncoc1-c(c2)ccc(c23)NC(=O)C\3=C/Nc(cc4)cc(c45)CS(=O)(=O)C5
474	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08125	experimental	4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide	c1cccc(c12)NC(=O)C\2=C/Nc3ccc(cc3)S(=O)(=O)Nc4nccs4
475	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08126	experimental	3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole	NC(=N)NS(=O)(=O)c1ccc(cc1)N/C=C2\C(=O)Nc(c23)cccc3
476	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08132	experimental	5-hydroxynaphthalene-1-sulfonamide	c1ccc(S(=O)(=O)N)c(c12)cccc2O
477	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08133	experimental	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	NS(=O)(=O)c1ccc(cc1)NC(=O)c2n[nH]c(c23)cccc3
478	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08134	experimental	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	NS(=O)(=O)c1ccc(cc1)Nc2nc(Cl)cnc2
479	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08135	experimental	N-phenyl-1H-pyrazole-3-carboxamide	n1[nH]ccc1C(=O)Nc2ccccc2
480	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08136	experimental	4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide	CC(=O)Nc1c[nH]nc1C(=O)Nc2ccc(F)cc2
481	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08137	experimental	(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide	Fc1ccc(cc1)NC(=O)c2n[nH]cc2NC(=O)c3ccccc3
482	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08138	experimental	{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide	Fc1ccc(cc1)NC(=O)c2n[nH]cc2NC(=O)c3c(F)cccc3F
483	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08139	experimental	5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile	CC(C)Nc1cc(Cl)nc(n12)c(cn2)C#N
484	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08140	experimental	5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE	N[C@H]1CC[C@@H](CC1)Nc(nc(n23)c(cn3)C#N)cc2NC(C)C
485	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08141	experimental	4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide	C1CCNC[C@H]1NC(=O)c2n[nH]cc2NC(=O)c3c(F)cccc3F
486	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08142	investigational	AT-7519	Clc1cccc(Cl)c1C(=O)Nc2c[nH]nc2C(=O)NC3CCNCC3
487	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08178	experimental	4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	n1ccc(OC)c(c12)c(c[nH]2)-c3nc(N)ncc3
488	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08182	experimental	4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	CCCOc(ccn1)c(c12)c(c[nH]2)-c3nc(N)ncc3
489	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08218	experimental	HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM	O=N(=O)c1cccc(c1)/N=C2/N=CCC(=N2)c3cccc(c3)Cn4cncn4
490	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08219	experimental	4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine	Nc1nc(C)c(s1)C2=N/C(N=CC2)=N\c3ccc(cc3)N4CCOCC4
491	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08233	experimental	6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE	Oc1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
492	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08241	experimental	4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE	NC(=O)c1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
493	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08247	experimental	6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE	CC(C)c([nH]1)nc(c12)c(nc(n2)N)OCC3CCCCC3
494	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08248	experimental	3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE	NS(=O)(=O)c1cccc(c1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
495	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08285	experimental	(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol	n1cc(C(C)C)c(n12)nc(N[C@H](CC)CO)nc2NCc3ccccc3
496	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08309	experimental	3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL	OCCCNCCS(=O)(=O)c1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
497	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08312	experimental	6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE	Nc1nc(N)c(N=O)c(n1)OCC2CCCCC2
498	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08355	experimental	1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid	Cn1nc(C(=O)O)c(c12)CCc3c2nc(nc3)Nc4ccccc4
499	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08441	experimental	6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE	Brc(c12)cnc(n1)Nc3cccc(c3)S(=O)(=O)NCCCN2
500	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08463	experimental	(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol	n1cn(C(C)C)c(c12)nc(N[C@H](CC)CO)nc2NCc3ccc(cc3)-c4ccccn4
501	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08527	experimental	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	O=S(=O)(N)c1ccc(cc1)-n(nc2C(=O)N)c(c23)c4c(cc3)[nH]nc4
502	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08531	experimental	5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	Clc1cccc(c1Cl)-c(nc(n23)ccn3)cc2NCc4ccncc4
503	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08532	experimental	6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine	Fc1ccccc1-c(cn(c23)ccn3)nc2NCc4cccnc4
504	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08533	experimental	3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine	Cc1cnc(n12)c(ncc2)NCc3ccncc3
505	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08534	experimental	5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	Fc1ccccc1-c(nc(n23)ccn3)cc2NCc4ccncc4
506	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08535	experimental	3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	c1ccccc1-c(nc(n23)c(Br)cn3)cc2NCc4cccnc4
507	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08536	experimental	3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine	c1ccccc1-c(cc(n23)c(Br)cn3)cc2NCc4cncnc4
508	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08537	experimental	3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine	c1ccccc1-c(c2)cc(c(n23)ncc3Br)NCc4cncnc4
509	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08538	experimental	N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine	Nc1ncc(cn1)CNc2cc(nc(n23)c(cn3)CC)-c4c(F)cccc4F
510	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08539	experimental	3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	c1ncccc1CNc2cc(nc(n23)c(cn3)C4CC4)-c5ccccc5
511	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08572	experimental	4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE	NC(=O)c1ccc(cc1)Nc2nc(c(N=O)c(n2)N)OCC3CCCCC3
512	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08673	experimental	4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE	CC(C)c1cnc(s1)Nc2ccc(cc2)S(=O)(=O)N
513	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08677	experimental	N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide	CC(C)c1sc(nc1)NC(=O)Cc2cnccc2
514	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08694	experimental	Variolin B	Nc1nccc(n1)-c2c(ccnc3N)n3c(c24)nccc4O
515	sp|P61075|CDC2H_PL	P24941	99.65	1.0	288.0	DB08768	experimental	N(6)-dimethylallyladenine	CC(C)=CCNc1ncnc(c12)[nH]cn2
516	sp|P61075|CDC2H_PL	P29597	107.29	590.0	899.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
517	sp|P61075|CDC2H_PL	P29597	107.29	590.0	899.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
518	sp|P61075|CDC2H_PL	P29597	107.29	590.0	899.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
519	sp|P61075|CDC2H_PL	P29597	70.14	898.0	1100.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
520	sp|P61075|CDC2H_PL	P29597	70.14	898.0	1100.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
521	sp|P61075|CDC2H_PL	P29597	70.14	898.0	1100.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
522	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
523	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
524	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB02950	experimental	Hymenialdisine	O=C1NCC[C@@H]([C@@H](C12)C=C(Br)N=2)C3=NC(N)=NC3=O
525	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB03428	experimental	SU9516	COc(c1)ccc(c12)NC(=O)C\2=C/c3cnc[nH]3
526	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
527	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB04014	experimental	Alsterpaullone	[O-][N+](=O)c(cc1)cc(c12)c3c([nH]2)c4c(NC(=O)C3)cccc4
528	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
529	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB08142	investigational	AT-7519	Clc1cccc(Cl)c1C(=O)Nc2c[nH]nc2C(=O)NC3CCNCC3
530	sp|P61075|CDC2H_PL	P06493	100.0	1.0	289.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
531	sp|P61075|CDC2H_PL	Q00535	99.65	1.0	288.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
532	sp|P61075|CDC2H_PL	Q00535	99.65	1.0	288.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
533	sp|P61075|CDC2H_PL	Q00535	99.65	1.0	288.0	DB02950	experimental	Hymenialdisine	O=C1NCC[C@@H]([C@@H](C12)C=C(Br)N=2)C3=NC(N)=NC3=O
534	sp|P61075|CDC2H_PL	Q00535	99.65	1.0	288.0	DB03428	experimental	SU9516	COc(c1)ccc(c12)NC(=O)C\2=C/c3cnc[nH]3
535	sp|P61075|CDC2H_PL	Q00535	99.65	1.0	288.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
536	sp|P61075|CDC2H_PL	Q00535	99.65	1.0	288.0	DB04014	experimental	Alsterpaullone	[O-][N+](=O)c(cc1)cc(c12)c3c([nH]2)c4c(NC(=O)C3)cccc4
537	sp|P61075|CDC2H_PL	Q00535	99.65	1.0	288.0	DB07364	experimental	6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE	n1ccnc(c12)[nH]c(c2CCCC)-c3ccc(O)cc3
538	sp|P61075|CDC2H_PL	P52333	89.24	521.0	778.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
539	sp|P61075|CDC2H_PL	P52333	89.24	521.0	778.0	DB06321	investigational	R-348	CCC(=O)NS(=O)(=O)c1cc(ccc1C)Nc2ncc(F)c(n2)Nc3ccc(cc3)OCC#C
540	sp|P61075|CDC2H_PL	P52333	89.24	521.0	778.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
541	sp|P61075|CDC2H_PL	P52333	89.24	521.0	778.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
542	sp|P61075|CDC2H_PL	P52333	89.24	521.0	778.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
543	sp|P61075|CDC2H_PL	P52333	89.24	521.0	778.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
544	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB01064	approved; investigational	Isoprenaline	CC(C)NCC(O)c1cc(O)c(O)cc1
545	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
546	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
547	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
548	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
549	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB04338	experimental	SB220025	Nc1nccc(n1)-c2c(-c3ccc(F)cc3)ncn2C4CCNCC4
550	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
551	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB06641	investigational	Perifosine	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC(CC1)CC[N+]1(C)C
552	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB06877	experimental	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	CN(C)C(=O)c1cc(c[nH]1)-c2n[nH]cc2-c3ccccc3
553	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB07010	experimental	N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE	Clc1cc(ccc1)-c2c[nH]nc2-c3c[nH]c(c3)C(=O)NCc4ccccc4
554	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB07264	experimental	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Fc1ccc(cc1Cl)[C@@H](CO)NC(=O)c2cc(c[nH]2)-c3n[nH]cc3-c4cccc(Cl)c4
555	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB07788	experimental	(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE	Oc1cc(OC)cc(c12)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@@H](C)OC2=O
556	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB07794	experimental	5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE	Nc1n[nH]c(c12)nnc(c2)-c(c(n34)cccc4)c(n3)-c5ccccc5
557	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB07905	experimental	(1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione	Oc1cc(OC)cc(c12)[C@@H]3[C@H](O3)C[C@H](O)[C@H](O)C(=O)\C=C\C[C@H](C)OC2=O
558	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB08513	experimental	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Cc1cc(ccc1)Nc2nc(ncc2C(=O)N)Nc3ccc(cc3)CC(=O)O
559	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB08521	experimental	4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine	C[S@@](=O)c1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4
560	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB11120	approved; experimental	Turpentine	 
561	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB13930	investigational	Ulixertinib	Clc1cccc(c1)[C@@H](CO)NC(=O)c2cc(c[nH]2)-c3cc(ncc3Cl)NC(C)C
562	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
563	sp|P61075|CDC2H_PL	P28482	101.04	24.0	315.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
564	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB00605	approved; investigational	Sulindac	c1cc(F)cc(c12)C(CC(=O)O)=C(C)/C2=C/c3ccc(cc3)S(=O)C
565	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
566	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
567	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB04604	experimental	5-iodotubercidin	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cc(I)c(c23)c(N)ncn3
568	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
569	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB08862	approved; investigational	Cholecystokinin	 
570	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB13930	investigational	Ulixertinib	Clc1cccc(c1)[C@@H](CO)NC(=O)c2cc(c[nH]2)-c3cc(ncc3Cl)NC(C)C
571	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
572	sp|P61075|CDC2H_PL	P27361	101.04	41.0	332.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
573	sp|P61075|CDC2H_PL	P53778	99.31	27.0	313.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
574	sp|P61075|CDC2H_PL	P53778	99.31	27.0	313.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
575	sp|P61075|CDC2H_PL	P53778	99.31	27.0	313.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
576	sp|P61075|CDC2H_PL	P53778	99.31	27.0	313.0	DB05157	investigational	KC706	 
577	sp|P61075|CDC2H_PL	P53778	99.31	27.0	313.0	DB05403	investigational	CEP-1347	COOC(=O)[C@H]1C[C@H](O2)n(c3c4n5[C@]12C)c6c(cc(cc6)CSCC)c3c7c(CNC7=O)c4c8c5ccc(c8)CSCC
578	sp|P61075|CDC2H_PL	O15264	98.61	25.0	309.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
579	sp|P61075|CDC2H_PL	O15264	98.61	25.0	309.0	DB05157	investigational	KC706	 
580	sp|P61075|CDC2H_PL	O15264	98.61	25.0	309.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
581	sp|P61075|CDC2H_PL	Q00537	99.31	189.0	475.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
582	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
583	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB01761	experimental	4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine	c1ccccc1[C@H](C)Nc2nc(ccn2)-c3c(-c4cccc(c4)C(F)(F)F)nc(n3C)C5CCNCC5
584	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB01807	experimental	N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea	c1ccccc1-n2nc(C(C)(C)C)cc2NC(=O)Nc3ccc(Cl)cc3
585	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB01948	experimental	1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One	c1cc(F)cc(F)c1-c2cc(C3CCNCC3)cc(c24)N(C(=O)CC4)c5c(Cl)cccc5Cl
586	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB01953	experimental	Inhibitor of P38 Kinase	c1cccc(c12)[nH]cc2CCc3ccncc3
587	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB01988	experimental	6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine	c1ccccc1C[C@H]2CN(CCN2)c3nnc(c(c3)-c4ccncc4)-c(cc5)cc(c56)cccc6
588	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB02195	experimental	3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine	c1cnccc1-c(n(O)c(c23)cccn3)c2-c4ccc(F)cc4
589	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB02277	experimental	1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea	Cn1nc(C(C)(C)C)cc1NC(=O)Nc2ccc(Cl)cc2
590	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB02352	experimental	3-(Benzyloxy)Pyridin-2-Amine	Nc1ncccc1OCc2ccccc2
591	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB02873	experimental	1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One	C1CNCCN1c(c2)cc(-c(c(F)c3)ccc3F)c(c24)CNC(=O)N4c5c(Cl)cccc5Cl
592	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB02984	experimental	4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline	COc(c1)c(OC)cc(c12)ncnc2Nc3cc(SC)ccc3
593	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB03044	investigational	Doramapimod	Cc1ccc(cc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc3ccc(c(c34)cccc4)OCCN5CCOCC5
594	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB03110	experimental	2-Chlorophenol	Oc1ccccc1Cl
595	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB03980	experimental	4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole	Fc1ccc(cc1)-c2c(n(cn2)CC3CC3)-c4ccnc(n4)N
596	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB04338	experimental	SB220025	Nc1nccc(n1)-c2c(-c3ccc(F)cc3)ncn2C4CCNCC4
597	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB04632	experimental	4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE	Oc1ccccc1CNC2CCN(CC2)S(=O)(=O)Nc3cc(ccc3)Oc4ccc(F)cc4
598	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB04797	experimental	Triazolopyridine	CC(C)c1nnc(n12)ccc(c2)-c3c(nco3)-c4ccc(F)cc4
599	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB05157	investigational	KC706	 
600	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB05412	investigational	Talmapimod	CN(C)C(=O)C(=O)c1cn(C)c(c12)cc(Cl)c(c2)C(=O)N3C[C@H](C)N(C[C@H]3C)Cc4ccc(F)cc4
601	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB05470	investigational	VX-702	Fc1cccc(F)c1N(C(=O)N)c2ccc(C(=O)N)c(n2)-c3ccc(F)cc3F
602	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB06518	investigational	R-1487	C1COCCC1Nc(n2)ncc(c23)cc(c(=O)n3C)Oc4ccc(F)cc4F
603	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB06882	experimental	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea	Nc1cc(ccc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc(ccc3)c(c34)cccc4
604	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB06940	experimental	N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide	CCNC(=O)c(c1C)cn(c12)ncnc2Nc3cc(ccc3C)C(=O)NOC
605	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB06991	experimental	N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide	CC[C@@H](C)Nc1ncc(s1)C(=O)Nc2c(C)ccc(c2)C(=O)NC
606	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07138	investigational	Neflamapimod	Fc1cc(F)c(cc1)Sc(cc2)nn(c23)cnc(=O)c3-c4c(Cl)cccc4Cl
607	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07307	experimental	N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide	Cc1ccccc1-c2nncc(c23)cc(cc3)-c4c(C)ccc(c4)C(=O)NC5CC5
608	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07459	experimental	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	n1ccccc1CNC(=O)c2ccc(cc2)Oc3ccccc3
609	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07607	experimental	4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE	C[S@@](=O)c1ccc(cc1)-c2nc(-c3ccncc3)c([nH]2)-c4cc(I)ccc4
610	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07811	experimental	N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide	Cc1nnc(o1)-c2ccc(c(C)c2)-c3cc(ccc3C)C(=O)NC4CC4
611	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07829	experimental	4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE	Fc1ccc(cc1)-c2n[nH]cc2-c3ccncc3
612	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07832	experimental	4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde	Oc1ccc(C)c(c1)Nc2ccnc(c23)cc(cc3)-c4csc(n4)C=O
613	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07833	experimental	N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide	Cc1nnc(o1)-c2ccc(C)c(c2)-c3ccc(cc3)C(=O)Nc4cc(C#N)ccc4
614	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07834	experimental	N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide	Cc1nnc(o1)-c2ccc(C)c(c2)-c3ccc(cc3)C(=O)NCC4CC4
615	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07835	experimental	N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide	C1CC1NC(=O)c2ccc(C)c(c2)-c3ccc(cc3)C(=O)NCC4CC4
616	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07941	investigational	PH-797804	CNC(=O)c1ccc(C)c(c1)-n2c(C)cc(c(Br)c2=O)OCc3c(F)cc(F)cc3
617	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07942	experimental	2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine	Fc1ccc(cc1)-c2c[nH]nc2-c3cc(F)ncc3
618	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB07943	investigational	SD-0006	OCC(=O)N1CCC(CC1)c2n[nH]c(c2-c3ccncn3)-c4ccc(Cl)cc4
619	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08064	experimental	N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA	CC(C)(C)c1n[nH]c(c1)NC(=O)Nc2ccc(Cl)c(c2)COc3cccnc3
620	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08068	experimental	N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-	C1COCCN1[C@@H]2C[C@@H](F)C=C(C2)C(=O)Nc3ccc(Cl)c(c3)COc4cnccc4
621	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08091	experimental	3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE	C1COCCN1c2cc(F)cc(c2)C(=O)Nc(c3)ccc(c34)[nH]cc4CCc5ccncc5
622	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08092	experimental	3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide	C1COCCN1c2cc(F)cc(c2)C(=O)Nc(c3)ccc(c34)[nH]cc4
623	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08093	experimental	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	Nc1ncccc1OCc2cccc(c23)cccc3
624	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08095	experimental	3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA	CC(C)(O)[C@H](C)Nc1nccc(n1)N(c2ccc(OC)cc2)C(=O)Nc3ccccc3Cl
625	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08096	experimental	8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM	Clc1ccccc1Nc(n2CC)nc(c23)cnc(n3)Nc4c(F)cccc4F
626	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08097	experimental	2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE	Fc1ccccc1Nc(n2C(C)C)nc(c23)cnc(n3)Oc4c(F)cccc4F
627	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08242	experimental	N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide	CNC(=O)c1cc(c(C)cc1)Nc(ncn2)c(c23)cnn3-c4ccccc4
628	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08349	experimental	N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide	Fc1ccc(c(F)c1)-n(nc2)c(c23)n(C)c(=O)cc3Nc4c(C)ccc(c4)C(=O)NC5CC5
629	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08351	experimental	N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide	C1CC1NC(=O)c2ccc(C)c(c2)-c(cc3)cc(c34)cnc(n4)NCCN5CCOCC5
630	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08352	experimental	6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine	CC(C)Nc(s1)nc(c12)ccc(c2)-c3c(nco3)-c4ccccc4F
631	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08395	experimental	2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE	CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c3ccnc(n3)Oc4ccccc4O
632	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08423	experimental	[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE	Fc1ccc(cc1)-n2ncc(c2N)C(=O)c3cc(ccc3)OC4CCNCC4
633	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08424	experimental	[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE	OC[C@H](O)COc1cc(ccc1)C(=O)c2c(N)n(nc2)-c3ccc(F)cc3
634	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08521	experimental	4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine	C[S@@](=O)c1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4
635	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08522	experimental	4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE	Fc1ccc(cc1)-c2c(n(cn2)CC3CC3)-c4ccncc4
636	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB08730	experimental	3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE	C1COCCN1c2cc(F)cc(c2)C(=O)Nc(c3)ccc(c34)ccn4CCc5ccncc5
637	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
638	sp|P61075|CDC2H_PL	Q16539	100.0	22.0	310.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
639	sp|P61075|CDC2H_PL	Q9UPZ9	98.61	1.0	285.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
640	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
641	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB15624	experimental	Halicin	Nc1nnc(s1)Sc2ncc(s2)[N+]([O-])=O
642	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB01782	experimental	Pyrazolanthrone	c1cccc(c12)c3c4c([nH]n3)cccc4C2=O
643	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB02388	experimental	Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	C1CNCCC1c2n(CCC)c(c(n2)-c3ccc(Cl)c(Cl)c3)-c4ccnc(n4)NC5CCCCC5
644	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB03084	experimental	Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	CN1CCC(CC1)c2n(CCC)c(c(n2)-c3ccc(Cl)c(Cl)c3)-c4ccnc(n4)NC5CC5
645	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB03623	experimental	9-(4-Hydroxyphenyl)-2,7-Phenanthroline	Oc1ccc(cc1)-c(cn2)cc(c23)c4c(cc3)ccnc4
646	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
647	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB06933	experimental	N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide	CC(C)(C)NS(=O)(=O)c1ccc(cc1)-c(c2)cnc(c23)cccc3Nc4ccccn4
648	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB07010	experimental	N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE	Clc1cc(ccc1)-c2c[nH]nc2-c3c[nH]c(c3)C(=O)NCc4ccccc4
649	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB07217	experimental	N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide	Fc1ccccc1C(=O)Nc(s2)c(C#N)c(c23)CCCC3
650	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08005	experimental	4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide	CCNC(=O)N1CCC(CC1)Nc2nc(c(Cl)cn2)-c3c[nH]c(c34)cccc4
651	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08010	experimental	(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime	c1ccccc1/C=C/c2cccc(c23)N(C(=O)C\3=N/O)Cc(cc(F)c4)c(c45)OCOC5
652	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08011	experimental	(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime	Fc(c1)ccc(c12)N(C(=O)C\2=N\O)Cc3cc(F)cc(c34)COCO4
653	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08015	experimental	(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime	c1ccccc1-c2cccc(c23)N(C(=O)C\3=N/O)Cc4cc(F)cc(c45)COCO5
654	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08021	experimental	5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide	C#CCN1CCN(CC1)c2c(Cl)cccc2NC(=O)c3ccc(Br)o3
655	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08023	experimental	N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine	C1CCCCC1N(C)c2nc(ccn2)-c3cnc(n34)cccc4
656	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08025	experimental	N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE	CO[C@H]1CC[C@@H](CC1)C(=O)Nc2cc(ccn2)-c3cc(ncc3)Nc4ccc(F)cc4
657	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08026	experimental	2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide	CNC(=O)CN1CCC(CC1)Nc2nc(ccn2)-c3cnc(n34)cccc4
658	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB08555	experimental	1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline	COc(c(Cl)c1)cc(c12)CCN=C2c3cccc(Br)c3
659	sp|P61075|CDC2H_PL	P53779	103.82	61.0	360.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
660	sp|P61075|CDC2H_PL	Q00532	100.0	2.0	290.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
661	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
662	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB01782	experimental	Pyrazolanthrone	c1cccc(c12)c3c4c([nH]n3)cccc4C2=O
663	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB07218	experimental	6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE	Cn1nc(C)c(c12)c(=O)c3c(n2O)ccc(Cl)c3
664	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB07268	experimental	2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE	NC(=O)c1ccccc1Nc2nc(ncc2)Nc3cc(O)ccc3
665	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB07272	experimental	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	CCOc1nc(cc(N)c1C#N)NC(=O)Cc2cc(OC)c(Br)cc2OC
666	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB07276	experimental	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	CCOc1nc(ccc1C#N)C(=O)NCc2cc(OC)ccc2OC
667	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB07845	experimental	2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide	CS(=O)(=O)Cc1cc(OC)c(cc1)Nc(nc(c23)[nH]cc3)nc2Nc4cccc(F)c4C(=O)N
668	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
669	sp|P61075|CDC2H_PL	P45983	103.82	23.0	322.0	DB15624	experimental	Halicin	Nc1nnc(s1)Sc2ncc(s2)[N+]([O-])=O
670	sp|P61075|CDC2H_PL	Q00536	98.61	162.0	446.0	DB07766	experimental	(2Z,3E)-2,3'-biindole-2',3(1H,1'H)-dione 3-{O-[(3R)-3,4-dihydroxybutyl]oxime}	c1cccc(c12)/C(C(=O)N2)=C(/Nc(c34)cccc4)\C3=N\OCC[C@@H](O)CO
671	sp|P61075|CDC2H_PL	Q00536	98.61	162.0	446.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
672	sp|P61075|CDC2H_PL	P45984	103.82	23.0	322.0	DB07020	experimental	N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide	c1ccoc1C(=O)Nc2cc(ccc2)-c3n[nH]c(c34)ccc(c4)-c5n[nH]cn5
673	sp|P61075|CDC2H_PL	P45984	103.82	23.0	322.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
674	sp|P61075|CDC2H_PL	P45984	103.82	23.0	322.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
675	sp|P61075|CDC2H_PL	P45984	103.82	23.0	322.0	DB15624	experimental	Halicin	Nc1nnc(s1)Sc2ncc(s2)[N+]([O-])=O
676	sp|P61075|CDC2H_PL	Q15759	99.65	23.0	310.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
677	sp|P61075|CDC2H_PL	Q15759	99.65	23.0	310.0	DB05157	investigational	KC706	 
678	sp|P61075|CDC2H_PL	Q15759	99.65	23.0	310.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
679	sp|P61075|CDC2H_PL	Q92772	100.0	1.0	289.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
680	sp|P61075|CDC2H_PL	Q13164	102.78	53.0	349.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
681	sp|P61075|CDC2H_PL	Q13164	102.78	53.0	349.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
682	sp|P61075|CDC2H_PL	Q13164	102.78	53.0	349.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
683	sp|P61075|CDC2H_PL	P50613	99.65	10.0	297.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
684	sp|P61075|CDC2H_PL	P50613	99.65	10.0	297.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
685	sp|P61075|CDC2H_PL	P50613	99.65	10.0	297.0	DB05969	investigational	SNS-032	CC(C)(C)c1cnc(o1)CSc2cnc(s2)NC(=O)C3CCNCC3
686	sp|P61075|CDC2H_PL	P50613	99.65	10.0	297.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
687	sp|P61075|CDC2H_PL	Q8TD08	102.43	11.0	306.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
688	sp|P61075|CDC2H_PL	Q8TD08	102.43	11.0	306.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
689	sp|P61075|CDC2H_PL	Q8TD08	102.43	11.0	306.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
690	sp|P61075|CDC2H_PL	Q00534	101.04	11.0	302.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
691	sp|P61075|CDC2H_PL	Q00534	101.04	11.0	302.0	DB07379	experimental	(2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol	n1cn(C(C)C)c(c12)nc(N[C@H](CO)C(C)C)nc2Nc3cc(Cl)cc(N)c3
692	sp|P61075|CDC2H_PL	Q00534	101.04	11.0	302.0	DB07795	experimental	Fisetin	c1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
693	sp|P61075|CDC2H_PL	Q00534	101.04	11.0	302.0	DB09073	approved; investigational	Palbociclib	C1CCCC1n2c(=O)c(C(=O)C)c(C)c(c23)cnc(n3)Nc4ncc(cc4)N5CCNCC5
694	sp|P61075|CDC2H_PL	Q00534	101.04	11.0	302.0	DB11730	approved; investigational	Ribociclib	C1CCCC1n2c(C(=O)N(C)C)cc(c23)cnc(n3)Nc4ccc(cn4)N5CCNCC5
695	sp|P61075|CDC2H_PL	Q00534	101.04	11.0	302.0	DB12001	approved; investigational	Abemaciclib	CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(F)c(n3)-c(c4)cc(F)c(c45)nc(C)n5C(C)C
696	sp|P61075|CDC2H_PL	P50750	103.47	17.0	315.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
697	sp|P61075|CDC2H_PL	P50750	103.47	17.0	315.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
698	sp|P61075|CDC2H_PL	Q96Q40	99.65	102.0	389.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
699	sp|P61075|CDC2H_PL	Q96Q40	99.65	102.0	389.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
700	sp|P61075|CDC2H_PL	Q96Q40	99.65	102.0	389.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
701	sp|P61075|CDC2H_PL	P11802	102.08	4.0	298.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
702	sp|P61075|CDC2H_PL	P11802	102.08	4.0	298.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
703	sp|P61075|CDC2H_PL	P11802	102.08	4.0	298.0	DB09073	approved; investigational	Palbociclib	C1CCCC1n2c(=O)c(C(=O)C)c(C)c(c23)cnc(n3)Nc4ncc(cc4)N5CCNCC5
704	sp|P61075|CDC2H_PL	P11802	102.08	4.0	298.0	DB11730	approved; investigational	Ribociclib	C1CCCC1n2c(C(=O)N(C)C)cc(c23)cnc(n3)Nc4ccc(cn4)N5CCNCC5
705	sp|P61075|CDC2H_PL	P11802	102.08	4.0	298.0	DB12001	approved; investigational	Abemaciclib	CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(F)c(n3)-c(c4)cc(F)c(c45)nc(C)n5C(C)C
706	sp|P61075|CDC2H_PL	P11802	102.08	4.0	298.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
707	sp|P61075|CDC2H_PL	P62344	82.99	54.0	293.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
708	sp|P61075|CDC2H_PL	Q96L34	75.0	58.0	274.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
709	sp|P61075|CDC2H_PL	Q13557	79.51	12.0	241.0	DB07853	experimental	2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile	N#CCC1C=CC(C=C1)=Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
710	sp|P61075|CDC2H_PL	Q13557	79.51	12.0	241.0	DB08039	experimental	(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE	CN(C)S(=O)(=O)c(c1)ccc(c12)NC(=O)C\2=C/c([nH]3)cc(c34)CCCC4
711	sp|P61075|CDC2H_PL	Q13557	79.51	12.0	241.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
712	sp|P61075|CDC2H_PL	Q9UQM7	79.51	11.0	240.0	DB04119	experimental	Hexatantalum Dodecabromide	[Br]
713	sp|P61075|CDC2H_PL	Q9UQM7	79.51	11.0	240.0	DB04447	experimental	1,4-Dithiothreitol	SC[C@H](O)[C@@H](O)CS
714	sp|P61075|CDC2H_PL	Q9UQM7	79.51	11.0	240.0	DB07766	experimental	(2Z,3E)-2,3'-biindole-2',3(1H,1'H)-dione 3-{O-[(3R)-3,4-dihydroxybutyl]oxime}	c1cccc(c12)/C(C(=O)N2)=C(/Nc(c34)cccc4)\C3=N\OCC[C@@H](O)CO
715	sp|P61075|CDC2H_PL	Q9UQM7	79.51	11.0	240.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
716	sp|P61075|CDC2H_PL	P27448	75.35	55.0	272.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
717	sp|P61075|CDC2H_PL	Q8IU85	77.43	23.0	246.0	DB08454	experimental	N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE	Cc1cc(n[nH]1)Nc(c(c23)cccc3)nc(n2)-c4ccccc4
718	sp|P61075|CDC2H_PL	Q8IU85	77.43	23.0	246.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
719	sp|P61075|CDC2H_PL	Q7KZI7	75.0	52.0	268.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
720	sp|P61075|CDC2H_PL	Q14012	77.43	20.0	243.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
721	sp|P61075|CDC2H_PL	Q16659	103.47	19.0	317.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
722	sp|P61075|CDC2H_PL	Q16659	103.47	19.0	317.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
723	sp|P61075|CDC2H_PL	Q9P0L2	75.0	59.0	275.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
724	sp|P61075|CDC2H_PL	Q9BYT3	80.21	116.0	347.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
725	sp|P61075|CDC2H_PL	Q13555	79.51	12.0	241.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
726	sp|P61075|CDC2H_PL	Q13555	79.51	12.0	241.0	DB08699	experimental	1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	Cc1cc(ccc1)Cc2nn(C(C)(C)C)c(c23)ncnc3N
727	sp|P61075|CDC2H_PL	Q13555	79.51	12.0	241.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
728	sp|P61075|CDC2H_PL	Q9NRH2	76.39	16.0	236.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
729	sp|P61075|CDC2H_PL	Q9NRP7	73.61	1.0	213.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
730	sp|P61075|CDC2H_PL	Q96NX5	77.43	21.0	244.0	DB08009	experimental	SU-11652	CCN(CC)CCNC(=O)c1c(C)[nH]c(c1C)/C=C2\C(=O)Nc(c23)ccc(Cl)c3
731	sp|P61075|CDC2H_PL	Q96NX5	77.43	21.0	244.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
732	sp|P61075|CDC2H_PL	Q13131	74.65	26.0	241.0	DB00131	approved; investigational; nutraceutical	Adenosine phosphate	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)O
733	sp|P61075|CDC2H_PL	Q13131	74.65	26.0	241.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
734	sp|P61075|CDC2H_PL	Q13131	74.65	26.0	241.0	DB00914	approved; investigational; withdrawn	Phenformin	NC(=N)NC(=N)NCCc1ccccc1
735	sp|P61075|CDC2H_PL	Q13131	74.65	26.0	241.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
737	sp|P61075|CDC2H_PL	Q13131	74.65	26.0	241.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
739	sp|P61075|CDC2H_PL	Q8IBS5	79.17	68.0	296.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
740	sp|P61075|CDC2H_PL	P31152	102.08	19.0	313.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
741	sp|P61075|CDC2H_PL	P31152	102.08	19.0	313.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
742	sp|P61075|CDC2H_PL	P31152	102.08	19.0	313.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
743	sp|P61075|CDC2H_PL	O43293	79.86	11.0	241.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
744	sp|P61075|CDC2H_PL	O43293	79.86	11.0	241.0	DB07125	experimental	4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid	CC[C@H](CO)Nc(cc1)nn(c12)c(cn2)-c3ccc(cc3)C(=O)O
745	sp|P61075|CDC2H_PL	O43293	79.86	11.0	241.0	DB07242	experimental	(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile	C1CN(C)CCC12[C@H](C#N)c3c(C(=O)N2)n(C)c4c3ccc(Cl)c4Cl
746	sp|P61075|CDC2H_PL	O43293	79.86	11.0	241.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
747	sp|P61075|CDC2H_PL	Q9H093	76.74	51.0	272.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
748	sp|P61075|CDC2H_PL	P57059	73.26	27.0	238.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
749	sp|P61075|CDC2H_PL	P57059	73.26	27.0	238.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
750	sp|P61075|CDC2H_PL	Q13554	79.51	12.0	241.0	DB07168	experimental	[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile	N#CCc1ccc(cc1)Nc2nc(NC)cc(n2)Nc3n[nH]c(c3)C4CC4
751	sp|P61075|CDC2H_PL	Q13554	79.51	12.0	241.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
752	sp|P61075|CDC2H_PL	Q13153	74.31	268.0	482.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
753	sp|P61075|CDC2H_PL	Q13177	74.31	247.0	461.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
754	sp|P61075|CDC2H_PL	O60285	76.04	53.0	272.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
755	sp|P61075|CDC2H_PL	Q9P289	73.26	24.0	235.0	DB07853	experimental	2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile	N#CCC1C=CC(C=C1)=Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
756	sp|P61075|CDC2H_PL	Q9P289	73.26	24.0	235.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
757	sp|P61075|CDC2H_PL	Q9Y6E0	73.26	36.0	247.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
758	sp|P61075|CDC2H_PL	O75914	73.26	281.0	492.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
759	sp|P61075|CDC2H_PL	O00444	75.35	9.0	226.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
760	sp|P61075|CDC2H_PL	Q13188	71.88	26.0	233.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
761	sp|P61075|CDC2H_PL	Q9C098	74.31	354.0	568.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
762	sp|P61075|CDC2H_PL	P54646	73.96	15.0	228.0	DB00131	approved; investigational; nutraceutical	Adenosine phosphate	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)O
763	sp|P61075|CDC2H_PL	P54646	73.96	15.0	228.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
764	sp|P61075|CDC2H_PL	P54646	73.96	15.0	228.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
765	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
766	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB05169	investigational	AT9283	 
767	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB05198	investigational	CYC116	 
768	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB05220	investigational	Alisertib	OC(=O)c1ccc(cc1OC)Nc(n2)ncc(c23)CN=C(c4c3ccc(Cl)c4)c5c(OC)cccc5F
769	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB06134	investigational	SNS-314	Clc1cccc(c1)NC(=O)Nc2ncc(s2)CCNc(ncn3)c(c34)scc4
770	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB06347	investigational	Cenisertib	[C@@H]12C[C@@H](C=C1)[C@H](C(=O)N)[C@@H]2Nc3c(F)cnc(n3)Nc4ccc(c(C)c4)N5CCN(C)CC5
771	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
772	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB07186	experimental	4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE	CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3n[nH]c(c34)cn(c4)C(=O)Cc5cccs5
773	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB07266	experimental	AKI-001	CCN1C(=O)C(C)(C)c(c12)cc3c(c2)c4c([nH]3)c5c(c([nH]n5)C)CCC4
774	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB07360	experimental	1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea	FC(F)(F)c1cccc(c1)NC(=O)Nc2ncc(s2)CCNc3ncnc(c34)ccs4
775	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB07362	experimental	1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea	Cn1ncc(c12)ncnc2NCCc3cnc(s3)NC(=O)Nc4cccc(c4)C(F)(F)F
776	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB07545	experimental	N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE	FC(F)(F)c1cccc(c1)Nc2nc(ncc2)Nc3cc(ccc3)NC(=O)C4CC4
777	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB07801	experimental	N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide	CCCCNC(=O)c1cccc(c1)NC(=O)CCCCCNc(ncn2)c(c23)nc[nH]3
778	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB08065	experimental	2-(1H-pyrazol-3-yl)-1H-benzimidazole	c1c[nH]nc1-c([nH]2)nc(c23)cccc3
779	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB08066	experimental	N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE	c1ccccc1C(=O)Nc2c[nH]nc2-c([nH]3)nc(c34)cccc4
780	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
781	sp|P61075|CDC2H_PL	O14965	75.69	130.0	348.0	DB13061	investigational	MLN8054	OC(=O)c1ccc(cc1)Nc(n2)ncc(c23)CN=C(c4c3ccc(Cl)c4)c5c(F)cccc5F
782	sp|P61075|CDC2H_PL	Q9H0K1	70.49	20.0	223.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
783	sp|P61075|CDC2H_PL	P31751	75.0	149.0	365.0	DB07812	experimental	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide	c1ccccc1[C@@H](CN)NC(=O)c2ccc(s2)-c(ccn3)c(c34)cc[nH]4
784	sp|P61075|CDC2H_PL	P31751	75.0	149.0	365.0	DB07859	experimental	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c4c[nH]nc4
785	sp|P61075|CDC2H_PL	P31751	75.0	149.0	365.0	DB07947	experimental	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	Clc1ccc(cc1)COCCNCCNS(=O)(=O)c2cccc(c23)cncc3
786	sp|P61075|CDC2H_PL	P31751	75.0	149.0	365.0	DB08073	experimental	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)-c(c4)ccc(c45)[nH]nc5C
787	sp|P61075|CDC2H_PL	Q14680	76.74	8.0	229.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
788	sp|P61075|CDC2H_PL	Q9UIK4	79.86	23.0	253.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
789	sp|P61075|CDC2H_PL	Q9UQB9	74.65	41.0	256.0	DB06134	investigational	SNS-314	Clc1cccc(c1)NC(=O)Nc2ncc(s2)CCNc(ncn3)c(c34)scc4
790	sp|P61075|CDC2H_PL	Q9UQB9	74.65	41.0	256.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
791	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
792	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
793	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB01645	investigational	Genistein	Oc1ccc(cc1)-c(c2=O)coc(c23)cc(O)cc3O
794	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB01863	experimental	Inositol 1,3,4,5-Tetrakisphosphate	OP(=O)(O)O[C@@H]1[C@H](O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@@H]([C@H]1O)OP(=O)(O)O
795	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB02709	investigational	Resveratrol	Oc1ccc(cc1)/C=C/c2cc(O)cc(O)c2
796	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB05971	investigational	Archexin	 
797	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
798	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB06641	investigational	Perifosine	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC(CC1)CC[N+]1(C)C
799	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB07584	experimental	N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	Cc1nnc([nH]1)-c2ccccc2Nc3ncnc(c34)[nH]cc4
800	sp|P61075|CDC2H_PL	P31749	75.35	147.0	364.0	DB07585	experimental	5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	Clc1c[nH]c(c12)ncnc2N(C3)CCc(c34)[nH]cn4
801	sp|P61075|CDC2H_PL	O95747	78.82	15.0	242.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
802	sp|P61075|CDC2H_PL	P53355	79.51	12.0	241.0	DB04069	experimental	5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine	Nc(c1)nnc(c12)c3c(CC2)cccc3
803	sp|P61075|CDC2H_PL	P53355	79.51	12.0	241.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
804	sp|P61075|CDC2H_PL	P53355	79.51	12.0	241.0	DB07444	experimental	6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE	c1cc(C)cc(c12)c3c(n2CCCN)cc(C)c4c3C(=O)NC4=O
805	sp|P61075|CDC2H_PL	P53355	79.51	12.0	241.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
806	sp|P61075|CDC2H_PL	Q16816	82.99	18.0	257.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
807	sp|P61075|CDC2H_PL	Q32MK0	74.65	518.0	733.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
808	sp|P61075|CDC2H_PL	Q86YV6	76.74	108.0	329.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
809	sp|P61075|CDC2H_PL	Q9H4B4	76.04	61.0	280.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
810	sp|P61075|CDC2H_PL	O96017	76.39	218.0	438.0	DB05149	investigational	XL844	 
811	sp|P61075|CDC2H_PL	O96017	76.39	218.0	438.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
812	sp|P61075|CDC2H_PL	O96017	76.39	218.0	438.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
813	sp|P61075|CDC2H_PL	Q9NQU5	70.49	412.0	615.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
814	sp|P61075|CDC2H_PL	Q9Y2K2	73.26	66.0	277.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
815	sp|P61075|CDC2H_PL	O15075	75.0	388.0	604.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
816	sp|P61075|CDC2H_PL	P49840	99.31	119.0	405.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
817	sp|P61075|CDC2H_PL	Q96GD4	75.0	74.0	290.0	DB04703	approved; investigational	Hesperidin	COc1ccc(cc1O)[C@@H](O2)CC(=O)c(c23)c(O)cc(c3)O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O
818	sp|P61075|CDC2H_PL	Q96GD4	75.0	74.0	290.0	DB05169	investigational	AT9283	 
819	sp|P61075|CDC2H_PL	Q96GD4	75.0	74.0	290.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
820	sp|P61075|CDC2H_PL	Q96GD4	75.0	74.0	290.0	DB07340	experimental	Reversine	C1CCCCC1Nc2nc(nc(c23)[nH]cn3)Nc4ccc(cc4)N5CCOCC5
821	sp|P61075|CDC2H_PL	Q96GD4	75.0	74.0	290.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
822	sp|P61075|CDC2H_PL	Q9P286	71.18	454.0	659.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
823	sp|P61075|CDC2H_PL	Q8IVH8	76.39	14.0	234.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
824	sp|P61075|CDC2H_PL	Q8IYT8	77.43	8.0	231.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
825	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB01356	experimental	Lithium cation	[Li+]
826	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB01772	experimental	3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione	OC[C@@H](O)CNc1cccc(c1)C2=C(C(=O)NC2=O)c3cn(C)c(c34)ccc(F)c4
827	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB01793	experimental	SB-409513	OC(=O)c1cc(ccc1Cl)NC2=C(C(=O)NC2=O)c3cc(Cl)ccc3
828	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB01950	experimental	AR-AO-14418	COc1ccc(cc1)CNC(=O)Nc2ncc(s2)[N+]([O-])=O
829	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
830	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
831	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB03444	experimental	6-bromoindirubin-3'-oxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cc(Br)cc4
832	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB04014	experimental	Alsterpaullone	[O-][N+](=O)c(cc1)cc(c12)c3c([nH]2)c4c(NC(=O)C3)cccc4
833	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
834	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07014	experimental	2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole	COc1c(F)cc(cc1)CSc2nnc(o2)-c(cc3)cc(c34)OCO4
835	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07058	experimental	5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione	COc1ccc(cc1)-n2cnc(c23)ccc(c3)-c4n[nH]c(=S)o4
836	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07149	experimental	(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one	FCC[C@H]1CNC(=O)c(c12)cc([nH]2)-c3nc(N)ncc3
837	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07584	experimental	N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	Cc1nnc([nH]1)-c2ccccc2Nc3ncnc(c34)[nH]cc4
838	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07585	experimental	5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	Clc1c[nH]c(c12)ncnc2N(C3)CCc(c34)[nH]cn4
839	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07676	experimental	3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one	OC[C@@H](O)CCONc1c([nH]c(c12)cccc2)C(C(=O)N=3)=c(c34)cccc4
840	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07812	experimental	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide	c1ccccc1[C@@H](CN)NC(=O)c2ccc(s2)-c(ccn3)c(c34)cc[nH]4
841	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07859	experimental	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c4c[nH]nc4
842	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB07947	experimental	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	Clc1ccc(cc1)COCCNCCNS(=O)(=O)c2cccc(c23)cncc3
843	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB08073	experimental	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)-c(c4)ccc(c45)[nH]nc5C
844	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
845	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB12129	investigational; withdrawn	Tideglusib	c1cccc(c12)c(ccc2)-n3sc(=O)n(c3=O)Cc4ccccc4
846	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB14507	approved	Lithium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
847	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB14508	experimental	Lithium succinate	[O-]C(=O)CCC([O-])=O
848	sp|P61075|CDC2H_PL	P49841	99.65	55.0	342.0	DB14509	approved	Lithium carbonate	[O-]C([O-])=O
849	sp|P61075|CDC2H_PL	Q6PHR2	74.31	12.0	226.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
850	sp|P61075|CDC2H_PL	O75385	77.08	15.0	237.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
851	sp|P61075|CDC2H_PL	P51957	78.12	4.0	229.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
852	sp|P61075|CDC2H_PL	O96013	70.83	326.0	530.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
853	sp|P61075|CDC2H_PL	P53350	76.04	52.0	271.0	DB06897	experimental	3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol	c1ccccc1[C@H](C)Nc(nc2)cc(c23)c(no3)-c4cc(Cl)cc(c4)CCCO
854	sp|P61075|CDC2H_PL	P53350	76.04	52.0	271.0	DB06963	experimental	3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide	c1ccccc1[C@H](C)Nc(nc2)cc(c23)n(nc3C)-c4cccc(c4)CCC(=O)N
855	sp|P61075|CDC2H_PL	P53350	76.04	52.0	271.0	DB07186	experimental	4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE	CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3n[nH]c(c34)cn(c4)C(=O)Cc5cccs5
856	sp|P61075|CDC2H_PL	P53350	76.04	52.0	271.0	DB07789	experimental	1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea	Cc1cc(c(o1)C(F)(F)F)NC(=O)Nc2ncc(s2)CCNc3cc(ncn3)Nc4ncn[nH]4
857	sp|P61075|CDC2H_PL	P53350	76.04	52.0	271.0	DB08059	experimental	Wortmannin	O=C1CC[C@H]([C@@]12C)C3=C([C@@H](C2)OC(=O)C)[C@]4(C)c5c(C3=O)occ5C(=O)O[C@@H]4COC
858	sp|P61075|CDC2H_PL	P53350	76.04	52.0	271.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
859	sp|P61075|CDC2H_PL	O00141	75.35	97.0	314.0	DB03247	approved; investigational	Flavin mononucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
860	sp|P61075|CDC2H_PL	O00141	75.35	97.0	314.0	DB07837	experimental	[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid	OC(=O)Cc1ccc(cc1)-c2c[nH]c(c23)ncc(c3)-c(c4)ccc(c45)cccc5
861	sp|P61075|CDC2H_PL	O00141	75.35	97.0	314.0	DB08191	experimental	4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid	OC(=O)c1ccc(cc1)-c2c[nH]c(c23)ncc(c3)-c4ccccc4
862	sp|P61075|CDC2H_PL	O14936	81.25	11.0	245.0	DB01942	experimental; investigational	Formic acid	OC=O
863	sp|P61075|CDC2H_PL	O14936	81.25	11.0	245.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
864	sp|P61075|CDC2H_PL	Q9UEW8	78.82	61.0	288.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
865	sp|P61075|CDC2H_PL	Q9NYY3	76.74	80.0	301.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
866	sp|P61075|CDC2H_PL	Q8IIR9	100.35	41.0	330.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
867	sp|P61075|CDC2H_PL	Q8N568	75.35	391.0	608.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
868	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB00144	approved; investigational; nutraceutical	Phosphatidyl serine	CCCC(=O)O[C@H](COC(=O)CC)COP(=O)(O)OC[C@H](N)C(=O)O
869	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB00163	approved; nutraceutical; vet_approved	Vitamin E	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(O)c(C)c2C
870	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB05013	approved	Ingenol mebutate	C[C@@H]1C[C@@H](C2(C)C)[C@@H]2[C@H](C3=O)C=C(CO)[C@@H](O)[C@]([C@@]134)(O)[C@H](C(=C4)C)OC(=O)/C(C)=C\C
871	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB06451	investigational	Aprinocarsen	n1cnc(N)c(c12)ncn2C3CC(O)C(O3)COP(=S)(O)OC4CC(n5ccc(=N)nc5O)OC4COP(=S)(O)OC6CC(n7cc(C)c(O)nc7=O)OC6COP(=S)(O)OC8CC(n9cc(C)c(O)nc9=O)OC8COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(N)ncn3)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2ccc(=N)nc2O)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2ccc(=N)nc2O)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2ccc(=N)nc2O)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(OC1CO)n1cnc(c12)c(O)nc([nH]2)=N
872	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB06595	approved; investigational	Midostaurin	c1ccccc1C(=O)N(C)[C@@H]([C@H]2OC)C[C@@H](O3)n(c4c5n6[C@]23C)c7c(cccc7)c4c8c(CNC8=O)c5c9c6cccc9
873	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB06641	investigational	Perifosine	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC(CC1)CC[N+]1(C)C
874	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
875	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB11752	investigational	Bryostatin 1	 
876	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB14001	approved; nutraceutical; vet_approved	alpha-Tocopherol succinate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)CCC(=O)O
877	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB14002	approved; nutraceutical; vet_approved	D-alpha-Tocopherol acetate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)C
878	sp|P61075|CDC2H_PL	P17252	80.56	337.0	569.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
879	sp|P61075|CDC2H_PL	P51956	77.08	1.0	223.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
880	sp|P61075|CDC2H_PL	Q9UEE5	78.12	64.0	289.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
881	sp|P61075|CDC2H_PL	Q15139	71.88	587.0	794.0	DB11752	investigational	Bryostatin 1	 
882	sp|P61075|CDC2H_PL	Q15139	71.88	587.0	794.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
883	sp|P61075|CDC2H_PL	Q15746	77.43	1464.0	1687.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
884	sp|P61075|CDC2H_PL	P49759	110.42	160.0	478.0	DB04367	experimental	Debromohymenialdisine	NC1=NC(=O)/C(N1)=C2\CCNC(=O)c(c23)[nH]cc3
885	sp|P61075|CDC2H_PL	P49759	110.42	160.0	478.0	DB06376	investigational	CHGN111	 
886	sp|P61075|CDC2H_PL	P49759	110.42	160.0	478.0	DB08691	experimental	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate	CCOC(=O)c(n1C)c(/C(C#N)=C\N)c(c12)ccc(Cl)c2Cl
887	sp|P61075|CDC2H_PL	P49759	110.42	160.0	478.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
888	sp|P61075|CDC2H_PL	Q16566	70.83	46.0	250.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
889	sp|P61075|CDC2H_PL	Q16566	70.83	46.0	250.0	DB07676	experimental	3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one	OC[C@@H](O)CCONc1c([nH]c(c12)cccc2)C(C(=O)N=3)=c(c34)cccc4
890	sp|P61075|CDC2H_PL	Q04759	75.0	377.0	593.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
891	sp|P61075|CDC2H_PL	Q04759	75.0	377.0	593.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
892	sp|P61075|CDC2H_PL	Q04759	75.0	377.0	593.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
893	sp|P61075|CDC2H_PL	Q04759	75.0	377.0	593.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
894	sp|P61075|CDC2H_PL	Q04759	75.0	377.0	593.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
895	sp|P61075|CDC2H_PL	P42685	81.6	233.0	468.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
896	sp|P61075|CDC2H_PL	P42685	81.6	233.0	468.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
897	sp|P61075|CDC2H_PL	P42685	81.6	233.0	468.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
898	sp|P61075|CDC2H_PL	P42685	81.6	233.0	468.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
899	sp|P61075|CDC2H_PL	P22694	75.35	41.0	258.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
900	sp|P61075|CDC2H_PL	P22694	75.35	41.0	258.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
901	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB01919	experimental	Pentanal	CCCCC=O
902	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB01940	experimental	Balanol Analog 2	Oc1ccc(cc1)C(=O)N[C@@H]2CNCCC[C@H]2OC(=O)c3ccc(cc3)C(=O)c4ccccc4O
903	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB02155	experimental	3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate	CC[C@H](C)c1c(O)ccc(c1)C(=O)N[C@@H]2CNCCC[C@H]2OC(=O)c3ccc(cc3)C(=O)c4c(O)ccc(c4)OC
904	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
905	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB02611	experimental	Balanol Analog 1	Oc1ccc(cc1)C(=O)N[C@@H]2CNCCC[C@H]2OC(=O)c3ccc(O)cc3
906	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB03374	experimental	3,5-Diiodotyrosine	OC(=O)[C@@H](N)Cc1cc(I)c(O)c(I)c1
907	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB04098	experimental	Balanol	OC(=O)c1cccc(O)c1C(=O)c2c(O)cc(cc2O)C(=O)O[C@@H]3CCCNC[C@@H]3NC(=O)c4ccc(O)cc4
908	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
909	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB04530	experimental	S,S-(2-Hydroxyethyl)Thiocysteine	OC(=O)[C@@H](N)CSSCCO
910	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB04707	experimental	Hydroxyfasudil	O=c1[nH]ccc(c12)c(ccc2)S(=O)(=O)N3CCCNCC3
911	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB06959	experimental	(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine	c1cccc(c12)N=CC2C[C@H](N)COc3cncc(c3)-c(cc4)cc(c45)ccnc5
912	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB06977	experimental	(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine	C1=CC=CC(C12)=C(C=N2)C[C@H](N)COc3cncc(c3)-c(cc4)cc(c45)c[nH]n5
913	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07107	experimental	(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)/C=C/c4ccncc4
914	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07124	experimental	(2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	C=1CC=CC(C12)=C(C=N2)C[C@H](N)COc3cncc(c3)C(C=4)=NCC(C45)=NN=C5
915	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07204	experimental	(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc(cnc3)c(c34)ccc(n4)-c5ccncc5
916	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07235	experimental	N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE	Clc1ccc(c(Cl)c1)C[C@@H](CN)NC(=O)c2ccc(s2)-c3ccnc(n3)NC
917	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07458	experimental	3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione	c1cccc(c12)c(c[nH]2)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)CC[C@@H]6CCCN6C
918	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07583	experimental	(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE	c1cncc(c12)cccc2S(=O)(=O)NC[C@@H]3C[C@H](CN3)OCc4ccc(Cl)cc4
919	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07854	experimental	N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE	CNCc1ccc(cc1)-c2ncnc(c23)[nH]cn3
920	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07855	experimental	(S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE	c1ccccc1[C@H](N)c2ccc(cc2)-c(ncn3)c(c34)nc[nH]4
921	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07856	experimental	6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c(ncn4)c(c45)nc[nH]5
922	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07857	experimental	(2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine	Clc1ccc(cc1)[C@H](CN)c2ccc(cc2)-c3c[nH]nc3
923	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07858	experimental	(2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine	Clc1ccc(cc1)[C@@H](CN)c2ccc(cc2)-c3c[nH]nc3
924	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07859	experimental	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c4c[nH]nc4
925	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07860	experimental	(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE	Clc1ccc(cc1)[C@H](CN)c2ccccc2
926	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07876	experimental	(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(C)cnc3
927	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07947	experimental	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	Clc1ccc(cc1)COCCNCCNS(=O)(=O)c2cccc(c23)cncc3
928	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07995	experimental	H-89	Brc1ccc(cc1)/C=C/CNCCNS(=O)(=O)c2cccc(c23)cncc3
929	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07996	experimental	5-(2-methylpiperazine-1-sulfonyl)isoquinoline	CC1CNCCN1S(=O)(=O)c(ccc2)c(c23)ccnc3
930	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB07997	experimental	N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE	CNCCNS(=O)(=O)c1cccc(c12)cncc2
931	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08070	experimental	2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE	Cc1n[nH]cc1-c2ccc(cc2)CCN
932	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08073	experimental	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)-c(c4)ccc(c45)[nH]nc5C
933	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08113	experimental	3-pyridin-4-yl-1H-indazole	c1cccc(c12)c(n[nH]2)-c3ccncc3
934	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08114	experimental	5-benzyl-1,3-thiazol-2-amine	Nc1ncc(s1)Cc2ccccc2
935	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08148	experimental	1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	Clc1ccc(cc1)C2(CN)CCN(CC2)c(ncn3)c(c34)cc[nH]4
936	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08149	experimental	1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	Clc1ccc(cc1)CC2(CN)CCN(CC2)c(ncn3)c(c34)cc[nH]4
937	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08150	experimental	4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium	Clc1ccc(cc1)CC2([NH3+])CCN(CC2)c(ncn3)c(c34)cc[nH]4
938	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08162	investigational	Fasudil	c1cncc(c12)cccc2S(=O)(=O)N3CCCNCC3
939	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
940	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08568	experimental	A-674563	Cc1n[nH]c(c12)ccc(c2)-c3cc(cnc3)OC[C@@H](N)Cc4ccccc4
941	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08569	experimental	3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE	Brc1ccc(cc1)C[C@H](N)COc2cncc(c2)-c(cc3)cc(c34)c(C)n[nH]4
942	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08756	experimental	Y-27632	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc2ccncc2
943	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
944	sp|P61075|CDC2H_PL	P17612	75.69	41.0	259.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
945	sp|P61075|CDC2H_PL	Q9H1R3	76.04	288.0	507.0	DB04825	approved; withdrawn	Prenylamine	c1ccccc1CC(C)NCCC(c2ccccc2)c3ccccc3
946	sp|P61075|CDC2H_PL	Q9H1R3	76.04	288.0	507.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
947	sp|P61075|CDC2H_PL	P54762	88.54	621.0	876.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
948	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
949	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB01765	experimental	(5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid	c1cccc(c12)n3c(c2CC(=O)O)[nH]c(=O)c4c3cccc4
950	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB02170	experimental	1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One	Oc1ccc([N+]([O-])=O)c(c12)oc3c(c2=O)c(O)ccc3
951	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB02709	investigational	Resveratrol	Oc1ccc(cc1)/C=C/c2cc(O)cc(O)c2
952	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB03035	experimental	1,8-Di-Hydroxy-4-Nitro-Anthraquinone	Oc1cccc(c12)C(=O)c3c(C2=O)c(O)ccc3[N+]([O-])=O
953	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB03127	experimental	Benzamidine	NC(=[NH2+])c1ccccc1
954	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB03924	experimental	5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone	Nc1ccc(N)c(c12)C(=O)c3c(C2=O)c(O)ccc3O
955	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
956	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
957	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB04462	experimental	Tetrabromo-2-Benzotriazole	n1[nH]nc(c12)c(Br)c(Br)c(Br)c2Br
958	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB04719	experimental	DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE	CN(C)c([nH]1)nc(c12)c(Br)c(Br)c(Br)c2Br
959	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB04720	experimental	S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE	CSc([nH]1)nc(c12)c(Br)c(Br)c(Br)c2Br
960	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB04721	experimental	N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE	CN1CCn(c12)c3c(n2)c(Br)c(Br)c(Br)c3Br
961	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB07715	investigational	Emodin	Cc(c1)cc(O)c(c12)C(=O)c3c(C2=O)cc(O)cc3O
962	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB07802	experimental	3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE	Cc1c(Br)c(=O)oc(c12)c(Br)c(O)cc2
963	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08338	experimental	19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one	O=C(N1)CCCCc2cnn(c(n3)NC4CC4)c2nc3Nc(c5)cccc15
964	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08340	experimental	N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE	c1ccccc1Nc(nc(n23)ccn3)nc2Nc4ccccc4
965	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08345	experimental	4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	c1nc[nH]c1CCNc2nc(nc(n23)c(cn3)C#N)Nc4ccccc4
966	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08353	experimental	2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	c1ccccc1Nc2nc(nc(n23)c(cn3)C#N)NCC4CCCCC4
967	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08354	experimental	2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	Clc1ccc(cc1)CNc(nc(n23)c(cn3)C#N)nc2Nc4ccccc4
968	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08360	experimental	2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	CCN1CCN(CC1)c(nc(n23)c(cn3)C#N)nc2Nc4ccccc4
969	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08362	experimental	N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE	CC(=O)Nc1cccc(c1)Nc(nc(n23)c(cn3)C#N)nc2Nc4ccccc4
970	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08473	experimental	Dichlororibofuranosylbenzimidazole	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)cc(Cl)c(Cl)c3
971	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08660	experimental	Quinalizarin	Oc1ccc(O)c(c12)C(=O)c3c(C2=O)ccc(O)c3O
972	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
973	sp|P61075|CDC2H_PL	P68400	100.0	37.0	325.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
974	sp|P61075|CDC2H_PL	P06241	77.08	270.0	492.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
975	sp|P61075|CDC2H_PL	P06241	77.08	270.0	492.0	DB02078	experimental	Triglyme	COCCOCCOCCOC
976	sp|P61075|CDC2H_PL	P06241	77.08	270.0	492.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
977	sp|P61075|CDC2H_PL	P19784	99.65	38.0	325.0	DB07546	experimental	[1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid	CC(C)Nc(cc1)cc(c12)n(nc2)-c3nc(cnc3)-n4ccc(c4)CC(=O)O
978	sp|P61075|CDC2H_PL	P19784	99.65	38.0	325.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
979	sp|P61075|CDC2H_PL	Q96BR1	74.65	161.0	376.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
980	sp|P61075|CDC2H_PL	Q56UN5	77.78	1061.0	1285.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
981	sp|P61075|CDC2H_PL	Q9HAZ1	110.42	158.0	476.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
982	sp|P61075|CDC2H_PL	Q9H2G2	75.35	34.0	251.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
983	sp|P61075|CDC2H_PL	Q9H2G2	75.35	34.0	251.0	DB07853	experimental	2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile	N#CCC1C=CC(C=C1)=Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
984	sp|P61075|CDC2H_PL	Q9H2G2	75.35	34.0	251.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
985	sp|P61075|CDC2H_PL	P42681	78.12	272.0	497.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
986	sp|P61075|CDC2H_PL	P42681	78.12	272.0	497.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
987	sp|P61075|CDC2H_PL	P29320	80.21	623.0	854.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
988	sp|P61075|CDC2H_PL	Q9UKE5	76.74	25.0	246.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
989	sp|P61075|CDC2H_PL	Q6P3R8	76.39	1.0	221.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
990	sp|P61075|CDC2H_PL	P54756	87.85	677.0	930.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
991	sp|P61075|CDC2H_PL	P54756	87.85	677.0	930.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
992	sp|P61075|CDC2H_PL	Q02156	75.0	405.0	621.0	DB06064	investigational	KAI-1455	 
993	sp|P61075|CDC2H_PL	Q02156	75.0	405.0	621.0	DB11752	investigational	Bryostatin 1	 
994	sp|P61075|CDC2H_PL	Q02156	75.0	405.0	621.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
995	sp|P61075|CDC2H_PL	Q02156	75.0	405.0	621.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
996	sp|P61075|CDC2H_PL	Q15375	80.21	635.0	866.0	DB07970	experimental	5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide	O=C(N)c1cncc(c1)Nc2c(C)ccc(c2)C(=O)Nc3cccc(c3)C(F)(F)F
997	sp|P61075|CDC2H_PL	Q15375	80.21	635.0	866.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
998	sp|P61075|CDC2H_PL	P42680	78.12	370.0	595.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
999	sp|P61075|CDC2H_PL	P42680	78.12	370.0	595.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1000	sp|P61075|CDC2H_PL	P07948	82.64	246.0	484.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1001	sp|P61075|CDC2H_PL	P07948	82.64	246.0	484.0	DB03023	experimental	1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	n1cnc(N)c(c12)c([nH+]n2C(C)(C)C)-c3ccc(Cl)cc3
1002	sp|P61075|CDC2H_PL	P07948	82.64	246.0	484.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
1003	sp|P61075|CDC2H_PL	P07948	82.64	246.0	484.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1004	sp|P61075|CDC2H_PL	P07948	82.64	246.0	484.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
1005	sp|P61075|CDC2H_PL	P07948	82.64	246.0	484.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1006	sp|P61075|CDC2H_PL	P16591	86.11	565.0	813.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1007	sp|P61075|CDC2H_PL	P29323	81.25	623.0	857.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1008	sp|P61075|CDC2H_PL	P29323	81.25	623.0	857.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1009	sp|P61075|CDC2H_PL	P49336	107.99	26.0	337.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
1010	sp|P61075|CDC2H_PL	P00521	87.15	128.0	379.0	DB02567	experimental	PD173955	CSc1cccc(c1)Nc(n2)ncc(c23)cc(c(=O)n3C)-c4c(Cl)cccc4Cl
1011	sp|P61075|CDC2H_PL	P00521	87.15	128.0	379.0	DB03814	experimental	2-(N-morpholino)ethanesulfonic acid	OS(=O)(=O)CCN1CCOCC1
1012	sp|P61075|CDC2H_PL	P00521	87.15	128.0	379.0	DB03878	experimental	N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide	c1ccncc1C(=O)Nc2ccc(C)c(c2)Nc3nccc(n3)-c4cccnc4
1013	sp|P61075|CDC2H_PL	P00521	87.15	128.0	379.0	DB05489	investigational	ACA 125	 
1014	sp|P61075|CDC2H_PL	Q96PY6	75.35	1.0	218.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1015	sp|P61075|CDC2H_PL	P07332	88.19	560.0	814.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1016	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1017	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB01678	experimental	RU84687	OP(=O)(O)Oc1c(C=O)cc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1018	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB01866	experimental	RU79256	OC(=O)[C@H](S(=O)(=O)O)c1ccccc1
1019	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB01893	experimental	N6-Benzyl Adenosine-5'-Diphosphate	OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(ncn3)NCc4ccccc4
1020	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB01908	experimental	RU85493	OC(=O)COc1c(P(=O)(O)O)cc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1021	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB01947	experimental	RU78262	OP(=O)(O)Oc1c(C=O)cccc1
1022	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB01962	experimental	Phosphonotyrosine	OC(=O)[C@@H](N)Cc1ccc(cc1)OP(=O)(O)O
1023	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB02175	experimental	Malonic acid	OC(=O)CC(=O)O
1024	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB02336	experimental	RU83876	O=P(O)(O)c1ccc(cc1P(=O)(O)O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1025	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB02432	experimental	RU90395	COC(=O)c1c(C(F)(C(=O)O)C(=O)O)ccc(c1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1026	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB02762	experimental	RU79072	OP(=O)(O)Oc1cccc(c12)ccc(n2)C#N
1027	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB02908	experimental	RU78783	OP(=O)(O)C(P(=O)(O)O)c1ccccc1
1028	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03023	experimental	1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	n1cnc(N)c(c12)c([nH+]n2C(C)(C)C)-c3ccc(Cl)cc3
1029	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03078	experimental	PASBN	O=Cc1ccccc1O[P@@](=O)(O)OCc2ccccc2
1030	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03104	experimental	2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid	OC(=O)Cc1c(C=O)cc(cc1)/C=C(\NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1031	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03114	experimental	PAS219	O=Cc1ccccc1O[P@@](=O)(O)OCC2CCCCC2
1032	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03217	experimental	DPI59	c1cccc(c12)cccc2[C@@H](O)P(=O)(O)O
1033	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03268	experimental	RU82197	O=C(O)c1ccc(cc1C=O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1034	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03298	experimental	Phenylphosphate	OP(=O)(O)Oc1ccccc1
1035	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03306	experimental	RU78300	COc1cccc(C=O)c1OP(=O)(O)O
1036	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03525	experimental	RU79073	OP(=O)(O)Oc(ccc1)c(c12)NCCC2
1037	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03591	experimental	RU82209	OP(=O)(O)C(F)(F)c1ccc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1038	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03628	experimental	ISO24	CCc1ccc(cc1)NC(=O)P(=O)(O)O
1039	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03712	experimental	RU85053	OC(=O)Cc1ccc(cc1C(=O)O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1040	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03828	experimental	RU78299	Cc1cc(C=O)c(c(C=O)c1)OP(=O)(O)O
1041	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB03902	experimental	Oxalic Acid	OC(=O)C(=O)O
1042	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB04080	experimental	RU78191	OC(=O)C(C(=O)O)c1ccccc1
1043	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB04272	approved; nutraceutical; vet_approved	Citric acid	OC(=O)CC(O)(C(=O)O)CC(=O)O
1044	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB04495	experimental	Paratoulene phosphate	OP(=O)(O)Oc1ccc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
1045	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB04739	experimental	4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cccc(c3)Nc4nccc(n4)-c5cnccc5
1046	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
1047	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB05184	investigational	XL228	 
1048	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB06137	investigational	KX-01	c1ccccc1CNC(=O)Cc2ccc(cn2)-c3ccc(cc3)OCCN4CCOCC4
1049	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
1050	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB06882	experimental	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea	Nc1cc(ccc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc(ccc3)c(c34)cccc4
1051	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB06883	experimental	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea	Nc1cc(ccc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc3ccccc3
1052	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB07335	experimental	3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL	n1cnc(N)c(c12)c(nn2C(C)C)-c3cccc(O)c3
1053	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB07662	experimental	PD-168393	Brc1cc(ccc1)Nc(ncn2)c(c23)cc(cc3)NC(=O)C=C
1054	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB07966	experimental	[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile	N#CCc1ccc(cc1)Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
1055	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB08052	experimental	PP-121	[nH]1ccc(c12)cc(cn2)-c3nn(C4CCCC4)c(c35)ncnc5N
1056	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB08053	experimental	1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	COc1c(OC)cc(cc1)-c2nn(C3CCC3)c(c24)ncnc4N
1057	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB08054	experimental	1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine	n1cnc(N)c(c12)c(nn2C(C)C)-c(cc3)cc(c34)cccn4
1058	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB08192	experimental	2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE	CC(C)c1sc(nc1C(=O)O)[C@@H](NC2)Cc(c23)cccc3
1059	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB08462	experimental	N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE	C=CC(=O)Nc(c1)ccc(c12)ncnc2Nc3ccccc3
1060	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB08564	experimental	(2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide	CN(C)C/C=C/C(=O)Nc(c1)ccc(c12)ncnc2Nc3cc(Br)ccc3
1061	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1062	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
1063	sp|P61075|CDC2H_PL	P12931	77.08	273.0	495.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1064	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB00163	approved; nutraceutical; vet_approved	Vitamin E	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(O)c(C)c2C
1065	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB01738	experimental	Phosphorylcolamine	NCCOP(=O)(O)O
1066	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
1067	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
1068	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB08862	approved; investigational	Cholecystokinin	 
1069	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB14001	approved; nutraceutical; vet_approved	alpha-Tocopherol succinate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)CCC(=O)O
1070	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB14002	approved; nutraceutical; vet_approved	D-alpha-Tocopherol acetate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)C
1071	sp|P61075|CDC2H_PL	P05771	79.51	340.0	569.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
1072	sp|P61075|CDC2H_PL	Q99759	78.12	362.0	587.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1073	sp|P61075|CDC2H_PL	Q9Y4K4	76.39	18.0	238.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1074	sp|P61075|CDC2H_PL	P54764	79.51	623.0	852.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1075	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1076	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB00619	approved	Imatinib	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(C)cc3)Nc4nccc(n4)-c5cnccc5
1077	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1078	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB03878	experimental	N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide	c1ccncc1C(=O)Nc2ccc(C)c(c2)Nc3nccc(n3)-c4cccnc4
1079	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB04868	approved; investigational	Nilotinib	Cc1cn(cn1)-c2cc(cc(c2)C(F)(F)F)NC(=O)c3ccc(C)c(c3)Nc4nccc(n4)-c5cnccc5
1080	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB05184	investigational	XL228	 
1081	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
1082	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB07831	experimental	2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	CCCc1ccc(cc1C(F)(F)F)NC(=O)c2ccccc2NCc3c[nH]c(=O)cc3
1083	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB08043	experimental	1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA	FC(F)(F)c1cc(ccc1)NC(=O)Nc2ccc(cc2)Oc3ccncc3
1084	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
1085	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB08339	experimental	PD-166326	Clc1cccc(Cl)c1-c(c(=O)n2C)cc(c23)cnc(n3)Nc4cccc(c4)CO
1086	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB08350	experimental	5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE	COc1ccccc1-c2c[nH]c(c23)ncc(c3)-c4cc(cnc4)C(=O)N(C)C
1087	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB08583	experimental	2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide	CCn1nccc1-c2c[nH]c(c23)ncc(c3)-c4cc(C(=O)N(C)C)c(N)cc4
1088	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1089	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1090	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1091	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1092	sp|P61075|CDC2H_PL	P00519	87.15	242.0	493.0	DB12323	investigational	Radotinib	Cc1cn(cn1)-c2cc(cc(c2)C(F)(F)F)NC(=O)c3ccc(C)c(c3)Nc4nccc(n4)-c5cnccn5
1093	sp|P61075|CDC2H_PL	Q9HBH9	97.92	88.0	370.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1094	sp|P61075|CDC2H_PL	P29317	88.89	616.0	872.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1095	sp|P61075|CDC2H_PL	P29317	88.89	616.0	872.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1096	sp|P61075|CDC2H_PL	P29317	88.89	616.0	872.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1097	sp|P61075|CDC2H_PL	P29317	88.89	616.0	872.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1098	sp|P61075|CDC2H_PL	Q12851	76.39	14.0	234.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1099	sp|P61075|CDC2H_PL	Q13882	78.47	189.0	415.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
1100	sp|P61075|CDC2H_PL	Q13882	78.47	189.0	415.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1101	sp|P61075|CDC2H_PL	Q13882	78.47	189.0	415.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1102	sp|P61075|CDC2H_PL	P63185	76.04	270.0	489.0	DB01773	experimental	4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid	C1CCCCC1CCCN(C)C(=O)[C@H](CCC(=O)O)NC(=O)N(CC(=O)O)Cc2ccc(cc2)OP(=O)(O)O
1103	sp|P61075|CDC2H_PL	Q05655	74.65	347.0	562.0	DB04376	experimental	13-Acetylphorbol	OCC(=C1)C[C@](O)(C(=O)C(=C2)C)[C@@H]2[C@@](O)([C@H](C)[C@H]3O)[C@@H]1[C@H](C4(C)C)[C@@]34OC(=O)C
1104	sp|P61075|CDC2H_PL	Q05655	74.65	347.0	562.0	DB05013	approved	Ingenol mebutate	C[C@@H]1C[C@@H](C2(C)C)[C@@H]2[C@H](C3=O)C=C(CO)[C@@H](O)[C@]([C@@]134)(O)[C@H](C(=C4)C)OC(=O)/C(C)=C\C
1105	sp|P61075|CDC2H_PL	Q05655	74.65	347.0	562.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1106	sp|P61075|CDC2H_PL	Q05655	74.65	347.0	562.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
1107	sp|P61075|CDC2H_PL	P00524	76.04	270.0	489.0	DB08434	experimental	2-METHYLCARBAMOYL-3-(4-PHOSPHONOOXY-PHENYL)-CYCLOPROPANECARBOXYLIC ACID	OC(=O)[C@H]1[C@H](C(=O)NC)[C@@H]1c2ccc(cc2)OP(=O)(O)O
1108	sp|P61075|CDC2H_PL	P42684	87.15	288.0	539.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1109	sp|P61075|CDC2H_PL	P42684	87.15	288.0	539.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1110	sp|P61075|CDC2H_PL	P42684	87.15	288.0	539.0	DB05184	investigational	XL228	 
1111	sp|P61075|CDC2H_PL	P42684	87.15	288.0	539.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
1112	sp|P61075|CDC2H_PL	P42684	87.15	288.0	539.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1113	sp|P61075|CDC2H_PL	P07947	79.17	280.0	508.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1114	sp|P61075|CDC2H_PL	P07947	79.17	280.0	508.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1115	sp|P61075|CDC2H_PL	Q8IY84	76.04	74.0	293.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1116	sp|P61075|CDC2H_PL	Q9UL54	74.31	28.0	242.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
1117	sp|P61075|CDC2H_PL	Q9UL54	74.31	28.0	242.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1118	sp|P61075|CDC2H_PL	O94768	78.47	36.0	262.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
1119	sp|P61075|CDC2H_PL	O94768	78.47	36.0	262.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1120	sp|P61075|CDC2H_PL	Q7L7X3	74.31	28.0	242.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1121	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1122	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB01830	experimental	AP-22408	O=P(O)(O)c1ccc(cc1P(=O)(O)O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCc(c23)cc(c(c3)C(=O)N)OCC4CCCCC4
1123	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1124	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB03023	experimental	1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	n1cnc(N)c(c12)c([nH+]n2C(C)(C)C)-c3ccc(Cl)cc3
1125	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB04003	experimental	{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid	C1CCCCC1COc2c(C(=O)N)cc(cc2)[C@H](C)NC(=O)[C@@H](NC(=O)C)Cc3cc(P(=O)(O)O)c(cc3)OCC(=O)O
1126	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1127	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB06925	experimental	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	FC(F)(F)c1cc(ccc1)NC(=O)c2ccc(C)c(c2)-c(c3)ccc(c34)nc(N)nc4
1128	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB07146	experimental	2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE	C1CNCCN1CCNc2ccnc(c23)oc(-c4ccccc4)c3-c5ccccc5
1129	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB07297	experimental	5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE	C1CNCCN1CCNc(ncn2)c(c23)c(-c4ccccc4)c(o3)-c5ccccc5
1130	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB08055	experimental	N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine	Clc1ccccc1Nc2ncc(n(c23)cnc3)-c4ccccc4
1131	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB08056	experimental	N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine	Cc1cccc(C)c1Nc2ncc(n(c23)cnc3)-c4ccccc4
1132	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB08057	experimental	N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine	C[C@H]1CN(CCN1)c(c2)ccc(c23)nc(c4n3cnc4)Nc5c(C)cccc5Cl
1133	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1134	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
1135	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1136	sp|P61075|CDC2H_PL	P06239	80.21	244.0	475.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1137	sp|P61075|CDC2H_PL	Q16513	76.04	654.0	873.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1138	sp|P61075|CDC2H_PL	Q9H2X6	115.28	197.0	529.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1139	sp|P61075|CDC2H_PL	Q9H2K8	74.31	24.0	238.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1140	sp|P61075|CDC2H_PL	P08631	80.21	262.0	493.0	DB01809	experimental	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	Cc1ccc(cc1)-c2nn(C(C)(C)C)c(c23)ncnc3N
1141	sp|P61075|CDC2H_PL	P08631	80.21	262.0	493.0	DB01962	experimental	Phosphonotyrosine	OC(=O)[C@@H](N)Cc1ccc(cc1)OP(=O)(O)O
1142	sp|P61075|CDC2H_PL	P08631	80.21	262.0	493.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
1143	sp|P61075|CDC2H_PL	P08631	80.21	262.0	493.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
1144	sp|P61075|CDC2H_PL	P08631	80.21	262.0	493.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1145	sp|P61075|CDC2H_PL	P05129	80.56	349.0	581.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
1146	sp|P61075|CDC2H_PL	P05129	80.56	349.0	581.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1147	sp|P61075|CDC2H_PL	P51451	76.74	241.0	462.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1148	sp|P61075|CDC2H_PL	P51451	76.74	241.0	462.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1149	sp|P61075|CDC2H_PL	O95819	76.74	25.0	246.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1150	sp|P61075|CDC2H_PL	Q08881	86.46	363.0	612.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1151	sp|P61075|CDC2H_PL	Q08881	86.46	363.0	612.0	DB06589	approved	Pazopanib	Cc1n(C)nc(c12)cc(cc2)N(C)c3ccnc(n3)Nc4ccc(C)c(c4)S(=O)(=O)N
1152	sp|P61075|CDC2H_PL	Q08881	86.46	363.0	612.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1153	sp|P61075|CDC2H_PL	Q08881	86.46	363.0	612.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1154	sp|P61075|CDC2H_PL	Q06187	78.12	401.0	626.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1155	sp|P61075|CDC2H_PL	Q06187	78.12	401.0	626.0	DB01863	experimental	Inositol 1,3,4,5-Tetrakisphosphate	OP(=O)(O)O[C@@H]1[C@H](O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@@H]([C@H]1O)OP(=O)(O)O
1156	sp|P61075|CDC2H_PL	Q06187	78.12	401.0	626.0	DB05204	investigational	XL418	 
1157	sp|P61075|CDC2H_PL	Q06187	78.12	401.0	626.0	DB09053	approved	Ibrutinib	C=CC(=O)N1C[C@@H](CCC1)n(c(c23)ncnc3N)nc2-c4ccc(cc4)Oc5ccccc5
1158	sp|P61075|CDC2H_PL	Q06187	78.12	401.0	626.0	DB11703	approved; investigational	Acalabrutinib	CC#CC(=O)N1CCC[C@H]1c2nc(c(n23)c(N)ncc3)-c4ccc(cc4)C(=O)Nc5ccccn5
1159	sp|P61075|CDC2H_PL	Q06187	78.12	401.0	626.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1160	sp|P61075|CDC2H_PL	Q06187	78.12	401.0	626.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1161	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB00482	approved; investigational	Celecoxib	Cc1ccc(cc1)-c2cc(C(F)(F)F)nn2-c3ccc(cc3)S(=O)(=O)N
1162	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB01863	experimental	Inositol 1,3,4,5-Tetrakisphosphate	OP(=O)(O)O[C@@H]1[C@H](O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@@H]([C@H]1O)OP(=O)(O)O
1163	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB01933	experimental; investigational	7-Hydroxystaurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c([C@@H](O)NC7=O)c4c8c5cccc8
1164	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB01946	experimental	Bisindolylmaleimide VIII	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(CCCN)c(c45)cccc5
1165	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1166	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB03777	experimental	Bisindolylmaleimide I	CN(C)CCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
1167	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
1168	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB06932	experimental	10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine	COc(c1)c(OC)cc(c12)ncc3c2c4c(nc3N)c(C)c(N)cc4
1169	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB07033	experimental	5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE	c1cc[nH]c1[C@H](C)C(C(=O)N=2)=c(c23)cc(O)cc3
1170	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB07132	experimental	1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA	c1cc[nH]c1[C@H](C)C(C(=O)N=2)=c(c23)cc(cc3)NC(=O)N
1171	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB07300	experimental	2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine	COCCOc(c1)c(OC)cc(c12)c3c(cn2)c(N)nc(c3)-n4ccnc4
1172	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB07456	experimental	3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione	c1cccc(c12)c(c[nH]2)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)CC[C@H]6CCCN6C
1173	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB07457	experimental	3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE	NCCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
1174	sp|P61075|CDC2H_PL	O15530	79.17	80.0	308.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1175	sp|P61075|CDC2H_PL	Q8NEV4	78.47	19.0	245.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1176	sp|P61075|CDC2H_PL	Q13237	76.39	451.0	671.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1177	sp|P61075|CDC2H_PL	P09769	83.33	264.0	504.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1178	sp|P61075|CDC2H_PL	P09769	83.33	264.0	504.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1179	sp|P61075|CDC2H_PL	P09769	83.33	264.0	504.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1180	sp|P61075|CDC2H_PL	O94804	75.35	35.0	252.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1181	sp|P61075|CDC2H_PL	Q9Y2U5	78.12	355.0	580.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
1182	sp|P61075|CDC2H_PL	Q9Y2U5	78.12	355.0	580.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1183	sp|P61075|CDC2H_PL	Q16620	84.72	540.0	784.0	DB00321	approved	Amitriptyline	CN(C)CCC=C1c(cccc2)c2CCc(c13)cccc3
1184	sp|P61075|CDC2H_PL	Q16620	84.72	540.0	784.0	DB11823	approved; investigational	Esketamine	C1CCCC(=O)[C@@]1(NC)c2ccccc2Cl
1185	sp|P61075|CDC2H_PL	Q16620	84.72	540.0	784.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
1186	sp|P61075|CDC2H_PL	Q16620	84.72	540.0	784.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1187	sp|P61075|CDC2H_PL	Q16620	84.72	540.0	784.0	DB14723	approved; investigational	Larotrectinib	O[C@H]1CCN(C1)C(=O)Nc(cn2)c(n23)nc(cc3)N4CCC[C@@H]4c5c(F)ccc(F)c5
1188	sp|P61075|CDC2H_PL	P41743	71.18	251.0	456.0	DB03777	experimental	Bisindolylmaleimide I	CN(C)CCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
1189	sp|P61075|CDC2H_PL	P41743	71.18	251.0	456.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1190	sp|P61075|CDC2H_PL	P41743	71.18	251.0	456.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
1191	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB02152	experimental	K-252a	COC(=O)[C@@]1(O)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1192	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB03115	experimental	5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide	OC[C@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc2c(F)cc(I)cc2
1193	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB05239	approved; investigational	Cobimetinib	C1CCCN[C@@H]1C2(O)CN(C2)C(=O)c3c(c(F)c(F)cc3)Nc4c(F)cc(I)cc4
1194	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
1195	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB06892	experimental	(5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide	OCCONC(=O)C1=CC=C(F)[C@@H](F)C\1=N/c2c(F)cc(I)cc2
1196	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB07046	experimental	2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide	OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc2ccc(I)cc2Cl
1197	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB07101	investigational	PD-0325901	OC[C@@H](O)CONC(=O)c1c(c(F)c(F)cc1)Nc2ccc(I)cc2F
1198	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB08130	experimental	N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine	NCCNc1nnc(o1)-c2c(c(F)c(F)cc2)Nc3ccc(I)cc3F
1199	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB08208	experimental	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	OCCONC(=O)c1ccc(F)c(F)c1Nc2ccc(cc2F)C#C
1200	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB08911	approved	Trametinib	Fc1cc(I)ccc1Nc2n(C)c(=O)c(C)c(c23)n(c(=O)n(c3=O)C4CC4)-c5cc(NC(=O)C)ccc5
1201	sp|P61075|CDC2H_PL	Q02750	103.47	66.0	364.0	DB11689	approved; investigational	Selumetinib	OCCONC(=O)c(c1)c(c(F)c(c12)ncn2C)Nc3c(Cl)cc(Br)cc3
1202	sp|P61075|CDC2H_PL	P51955	78.47	6.0	232.0	DB07180	experimental	5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide	CNC(=O)c1c(C)[nH]c(c1C)/C=C2\C(=O)Nc(c23)ccc(Cl)c3
1203	sp|P61075|CDC2H_PL	P51955	78.47	6.0	232.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1204	sp|P61075|CDC2H_PL	Q96RR4	83.33	162.0	402.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1205	sp|P61075|CDC2H_PL	Q13464	81.94	74.0	310.0	DB04707	experimental	Hydroxyfasudil	O=c1[nH]ccc(c12)c(ccc2)S(=O)(=O)N3CCCNCC3
1206	sp|P61075|CDC2H_PL	Q13464	81.94	74.0	310.0	DB07876	experimental	(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(C)cnc3
1207	sp|P61075|CDC2H_PL	Q13464	81.94	74.0	310.0	DB08162	investigational	Fasudil	c1cncc(c12)cccc2S(=O)(=O)N3CCCNCC3
1208	sp|P61075|CDC2H_PL	Q13464	81.94	74.0	310.0	DB08756	experimental	Y-27632	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc2ccncc2
1209	sp|P61075|CDC2H_PL	Q13464	81.94	74.0	310.0	DB13165	experimental	Ripasudil	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(F)cnc3
1210	sp|P61075|CDC2H_PL	Q13464	81.94	74.0	310.0	DB13931	approved	Netarsudil	Cc1cc(C)c(cc1)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc(c3)ccc(c34)cncc4
1212	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
1213	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB01109	approved; investigational	Heparin	 
1214	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB02058	experimental	3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone	c1cccc(c12)C(C(=O)N2)Cc3ccc(cc3)N4CCN(C=O)CC4
1215	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB05014	investigational	XL999	 
1216	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB07525	experimental	3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine	COc1cccc(c1)Cc2c[nH]c(c23)nccc3
1217	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB07840	experimental	(E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol	COc1cccc(c1)C(=O)c2c[nH]c(c23)nccc3-c4cc(F)cc(F)c4
1218	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB08577	experimental	3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE	OC(=O)CCc1c([nH]cc1C)/C=C2\C(=O)Nc(c23)cccc3
1219	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1220	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1221	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
1222	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
1223	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1224	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
1225	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
1226	sp|P61075|CDC2H_PL	P11362	96.18	478.0	755.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
1227	sp|P61075|CDC2H_PL	Q8N4C8	76.74	25.0	246.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1228	sp|P61075|CDC2H_PL	P21709	87.15	628.0	879.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1229	sp|P61075|CDC2H_PL	P51813	79.17	416.0	644.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1230	sp|P61075|CDC2H_PL	P51813	79.17	416.0	644.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1231	sp|P61075|CDC2H_PL	Q9Y6R4	76.39	1342.0	1562.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1232	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1233	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07249	experimental	N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine	O1COc(c12)ccc(Cl)c2Nc3ncnc(c34)cc(c(c4)OC)OCCCN5CCCCC5
1234	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07250	experimental	N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE	COc1c(OC)cc(cc1OC)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
1235	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07251	experimental	N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE	COc1c(OC)cc(cc1OC)Nc2ncnc(n2)Nc3cc(Cl)c(OC)cc3
1236	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07252	experimental	3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide	NS(=O)(=O)c1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
1237	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07253	experimental	N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine	CS(=O)(=O)c1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
1238	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07254	experimental	N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE	CS(=O)(=O)Nc1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
1239	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07255	experimental	N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE	O1COc(c12)c(c(Cl)cc2)Nc3nc(ncc3)Nc4cc(ccc4)N5CCOCC5
1240	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB07256	experimental	3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE	NC(=O)c1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
1241	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB11973	investigational	Tesevatinib	CN(C1)C[C@@H]([C@@H]12)C[C@@H](C2)COc(c(c3)OC)cc(c34)ncnc4Nc5ccc(Cl)c(Cl)c5F
1242	sp|P61075|CDC2H_PL	P54760	80.9	617.0	850.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1243	sp|P61075|CDC2H_PL	Q16512	76.04	612.0	831.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1244	sp|P61075|CDC2H_PL	P49760	111.11	161.0	481.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1245	sp|P61075|CDC2H_PL	Q9BXA7	76.04	12.0	231.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1246	sp|P61075|CDC2H_PL	Q9UF33	97.22	632.0	912.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1247	sp|P61075|CDC2H_PL	P36507	104.51	70.0	371.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
1248	sp|P61075|CDC2H_PL	P36507	104.51	70.0	371.0	DB08911	approved	Trametinib	Fc1cc(I)ccc1Nc2n(C)c(=O)c(C)c(c23)n(c(=O)n(c3=O)C4CC4)-c5cc(NC(=O)C)ccc5
1249	sp|P61075|CDC2H_PL	P36507	104.51	70.0	371.0	DB11689	approved; investigational	Selumetinib	OCCONC(=O)c(c1)c(c(F)c(c12)ncn2C)Nc3c(Cl)cc(Br)cc3
1250	sp|P61075|CDC2H_PL	P36507	104.51	70.0	371.0	DB11967	approved; investigational	Binimetinib	OCCONC(=O)c(c1)c(c(F)c(c12)ncn2C)Nc3ccc(Br)cc3F
1251	sp|P61075|CDC2H_PL	P36507	104.51	70.0	371.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1252	sp|P61075|CDC2H_PL	Q16644	71.88	42.0	249.0	DB07728	experimental	2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	Fc1ccccc1-c2cc(ccn2)-c([nH]3)cc(c34)C(=O)NCC4
1253	sp|P61075|CDC2H_PL	Q16644	71.88	42.0	249.0	DB08358	experimental	2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	O=C1NCCc(c12)[nH]c(c2)-c3cc(ncc3)-c(cn4)cc(c45)cccc5
1254	sp|P61075|CDC2H_PL	O75116	82.29	90.0	327.0	DB08162	investigational	Fasudil	c1cncc(c12)cccc2S(=O)(=O)N3CCCNCC3
1255	sp|P61075|CDC2H_PL	O75116	82.29	90.0	327.0	DB08756	experimental	Y-27632	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc2ccncc2
1256	sp|P61075|CDC2H_PL	O75116	82.29	90.0	327.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1257	sp|P61075|CDC2H_PL	O75116	82.29	90.0	327.0	DB13165	experimental	Ripasudil	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(F)cnc3
1258	sp|P61075|CDC2H_PL	O75116	82.29	90.0	327.0	DB13931	approved	Netarsudil	Cc1cc(C)c(cc1)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc(c3)ccc(c34)cncc4
1259	sp|P61075|CDC2H_PL	Q92918	76.39	15.0	235.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1260	sp|P61075|CDC2H_PL	Q9Y2H1	88.19	87.0	341.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1262	sp|P61075|CDC2H_PL	Q05397	87.15	420.0	671.0	DB07248	experimental	7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE	COc1c(OC)cc(cc1OC)Nc(n2)ncc(c23)ccn3-c4ccccn4
1263	sp|P61075|CDC2H_PL	Q05397	87.15	420.0	671.0	DB07460	experimental	2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE	CNC(=O)c1c(cccc1)Nc2nc(ncc2Cl)Nc3ccc(cc3OC)N4CCOCC4
1264	sp|P61075|CDC2H_PL	Q05397	87.15	420.0	671.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1265	sp|P61075|CDC2H_PL	Q13627	113.19	156.0	482.0	DB07608	experimental	N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide	Clc1cccc(c1)[C@H](CCN)C(=O)Nc(c2)ccc(c23)[nH]nc3NC(=O)c4ccccc4
1266	sp|P61075|CDC2H_PL	Q13627	113.19	156.0	482.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1267	sp|P61075|CDC2H_PL	Q9H422	115.28	195.0	527.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1268	sp|P61075|CDC2H_PL	P49137	71.88	61.0	268.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1269	sp|P61075|CDC2H_PL	P49137	71.88	61.0	268.0	DB07234	experimental	3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione	c1ccccc1[C@@H](C)Nc2c(c(=O)c2=O)Nc3ccncc3
1270	sp|P61075|CDC2H_PL	P49137	71.88	61.0	268.0	DB07406	experimental	(4R)-N-[4-({[2-(DIMETHYLAMINO)ETHYL]AMINO}CARBONYL)-1,3-THIAZOL-2-YL]-4-METHYL-1-OXO-2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLINE-6-CARBOXAMIDE	C[C@H]1CNC(=O)c(c12)[nH]c3c2cc(cc3)C(=O)Nc4nc(cs4)C(=O)NCCN(C)C
1271	sp|P61075|CDC2H_PL	P49137	71.88	61.0	268.0	DB07430	experimental	(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one	O=C1N[C@H](C)CNc(c12)c3c(s2)ccc4c3ccc(n4)-c5cnc(C)cc5
1272	sp|P61075|CDC2H_PL	P49137	71.88	61.0	268.0	DB07431	experimental	(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one	O=C1N[C@H](CN)CNc(c12)c3c(s2)ccc(c3)OC
1273	sp|P61075|CDC2H_PL	P49137	71.88	61.0	268.0	DB07728	experimental	2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	Fc1ccccc1-c2cc(ccn2)-c([nH]3)cc(c34)C(=O)NCC4
1274	sp|P61075|CDC2H_PL	P49137	71.88	61.0	268.0	DB08358	experimental	2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	O=C1NCCc(c12)[nH]c(c2)-c3cc(ncc3)-c(cn4)cc(c45)cccc5
1276	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB01041	approved; investigational; withdrawn	Thalidomide	c1cccc(c12)C(=O)N(C2=O)C3CCC(=O)NC3=O
1277	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB01109	approved; investigational	Heparin	 
1278	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB01901	experimental	Sucrosofate	O=S(=O)(O)OC[C@@H](O1)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@]1(COS(=O)(=O)O)O[C@H]2O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O
1279	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB02058	experimental	3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone	c1cccc(c12)C(C(=O)N2)Cc3ccc(cc3)N4CCN(C=O)CC4
1280	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB02491	experimental	4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine	CC(C)(N)c1ccc(cc1)-c2nc(ncc2Cl)Nc3ccc(cc3)CCN4CCOCC4
1281	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1282	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1283	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
1284	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
1287	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1288	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
1289	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
1290	sp|P61075|CDC2H_PL	P21802	96.53	480.0	758.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
1291	sp|P61075|CDC2H_PL	Q05513	71.88	249.0	456.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
1292	sp|P61075|CDC2H_PL	Q9Y463	112.85	108.0	433.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1293	sp|P61075|CDC2H_PL	Q8WU08	71.88	21.0	228.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1294	sp|P61075|CDC2H_PL	P29322	81.25	634.0	868.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1295	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB05149	investigational	XL844	 
1296	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
1297	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB06852	experimental	CHIR-124	c1cc(Cl)cc(c12)c(N[C@H](CN34)C(CC3)CC4)c(c(=O)[nH]2)-c([nH]5)nc(c56)cccc6
1298	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB06876	experimental	N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE	CN1CCN(CC1)c2ccc(cc2)-c(cn3)cc(c34)c(c[nH]4)NC(=O)c5cnccc5
1299	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07025	experimental	3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE	NCC1CCN(CC1)Cc(cc2)cc(c23)cc([nH]3)-c(c(=O)[nH]4)cc(c45)cccc5
1300	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07034	experimental	2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID	OC(=O)COc(c1)ccc(c12)c3c(C2=NO)cc(cc3)OCC(=O)O
1301	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07037	experimental	(2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL	NC[C@H](O)CNc(ccc1[N+]([O-])=O)c(c12)nccc2
1302	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07038	experimental	2-(cyclohexylamino)benzoic acid	OC(=O)c1ccccc1NC2CCCCC2
1303	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07075	experimental	3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE	NCC1CCN(CC1)Cc(cc2)cc(c23)cc([nH]3)-c4n[nH]c(c45)cc(C#N)cc5
1304	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07078	experimental	(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE	COc1cc(ccc1O)-c(cc2)cc(c23)NC(=O)C\3=C/c4ccc[nH]4
1305	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07158	experimental	5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE	c1cccc(c12)c3c(c(C)n[nH]3)c(=O)n2CC
1306	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07213	experimental	(5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL	OCc1n[nH]nc1-c(cc2)cc(c23)[nH]nc3-c([nH]4)cc(c45)cc(cc5)CN6CCCCC6
1307	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07228	experimental	1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA	CN(C)C[C@H](C)Oc1cncc(n1)NC(=O)Nc2c(OC)ccc(Cl)c2
1308	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07243	experimental	(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE	[C@@H]12CC[C@@H](N1C)C[C@@H](C2)OC(=O)c3c[nH]c(c34)nccc4
1309	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07311	experimental	18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE	c1cc(Cl)cc(c12)NC(=O)Nc3cncc(n3)OCCCCCO2
1310	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07314	experimental	1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA	COc1cc(OC)c(cc1Cl)NC(=O)Nc2ncc(C#N)nc2
1311	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07320	experimental	4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID	C[C@H]1CC[C@H](CC1)NCc(cc2)cc(c23)Cc4c3[nH]nc4-c5ccc(cc5)C(=O)O
1312	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07336	experimental	4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL	COc1cc(ccc1O)-c(cc2)cc(c23)[nH]nc3-c([nH]4)nc(c45)cccc5
1313	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07647	experimental	(2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL	C[C@@H](O)CNc(ncn1)c(c12)c(-c3ccccc3)c([nH]2)-c4ccccc4
1314	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07648	experimental	(2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL	OC[C@H](O)CNc(ncn1)c(c12)c(-c3ccccc3)c([nH]2)-c4ccccc4
1315	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07653	experimental	N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE	OC(=O)CNc1ncnc(c12)oc(-c3ccccc3)c2-c4ccccc4
1316	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07654	experimental	(5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC	OCCN(C)c1ncnc(c12)oc(-c3ccccc3)c2-c4ccccc4
1317	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07655	experimental	3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE	OCCNc1ncnc(c12)[nH]c(-c3ccccc3)c2-c4ccccc4
1318	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB07959	experimental	3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE	c1cccc(c12)c(n[nH]2)-c([nH]3)nc(c34)cccc4
1319	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08392	experimental	2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL	COc1ccc(cc1)-c(c(c23)c(ncn3)NCCO)c(o2)-c4ccc(cc4)OC
1320	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08393	experimental	2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL	OCCNc1ncnc(c12)oc(-c3ccccc3)c2-c4ccccc4
1321	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08683	experimental	REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE	c1cccc(c12)n3c4c2c5c(C(=O)NC5=O)c6c7c(cccc7)n(c46)[C@H]8O[C@@H]3CC8
1322	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08774	experimental	1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine	NC[C@H]1CN(CCO1)c2c(cnc(c23)[nH]nc3)-c4ccccc4
1323	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08776	experimental	N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE	CC(=O)Nc(s1)nc(c12)CCCNC2=O
1324	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08777	experimental	5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE	O=c1[nH]cnc(c12)sc3c2CCCC3
1325	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08778	experimental	[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone	CC(C)(C)Nc1nc(N)c(s1)C(=O)c2ccccc2
1326	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08779	experimental	2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol	CSc1nc(O)c([nH]1)Cc2cccs2
1327	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08780	experimental	6-MORPHOLIN-4-YL-9H-PURINE	C1COCCN1c(ncn2)c(c23)nc[nH]3
1328	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB08781	experimental	1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE	NC[C@H]1CN(CCO1)c2c(Br)cnc(c23)[nH]nc3
1329	sp|P61075|CDC2H_PL	O14757	71.53	7.0	213.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1330	sp|P61075|CDC2H_PL	P49761	110.76	302.0	621.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
1331	sp|P61075|CDC2H_PL	P49761	110.76	302.0	621.0	DB08691	experimental	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate	CCOC(=O)c(n1C)c(/C(C#N)=C\N)c(c12)ccc(Cl)c2Cl
1332	sp|P61075|CDC2H_PL	P49761	110.76	302.0	621.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1333	sp|P61075|CDC2H_PL	Q9H3Y6	78.12	229.0	454.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1334	sp|P61075|CDC2H_PL	Q15208	88.89	86.0	342.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1335	sp|P61075|CDC2H_PL	Q8N5S9	80.21	125.0	356.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1336	sp|P61075|CDC2H_PL	Q13523	111.46	685.0	1006.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1337	sp|P61075|CDC2H_PL	Q8TD19	76.39	52.0	272.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1339	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB05014	investigational	XL999	 
1340	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB06589	approved	Pazopanib	Cc1n(C)nc(c12)cc(cc2)N(C)c3ccnc(n3)Nc4ccc(C)c(c4)S(=O)(=O)N
1341	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1342	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
1343	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
1344	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1345	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
1346	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
1347	sp|P61075|CDC2H_PL	P22607	96.18	472.0	749.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
1348	sp|P61075|CDC2H_PL	Q8NG66	78.82	27.0	254.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
1349	sp|P61075|CDC2H_PL	Q8NG66	78.82	27.0	254.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1350	sp|P61075|CDC2H_PL	P41240	81.94	192.0	428.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1351	sp|P61075|CDC2H_PL	P41240	81.94	192.0	428.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1352	sp|P61075|CDC2H_PL	P41240	81.94	192.0	428.0	DB05075	investigational	TG-100801	c1ccccc1C(=O)Oc2ccc(Cl)c(c2)-c(c3)cc(C)c(c34)nc(nn4)Nc5ccc(cc5)OCCN6CCCC6
1353	sp|P61075|CDC2H_PL	P41240	81.94	192.0	428.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1354	sp|P61075|CDC2H_PL	Q16288	90.28	540.0	800.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
1355	sp|P61075|CDC2H_PL	Q16288	90.28	540.0	800.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1356	sp|P61075|CDC2H_PL	Q16288	90.28	540.0	800.0	DB14723	approved; investigational	Larotrectinib	O[C@H]1CCN(C1)C(=O)Nc(cn2)c(n23)nc(cc3)N4CCC[C@@H]4c5c(F)ccc(F)c5
1357	sp|P61075|CDC2H_PL	Q9Y2H9	79.17	372.0	600.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1358	sp|P61075|CDC2H_PL	P35626	73.26	188.0	399.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1359	sp|P61075|CDC2H_PL	Q15303	100.0	718.0	1006.0	DB08916	approved	Afatinib	CN(C)C/C=C/C(=O)Nc(c1)c(O[C@H]2CCOC2)cc(c13)ncnc3Nc4cc(Cl)c(F)cc4
1360	sp|P61075|CDC2H_PL	Q15303	100.0	718.0	1006.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1361	sp|P61075|CDC2H_PL	Q15303	100.0	718.0	1006.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1362	sp|P61075|CDC2H_PL	Q15303	100.0	718.0	1006.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1363	sp|P61075|CDC2H_PL	Q13233	79.86	1243.0	1473.0	DB06061	investigational	AZD-8330	OCCONC(=O)c1cc(C)c(=O)n(C)c1Nc2ccc(I)cc2F
1364	sp|P61075|CDC2H_PL	Q13233	79.86	1243.0	1473.0	DB11967	approved; investigational	Binimetinib	OCCONC(=O)c(c1)c(c(F)c(c12)ncn2C)Nc3ccc(Br)cc3F
1365	sp|P61075|CDC2H_PL	Q13233	79.86	1243.0	1473.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1366	sp|P61075|CDC2H_PL	O43283	83.68	167.0	408.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1367	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB00244	approved	Mesalazine	Nc1cc(C(=O)O)c(O)cc1
1368	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB00795	approved	Sulfasalazine	OC(=O)c1cc(ccc1O)/N=N/c2ccc(cc2)S(=O)(=O)Nc3ncccc3
1369	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
1370	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB00995	approved; investigational	Auranofin	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@H]1OC(=O)C
1371	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
1372	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB05183	investigational	MLN0415	 
1373	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB06151	approved; investigational	Acetylcysteine	CC(=O)N[C@@H](CS)C(=O)O
1374	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB06521	investigational	Ertiprotafib	c1cccc(c2Br)c1c(c(c23)c(C)c(s3)C)-c4cc(C)c(c(C)c4)O[C@@H](C(=O)O)Cc5ccccc5
1375	sp|P61075|CDC2H_PL	O14920	95.49	15.0	290.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1377	sp|P61075|CDC2H_PL	P22455	96.53	467.0	745.0	DB01109	approved; investigational	Heparin	 
1378	sp|P61075|CDC2H_PL	P22455	96.53	467.0	745.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1379	sp|P61075|CDC2H_PL	P22455	96.53	467.0	745.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
1380	sp|P61075|CDC2H_PL	P22455	96.53	467.0	745.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
1381	sp|P61075|CDC2H_PL	P22455	96.53	467.0	745.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
1382	sp|P61075|CDC2H_PL	O15111	94.44	15.0	287.0	DB00233	approved	Aminosalicylic acid	Nc1cc(O)c(cc1)C(=O)O
1383	sp|P61075|CDC2H_PL	O15111	94.44	15.0	287.0	DB00244	approved	Mesalazine	Nc1cc(C(=O)O)c(O)cc1
1384	sp|P61075|CDC2H_PL	O15111	94.44	15.0	287.0	DB00795	approved	Sulfasalazine	OC(=O)c1cc(ccc1O)/N=N/c2ccc(cc2)S(=O)(=O)Nc3ncccc3
1385	sp|P61075|CDC2H_PL	O15111	94.44	15.0	287.0	DB06151	approved; investigational	Acetylcysteine	CC(=O)N[C@@H](CS)C(=O)O
1394	sp|P61075|CDC2H_PL	P06213	92.71	1022.0	1289.0	DB03909	experimental	Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate	OP(=O)(O)CP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
1395	sp|P61075|CDC2H_PL	P06213	92.71	1022.0	1289.0	DB05115	investigational	NN344	 
1396	sp|P61075|CDC2H_PL	P06213	92.71	1022.0	1289.0	DB05120	investigational	AT1391	 
1397	sp|P61075|CDC2H_PL	P06213	92.71	1022.0	1289.0	DB08513	experimental	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Cc1cc(ccc1)Nc2nc(ncc2C(=O)N)Nc3ccc(cc3)CC(=O)O
1398	sp|P61075|CDC2H_PL	P06213	92.71	1022.0	1289.0	DB09129	approved	Chromic chloride	[Cl-]
1400	sp|P61075|CDC2H_PL	P06213	92.71	1022.0	1289.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1401	sp|P61075|CDC2H_PL	P06213	92.71	1022.0	1289.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1403	sp|P61075|CDC2H_PL	P43403	77.08	343.0	565.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1404	sp|P61075|CDC2H_PL	P43403	77.08	343.0	565.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1405	sp|P61075|CDC2H_PL	P04629	92.36	515.0	781.0	DB00321	approved	Amitriptyline	CN(C)CCC=C1c(cccc2)c2CCc(c13)cccc3
1406	sp|P61075|CDC2H_PL	P04629	92.36	515.0	781.0	DB00619	approved	Imatinib	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(C)cc3)Nc4nccc(n4)-c5cnccc5
1407	sp|P61075|CDC2H_PL	P04629	92.36	515.0	781.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1408	sp|P61075|CDC2H_PL	P04629	92.36	515.0	781.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
1409	sp|P61075|CDC2H_PL	P04629	92.36	515.0	781.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1411	sp|P61075|CDC2H_PL	P04629	92.36	515.0	781.0	DB14723	approved; investigational	Larotrectinib	O[C@H]1CCN(C1)C(=O)Nc(cn2)c(n23)nc(cc3)N4CCC[C@@H]4c5c(F)ccc(F)c5
1412	sp|P61075|CDC2H_PL	Q8IW41	80.56	25.0	257.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1413	sp|P61075|CDC2H_PL	Q86UE8	80.56	460.0	692.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1414	sp|P61075|CDC2H_PL	P43405	80.21	375.0	606.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1415	sp|P61075|CDC2H_PL	P43405	80.21	375.0	606.0	DB06834	experimental	N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide	OCC(C)(C)NC(=O)c(cc1)cc(c12)c(cn2C)-c([nH]3)cc(c34)cccn4
1416	sp|P61075|CDC2H_PL	P43405	80.21	375.0	606.0	DB07159	experimental; investigational	Tamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(n3)ccc(c34)OC(C)(C)C(=O)N4
1417	sp|P61075|CDC2H_PL	P43405	80.21	375.0	606.0	DB07194	experimental	2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide	OC[C@H](C)NC(=O)c1c(C)nc(s1)-c2nc(ncc2)Nc3cc(C)cc(C)c3
1418	sp|P61075|CDC2H_PL	P43405	80.21	375.0	606.0	DB08361	experimental	2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide	N[C@H]1CCCC[C@H]1Nc2nc(c(cn2)C(=O)N)Nc3cccc(C)c3
1419	sp|P61075|CDC2H_PL	P43405	80.21	375.0	606.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
1420	sp|P61075|CDC2H_PL	P43405	80.21	375.0	606.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1421	sp|P61075|CDC2H_PL	Q14289	87.5	428.0	680.0	DB01097	approved; investigational	Leflunomide	Cc1oncc1C(=O)Nc2ccc(C(F)(F)F)cc2
1422	sp|P61075|CDC2H_PL	Q14289	87.5	428.0	680.0	DB01645	investigational	Genistein	Oc1ccc(cc1)-c(c2=O)coc(c23)cc(O)cc3O
1423	sp|P61075|CDC2H_PL	Q14289	87.5	428.0	680.0	DB08341	experimental	4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide	CN(C)[C@@H]1CCC[C@H]1Nc2nc(ncc2C(F)(F)F)Nc3ccc(cc3)S(=O)(=O)NC
1424	sp|P61075|CDC2H_PL	Q14289	87.5	428.0	680.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
1425	sp|P61075|CDC2H_PL	Q14289	87.5	428.0	680.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1426	sp|P61075|CDC2H_PL	P04049	80.56	353.0	585.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
1428	sp|P61075|CDC2H_PL	P04049	80.56	353.0	585.0	DB05190	investigational	XL281	 
1429	sp|P61075|CDC2H_PL	P04049	80.56	353.0	585.0	DB05268	investigational	iCo-007	 
1430	sp|P61075|CDC2H_PL	P04049	80.56	353.0	585.0	DB08862	approved; investigational	Cholecystokinin	 
1431	sp|P61075|CDC2H_PL	P04049	80.56	353.0	585.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1432	sp|P61075|CDC2H_PL	P04049	80.56	353.0	585.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
1433	sp|P61075|CDC2H_PL	P04049	80.56	353.0	585.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1434	sp|P61075|CDC2H_PL	P42679	86.81	233.0	483.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1435	sp|P61075|CDC2H_PL	P25098	73.61	188.0	400.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1436	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
1437	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB05190	investigational	XL281	 
1438	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB05984	investigational	RAF-265	FC(F)(F)c1ccc(cc1)Nc(n2C)nc(c23)cc(cc3)Oc4ccnc(c4)-c5ncc([nH]5)C(F)(F)F
1439	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB06999	experimental	PLX-4720	CCCS(=O)(=O)Nc1ccc(F)c(c1F)C(=O)c2c[nH]c(c23)ncc(Cl)c3
1440	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB07000	experimental	N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide	CCS(=O)(=O)Nc1ccc(F)c(c1F)C(=O)c2c[nH]c(c23)ncc(c3)-c4cnccc4
1441	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB08553	experimental	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime	O/N=C1\CCc(c12)cc(cc2)-c3cn(C4CCNCC4)nc3-c5ccncc5
1442	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB08881	approved	Vemurafenib	CCCS(=O)(=O)Nc1c(F)c(c(F)cc1)C(=O)c2c[nH]c(c23)ncc(c3)-c4ccc(Cl)cc4
1443	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1444	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
1445	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB11718	approved; investigational	Encorafenib	COC(=O)N[C@@H](C)CNc1nccc(n1)-c2cn(C(C)C)nc2-c3cc(Cl)cc(c3F)NS(=O)(=O)C
1446	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1447	sp|P61075|CDC2H_PL	P15056	80.9	458.0	691.0	DB14840	approved	Ripretinib	CNc(c1)ncc(c12)cc(c(=O)n2CC)-c3c(Br)cc(F)c(c3)NC(=O)Nc4ccccc4
1448	sp|P61075|CDC2H_PL	Q59EB3	92.01	402.0	667.0	DB08111	experimental	4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol	Oc1ccc(cc1)Cc2nnc(n23)ccc(n3)-c4ccccc4
1449	sp|P61075|CDC2H_PL	O14578	79.51	95.0	324.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1450	sp|P61075|CDC2H_PL	Q6DT37	78.12	69.0	294.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1451	sp|P61075|CDC2H_PL	Q9NYL2	96.18	14.0	291.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
1452	sp|P61075|CDC2H_PL	Q9NYL2	96.18	14.0	291.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1453	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
1454	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB01809	experimental	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	Cc1ccc(cc1)-c2nn(C(C)(C)C)c(c23)ncnc3N
1455	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
1456	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB08875	approved; investigational	Cabozantinib	COc(c1)c(OC)cc(c12)nccc2Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5
1457	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1458	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1459	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
1460	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1461	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB12742	investigational	Amuvatinib	O1COc(c12)ccc(c2)CNC(=S)N3CCN(CC3)c4ncnc(c45)c6c(o5)cccc6
1462	sp|P61075|CDC2H_PL	P07949	96.88	726.0	1005.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
1463	sp|P61075|CDC2H_PL	Q9UKI8	79.86	454.0	684.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1464	sp|P61075|CDC2H_PL	O95382	70.14	653.0	855.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1465	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB02152	experimental	K-252a	COC(=O)[C@@]1(O)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1466	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB06314	investigational	SGX-523	Cn1cc(cn1)-c(cc2)nn(c23)c(nn3)Sc(c4)ccc(c45)nccc5
1467	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB06896	experimental	1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide	Fc1ccc(cc1)-n2cccc(c2=O)C(=O)Nc3ccc(c(F)c3)Oc4ccnc(c45)[nH]cc5
1468	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB06995	experimental	N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide	Nc1nccc(c1)Oc2c(F)cc(cc2)NC(=O)NC(=O)Cc3ccc(F)cc3
1469	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB06997	experimental	2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide	Fc1ccc(cc1)CC(=O)NC(=O)Nc2cc(F)c(cc2)Oc3ccnc(c34)[nH]cc4
1470	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB07369	experimental	N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide	Clc1cccc(c1)N(C)S(=O)(=O)c(cc2)cc(c2=3)=C(C(N3)=O)Cc4c(C)c(C)c(C)[nH]4
1471	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB07969	experimental	3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol	CN1CCN(CC1)c(cn2)nc(c23)c(cc(c3)C(F)(F)F)-c4cc(O)ccc4
1472	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB08079	investigational	AMG-208	COc(cc1)cc(c12)nccc2OCc3nnc(n34)ccc(n4)-c5ccccc5
1473	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB08791	experimental	1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE	NC(=O)c(c1)cnc(c12)ccn2S(=O)(=O)c3ccccc3[N+]([O-])=O
1474	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB08865	approved	Crizotinib	Clc1c(F)ccc(Cl)c1[C@@H](C)Oc2cc(cnc2N)-c3cn(nc3)C4CCNCC4
1475	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB08875	approved; investigational	Cabozantinib	COc(c1)c(OC)cc(c12)nccc2Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5
1476	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB11791	approved; investigational	Capmatinib	CNC(=O)c1c(F)cc(cc1)-c(cn2)nn(c23)c(cn3)Cc(cc4)cc(c45)cccn5
1477	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1478	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB12200	investigational	Tivantinib	c1cccc(c12)[nH]cc2[C@H]3[C@@H](C(=O)NC3=O)c4cn5CCCc(c5c46)ccc6
1479	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1480	sp|P61075|CDC2H_PL	P08581	92.01	1080.0	1345.0	DB12742	investigational	Amuvatinib	O1COc(c12)ccc(c2)CNC(=S)N3CCN(CC3)c4ncnc(c45)c6c(o5)cccc6
1481	sp|P61075|CDC2H_PL	Q02763	93.4	823.0	1092.0	DB00415	approved; vet_approved	Ampicillin	O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3
1482	sp|P61075|CDC2H_PL	Q02763	93.4	823.0	1092.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
1483	sp|P61075|CDC2H_PL	Q02763	93.4	823.0	1092.0	DB08221	experimental	N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE	FC(F)(F)c1cc(ccc1)C(=O)Nc2ccc(C)c(c2)Nc3ncccc3-c4ccncn4
1484	sp|P61075|CDC2H_PL	Q02763	93.4	823.0	1092.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1485	sp|P61075|CDC2H_PL	Q02763	93.4	823.0	1092.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
1486	sp|P61075|CDC2H_PL	Q02763	93.4	823.0	1092.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1487	sp|P61075|CDC2H_PL	Q02763	93.4	823.0	1092.0	DB14840	approved	Ripretinib	CNc(c1)ncc(c12)cc(c(=O)n2CC)-c3c(Br)cc(F)c(c3)NC(=O)Nc4ccccc4
1496	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1497	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB05023	investigational	ATL1101	 
1498	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB05184	investigational	XL228	 
1499	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB05897	investigational	rhIGFBP-3	 
1500	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB06075	investigational	Linsitinib	C[C@]1(O)C[C@H](C1)c2nc(c(n23)c(N)ncc3)-c(c4)ccc(c45)ccc(n5)-c6ccccc6
1502	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB07156	experimental	(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione	Brc(c1)ccc(c12)C(=O)NC(=O)C\2=C/Nc3ccc(cc3)CN4CCCC4
1503	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB07474	experimental	3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE	c1cncn1-c(cc2C)cc(c23)[nH]c(n3)-c4c(cc[nH]c4=O)NCc5ncccc5
1507	sp|P61075|CDC2H_PL	P08069	94.44	998.0	1270.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1509	sp|P61075|CDC2H_PL	O15146	89.93	574.0	833.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1510	sp|P61075|CDC2H_PL	Q9NWZ3	84.38	190.0	433.0	DB08590	experimental	1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE	CC(C)(C)C(=O)Oc(c1)ccc(c12)n(CCCO)c(n2)NC(=O)c3cc([N+]([O-])=O)ccc3
1511	sp|P61075|CDC2H_PL	Q9NWZ3	84.38	190.0	433.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1512	sp|P61075|CDC2H_PL	Q07912	82.99	125.0	364.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1513	sp|P61075|CDC2H_PL	Q07912	82.99	125.0	364.0	DB04367	experimental	Debromohymenialdisine	NC1=NC(=O)/C(N1)=C2\CCNC(=O)c(c23)[nH]cc3
1514	sp|P61075|CDC2H_PL	Q07912	82.99	125.0	364.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
1515	sp|P61075|CDC2H_PL	Q07912	82.99	125.0	364.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1517	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB00281	approved; vet_approved	Lidocaine	CCN(CC)CC(=O)Nc1c(C)cccc1C
1518	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB00317	approved; investigational	Gefitinib	C1COCCN1CCCOc(c(c2)OC)cc(c23)c(ncn3)Nc4cc(Cl)c(F)cc4
1519	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB00530	approved; investigational	Erlotinib	COCCOc(c1)c(OCCOC)cc(c12)ncnc2Nc3cc(C#C)ccc3
1520	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB01259	approved; investigational	Lapatinib	CS(=O)(=O)CCNCc1ccc(o1)-c(cc2)cc(c23)c(ncn3)Nc4cc(Cl)c(cc4)OCc5cc(F)ccc5
1522	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
1525	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
1526	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB05374	investigational	Rindopepimut	 
1527	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB05424	investigational	Canertinib	Fc1c(Cl)cc(cc1)Nc2ncnc(c23)cc(c(c3)NC(=O)C=C)OCCCN4CCOCC4
1528	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB05524	investigational	Pelitinib	CN(C)C/C=C/C(=O)Nc(c1)c(OCC)cc(c12)ncc(C#N)c2Nc3cc(Cl)c(F)cc3
1529	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB05944	investigational	Varlitinib	C[C@@H]1COC(=N1)Nc(c2)ccc(c23)ncnc3Nc4ccc(c(Cl)c4)OCc5nccs5
1530	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB06021	investigational	AV-412	CN1CCN(CC1)C(C)(C)C#Cc(c2)c(NC(=O)C=C)cc(c23)c(ncn3)Nc4ccc(F)c(Cl)c4
1531	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB07602	experimental	S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE	OC(=O)[C@@H](N)CSCCC(=O)Nc(cc1)cc(c12)c(ncn2)Nc3ccccc3
1532	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB07662	experimental	PD-168393	Brc1cc(ccc1)Nc(ncn2)c(c23)cc(cc3)NC(=O)C=C
1533	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB08916	approved	Afatinib	CN(C)C/C=C/C(=O)Nc(c1)c(O[C@H]2CCOC2)cc(c13)ncnc3Nc4cc(Cl)c(F)cc4
1534	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB09330	approved	Osimertinib	CN(C)CCN(C)c1cc(OC)c(cc1NC(=O)C=C)Nc2nccc(n2)-c3cn(C)c(c34)cccc4
1538	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB11737	experimental; investigational	Icotinib	C#Cc1cccc(c1)Nc2ncnc(c23)cc4c(c3)OCCOCCOCCO4
1539	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB11828	approved; investigational	Neratinib	CN(C)C/C=C/C(=O)Nc(c(c1)OCC)cc(c12)c(c(cn2)C#N)Nc3ccc(c(Cl)c3)OCc4ccccn4
1540	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB11963	approved; investigational	Dacomitinib	C1CCCCN1C/C=C/C(=O)Nc(c(c2)OC)cc(c23)c(ncn3)Nc4cc(Cl)c(F)cc4
1541	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1543	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1544	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB13164	investigational	Olmutinib	CN1CCN(CC1)c2ccc(cc2)Nc(n3)nc(c(c34)scc4)Oc5cccc(c5)NC(=O)C=C
1545	sp|P61075|CDC2H_PL	P00533	96.18	711.0	988.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1546	sp|P61075|CDC2H_PL	P80192	84.38	144.0	387.0	DB08703	experimental	12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one	CC(C)Oc(c1)ccc(c12)c3c(CC2)c4c(c5c3C(=O)N=C5)c6c(n4CCO)cccc6
1547	sp|P61075|CDC2H_PL	P80192	84.38	144.0	387.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1548	sp|P61075|CDC2H_PL	Q16584	93.4	116.0	385.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1549	sp|P61075|CDC2H_PL	Q16832	84.03	564.0	806.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
1550	sp|P61075|CDC2H_PL	Q16832	84.03	564.0	806.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1551	sp|P61075|CDC2H_PL	P46734	76.04	65.0	284.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1552	sp|P61075|CDC2H_PL	Q09013	80.56	69.0	301.0	DB01946	experimental	Bisindolylmaleimide VIII	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(CCCN)c(c45)cccc5
1553	sp|P61075|CDC2H_PL	P30530	93.75	538.0	808.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1554	sp|P61075|CDC2H_PL	P30530	93.75	538.0	808.0	DB12141	approved; investigational	Gilteritinib	C1COCCC1Nc2c(CC)nc(C(=O)N)c(n2)Nc3ccc(c(c3)OC)N4CCC(CC4)N5CCN(C)CC5
1555	sp|P61075|CDC2H_PL	O95835	90.97	705.0	967.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1556	sp|P61075|CDC2H_PL	P52564	76.74	52.0	273.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1557	sp|P61075|CDC2H_PL	P10398	73.61	311.0	523.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1558	sp|P61075|CDC2H_PL	Q04912	88.89	1086.0	1342.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1559	sp|P61075|CDC2H_PL	Q02779	80.9	97.0	330.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1560	sp|P61075|CDC2H_PL	P35590	90.62	838.0	1099.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1562	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB01259	approved; investigational	Lapatinib	CS(=O)(=O)CCNCc1ccc(o1)-c(cc2)cc(c23)c(ncn3)Nc4cc(Cl)c(cc4)OCc5cc(F)ccc5
1565	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB05944	investigational	Varlitinib	C[C@@H]1COC(=N1)Nc(c2)ccc(c23)ncnc3Nc4ccc(c(Cl)c4)OCc5nccs5
1566	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB06021	investigational	AV-412	CN1CCN(CC1)C(C)(C)C#Cc(c2)c(NC(=O)C=C)cc(c23)c(ncn3)Nc4ccc(F)c(Cl)c4
1568	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB08916	approved	Afatinib	CN(C)C/C=C/C(=O)Nc(c1)c(O[C@H]2CCOC2)cc(c13)ncnc3Nc4cc(Cl)c(F)cc4
1569	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB11652	approved; investigational	Tucatinib	CC1(C)N=C(OC1)Nc(c2)ccc(c23)ncnc3Nc4cc(C)c(cc4)Oc(cc5)cc(n56)ncn6
1570	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB11973	investigational	Tesevatinib	CN(C1)C[C@@H]([C@@H]12)C[C@@H](C2)COc(c(c3)OC)cc(c34)ncnc4Nc5ccc(Cl)c(Cl)c5F
1571	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1572	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1573	sp|P61075|CDC2H_PL	P04626	90.97	720.0	982.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
1574	sp|P61075|CDC2H_PL	Q08345	86.46	610.0	859.0	DB00619	approved	Imatinib	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(C)cc3)Nc4nccc(n4)-c5cnccc5
1575	sp|P61075|CDC2H_PL	Q08345	86.46	610.0	859.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1576	sp|P61075|CDC2H_PL	P08922	88.54	1949.0	2204.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
1577	sp|P61075|CDC2H_PL	P08922	88.54	1949.0	2204.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1578	sp|P61075|CDC2H_PL	P33981	80.21	525.0	756.0	DB01782	experimental	Pyrazolanthrone	c1cccc(c12)c3c4c([nH]n3)cccc4C2=O
1579	sp|P61075|CDC2H_PL	P33981	80.21	525.0	756.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1580	sp|P61075|CDC2H_PL	P33981	80.21	525.0	756.0	DB15498	experimental	BOS172722	Cn1cnnc1-c2cc(OCC)c(cc2)Nc(n3)ncc(c34)cc(C)nc4NCC(C)(C)C
1581	sp|P61075|CDC2H_PL	Q12866	82.64	589.0	827.0	DB08325	experimental	2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol	CC(C)n1cnc(c12)c(nc(n2)NCCO)Nc3cc(Cl)ccc3
1582	sp|P61075|CDC2H_PL	Q12866	82.64	589.0	827.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1583	sp|P61075|CDC2H_PL	P14616	94.44	978.0	1250.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1584	sp|P61075|CDC2H_PL	Q59H18	74.31	461.0	675.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1585	sp|P61075|CDC2H_PL	P9WI81	81.94	9.0	245.0	DB02930	experimental	Adenosine 5'-[gamma-thio]triphosphate	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=S)(O)O
1586	sp|P61075|CDC2H_PL	P9WI81	81.94	9.0	245.0	DB03909	experimental	Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate	OP(=O)(O)CP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
1587	sp|P61075|CDC2H_PL	P9WI81	81.94	9.0	245.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1588	sp|P61075|CDC2H_PL	P53671	71.53	334.0	540.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1589	sp|P61075|CDC2H_PL	Q06418	87.5	516.0	768.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1590	sp|P61075|CDC2H_PL	Q13546	84.03	16.0	258.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1591	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB01754	experimental	3,4-Dihydroxy-1-Methylquinolin-2(1h)-One	Cn1c(=O)c(O)c(O)c(c12)cccc2
1592	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
1593	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB02656	experimental	LY-294002	C1COCCN1c(cc2=O)oc(c23)c(ccc3)-c4ccccc4
1594	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB03366	experimental; investigational	Imidazole	[nH]1ccnc1
1595	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB03650	experimental	(3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One	Oc1ccc(cc1)/N=C2\C(=O)Nc(c23)cccc3
1596	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB03777	experimental	Bisindolylmaleimide I	CN(C)CCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
1597	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
1598	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1599	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
1600	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB04530	experimental	S,S-(2-Hydroxyethyl)Thiocysteine	OC(=O)[C@@H](N)CSSCCO
1601	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB04715	experimental	IMIDAZOPYRIDAZIN 1	CC(=O)c1cccc(c1)-c2cnc(n23)ccc(n3)NCC4CC4
1602	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB07151	experimental	4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one	Oc1ccc(cc1C)C2=NC(=O)N=C(C2)c3ccccc3
1603	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB07242	experimental	(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile	C1CN(C)CCC12[C@H](C#N)c3c(C(=O)N2)n(C)c4c3ccc(Cl)c4Cl
1604	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB07524	experimental	N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine	c1ccccc1Nc2c[nH]c(c23)nccc3
1605	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB08022	experimental	(2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile	c1cccc(c12)nc(s2)[C@H](C#N)c3nc(ncc3)NCCc4cccnc4
1606	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB08166	experimental	(4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile	C1CNCCC12[C@H](C#N)c3c(C(=O)N2)n(C)c4c3ccc(Cl)c4
1607	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB08230	experimental	Tricetin	Oc(c1)cc(O)c(c12)c(=O)cc(o2)-c3cc(O)c(O)c(O)c3
1608	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB08705	experimental	6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE	Brc1ccc(O)c(c1)-c2cc(c(C#N)c(=O)[nH]2)-c3ccccc3
1609	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB08707	experimental	4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine	Nc1nccc(n1)-c(cc2)cc(c23)c(on3)-c4ccc(Cl)cc4
1610	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB08708	experimental	N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine	FC(F)(F)c1cccc(c1)-c2nnc(n23)ccc(n3)NC4CCCCC4
1611	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB08709	experimental	2,3-diphenyl-1H-indole-7-carboxylic acid	O=C(O)c1cccc(c12)c(-c3ccccc3)c([nH]2)-c4ccccc4
1612	sp|P61075|CDC2H_PL	P11309	72.92	128.0	338.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1613	sp|P61075|CDC2H_PL	Q8TDR2	111.46	201.0	522.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1615	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1616	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB08865	approved	Crizotinib	Clc1c(F)ccc(Cl)c1[C@@H](C)Oc2cc(cnc2N)-c3cn(nc3)C4CCNCC4
1617	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB09063	approved	Ceritinib	C1CNCCC1c2cc(OC(C)C)c(cc2C)Nc3ncc(Cl)/c([nH]3)=N\c4ccccc4S(=O)(=O)C(C)C
1618	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB11363	approved; investigational	Alectinib	C1COCCN1C2CCN(CC2)c(c3)c(CC)cc(c34)C(=O)c5c(C4(C)C)[nH]c6c5ccc(c6)C#N
1619	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1620	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB12130	approved; investigational	Lorlatinib	Fc(c1)ccc(c12)C(=O)N(C)Cc3c(c(C#N)n(n3)C)c4cc(O[C@@H]2C)c(N)nc4
1621	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB12141	approved; investigational	Gilteritinib	C1COCCC1Nc2c(CC)nc(C(=O)N)c(n2)Nc3ccc(c(c3)OC)N4CCC(CC4)N5CCN(C)CC5
1622	sp|P61075|CDC2H_PL	Q9UM73	91.67	1115.0	1379.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
1623	sp|P61075|CDC2H_PL	O00238	98.96	202.0	487.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1624	sp|P61075|CDC2H_PL	Q86V86	73.61	38.0	250.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1625	sp|P61075|CDC2H_PL	P19525	77.43	266.0	489.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1626	sp|P61075|CDC2H_PL	P29376	97.22	511.0	791.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1627	sp|P61075|CDC2H_PL	P36897	96.88	207.0	486.0	DB03921	experimental	4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline	n1ccccc1-c2n[nH]cc2-c(ccn3)c(c34)cccc4
1628	sp|P61075|CDC2H_PL	P36897	96.88	207.0	486.0	DB04434	experimental	Naphthyridine Inhibitor	Cc1cccc(n1)C2=C(CNN2)c(n3)ccc(c34)nccc4
1629	sp|P61075|CDC2H_PL	P36897	96.88	207.0	486.0	DB04480	experimental	3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole	C1CCn(c12)nc(-c(nc3C)ccc3)c2-c4ccc(F)cc4
1630	sp|P61075|CDC2H_PL	P36897	96.88	207.0	486.0	DB07152	experimental	N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide	Fc1ccc(nc1C)-c2nc(NC(=O)C)[nH]c2-c(c3)ccc(c34)nccn4
1631	sp|P61075|CDC2H_PL	P36897	96.88	207.0	486.0	DB07267	experimental	2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine	Cc1cccc(n1)-c(n2)nc(c(c23)cccc3)Nc4ccncc4
1632	sp|P61075|CDC2H_PL	P36897	96.88	207.0	486.0	DB08450	experimental	N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine	Cc1cccc(n1)-c(n2)nc(c(c23)cccc3)Nc(c4)ccc(c45)[nH]nc5
1633	sp|P61075|CDC2H_PL	P36897	96.88	207.0	486.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1634	sp|P61075|CDC2H_PL	Q99640	71.88	108.0	315.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1635	sp|P61075|CDC2H_PL	Q04771	98.61	207.0	491.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1636	sp|P61075|CDC2H_PL	Q04771	98.61	207.0	491.0	DB08597	experimental	Dorsomorphin	C1CCCCN1CCOc2ccc(cc2)-c(cn3)cn(c34)ncc4-c5ccncc5
1637	sp|P61075|CDC2H_PL	Q04771	98.61	207.0	491.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1638	sp|P61075|CDC2H_PL	Q52WX2	73.26	51.0	262.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1639	sp|P61075|CDC2H_PL	O14976	78.82	41.0	268.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1640	sp|P61075|CDC2H_PL	Q14164	81.94	11.0	247.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1641	sp|P61075|CDC2H_PL	P21860	90.28	709.0	969.0	DB11652	approved; investigational	Tucatinib	CC1(C)N=C(OC1)Nc(c2)ccc(c23)ncnc3Nc4cc(C)c(cc4)Oc(cc5)cc(n56)ncn6
1642	sp|P61075|CDC2H_PL	Q9UHD2	80.56	12.0	244.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1644	sp|P61075|CDC2H_PL	O15197	75.35	671.0	888.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1645	sp|P61075|CDC2H_PL	P36896	96.53	209.0	487.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1646	sp|P61075|CDC2H_PL	P36896	96.53	209.0	487.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1647	sp|P61075|CDC2H_PL	P57078	79.51	21.0	250.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1649	sp|P61075|CDC2H_PL	Q13873	102.43	201.0	496.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1650	sp|P61075|CDC2H_PL	Q8NFD2	73.96	26.0	239.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1651	sp|P61075|CDC2H_PL	P37023	97.57	204.0	485.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1652	sp|P61075|CDC2H_PL	O75716	75.69	18.0	236.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1653	sp|P61075|CDC2H_PL	O43353	79.86	19.0	249.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1654	sp|P61075|CDC2H_PL	Q13470	80.21	119.0	350.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1655	sp|P61075|CDC2H_PL	O75460	70.83	574.0	778.0	DB07382	experimental	N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine	C1CC1c2n[nH]c(c2)Nc3ccnc(n3)Nc(cc4)cc(c45)nc[nH]5
1656	sp|P61075|CDC2H_PL	O75460	70.83	574.0	778.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1657	sp|P61075|CDC2H_PL	Q5S007	71.88	1885.0	2092.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1660	sp|P61075|CDC2H_PL	P37173	99.65	247.0	534.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1661	sp|P61075|CDC2H_PL	P51617	77.08	211.0	433.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1662	sp|P61075|CDC2H_PL	Q2M2I8	75.69	47.0	265.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1663	sp|P61075|CDC2H_PL	Q9NSY1	75.0	53.0	269.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1664	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB04608	experimental	9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE	c1cc(O)cc(c12)c3c([nH]2)cc(c4c3C(=O)NC4=O)-c5ccccc5
1665	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB07006	experimental	9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE	COc1ccccc1-c2cc(c3c(c24)C(=O)NC4=O)n(CCCO)c5c3cc(O)cc5
1666	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB07226	experimental	N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE	Clc1ccccc1-c2cc(c3c(c24)C(=O)NC4=O)[nH]c5c3cc(cc5)NC=O
1667	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB07257	experimental	4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione	OCCc(cn1C)c(c12)c3c(C(=O)NC3=O)c(c2)-c4ccccc4Cl
1668	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB07265	experimental	3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID	Oc(c1)ccc(c12)n(CCC(=O)O)c3c2c4c(C(=O)NC4=O)c(c3)-c5ccccc5
1669	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB08365	experimental	8-bromo-4-(2-chlorophenyl)-N-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide	OCCNC(=O)c(c1Br)n(C)c(c12)cc(c3c2C(=O)NC3=O)-c4c(Cl)cccc4
1670	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB11740	investigational	MK-1775	CN1CCN(CC1)c2ccc(cc2)Nc(n3)ncc(c34)c(=O)n(CC=C)n4-c5nc(C(C)(C)O)ccc5
1671	sp|P61075|CDC2H_PL	P30291	78.82	298.0	525.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1672	sp|P61075|CDC2H_PL	Q9Y6M4	79.17	42.0	270.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
1673	sp|P61075|CDC2H_PL	Q9Y6M4	79.17	42.0	270.0	DB07488	experimental	{4-Amino-2-[(4-methoxyphenyl)amino]-1,3-thiazol-5-yl}(4-methoxyphenyl)methanone	COc1ccc(cc1)/N=c2/[nH]c(N)c(s2)C(=O)c3ccc(OC)cc3
1674	sp|P61075|CDC2H_PL	Q9Y6M4	79.17	42.0	270.0	DB07489	experimental	4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium	Fc1ccc(cc1)C(=O)c2c(N)[nH+]c(s2)Nc3cc(Cl)ccc3
1675	sp|P61075|CDC2H_PL	Q9Y6M4	79.17	42.0	270.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
1676	sp|P61075|CDC2H_PL	Q9Y616	78.47	164.0	390.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1677	sp|P61075|CDC2H_PL	Q9HCP0	81.25	43.0	277.0	DB08325	experimental	2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol	CC(C)n1cnc(c12)c(nc(n2)NCCO)Nc3cc(Cl)ccc3
1678	sp|P61075|CDC2H_PL	P48729	77.78	16.0	240.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1679	sp|P61075|CDC2H_PL	P78368	79.17	45.0	273.0	DB03083	experimental	IC261	COc1cc(OC)c(c(c1)OC)/C=C2/C(=O)Nc(c23)cccc3
1680	sp|P61075|CDC2H_PL	P78368	79.17	45.0	273.0	DB03693	experimental	N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide	NCCNS(=O)(=O)c1ccc(Cl)c(c12)ccnc2
1681	sp|P61075|CDC2H_PL	P78368	79.17	45.0	273.0	DB04604	experimental	5-iodotubercidin	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cc(I)c(c23)c(N)ncn3
1682	sp|P61075|CDC2H_PL	P49674	78.82	7.0	234.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
1683	sp|P61075|CDC2H_PL	P20594	72.22	538.0	746.0	DB01613	approved; experimental; investigational	Erythrityl tetranitrate	[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O
1685	sp|P61075|CDC2H_PL	Q16671	102.43	206.0	501.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1686	sp|P61075|CDC2H_PL	P16066	74.65	547.0	762.0	DB00325	approved; investigational	Nitroprusside	O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N
1687	sp|P61075|CDC2H_PL	P16066	74.65	547.0	762.0	DB00727	approved; investigational	Nitroglycerin	[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O
1688	sp|P61075|CDC2H_PL	P16066	74.65	547.0	762.0	DB00883	approved; investigational	Isosorbide dinitrate	[O-][N+](=O)O[C@H]1CO[C@@H]([C@@H]12)[C@@H](CO2)O[N+]([O-])=O
1689	sp|P61075|CDC2H_PL	P16066	74.65	547.0	762.0	DB01612	approved	Amyl Nitrite	CCCCCON=O
1690	sp|P61075|CDC2H_PL	P16066	74.65	547.0	762.0	DB01613	approved; experimental; investigational	Erythrityl tetranitrate	[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O
1692	sp|P61075|CDC2H_PL	P16066	74.65	547.0	762.0	DB05034	investigational	Ularitide	O=C1NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)O)Cc3ccc(O)cc3)CSSC[C@@H](C(=O)N[C@@H](Cc4ccccc4)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@H]1[C@@H](C)CC)CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]5CCCN5C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O
1693	sp|P61075|CDC2H_PL	P0C264	70.14	41.0	243.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1694	sp|Q8IBZ9|CRT_PLAF	Q9N623	99.76	1.0	424.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1695	sp|Q8I4X0|ACT1_PLA	P60709	99.2	2.0	375.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
1696	sp|Q8I4X0|ACT1_PLA	P60709	99.2	2.0	375.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
1697	sp|Q8I4X0|ACT1_PLA	P63261	99.2	2.0	375.0	DB09130	approved; investigational	Copper	[Cu]
1698	sp|Q8I4X0|ACT1_PLA	P63261	99.2	2.0	375.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1699	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB02621	experimental	Latrunculin A	O=C1N[C@@H](CS1)[C@@](O)(C[C@@H]23)O[C@@H](C2)CC[C@H](C)/C=C\C=C\CC/C(C)=C\C(=O)O3
1700	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB02772	approved; experimental; investigational	Sucrose	OC[C@@H](O1)[C@@H](O)[C@H](O)[C@]1(CO)O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O
1701	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB03021	experimental	Ulapualide A	OCN(C)/C=C/C(C)C(OC(=O)C)[C@H](C)C(=O)CC[C@H](C)[C@@H](OC)C[C@@H]([C@H](C)[C@@H](OC)C/C=C/1)OC(=O)C[C@@H](O)CCCC(=O)C[C@H](C)c(co2)nc2c(co3)nc3c(nc14)co4
1702	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB03616	experimental	Kabiramide C	OCN(C)/C=C/[C@@H](C)[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@@H](OC)C[C@@H]([C@H](C)[C@@H](OC)C/C=C/1)OC(=O)C[C@@H](O[C@H](N)O)C[C@H](C)C[C@H](O)[C@H](C)[C@@H](OC)c(co2)nc2c(co3)nc3c(nc14)co4
1703	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB03850	experimental	Jaspisamide A	OCN(C)/C=C/C[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@@H](OC)C[C@@H]([C@H](C)CC/C=C/1)OC(=O)C[C@@H](O)C[C@H](O)CC(=O)[C@H](C)[C@H](OC)c(co2)nc2c(co3)nc3c(nc14)co4
1704	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB03903	experimental	Tmr	CN(C)C(C=1)=CCC(C12)=C(c3c(O2)cc(cc3)N(C)C)c4ccc(cc4C(=O)O)N5C(=O)C=CC5=O
1705	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB04151	experimental	1-Methylhistidine	Cn1cnc(c1)C[C@H](N)C(=O)O
1706	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1707	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB04629	experimental	Aplyronine A	COC[C@H](N(C)C)C(=O)O[C@@H]1C/C=C/C=C/C(=O)O[C@H]([C@@H](C)[C@@H](O)[C@@H](C)CC[C@@H](OC(=O)[C@H](C)N(C)C)[C@H](C)[C@H](OC(=O)C)[C@H](C)/C=C/N(C)C=O)C/C=C/[C@H](OC)C[C@H](C)C/C=C(\C)[C@@H](OC)CC[C@@H](C)[C@@H](O)[C@@H]1C
1708	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB04774	experimental	Reidispongiolide A	O=CN(C)/C=C/C[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@H](OC)[C@H](C)[C@@H](OC(=O)/C=C/C=C(\C)C[C@@H](OC)CC(C1)=CC(O2)=O)[C@@H](C)/C=C/[C@H](OC)C[C@H](OC)[C@@H](C)/C=C/[C@@H](OC)C[C@H](OC)[C@@H](C)[C@@H]12
1709	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB04775	experimental	Reidispongiolide C	C12=CC(=O)O[C@H](C1)[C@H](C)[C@@H](OC)C[C@H](OC)\C=C\[C@H](C)[C@@H](OC)C[C@@H](OC)\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C(C)\C[C@H](C2)OC)[C@@H](C)[C@@H](OC)[C@@H](C)CCC(=O)[C@H](C)[C@H](OC)CCC(=O)O
1710	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB04783	experimental	Sphinxolide B	O=CN(C)/C=C/C[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@H](OC)[C@H](C)[C@@H](OC(=O)/C=C/C=C(/C)C[C@@H](OC)CC([C@@H]1O)=CC(O2)=O)[C@@H](C)/C=C/[C@H](OC)C[C@H](O)[C@@H](C)/C=C/[C@@H](OC)C[C@H](OC)[C@@H](C)[C@@H]12
1711	sp|Q8I4X0|ACT1_PLA	P68133	99.2	4.0	377.0	DB08080	experimental	Latrunculin B	O=C1N[C@@H](CS1)[C@@](O)(C[C@@H]23)O[C@@H](C2)CC[C@H](C)/C=C\CC/C(C)=C\C(=O)O3
1712	sp|Q8I4X0|ACT1_PLA	P62736	99.2	4.0	377.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
1713	sp|Q8I4X0|ACT1_PLA	P86287	99.73	1.0	376.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1714	sp|Q8I4X0|ACT1_PLA	P61160	101.6	5.0	387.0	DB08235	experimental	N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide	c1cccc(c12)c(c([nH]2)C)CCNC(=O)c3cccs3
1715	sp|Q8I4X0|ACT1_PLA	P61160	101.6	5.0	387.0	DB08236	experimental	(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one	Brc1cc(ccc1)[C@@H]2SCC(=O)N2c3cc(Cl)ccc3O
1716	sp|Q8I4X0|ACT1_PLA	P61158	107.45	6.0	410.0	DB08235	experimental	N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide	c1cccc(c12)c(c([nH]2)C)CCNC(=O)c3cccs3
1717	sp|Q8I4X0|ACT1_PLA	P61158	107.45	6.0	410.0	DB08236	experimental	(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one	Brc1cc(ccc1)[C@@H]2SCC(=O)N2c3cc(Cl)ccc3O
1718	sp|Q7KQM0|TPIS_PLA	Q07412	99.6	1.0	248.0	DB01709	experimental	2-phospho-D-glyceric acid	OC[C@H](C(=O)O)OP(=O)(O)O
1719	sp|Q7KQM0|TPIS_PLA	Q07412	99.6	1.0	248.0	DB01779	experimental	Glycerol 2-phosphate	OCC(CO)OP(=O)(O)O
1720	sp|Q7KQM0|TPIS_PLA	Q07412	99.6	1.0	248.0	DB02515	experimental	sn-glycerol 3-phosphate	OC[C@@H](O)COP(=O)(O)O
1721	sp|Q7KQM0|TPIS_PLA	Q07412	99.6	1.0	248.0	DB02726	experimental	2-Phosphoglycolic Acid	OC(=O)COP(=O)(O)O
1722	sp|Q7KQM0|TPIS_PLA	Q07412	99.6	1.0	248.0	DB02951	experimental	3-Hydroxypyruvic Acid	OCC(=O)C(=O)O
1723	sp|Q7KQM0|TPIS_PLA	Q07412	99.6	1.0	248.0	DB04510	experimental	3-phospho-D-glyceric acid	OC(=O)[C@H](O)COP(=O)(O)O
1724	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB01593	approved; investigational	Zinc	[Zn]
1725	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB01695	experimental	N-Hydroxy-4-Phosphono-Butanamide	ONC(=O)CCCP([O-])([O-])=O
1726	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB02726	experimental	2-Phosphoglycolic Acid	OC(=O)COP(=O)(O)O
1727	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB03026	experimental	Phosphoglycolohydroxamic Acid	ONC(=O)COP(=O)(O)O
1728	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB03132	experimental	3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid	OS(=O)(=O)CCCSc(s1)nc(c12)cccc2
1729	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB03135	experimental	[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid	O=CN(O)CCP(=O)(O)O
1730	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB03314	experimental	5-fluorotryptophan	OC(=O)[C@@H](N)Cc1c[nH]c(c12)ccc(F)c2
1731	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB03379	experimental	2-Carboxyethylphosphonic Acid	OC(=O)CCP(=O)(O)O
1732	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB03900	experimental	tert-butanol	CC(C)(C)O
1733	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB04326	investigational	Dihydroxyacetone phosphate	OCC(=O)COP(=O)(O)O
1734	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB04447	experimental	1,4-Dithiothreitol	SC[C@H](O)[C@@H](O)CS
1735	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB04510	experimental	3-phospho-D-glyceric acid	OC(=O)[C@H](O)COP(=O)(O)O
1736	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB07387	experimental	3-(BUTYLSULPHONYL)-PROPANOIC ACID	CCCCS(=O)(=O)CCC(=O)O
1737	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1738	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1739	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1740	sp|Q7KQM0|TPIS_PLA	P60174	97.98	41.0	284.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1741	sp|Q7KQM0|TPIS_PLA	P36204	99.19	401.0	647.0	DB04510	experimental	3-phospho-D-glyceric acid	OC(=O)[C@H](O)COP(=O)(O)O
1742	sp|Q7KQM0|TPIS_PLA	P52270	97.58	7.0	249.0	DB03132	experimental	3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid	OS(=O)(=O)CCCSc(s1)nc(c12)cccc2
1743	sp|Q7KQM0|TPIS_PLA	P00943	99.6	2.0	249.0	DB02726	experimental	2-Phosphoglycolic Acid	OC(=O)COP(=O)(O)O
1744	sp|Q7KQM0|TPIS_PLA	P50921	100.4	2.0	251.0	DB02726	experimental	2-Phosphoglycolic Acid	OC(=O)COP(=O)(O)O
1745	sp|O97313|RS3A_PLA	O97313	99.62	1.0	262.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1746	sp|Q8I5R7|SYP_PLAF	P07814	77.61	933.0	1512.0	DB00142	approved; nutraceutical	Glutamic acid	OC(=O)[C@@H](N)CCC(=O)O
1747	sp|Q8I5R7|SYP_PLAF	P07814	77.61	933.0	1512.0	DB00172	nutraceutical	Proline	OC(=O)[C@@H]1CCCN1
1748	sp|Q8I5R7|SYP_PLAF	P07814	77.61	933.0	1512.0	DB02510	experimental	5'-O-(L-Prolylsulfamoyl)adenosine	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COS(=O)(=O)NC(=O)[C@@H]4CCCN4
1749	sp|Q8I5R7|SYP_PLAF	P07814	77.61	933.0	1512.0	DB02684	experimental	5'-O-(L-Cysteinylsulfamoyl)adenosine	SC[C@H](N)C(=O)NS(=O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
1750	sp|Q8I5R7|SYP_PLAF	P07814	77.61	933.0	1512.0	DB03376	experimental	5'-O-(N-(Alanyl)sulfamoyl)adenosine	N[C@@H](C)C(=O)NS(=O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
1751	sp|Q9TW89|SODF_PLA	P04179	95.96	27.0	217.0	DB03297	experimental	Benzylsulfonic acid	OS(=O)(=O)Cc1ccccc1
1752	sp|Q9TW89|SODF_PLA	P04179	95.96	27.0	217.0	DB04436	experimental	3-Fluoro-L-tyrosine	OC(=O)[C@@H](N)Cc1cc(F)c(O)cc1
1753	sp|Q7KQL8|THIO_PLA	C0H4Y6	81.73	38.0	123.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1754	sp|Q7KQL8|THIO_PLA	C0H4Y6	82.69	356.0	442.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1755	sp|Q7KQL8|THIO_PLA	P07237	79.81	28.0	111.0	DB01593	approved; investigational	Zinc	[Zn]
1756	sp|Q7KQL8|THIO_PLA	P07237	79.81	28.0	111.0	DB03615	approved; experimental	Ribostamycin	O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N
1757	sp|Q7KQL8|THIO_PLA	P07237	79.81	28.0	111.0	DB09130	approved; investigational	Copper	[Cu]
1758	sp|Q7KQL8|THIO_PLA	P07237	79.81	28.0	111.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1759	sp|Q7KQL8|THIO_PLA	P07237	79.81	28.0	111.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1760	sp|Q7KQL8|THIO_PLA	P07237	79.81	28.0	111.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1761	sp|Q7KQL8|THIO_PLA	P07237	79.81	28.0	111.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1762	sp|Q7KQL8|THIO_PLA	P07237	77.88	369.0	450.0	DB01593	approved; investigational	Zinc	[Zn]
1763	sp|Q7KQL8|THIO_PLA	P07237	77.88	369.0	450.0	DB03615	approved; experimental	Ribostamycin	O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N
1764	sp|Q7KQL8|THIO_PLA	P07237	77.88	369.0	450.0	DB09130	approved; investigational	Copper	[Cu]
1765	sp|Q7KQL8|THIO_PLA	P07237	77.88	369.0	450.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1766	sp|Q7KQL8|THIO_PLA	P07237	77.88	369.0	450.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1767	sp|Q7KQL8|THIO_PLA	P07237	77.88	369.0	450.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1768	sp|Q7KQL8|THIO_PLA	P07237	77.88	369.0	450.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1769	sp|Q7KQL8|THIO_PLA	P30101	82.69	33.0	119.0	DB01593	approved; investigational	Zinc	[Zn]
1770	sp|Q7KQL8|THIO_PLA	P30101	82.69	33.0	119.0	DB09130	approved; investigational	Copper	[Cu]
1771	sp|Q7KQL8|THIO_PLA	P30101	82.69	33.0	119.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1772	sp|Q7KQL8|THIO_PLA	P30101	82.69	33.0	119.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1773	sp|Q7KQL8|THIO_PLA	P30101	82.69	33.0	119.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1774	sp|Q7KQL8|THIO_PLA	P30101	81.73	378.0	463.0	DB01593	approved; investigational	Zinc	[Zn]
1775	sp|Q7KQL8|THIO_PLA	P30101	81.73	378.0	463.0	DB09130	approved; investigational	Copper	[Cu]
1776	sp|Q7KQL8|THIO_PLA	P30101	81.73	378.0	463.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1777	sp|Q7KQL8|THIO_PLA	P30101	81.73	378.0	463.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1778	sp|Q7KQL8|THIO_PLA	P30101	81.73	378.0	463.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1779	sp|Q7KQL8|THIO_PLA	P10599	98.08	1.0	103.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
1780	sp|Q7KQL8|THIO_PLA	Q8IKL4	97.12	12.0	113.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1781	sp|Q7KQL8|THIO_PLA	Q8IB72	82.69	191.0	277.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1782	sp|Q8IAY6|SODF_PLA	P04179	95.96	27.0	217.0	DB03297	experimental	Benzylsulfonic acid	OS(=O)(=O)Cc1ccccc1
1783	sp|Q8IAY6|SODF_PLA	P04179	95.96	27.0	217.0	DB04436	experimental	3-Fluoro-L-tyrosine	OC(=O)[C@@H](N)Cc1cc(F)c(O)cc1
1785	sp|Q8IJD4|RSSA_PLA	P08865	92.02	9.0	251.0	DB09130	approved; investigational	Copper	[Cu]
1786	sp|P61076|TRXR2_PL	Q9NNW7	79.58	33.0	524.0	DB05428	investigational	Motexafin gadolinium	CCc(c12)c(CC)c([n-]1)cc3nc(c(C)c3CCCO)cnc4c(ncc5nc(c2)c(c5C)CCCO)cc(OCCOCCOCCOC)c(c4)OCCOCCOCCOC
1787	sp|P61076|TRXR2_PL	Q16881	79.42	159.0	649.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
1788	sp|P61076|TRXR2_PL	Q16881	79.42	159.0	649.0	DB02338	experimental	NADPH	NC(=O)C1=CN(C=CC1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@H]([C@@H]([C@@H]3O)OP(=O)(O)O)n4cnc(c45)c(N)ncn5
1789	sp|P61076|TRXR2_PL	Q16881	79.42	159.0	649.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1790	sp|P61076|TRXR2_PL	Q16881	79.42	159.0	649.0	DB03566	experimental	Spermidine	NCCCCNCCCN
1791	sp|P61076|TRXR2_PL	Q16881	79.42	159.0	649.0	DB04106	investigational	Fotemustine	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(N=O)CCCl
1792	sp|P61076|TRXR2_PL	Q16881	79.42	159.0	649.0	DB05428	investigational	Motexafin gadolinium	CCc(c12)c(CC)c([n-]1)cc3nc(c(C)c3CCCO)cnc4c(ncc5nc(c2)c(c5C)CCCO)cc(OCCOCCOCCOC)c(c4)OCCOCCOCCOC
1793	sp|P61076|TRXR2_PL	Q16881	79.42	159.0	649.0	DB05448	investigational	PX-12	CCC(C)SSc1ncc[nH]1
1794	sp|P61076|TRXR2_PL	P06715	72.45	2.0	449.0	DB00336	approved; investigational; vet_approved	Nitrofural	NC(=O)N/N=C/c1ccc(o1)[N+]([O-])=O
1795	sp|P61076|TRXR2_PL	P06715	72.45	2.0	449.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1796	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
1797	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB00157	approved; nutraceutical	NADH	NC(=O)C1=CN(C=CC1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n4cnc(c45)c(N)ncn5
1798	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB00262	approved; investigational	Carmustine	ClCCNC(=O)N(N=O)CCCl
1799	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB01644	experimental	3,6-dihydroxy-xanthene-9-propionic acid	OC(=O)CCC1c(ccc(c2)O)c2Oc(c13)cc(O)cc3
1800	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB02153	experimental	3-sulfino-L-alanine	OC(=O)[C@@H](N)C[S@](=O)O
1801	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB02553	experimental	Glutathionylspermidine disulfide	NCCCCNCCCNC(=O)CNC(=O)[C@@H](NC(=O)CC[C@@H](N)C(=O)O)CSSC[C@H](NC(=O)CC[C@@H](N)C(=O)O)C(=O)NCC(=O)NCCCNCCCCN
1802	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB02895	experimental	3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol	S/C=C/C[S@](=O)CC=C
1803	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1804	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
1805	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB03867	experimental	3-nitro-L-tyrosine	OC(=O)[C@@H](N)Cc1cc([N+]([O-])=O)c(O)cc1
1806	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB07393	experimental	2-(2-PHENYL-3-PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-2H-ISOPHOSPHINDOL-1-YL)PYRIDINE	n1ccccc1-c2p(-c3ccccc3)c(c(c24)CCCC4)-c5ncccc5
1807	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB07714	experimental	6-(3-METHYL-1,4-DIOXO-1,4-DIHYDRONAPHTHALEN-2-YL)HEXANOIC ACID	c1cccc(c12)C(=O)C(=C(C2=O)C)CCCCCC(=O)O
1808	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB09061	approved; investigational	Cannabidiol	CCCCCc1cc(O)c(c(O)c1)[C@@H]2C=C(C)CC[C@H]2C(C)=C
1809	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB09130	approved; investigational	Copper	[Cu]
1811	sp|P61076|TRXR2_PL	P00390	74.23	63.0	521.0	DB14011	investigational	Nabiximols	CC(=C)[C@@H]1CCC(C)=C[C@H]1c2c(O)cc(cc2O)CCCCC
1812	sp|P61076|TRXR2_PL	P14218	75.36	2.0	467.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1813	sp|P61076|TRXR2_PL	Q94655	79.74	3.0	495.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1814	sp|P61076|TRXR2_PL	P18925	75.36	2.0	467.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1815	sp|P61076|TRXR2_PL	P09622	76.34	36.0	507.0	DB00157	approved; nutraceutical	NADH	NC(=O)C1=CN(C=CC1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n4cnc(c45)c(N)ncn5
1816	sp|P61076|TRXR2_PL	P09622	76.34	36.0	507.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1817	sp|P61076|TRXR2_PL	P28593	75.85	4.0	472.0	DB02240	experimental	Quinacrine mustard	c1cc(Cl)cc(n2)c1c(c(c23)cc(OC)cc3)NC(C)CCCN(CCCl)CCCl
1818	sp|P61076|TRXR2_PL	P28593	75.85	4.0	472.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1819	sp|P61076|TRXR2_PL	P28593	75.85	4.0	472.0	DB03470	experimental	Trypanothione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(=O)O
1820	sp|P61076|TRXR2_PL	P28593	75.85	4.0	472.0	DB04299	experimental	Maleic Acid	OC(=O)/C=C\C(=O)O
1821	sp|P61076|TRXR2_PL	Q51225	75.04	114.0	577.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1822	sp|P61076|TRXR2_PL	P09063	72.61	2.0	450.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1824	sp|P61076|TRXR2_PL	Q56839	76.5	25.0	497.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
1825	sp|P61076|TRXR2_PL	Q56839	76.5	25.0	497.0	DB03163	experimental	2-oxopropyl-CoM	CC(=O)CSCCS(=O)(=O)O
1826	sp|P21422|RPOC1_PL	P0A8T7	83.13	34.0	512.0	DB00615	approved; investigational	Rifabutin	CC(C)CN(CC1)CCC12N=C3c4c5c6c(C)c(O)c4C(=O)C(=C3N2)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@H](C)[C@@H](OC)/C=C/O[C@](O6)(C)C5=O
1827	sp|P21422|RPOC1_PL	P0A8T7	83.13	34.0	512.0	DB11753	approved; investigational	Rifamycin	C[C@@]12O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(=O)C)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)C(=O)Nc3c(O)c4c(c(c3)O)c(C1=O)c(O2)c(C)c4O
1828	sp|Q7KQL3|ARF1_PLA	P84077	99.45	1.0	181.0	DB02774	experimental	1,3-Propanediol	OCCCO
1829	sp|Q7KQL3|ARF1_PLA	P84077	99.45	1.0	181.0	DB04121	experimental	Guanosine-3'-monophosphate-5'-diphosphate	Nc([nH]1)nc(=O)c(c12)ncn2[C@@H]3O[C@@H]([C@H]([C@H]3O)OP(=O)(O)O)COP(=O)(O)OP(=O)(O)O
1830	sp|Q7KQL3|ARF1_PLA	P84077	99.45	1.0	181.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1831	sp|Q7KQL3|ARF1_PLA	P84077	99.45	1.0	181.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1832	sp|Q7KQL3|ARF1_PLA	P84077	99.45	1.0	181.0	DB07348	experimental	Brefeldin A	O[C@H](C1)C[C@H]([C@@H]12)\C=C\CCC[C@H](C)OC(=O)\C=C\[C@H]2O
1833	sp|Q7KQL3|ARF1_PLA	P84077	99.45	1.0	181.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
1834	sp|Q7KQL3|ARF1_PLA	P84077	99.45	1.0	181.0	DB09462	approved; investigational	Glycerin	OCC(O)CO
1835	sp|Q7KQL3|ARF1_PLA	P18085	97.79	1.0	178.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1836	sp|Q7KQL3|ARF1_PLA	P62330	95.03	2.0	174.0	DB01864	experimental	5'-Guanosine-Diphosphate-Monothiophosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=S)(O)O
1837	sp|Q7KQL3|ARF1_PLA	P62330	95.03	2.0	174.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1838	sp|Q7KQL3|ARF1_PLA	P62330	95.03	2.0	174.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
1839	sp|Q7KQL3|ARF1_PLA	P40616	98.34	1.0	179.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1840	sp|Q7KQL3|ARF1_PLA	Q9Y689	97.24	1.0	177.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1841	sp|Q7KQL3|ARF1_PLA	Q96KC2	96.69	1.0	176.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1842	sp|Q7KQL3|ARF1_PLA	P36405	97.24	4.0	180.0	DB03814	experimental	2-(N-morpholino)ethanesulfonic acid	OS(=O)(=O)CCN1CCOCC1
1843	sp|Q7KQL3|ARF1_PLA	P36405	97.24	4.0	180.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1845	sp|Q7KQL3|ARF1_PLA	P01112	90.06	3.0	166.0	DB02210	experimental	Hexane-1,6-Diol	OCCCCCCO
1846	sp|Q7KQL3|ARF1_PLA	P01112	90.06	3.0	166.0	DB03226	experimental	Trifluoroethanol	OCC(F)(F)F
1847	sp|Q7KQL3|ARF1_PLA	P01112	90.06	3.0	166.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1848	sp|Q7KQL3|ARF1_PLA	P01112	90.06	3.0	166.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1849	sp|Q7KQL3|ARF1_PLA	P01112	90.06	3.0	166.0	DB08751	experimental	N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	CC(=O)N(C)CCN(C)c1ccc([N+]([O-])=O)c(c12)non2
1850	sp|Q7KQL3|ARF1_PLA	P01116	89.5	3.0	165.0	DB07771	experimental	[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID	CC(C)=CCC/C(C)=C/CC/C(C)=C/CONC(=O)CP(=O)(O)O
1851	sp|Q7KQL3|ARF1_PLA	P01116	89.5	3.0	165.0	DB07780	experimental	Farnesyl diphosphate	CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O
1852	sp|Q7KQL3|ARF1_PLA	P01116	89.5	3.0	165.0	DB15568	investigational	MRTX849	 
1853	sp|Q7KQL3|ARF1_PLA	P01116	89.5	3.0	165.0	DB15569	investigational	AMG-510	Fc1cccc(O)c1-c(n2)c(F)cc(c23)c(N4CCN(C[C@@H]4C)C(=O)C=C)nc(=O)n3-c5c(C)ccnc5C(C)C
1854	sp|Q7KQL3|ARF1_PLA	Q92930	88.95	9.0	170.0	DB02082	experimental	Phosphoaminophosphonic acid guanylate ester	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)NP(=O)(O)O
1855	sp|Q7KQL3|ARF1_PLA	Q92930	88.95	9.0	170.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1856	sp|Q7KQL3|ARF1_PLA	P11233	90.06	15.0	178.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1857	sp|Q7KQL3|ARF1_PLA	P38545	88.4	9.0	169.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1858	sp|Q7KQL3|ARF1_PLA	P62826	87.85	9.0	168.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1859	sp|Q7KQL3|ARF1_PLA	P10114	90.06	2.0	165.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1860	sp|Q7KQL3|ARF1_PLA	P10114	90.06	2.0	165.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1861	sp|Q7KQL3|ARF1_PLA	P20339	88.95	20.0	181.0	DB02467	experimental	L-methionine (S)-S-oxide	C[S@](=O)CC[C@@H](C([O-])=O)[NH3+]
1862	sp|Q7KQL3|ARF1_PLA	P20339	88.95	20.0	181.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1863	sp|Q7KQL3|ARF1_PLA	P20339	88.95	20.0	181.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1865	sp|Q7KQL3|ARF1_PLA	P51149	91.16	7.0	172.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1866	sp|Q7KQL3|ARF1_PLA	Q9Y6B6	97.24	21.0	197.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1868	sp|Q7KQL3|ARF1_PLA	P62491	88.4	12.0	172.0	DB01864	experimental	5'-Guanosine-Diphosphate-Monothiophosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=S)(O)O
1869	sp|Q7KQL3|ARF1_PLA	P62491	88.4	12.0	172.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1870	sp|Q7KQL3|ARF1_PLA	P61586	93.37	6.0	175.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1871	sp|Q7KQL3|ARF1_PLA	Q9X1F8	89.5	4.0	166.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1872	sp|Q7KQL3|ARF1_PLA	Q9X1F8	93.92	179.0	349.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1873	sp|Q7KQL3|ARF1_PLA	P51151	91.71	6.0	172.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1874	sp|Q7KQL3|ARF1_PLA	P63000	94.48	2.0	173.0	DB00514	approved	Dextromethorphan	C1CCC[C@@H]([C@]123)[C@@H](N(C)CC2)Cc4c3cc(OC)cc4
1875	sp|Q7KQL3|ARF1_PLA	P63000	94.48	2.0	173.0	DB00993	approved	Azathioprine	Cn1cnc([N+]([O-])=O)c1Sc2ncnc(c23)nc[nH]3
1876	sp|Q7KQL3|ARF1_PLA	P63000	94.48	2.0	173.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1877	sp|Q7KQL3|ARF1_PLA	P15153	94.48	2.0	173.0	DB00514	approved	Dextromethorphan	C1CCC[C@@H]([C@]123)[C@@H](N(C)CC2)Cc4c3cc(OC)cc4
1878	sp|Q7KQL3|ARF1_PLA	P60953	93.37	2.0	171.0	DB02623	experimental	Aminophosphonic acid-guanylate ester	Nc([nH]1)nc(=O)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)N
1879	sp|Q7KQL3|ARF1_PLA	P60953	93.37	2.0	171.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1880	sp|Q7KQL3|ARF1_PLA	Q15382	88.95	3.0	164.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1881	sp|Q7KQL3|ARF1_PLA	Q15382	88.95	3.0	164.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1882	sp|Q7KQL3|ARF1_PLA	P61587	91.71	20.0	186.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1883	sp|Q7KQL3|ARF1_PLA	Q8I4W4	85.64	49.0	204.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1885	sp|Q7KQL3|ARF1_PLA	Q5S007	85.08	1326.0	1480.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1887	sp|Q7KQL3|ARF1_PLA	P15170	75.69	135.0	272.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1888	sp|Q7KQL3|ARF1_PLA	Q00080	84.53	48.0	201.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1889	sp|Q7KQL3|ARF1_PLA	P20964	92.27	163.0	330.0	DB04022	experimental	Guanosine tetraphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@H](COP(=O)(O)OP(=O)(O)O)[C@H]([C@H]3O)OP(=O)(O)OP(=O)(O)O
1890	sp|Q7KQL3|ARF1_PLA	Q83JC4	80.66	17.0	163.0	DB02975	experimental	GE-2270A	NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2COC(=N2)c3csc(n3)-c(n4)ccc5c(sc6)nc6C(=O)N[C@@H](CC(=O)NC)c(sc7C)nc7C(=O)N[C@@H](C(C)C)c(sc8COC)nc8C(=O)NCC(=O)N[C@@H]([C@@H](O)c9ccccc9)c(n1)scc1c(n1)scc1c45
1891	sp|Q7KQL3|ARF1_PLA	Q83JC4	80.66	17.0	163.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1892	sp|Q7KQL3|ARF1_PLA	Q01698	79.01	17.0	160.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1893	sp|Q7KQL3|ARF1_PLA	Q01698	79.01	17.0	160.0	DB08185	experimental	2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE	OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(nc(n3)SC)NCCC(C)C
1894	sp|Q7KQL3|ARF1_PLA	P60339	78.45	18.0	160.0	DB04124	experimental	Aurodox	O=c1n(C)ccc(O)c1C(=O)/C(C)=C/C=C/C=C/[C@H]2O[C@H]([C@@H](O)[C@H]2O)[C@H](C)[C@H](OC)/C(C)=C/C=C/CNC(=O)[C@@H](CC)[C@@]3(O)O[C@H](C(C)(C)[C@@H](O)[C@H]3O)/C=C/C=C\C
1895	sp|Q7KQL3|ARF1_PLA	P60339	78.45	18.0	160.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1896	sp|Q7KQL3|ARF1_PLA	P49411	73.48	62.0	195.0	DB01593	approved; investigational	Zinc	[Zn]
1897	sp|Q7KQL3|ARF1_PLA	P49411	73.48	62.0	195.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1898	sp|Q7KQL3|ARF1_PLA	P49411	73.48	62.0	195.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1899	sp|Q7KQL3|ARF1_PLA	P49411	73.48	62.0	195.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1900	sp|Q7KQL3|ARF1_PLA	P49411	73.48	62.0	195.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1901	sp|Q7KQL3|ARF1_PLA	P38424	73.48	26.0	159.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
1902	sp|Q7KQL3|ARF1_PLA	P38424	73.48	26.0	159.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1903	sp|Q8ID92|CADF2_PL	P23528	101.4	1.0	146.0	DB04147	experimental	Dodecyldimethylamine N-oxide	CCCCCCCCCCCC[N+]([O-])(C)C
1904	sp|Q8ID92|CADF2_PL	P23528	101.4	1.0	146.0	DB09130	approved; investigational	Copper	[Cu]
1905	sp|Q8ID92|CADF2_PL	P23528	101.4	1.0	146.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1906	sp|Q8ID92|CADF2_PL	P60981	100.0	1.0	144.0	DB04147	experimental	Dodecyldimethylamine N-oxide	CCCCCCCCCCCC[N+]([O-])(C)C
1907	sp|Q25820|EFTU_PLA	Q01698	98.29	1.0	404.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1908	sp|Q25820|EFTU_PLA	Q01698	98.29	1.0	404.0	DB08185	experimental	2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE	OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(nc(n3)SC)NCCC(C)C
1909	sp|Q25820|EFTU_PLA	P60339	98.29	1.0	404.0	DB04124	experimental	Aurodox	O=c1n(C)ccc(O)c1C(=O)/C(C)=C/C=C/C=C/[C@H]2O[C@H]([C@@H](O)[C@H]2O)[C@H](C)[C@H](OC)/C(C)=C/C=C/CNC(=O)[C@@H](CC)[C@@]3(O)O[C@H](C(C)(C)[C@@H](O)[C@H]3O)/C=C/C=C\C
1910	sp|Q25820|EFTU_PLA	P60339	98.29	1.0	404.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1911	sp|Q25820|EFTU_PLA	Q83JC4	95.37	1.0	392.0	DB02975	experimental	GE-2270A	NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2COC(=N2)c3csc(n3)-c(n4)ccc5c(sc6)nc6C(=O)N[C@@H](CC(=O)NC)c(sc7C)nc7C(=O)N[C@@H](C(C)C)c(sc8COC)nc8C(=O)NCC(=O)N[C@@H]([C@@H](O)c9ccccc9)c(n1)scc1c(n1)scc1c45
1912	sp|Q25820|EFTU_PLA	Q83JC4	95.37	1.0	392.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1913	sp|Q25820|EFTU_PLA	P68104	107.32	1.0	441.0	DB01593	approved; investigational	Zinc	[Zn]
1914	sp|Q25820|EFTU_PLA	P68104	107.32	1.0	441.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1915	sp|Q25820|EFTU_PLA	P68104	107.32	1.0	441.0	DB09130	approved; investigational	Copper	[Cu]
1916	sp|Q25820|EFTU_PLA	P68104	107.32	1.0	441.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1917	sp|Q25820|EFTU_PLA	P68104	107.32	1.0	441.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1918	sp|Q25820|EFTU_PLA	P68104	107.32	1.0	441.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1919	sp|Q25820|EFTU_PLA	P68104	107.32	1.0	441.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1920	sp|Q25820|EFTU_PLA	P49411	95.37	47.0	438.0	DB01593	approved; investigational	Zinc	[Zn]
1921	sp|Q25820|EFTU_PLA	P49411	95.37	47.0	438.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1922	sp|Q25820|EFTU_PLA	P49411	95.37	47.0	438.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1923	sp|Q25820|EFTU_PLA	P49411	95.37	47.0	438.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1924	sp|Q25820|EFTU_PLA	P49411	95.37	47.0	438.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1925	sp|Q25820|EFTU_PLA	Q00080	104.15	1.0	428.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1926	sp|Q25820|EFTU_PLA	Q96RE1	90.98	4.0	377.0	DB09130	approved; investigational	Copper	[Cu]
1927	sp|Q25820|EFTU_PLA	P15170	103.17	71.0	494.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1928	sp|Q25820|EFTU_PLA	P41091	99.76	34.0	443.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
1929	sp|Q7KQL9|ALF_PLAF	P14223	99.73	1.0	369.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1930	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB01593	approved; investigational	Zinc	[Zn]
1931	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB02512	experimental	1,6-Fructose Diphosphate (Linear Form)	OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)C(=O)COP(=O)(O)O
1932	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB04326	investigational	Dihydroxyacetone phosphate	OCC(=O)COP(=O)(O)O
1933	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB04733	experimental	1,6-DI-O-PHOSPHONO-D-MANNITOL	OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
1934	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB08240	experimental	N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE	c1cccc(c12)cc(c(c2)OP(=O)(O)O)C(=O)Nc3ccc(Cl)cc3
1935	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1936	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB14487	approved; investigational	Zinc acetate	CC([O-])=O
1937	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB14533	approved; investigational	Zinc chloride	[Cl-]
1938	sp|Q7KQL9|ALF_PLAF	P04075	96.48	8.0	364.0	DB14548	approved; experimental	Zinc sulfate, unspecified form	 
1939	sp|Q7KQL9|ALF_PLAF	P05062	96.48	8.0	364.0	DB02512	experimental	1,6-Fructose Diphosphate (Linear Form)	OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)C(=O)COP(=O)(O)O
1940	sp|Q7KQL9|ALF_PLAF	P05062	96.48	8.0	364.0	DB02515	experimental	sn-glycerol 3-phosphate	OC[C@@H](O)COP(=O)(O)O
1941	sp|Q7KQL9|ALF_PLAF	P05062	96.48	8.0	364.0	DB04326	investigational	Dihydroxyacetone phosphate	OCC(=O)COP(=O)(O)O
1942	sp|Q8IIJ9|CATC_PLA	A0A144A2G5	99.86	1.0	700.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1943	sp|Q9NJU9|CDPK3_PL	Q8IBS5	90.21	15.0	522.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1944	sp|Q9NJU9|CDPK3_PL	P62344	89.32	14.0	516.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
1945	sp|Q8ILW9|ACT2_PLA	P60709	99.47	1.0	375.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
1946	sp|Q8ILW9|ACT2_PLA	P60709	99.47	1.0	375.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
1947	sp|Q8ILW9|ACT2_PLA	P63261	99.47	1.0	375.0	DB09130	approved; investigational	Copper	[Cu]
1948	sp|Q8ILW9|ACT2_PLA	P63261	99.47	1.0	375.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1949	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB02621	experimental	Latrunculin A	O=C1N[C@@H](CS1)[C@@](O)(C[C@@H]23)O[C@@H](C2)CC[C@H](C)/C=C\C=C\CC/C(C)=C\C(=O)O3
1950	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB02772	approved; experimental; investigational	Sucrose	OC[C@@H](O1)[C@@H](O)[C@H](O)[C@]1(CO)O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O
1951	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB03021	experimental	Ulapualide A	OCN(C)/C=C/C(C)C(OC(=O)C)[C@H](C)C(=O)CC[C@H](C)[C@@H](OC)C[C@@H]([C@H](C)[C@@H](OC)C/C=C/1)OC(=O)C[C@@H](O)CCCC(=O)C[C@H](C)c(co2)nc2c(co3)nc3c(nc14)co4
1952	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB03616	experimental	Kabiramide C	OCN(C)/C=C/[C@@H](C)[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@@H](OC)C[C@@H]([C@H](C)[C@@H](OC)C/C=C/1)OC(=O)C[C@@H](O[C@H](N)O)C[C@H](C)C[C@H](O)[C@H](C)[C@@H](OC)c(co2)nc2c(co3)nc3c(nc14)co4
1953	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB03850	experimental	Jaspisamide A	OCN(C)/C=C/C[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@@H](OC)C[C@@H]([C@H](C)CC/C=C/1)OC(=O)C[C@@H](O)C[C@H](O)CC(=O)[C@H](C)[C@H](OC)c(co2)nc2c(co3)nc3c(nc14)co4
1954	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB03903	experimental	Tmr	CN(C)C(C=1)=CCC(C12)=C(c3c(O2)cc(cc3)N(C)C)c4ccc(cc4C(=O)O)N5C(=O)C=CC5=O
1955	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB04151	experimental	1-Methylhistidine	Cn1cnc(c1)C[C@H](N)C(=O)O
1956	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1957	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB04629	experimental	Aplyronine A	COC[C@H](N(C)C)C(=O)O[C@@H]1C/C=C/C=C/C(=O)O[C@H]([C@@H](C)[C@@H](O)[C@@H](C)CC[C@@H](OC(=O)[C@H](C)N(C)C)[C@H](C)[C@H](OC(=O)C)[C@H](C)/C=C/N(C)C=O)C/C=C/[C@H](OC)C[C@H](C)C/C=C(\C)[C@@H](OC)CC[C@@H](C)[C@@H](O)[C@@H]1C
1958	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB04774	experimental	Reidispongiolide A	O=CN(C)/C=C/C[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@H](OC)[C@H](C)[C@@H](OC(=O)/C=C/C=C(\C)C[C@@H](OC)CC(C1)=CC(O2)=O)[C@@H](C)/C=C/[C@H](OC)C[C@H](OC)[C@@H](C)/C=C/[C@@H](OC)C[C@H](OC)[C@@H](C)[C@@H]12
1959	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB04775	experimental	Reidispongiolide C	C12=CC(=O)O[C@H](C1)[C@H](C)[C@@H](OC)C[C@H](OC)\C=C\[C@H](C)[C@@H](OC)C[C@@H](OC)\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C(C)\C[C@H](C2)OC)[C@@H](C)[C@@H](OC)[C@@H](C)CCC(=O)[C@H](C)[C@H](OC)CCC(=O)O
1960	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB04783	experimental	Sphinxolide B	O=CN(C)/C=C/C[C@@H](OC)[C@@H](C)C(=O)CC[C@H](C)[C@H](OC)[C@H](C)[C@@H](OC(=O)/C=C/C=C(/C)C[C@@H](OC)CC([C@@H]1O)=CC(O2)=O)[C@@H](C)/C=C/[C@H](OC)C[C@H](O)[C@@H](C)/C=C/[C@@H](OC)C[C@H](OC)[C@@H](C)[C@@H]12
1961	sp|Q8ILW9|ACT2_PLA	P68133	99.2	4.0	377.0	DB08080	experimental	Latrunculin B	O=C1N[C@@H](CS1)[C@@](O)(C[C@@H]23)O[C@@H](C2)CC[C@H](C)/C=C\CC/C(C)=C\C(=O)O3
1962	sp|Q8ILW9|ACT2_PLA	P62736	99.2	4.0	377.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
1963	sp|Q8ILW9|ACT2_PLA	P86287	99.2	3.0	376.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1964	sp|Q8ILW9|ACT2_PLA	P61160	101.33	6.0	387.0	DB08235	experimental	N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide	c1cccc(c12)c(c([nH]2)C)CCNC(=O)c3cccs3
1965	sp|Q8ILW9|ACT2_PLA	P61160	101.33	6.0	387.0	DB08236	experimental	(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one	Brc1cc(ccc1)[C@@H]2SCC(=O)N2c3cc(Cl)ccc3O
1966	sp|Q8ILW9|ACT2_PLA	P61158	107.71	5.0	410.0	DB08235	experimental	N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide	c1cccc(c12)c(c([nH]2)C)CCNC(=O)c3cccs3
1967	sp|Q8ILW9|ACT2_PLA	P61158	107.71	5.0	410.0	DB08236	experimental	(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one	Brc1cc(ccc1)[C@@H]2SCC(=O)N2c3cc(Cl)ccc3O
1968	sp|P61074|PCNA_PLA	P12004	93.8	1.0	258.0	DB00279	approved; vet_approved	Liothyronine	OC(=O)[C@@H](N)Cc1cc(I)c(c(I)c1)Oc2cc(I)c(O)cc2
1969	sp|P61074|PCNA_PLA	P12004	93.8	1.0	258.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
1970	sp|O77323|TCPH_PLA	O77323	99.81	1.0	539.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1971	sp|O77323|TCPH_PLA	P49368	97.4	4.0	529.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
1972	sp|O77323|TCPH_PLA	P49368	97.4	4.0	529.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1973	sp|Q76NM6|VATA_PLA	Q76NM6	99.84	1.0	611.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1974	sp|Q76NM6|VATA_PLA	P38606	98.2	15.0	615.0	DB01133	approved; investigational; vet_approved	Tiludronic acid	OP(=O)(O)C(P(=O)(O)O)Sc1ccc(Cl)cc1
1975	sp|Q76NM6|VATA_PLA	P38606	98.2	15.0	615.0	DB00630	approved	Alendronic acid	NCCCC(O)(P(=O)(O)O)P(=O)(O)O
1976	sp|Q76NM6|VATA_PLA	P38606	98.2	15.0	615.0	DB01077	approved	Etidronic acid	OP(=O)(O)C(C)(O)P(=O)(O)O
1977	sp|Q76NM6|VATA_PLA	P38606	98.2	15.0	615.0	DB06733	experimental	Bafilomycin A1	CO[C@H]1/C=C/C=C(\C)C[C@H](C)[C@H](O)[C@H](C)/C=C(\C)/C=C(\OC)C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@@]2(O)C[C@@H](O)[C@H](C)[C@H](O2)C(C)C
1978	sp|Q76NM6|VATA_PLA	P38606	98.2	15.0	615.0	DB06734	experimental	Bafilomycin B1	CO[C@H]1/C=C\C=C(\C)C[C@H](C)[C@H](O)[C@H](C)/C=C(/C)\C=C(\OC)C(=O)OC1[C@@H](C)[C@@H](O)[C@H](C)[C@@]2(O)C[C@H]([C@H](C)[C@H](O2)C(C)C)OC(=O)/C=C/C(=O)NC3=C(O)CCC3=O
1979	sp|Q8I3Z5|TCTP_PLA	Q8I3Z5	99.42	1.0	171.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
1980	sp|Q8I3Z5|TCTP_PLA	P13693	99.42	1.0	171.0	DB11093	approved; investigational	Calcium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
1981	sp|Q8I3Z5|TCTP_PLA	P13693	99.42	1.0	171.0	DB11348	approved	Calcium Phosphate	[O-]P([O-])([O-])=O
1982	sp|Q8I3Z5|TCTP_PLA	P13693	99.42	1.0	171.0	DB14481	approved	Calcium phosphate dihydrate	OP([O-])([O-])=O
1983	sp|Q7KQL5|TBB_PLAF	P68371	99.1	1.0	442.0	DB00518	approved; vet_approved	Albendazole	CCCSc(cc1)cc(c12)[nH]c(n2)NC(=O)OC
1984	sp|Q7KQL5|TBB_PLAF	P68371	99.1	1.0	442.0	DB00643	approved; vet_approved	Mebendazole	COC(=O)Nc([nH]1)nc(c12)ccc(c2)C(=O)c3ccccc3
1985	sp|Q7KQL5|TBB_PLAF	P68371	99.1	1.0	442.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
1986	sp|Q7KQL5|TBB_PLAF	P68371	99.1	1.0	442.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
1987	sp|Q7KQL5|TBB_PLAF	P68371	99.1	1.0	442.0	DB04910	investigational; vet_approved	Oxibendazole	CCCOc(cc1)cc(c12)[nH]c(n2)NC(=O)OC
1988	sp|Q7KQL5|TBB_PLAF	P68371	99.1	1.0	442.0	DB05147	investigational	CYT997	 
1989	sp|Q7KQL5|TBB_PLAF	P68371	99.1	1.0	442.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
1990	sp|Q7KQL5|TBB_PLAF	Q9BVA1	99.55	1.0	444.0	DB05147	investigational	CYT997	 
1991	sp|Q7KQL5|TBB_PLAF	Q9BVA1	99.55	1.0	444.0	DB07574	experimental	2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE	COc(c(=O)c1)ccc(c12)c3c(cc(OC)c(OC)c3OC)CC[C@@H]2NC(=O)CS
1992	sp|Q7KQL5|TBB_PLAF	Q13885	99.55	1.0	444.0	DB05147	investigational	CYT997	 
1993	sp|Q7KQL5|TBB_PLAF	Q13885	99.55	1.0	444.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
1994	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB00361	approved; investigational	Vinorelbine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(CN(C6)CC(=C7)CC)c9c([nH]8)cccc9
1995	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB00541	approved; investigational	Vincristine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C=O)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC
1996	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB00570	approved	Vinblastine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC
1997	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB01179	approved	Podofilox	COc1c(OC)cc(cc1OC)[C@@H]2c(cc3c(c4)OCO3)c4[C@H](O)[C@H]([C@@H]25)COC5=O
1998	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB01394	approved	Colchicine	COc1c(OC)c(OC)cc(c12)CCC(NC(=O)C)c3c2ccc(c(=O)c3)OC
1999	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2000	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2001	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB05147	investigational	CYT997	 
2002	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB05284	investigational	CA4P	COc1c(OC)cc(cc1OC)[C@@H](O)Cc2cc(O)c(OC)cc2
2003	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB06042	investigational	ZEN-012	 
2004	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB09130	approved; investigational	Copper	[Cu]
2005	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2006	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB11641	approved; investigational	Vinflunine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(CN(C6)C[C@@H](C7)C(F)(F)C)c9c([nH]8)cccc9
2008	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB12334	investigational	Milataxel	CC(=O)O[C@]12[C@H](OC1)C[C@H](OC(=O)CC)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@@H](C(C)=C([C@@H](O)C3=O)C5(C)C)OC(=O)[C@H](O)[C@H](c6ccco6)NC(=O)OC(C)(C)C
2009	sp|Q7KQL5|TBB_PLAF	P07437	99.1	1.0	442.0	DB15534	approved; experimental	Colchiceine	COc(c1)c(OC)c(OC)c(c12)c3c(C(CC2)NC(=O)C)cc(=O)c(O)cc3
2010	sp|Q7KQL5|TBB_PLAF	P04350	98.88	1.0	441.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2011	sp|Q7KQL5|TBB_PLAF	P04350	98.88	1.0	441.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2012	sp|Q7KQL5|TBB_PLAF	P04350	98.88	1.0	441.0	DB05147	investigational	CYT997	 
2013	sp|Q7KQL5|TBB_PLAF	P04350	98.88	1.0	441.0	DB06042	investigational	ZEN-012	 
2014	sp|Q7KQL5|TBB_PLAF	P04350	98.88	1.0	441.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2015	sp|Q7KQL5|TBB_PLAF	Q13509	99.1	1.0	442.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2016	sp|Q7KQL5|TBB_PLAF	Q13509	99.1	1.0	442.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2017	sp|Q7KQL5|TBB_PLAF	Q13509	99.1	1.0	442.0	DB04845	approved; investigational	Ixabepilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2018	sp|Q7KQL5|TBB_PLAF	Q13509	99.1	1.0	442.0	DB05147	investigational	CYT997	 
2019	sp|Q7KQL5|TBB_PLAF	Q13509	99.1	1.0	442.0	DB06042	investigational	ZEN-012	 
2020	sp|Q7KQL5|TBB_PLAF	Q13509	99.1	1.0	442.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
2021	sp|Q7KQL5|TBB_PLAF	Q7KQL5	99.55	1.0	444.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2022	sp|Q7KQL5|TBB_PLAF	F1L7U3	98.65	1.0	440.0	DB00518	approved; vet_approved	Albendazole	CCCSc(cc1)cc(c12)[nH]c(n2)NC(=O)OC
2023	sp|Q7KQL5|TBB_PLAF	Q9BUF5	99.55	1.0	444.0	DB05147	investigational	CYT997	 
2024	sp|Q7KQL5|TBB_PLAF	Q9BUF5	99.55	1.0	444.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2025	sp|Q7KQL5|TBB_PLAF	P68363	100.9	1.0	450.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2026	sp|Q7KQL5|TBB_PLAF	P68363	100.9	1.0	450.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2027	sp|Q7KQL5|TBB_PLAF	P68363	100.9	1.0	450.0	DB05147	investigational	CYT997	 
2028	sp|Q7KQL5|TBB_PLAF	P68363	100.9	1.0	450.0	DB07574	experimental	2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE	COc(c(=O)c1)ccc(c12)c3c(cc(OC)c(OC)c3OC)CC[C@@H]2NC(=O)CS
2029	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB00309	approved; investigational	Vindesine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](O)[C@](O)(C(=O)N)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC
2030	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB01229	approved; vet_approved	Paclitaxel	c1ccccc1C(=O)O[C@H]([C@@]23O)[C@H]4[C@@](C)([C@@H](O)C[C@@H]5[C@]4(CO5)OC(=O)C)C(=O)[C@H](OC(=O)C)C(C2(C)C)=C(C)[C@H](C3)OC(=O)[C@H](O)[C@H](c6ccccc6)NC(=O)c7ccccc7
2031	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB01248	approved; investigational	Docetaxel	c1ccccc1[C@H](NC(=O)OC(C)(C)C)[C@@H](O)C(=O)O[C@@H](C[C@]23O)C(C)=C(C2(C)C)[C@@H](O)C(=O)[C@@]4(C)[C@@H]([C@@]5(OC(=O)C)[C@H](OC5)C[C@@H]4O)[C@@H]3OC(=O)c6ccccc6
2032	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2033	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2034	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB05147	investigational	CYT997	 
2035	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB06042	investigational	ZEN-012	 
2036	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB06772	approved	Cabazitaxel	c1ccccc1C(=O)O[C@H]([C@@]23O)[C@H]4[C@@](C)([C@@H](OC)C[C@@H]5[C@]4(CO5)OC(=O)C)C(=O)[C@H](OC)C(C2(C)C)=C(C)[C@H](C3)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6
2037	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB08871	approved; investigational	Eribulin	[C@]123CC[C@@H]4O[C@H](C(C4)=C)CC[C@@H]5O[C@@H](C(=C)[C@@H](C5)C)C[C@H]6[C@@H]([C@@H](OC)[C@H](O6)C[C@H](O)CN)CC(=O)C[C@@H]7O[C@H]8[C@H](CC7)O[C@@H]9[C@H]([C@H]8O1)O[C@H]([C@@H]9O2)C3
2038	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB12334	investigational	Milataxel	CC(=O)O[C@]12[C@H](OC1)C[C@H](OC(=O)CC)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@@H](C(C)=C([C@@H](O)C3=O)C5(C)C)OC(=O)[C@H](O)[C@H](c6ccco6)NC(=O)OC(C)(C)C
2039	sp|Q7KQL5|TBB_PLAF	Q9H4B7	99.55	1.0	444.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
2040	sp|Q7KQL5|TBB_PLAF	P10875	98.2	1.0	438.0	DB00400	approved; investigational; vet_approved	Griseofulvin	COc(c1Cl)cc(OC)c(C2=O)c1O[C@]23[C@H](C)CC(=O)C=C3OC
2041	sp|Q7KQL5|TBB_PLAF	Q9BQE3	100.45	1.0	448.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2042	sp|Q7KQL5|TBB_PLAF	Q9BQE3	100.45	1.0	448.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2043	sp|Q7KQL5|TBB_PLAF	Q9BQE3	100.45	1.0	448.0	DB05147	investigational	CYT997	 
2044	sp|Q7KQL5|TBB_PLAF	Q9BQE3	100.45	1.0	448.0	DB07574	experimental	2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE	COc(c(=O)c1)ccc(c12)c3c(cc(OC)c(OC)c3OC)CC[C@@H]2NC(=O)CS
2045	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB00518	approved; vet_approved	Albendazole	CCCSc(cc1)cc(c12)[nH]c(n2)NC(=O)OC
2046	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB00570	approved	Vinblastine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC
2047	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB00643	approved; vet_approved	Mebendazole	COC(=O)Nc([nH]1)nc(c12)ccc(c2)C(=O)c3ccccc3
2048	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2049	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2050	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB05147	investigational	CYT997	 
2051	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB07574	experimental	2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE	COc(c(=O)c1)ccc(c12)c3c(cc(OC)c(OC)c3OC)CC[C@@H]2NC(=O)CS
2052	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2053	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
2054	sp|Q7KQL5|TBB_PLAF	Q71U36	100.9	1.0	450.0	DB15534	approved; experimental	Colchiceine	COc(c1)c(OC)c(OC)c(c12)c3c(C(CC2)NC(=O)C)cc(=O)c(O)cc3
2055	sp|Q7KQL5|TBB_PLAF	P68366	100.45	1.0	448.0	DB00541	approved; investigational	Vincristine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C=O)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC
2056	sp|Q7KQL5|TBB_PLAF	P68366	100.45	1.0	448.0	DB01179	approved	Podofilox	COc1c(OC)cc(cc1OC)[C@@H]2c(cc3c(c4)OCO3)c4[C@H](O)[C@H]([C@@H]25)COC5=O
2057	sp|Q7KQL5|TBB_PLAF	P68366	100.45	1.0	448.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2058	sp|Q7KQL5|TBB_PLAF	P68366	100.45	1.0	448.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2059	sp|Q7KQL5|TBB_PLAF	P68366	100.45	1.0	448.0	DB05147	investigational	CYT997	 
2060	sp|Q7KQL5|TBB_PLAF	P68366	100.45	1.0	448.0	DB06772	approved	Cabazitaxel	c1ccccc1C(=O)O[C@H]([C@@]23O)[C@H]4[C@@](C)([C@@H](OC)C[C@@H]5[C@]4(CO5)OC(=O)C)C(=O)[C@H](OC)C(C2(C)C)=C(C)[C@H](C3)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6
2061	sp|Q7KQL5|TBB_PLAF	P68366	100.45	1.0	448.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
2062	sp|Q7KQL5|TBB_PLAF	Q13748	100.67	1.0	449.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2063	sp|Q7KQL5|TBB_PLAF	Q13748	100.67	1.0	449.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2064	sp|Q7KQL5|TBB_PLAF	Q13748	100.67	1.0	449.0	DB05147	investigational	CYT997	 
2065	sp|Q7KQL5|TBB_PLAF	Q13748	100.67	1.0	449.0	DB09130	approved; investigational	Copper	[Cu]
2066	sp|Q7KQL5|TBB_PLAF	Q13748	100.67	1.0	449.0	DB12695	investigational	Phenethyl Isothiocyanate	S=C=NCCc1ccccc1
2067	sp|Q7KQL5|TBB_PLAF	Q6PEY2	100.45	1.0	448.0	DB05147	investigational	CYT997	 
2068	sp|Q7KQL5|TBB_PLAF	Q9NY65	100.45	1.0	448.0	DB01873	investigational	Epothilone D	Cc1nc(cs1)/C=C(\C)[C@@H](OC(=O)C[C@H](O)C2(C)C)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C2=O
2069	sp|Q7KQL5|TBB_PLAF	Q9NY65	100.45	1.0	448.0	DB03010	experimental; investigational	Patupilone	Cc1nc(cs1)/C=C(\C)[C@H](C[C@H](O2)[C@]23C)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC3
2070	sp|Q7KQL5|TBB_PLAF	P14642	101.35	1.0	452.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2071	sp|Q7KQL5|TBB_PLAF	P23258	98.2	3.0	440.0	DB00570	approved	Vinblastine	C1CN([C@@H]2[C@]134)CC=C[C@@]2(CC)[C@@H](OC(=O)C)[C@](O)(C(=O)OC)[C@@H]3N(C)c5c4cc(c(c5)OC)[C@](C[C@@H]67)(C(=O)OC)c8c(c9c([nH]8)cccc9)CCN(C6)C[C@@](O)(C7)CC
2072	sp|Q7KQM2|TPPC5_PL	Q8IUR0	94.02	10.0	183.0	DB08342	experimental	S-palmitoyl-L-cysteine	CCCCCCCCCCCCCCCC(=O)SC[C@H](N)C(=O)O
2073	sp|Q7KQM2|TPPC5_PL	O43617	76.63	11.0	152.0	DB03796	approved	Palmitic Acid	CCCCCCCCCCCCCCCC(=O)O
2074	sp|Q7KQM2|TPPC5_PL	O43617	76.63	11.0	152.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
2075	sp|Q7KQM2|TPPC5_PL	O43617	76.63	11.0	152.0	DB08342	experimental	S-palmitoyl-L-cysteine	CCCCCCCCCCCCCCCC(=O)SC[C@H](N)C(=O)O
2076	sp|Q7KQM2|TPPC5_PL	Q86SZ2	75.0	5.0	143.0	DB08342	experimental	S-palmitoyl-L-cysteine	CCCCCCCCCCCCCCCC(=O)SC[C@H](N)C(=O)O
2077	sp|Q7KQM2|TPPC5_PL	O75865	74.46	6.0	143.0	DB08342	experimental	S-palmitoyl-L-cysteine	CCCCCCCCCCCCCCCC(=O)SC[C@H](N)C(=O)O
2078	sp|Q8I467|CADF1_PL	P23528	107.38	1.0	132.0	DB04147	experimental	Dodecyldimethylamine N-oxide	CCCCCCCCCCCC[N+]([O-])(C)C
2079	sp|Q8I467|CADF1_PL	P23528	107.38	1.0	132.0	DB09130	approved; investigational	Copper	[Cu]
2080	sp|Q8I467|CADF1_PL	P23528	107.38	1.0	132.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2081	sp|Q8I467|CADF1_PL	P60981	107.38	1.0	132.0	DB04147	experimental	Dodecyldimethylamine N-oxide	CCCCCCCCCCCC[N+]([O-])(C)C
2082	sp|P27362|PGK_PLAF	P00558	99.28	3.0	416.0	DB03909	experimental	Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate	OP(=O)(O)CP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
2083	sp|P27362|PGK_PLAF	P00558	99.28	3.0	416.0	DB04510	experimental	3-phospho-D-glyceric acid	OC(=O)[C@H](O)COP(=O)(O)O
2084	sp|P27362|PGK_PLAF	P00558	99.28	3.0	416.0	DB09130	approved; investigational	Copper	[Cu]
2085	sp|P27362|PGK_PLAF	P00558	99.28	3.0	416.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2086	sp|P27362|PGK_PLAF	P36204	94.95	2.0	397.0	DB04510	experimental	3-phospho-D-glyceric acid	OC(=O)[C@H](O)COP(=O)(O)O
2087	sp|Q8I3W2|RPIA_PLA	P49247	97.03	79.0	308.0	DB01756	experimental	4-phospho-L-threonic acid	OC(=O)[C@H](O)[C@@H](O)COP(=O)(O)O
2088	sp|Q8I3W2|RPIA_PLA	Q5SIR5	91.53	6.0	222.0	DB02053	experimental	Ribose-5-phosphate	O=C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
2089	sp|Q8I3W2|RPIA_PLA	Q5SIR5	91.53	6.0	222.0	DB03745	experimental	Arabinose-5-phosphate	OC[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
2090	sp|Q8I3W2|RPIA_PLA	P0A7Z3	89.83	4.0	216.0	DB04127	experimental	beta-D-arabinofuranose 5-phosphate	O[C@@H]1O[C@@H]([C@@H](O)[C@@H]1O)COP(=O)(O)O
2091	sp|Q8I3W2|RPIA_PLA	P44725	88.98	5.0	215.0	DB04272	approved; nutraceutical; vet_approved	Citric acid	OC(=O)CC(O)(C(=O)O)CC(=O)O
2092	sp|Q8IDF6|PURA_PLA	Q9U8D3	99.77	1.0	442.0	DB02109	experimental	Hadacidin	O=CN(O)CC(=O)O
2093	sp|Q8IDF6|PURA_PLA	Q9U8D3	99.77	1.0	442.0	DB03510	experimental	6-O-Phosphoryl Inosine Monophosphate	OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(ncn3)OP(=O)(O)O
2094	sp|Q8IDF6|PURA_PLA	Q9U8D3	99.77	1.0	442.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
2095	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB02109	experimental	Hadacidin	O=CN(O)CC(=O)O
2096	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB03510	experimental	6-O-Phosphoryl Inosine Monophosphate	OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(ncn3)OP(=O)(O)O
2097	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB04137	experimental	Guanosine-5'-Triphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
2098	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
2099	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB04418	experimental	Adenylosuccinic acid	OP(=O)(O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O1)n2cnc(c23)c(ncn3)N[C@H](C(=O)O)CC(=O)O
2100	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB04566	experimental	Inosinic Acid	OP(=O)(O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O1)n2cnc(c23)c(=O)[nH]cn3
2101	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB05540	investigational	Alanosine	OC(=O)[C@@H](N)CN(O)N=O
2102	sp|Q8IDF6|PURA_PLA	Q8N142	96.15	29.0	454.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
2103	sp|Q8IDF6|PURA_PLA	P30520	96.15	28.0	453.0	DB00128	approved; nutraceutical	Aspartic acid	OC(=O)[C@@H](N)CC(=O)O
2104	sp|Q8IDF6|PURA_PLA	P30520	96.15	28.0	453.0	DB05540	investigational	Alanosine	OC(=O)[C@@H](N)CN(O)N=O
2106	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB02109	experimental	Hadacidin	O=CN(O)CC(=O)O
2107	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB02493	experimental	Hydantocidin-5'-phosphate	O=C(N1)NC(=O)[C@]12O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)O
2108	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB02666	experimental	(C8-R)-hydantocidin 5'-phosphate	OP(=O)(O)OC[C@@H](O1)[C@@H](O)[C@@H](O)[C@]12NC(=O)N(C2=O)CCC[C@H](C(=O)O)N(O)CO
2109	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB02836	experimental	Guanosine 5'-diphosphate 2':3'-cyclic monophosphate	Nc([nH]1)nc(=O)c(c12)ncn2[C@@H]3O[C@@H]([C@H]([C@H]34)O[P@@](O4)(=O)O)COP(=O)(O)OP(=O)(O)O
2110	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB02954	experimental	(Carboxyhydroxyamino)Ethanoic Acid	OC(=O)N(O)CC(=O)O
2111	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB03146	experimental	2-deazo-6-thiophosphate guanosine-5'-monophosphate	OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(nc[nH+]3)SP(=O)(O)O
2112	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB04315	experimental	Guanosine-5'-Diphosphate	O=c1[nH]c(N)nc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)O
2113	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB04460	experimental	(C8-S)-Hydantocidin 5'-phosphate	OP(=O)(O)OC[C@@H](O1)[C@@H](O)[C@@H](O)[C@]12NC(=O)N(C2=O)CCC[C@@H](C(=O)O)N(O)CO
2114	sp|Q8IDF6|PURA_PLA	P0A7D4	96.83	2.0	430.0	DB04566	experimental	Inosinic Acid	OP(=O)(O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O1)n2cnc(c23)c(=O)[nH]cn3
2115	sp|Q8IDF6|PURA_PLA	Q83P33	96.83	2.0	430.0	DB02954	experimental	(Carboxyhydroxyamino)Ethanoic Acid	OC(=O)N(O)CC(=O)O
2116	sp|Q8IDF6|PURA_PLA	Q83P33	96.83	2.0	430.0	DB04566	experimental	Inosinic Acid	OP(=O)(O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O1)n2cnc(c23)c(=O)[nH]cn3
2117	sp|Q8IDF6|PURA_PLA	Q8ZIV7	96.83	2.0	430.0	DB02580	experimental	Pentaglyme	COCCOCCOCCOCCOCCOC
2118	sp|Q8ILW6|NMT_PLAF	O60551	94.88	108.0	497.0	DB02180	experimental	Myristoyl-Coa	CCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(=O)(O)O)n2cnc(c23)c(N)ncn3
2119	sp|Q8ILW6|NMT_PLAF	O60551	94.88	108.0	497.0	DB02271	experimental	S-(2-oxo)pentadecylcoa	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@H]([C@H]3O)OP(=O)(O)O)COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@H](O)C(=O)NCCC(=O)NCCSCC(=O)CCCCCCCCCCCCC
2120	sp|Q8ILW6|NMT_PLAF	O60551	94.88	108.0	497.0	DB07061	experimental	1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL	C1CCCCC1NC[C@H](O)Cn2c(CCCC3)c3c(c24)cc(C)cc4
2121	sp|Q8ILW6|NMT_PLAF	O60551	94.88	108.0	497.0	DB07838	experimental	(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE	[O-][N+](=O)c1cccc(c1O)/C=C2\SC(=S)N(C2=O)Cc3ccccc3
2122	sp|Q8ILW6|NMT_PLAF	P30419	94.88	106.0	495.0	DB03062	experimental	(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone	Cn1ccnc1C(=O)c(o2)c(C)c(c23)c(ccc3)OCCCNCc4cnccc4
2123	sp|Q8ILW6|NMT_PLAF	P30418	97.8	27.0	428.0	DB02180	experimental	Myristoyl-Coa	CCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(=O)(O)O)n2cnc(c23)c(N)ncn3
2124	sp|Q8ILW6|NMT_PLAF	P30418	97.8	27.0	428.0	DB02477	experimental	N-({4-[4-(2-Methyl-1H-imidazol-1-yl)butyl]phenyl}acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide	Cc1nccn1CCCCc2ccc(cc2)CC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCCC3CCCCC3
2125	sp|Q8ILW6|NMT_PLAF	P30418	97.8	27.0	428.0	DB03062	experimental	(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone	Cn1ccnc1C(=O)c(o2)c(C)c(c23)c(ccc3)OCCCNCc4cnccc4
2126	sp|Q6LFH8|OAT_PLAF	Q6LFH8	99.76	1.0	414.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2127	sp|Q6LFH8|OAT_PLAF	P04181	97.1	37.0	439.0	DB00114	approved; investigational; nutraceutical	Pyridoxal phosphate	Cc1ncc(c(C=O)c1O)COP(=O)(O)O
2128	sp|Q6LFH8|OAT_PLAF	P04181	97.1	37.0	439.0	DB00129	approved; nutraceutical	Ornithine	NCCC[C@H](N)C(=O)O
2129	sp|Q6LFH8|OAT_PLAF	P04181	97.1	37.0	439.0	DB02054	experimental	Gabaculine	Nc1cccc(c1)C(=O)O
2130	sp|Q6LFH8|OAT_PLAF	P04181	97.1	37.0	439.0	DB02821	experimental	Canaline	NOCC[C@H](N)C(=O)O
2131	sp|Q6LFH8|OAT_PLAF	Q9BYV1	104.35	74.0	506.0	DB00114	approved; investigational; nutraceutical	Pyridoxal phosphate	Cc1ncc(c(C=O)c1O)COP(=O)(O)O
2132	sp|Q6LFH8|OAT_PLAF	Q9BYV1	104.35	74.0	506.0	DB00119	approved; investigational; nutraceutical	Pyruvic acid	CC(=O)C(=O)O
2133	sp|Q6LFH8|OAT_PLAF	Q9BYV1	104.35	74.0	506.0	DB00145	approved; nutraceutical; vet_approved	Glycine	NCC(=O)O
2134	sp|Q6LFH8|OAT_PLAF	Q9BYV1	104.35	74.0	506.0	DB00160	nutraceutical	Alanine	C[C@H](N)C(=O)O
2135	sp|Q6LFH8|OAT_PLAF	P22256	96.38	23.0	422.0	DB02142	experimental	Pyridoxamine-5'-Phosphate	Cc1ncc(c(CN)c1O)COP(=O)(O)O
2136	sp|Q6LFH8|OAT_PLAF	P22256	96.38	23.0	422.0	DB02783	experimental	4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate	Cc1ncc(COP(=O)(O)O)c(c1O)CNOCC(=O)O
2137	sp|Q6LFH8|OAT_PLAF	P12995	95.65	26.0	422.0	DB02274	experimental	7-Keto-8-Aminopelargonic Acid	C[C@H](N)C(=O)CCCCCC(=O)O
2138	sp|Q6LFH8|OAT_PLAF	P12995	95.65	26.0	422.0	DB02725	experimental	2-Amino-4-(4-Amino-Cyclohexa-2,5-Dienyl)-Butyric Acid	OC(=O)[C@@H](N)CC[C@H]1C=CC(N)C=C1
2139	sp|Q6LFH8|OAT_PLAF	P12995	95.65	26.0	422.0	DB04083	experimental	N(6)-(pyridoxal phosphate)-L-lysine	Cc1ncc(COP(=O)(O)O)c(c1O)/C=N/CCCC[C@H](N)C(=O)O
2140	sp|Q6LFH8|OAT_PLAF	Q8IUZ5	97.1	27.0	429.0	DB00114	approved; investigational; nutraceutical	Pyridoxal phosphate	Cc1ncc(c(C=O)c1O)COP(=O)(O)O
2141	sp|Q6LFH8|OAT_PLAF	Q8IUZ5	97.1	27.0	429.0	DB00160	nutraceutical	Alanine	C[C@H](N)C(=O)O
2142	sp|Q6LFH8|OAT_PLAF	P16932	97.83	25.0	430.0	DB02038	experimental	D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide	Cc1ncc(COP(=O)(O)O)c(c1O)CN[C@@H]2CONC2=O
2143	sp|Q6LFH8|OAT_PLAF	P16932	97.83	25.0	430.0	DB02849	experimental	N-Pyridoxyl-1-Amino-Cyclopropanecarboxylic Acid-5-Monophosphate	Cc1ncc(COP(=O)(O)O)c(c1O)CNC2(CC2)C(=O)O
2144	sp|Q6LFH8|OAT_PLAF	P16932	97.83	25.0	430.0	DB03787	experimental	(5-Hydroxy-6-methyl-4-{[(E)-(3-oxo-1,2-oxazolidin-4-ylidene)amino]methyl}-3-pyridinyl)methyl dihydrogen phosphate	Cc1ncc(COP(=O)(O)O)c(c1O)C/N=C2\CONC2=O
2145	sp|Q6LFH8|OAT_PLAF	P16932	97.83	25.0	430.0	DB04241	experimental	N-Pyridoxyl-2-Methylalanine-5-Phosphate	Cc1ncc(COP(=O)(O)O)c(c1O)CNC(C)(C)C(=O)O
2146	sp|Q6LFH8|OAT_PLAF	P9WQ77	98.07	39.0	445.0	DB08071	experimental	(2S)-1-methyl-2-[(2S,4R)-2-methyl-4-phenylpentyl]piperidine	CN1CCCC[C@H]1C[C@@H](C)C[C@@H](C)c2ccccc2
2147	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB00114	approved; investigational; nutraceutical	Pyridoxal phosphate	Cc1ncc(c(C=O)c1O)COP(=O)(O)O
2148	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB00119	approved; investigational; nutraceutical	Pyruvic acid	CC(=O)C(=O)O
2149	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB00142	approved; nutraceutical	Glutamic acid	OC(=O)[C@@H](N)CCC(=O)O
2150	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB00160	nutraceutical	Alanine	C[C@H](N)C(=O)O
2151	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB00780	approved	Phenelzine	NNCCc1ccccc1
2152	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB01080	approved	Vigabatrin	C=CC(N)CCC(=O)O
2153	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB01699	experimental	(4e)-4-Aminohex-4-Enoic Acid	C/C=C(/N)CCC(=O)O
2154	sp|Q6LFH8|OAT_PLAF	P80404	101.21	78.0	497.0	DB04235	experimental	4-Amino Hexanoic Acid	CC[C@@H](N)CCC(=O)O
2155	sp|Q6LFH8|OAT_PLAF	P24630	74.88	40.0	350.0	DB02054	experimental	Gabaculine	Nc1cccc(c1)C(=O)O
2156	sp|Q6LFH8|OAT_PLAF	P24630	74.88	40.0	350.0	DB02142	experimental	Pyridoxamine-5'-Phosphate	Cc1ncc(c(CN)c1O)COP(=O)(O)O
2157	sp|Q6LFH8|OAT_PLAF	Q9X266	74.88	32.0	342.0	DB02824	experimental	N-Pyridoxyl-Glycine-5-Monophosphate	Cc1ncc(COP(=O)(O)O)c(c1O)CNCC(=O)O
2158	sp|Q6LFH8|OAT_PLAF	Q9X266	74.88	32.0	342.0	DB03576	experimental	N-Pyridoxyl-Threonine-5-Monophosphate	CC(O)C(C(=O)O)NCc1c(COP(=O)(O)O)cnc(C)c1O
2159	sp|Q6LFH8|OAT_PLAF	Q9X266	74.88	32.0	342.0	DB04083	experimental	N(6)-(pyridoxal phosphate)-L-lysine	Cc1ncc(COP(=O)(O)O)c(c1O)/C=N/CCCC[C@H](N)C(=O)O
2160	sp|Q6LFH8|OAT_PLAF	P12998	85.02	28.0	380.0	DB03160	experimental	N-Pyridoxyl-7-Keto-8-Aminopelargonic Acid-5'-Monophosphate	OC(=O)CCCCCC(=O)[C@H](C)NCc1c(COP(=O)(O)O)cnc(C)c1O
2161	sp|Q8IIU6|RTCB_PLA	Q9Y3I0	97.83	10.0	505.0	DB02772	approved; experimental; investigational	Sucrose	OC[C@@H](O1)[C@@H](O)[C@H](O)[C@]1(CO)O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O
2162	sp|P62368|ISPF_PLA	Q9PM68	71.67	191.0	363.0	DB02552	experimental	Geranyl Diphosphate	CC(C)=CCC/C(C)=C/CO[P@@](=O)(O)OP(=O)(O)O
2163	sp|P62368|ISPF_PLA	Q9PM68	71.67	191.0	363.0	DB03403	experimental	Cytidine-5'-Monophosphate	Nc1nc(=O)n(cc1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)O
2164	sp|O15770|GSHR_PLA	Q94655	99.8	1.0	500.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2165	sp|O15770|GSHR_PLA	P06715	89.0	5.0	450.0	DB00336	approved; investigational; vet_approved	Nitrofural	NC(=O)N/N=C/c1ccc(o1)[N+]([O-])=O
2166	sp|O15770|GSHR_PLA	P06715	89.0	5.0	450.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2167	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2168	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB00157	approved; nutraceutical	NADH	NC(=O)C1=CN(C=CC1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n4cnc(c45)c(N)ncn5
2169	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB00262	approved; investigational	Carmustine	ClCCNC(=O)N(N=O)CCCl
2170	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB01644	experimental	3,6-dihydroxy-xanthene-9-propionic acid	OC(=O)CCC1c(ccc(c2)O)c2Oc(c13)cc(O)cc3
2171	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB02153	experimental	3-sulfino-L-alanine	OC(=O)[C@@H](N)C[S@](=O)O
2172	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB02553	experimental	Glutathionylspermidine disulfide	NCCCCNCCCNC(=O)CNC(=O)[C@@H](NC(=O)CC[C@@H](N)C(=O)O)CSSC[C@H](NC(=O)CC[C@@H](N)C(=O)O)C(=O)NCC(=O)NCCCNCCCCN
2173	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB02895	experimental	3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol	S/C=C/C[S@](=O)CC=C
2174	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2175	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2176	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB03867	experimental	3-nitro-L-tyrosine	OC(=O)[C@@H](N)Cc1cc([N+]([O-])=O)c(O)cc1
2177	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB07393	experimental	2-(2-PHENYL-3-PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-2H-ISOPHOSPHINDOL-1-YL)PYRIDINE	n1ccccc1-c2p(-c3ccccc3)c(c(c24)CCCC4)-c5ncccc5
2178	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB07714	experimental	6-(3-METHYL-1,4-DIOXO-1,4-DIHYDRONAPHTHALEN-2-YL)HEXANOIC ACID	c1cccc(c12)C(=O)C(=C(C2=O)C)CCCCCC(=O)O
2179	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB09061	approved; investigational	Cannabidiol	CCCCCc1cc(O)c(c(O)c1)[C@@H]2C=C(C)CC[C@H]2C(C)=C
2180	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB09130	approved; investigational	Copper	[Cu]
2182	sp|O15770|GSHR_PLA	P00390	91.4	65.0	522.0	DB14011	investigational	Nabiximols	CC(=C)[C@@H]1CCC(C)=C[C@H]1c2c(O)cc(cc2O)CCCCC
2183	sp|O15770|GSHR_PLA	Q9NNW7	93.6	40.0	508.0	DB05428	investigational	Motexafin gadolinium	CCc(c12)c(CC)c([n-]1)cc3nc(c(C)c3CCCO)cnc4c(ncc5nc(c2)c(c5C)CCCO)cc(OCCOCCOCCOC)c(c4)OCCOCCOCCOC
2184	sp|O15770|GSHR_PLA	Q16881	94.0	163.0	633.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
2185	sp|O15770|GSHR_PLA	Q16881	94.0	163.0	633.0	DB02338	experimental	NADPH	NC(=O)C1=CN(C=CC1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@H]([C@@H]([C@@H]3O)OP(=O)(O)O)n4cnc(c45)c(N)ncn5
2186	sp|O15770|GSHR_PLA	Q16881	94.0	163.0	633.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2187	sp|O15770|GSHR_PLA	Q16881	94.0	163.0	633.0	DB03566	experimental	Spermidine	NCCCCNCCCN
2188	sp|O15770|GSHR_PLA	Q16881	94.0	163.0	633.0	DB04106	investigational	Fotemustine	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(N=O)CCCl
2189	sp|O15770|GSHR_PLA	Q16881	94.0	163.0	633.0	DB05428	investigational	Motexafin gadolinium	CCc(c12)c(CC)c([n-]1)cc3nc(c(C)c3CCCO)cnc4c(ncc5nc(c2)c(c5C)CCCO)cc(OCCOCCOCCOC)c(c4)OCCOCCOCCOC
2190	sp|O15770|GSHR_PLA	Q16881	94.0	163.0	633.0	DB05448	investigational	PX-12	CCC(C)SSc1ncc[nH]1
2191	sp|O15770|GSHR_PLA	P14218	90.8	5.0	459.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2192	sp|O15770|GSHR_PLA	P28593	93.4	5.0	472.0	DB02240	experimental	Quinacrine mustard	c1cc(Cl)cc(n2)c1c(c(c23)cc(OC)cc3)NC(C)CCCN(CCCl)CCCl
2193	sp|O15770|GSHR_PLA	P28593	93.4	5.0	472.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2194	sp|O15770|GSHR_PLA	P28593	93.4	5.0	472.0	DB03470	experimental	Trypanothione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(=O)O
2195	sp|O15770|GSHR_PLA	P28593	93.4	5.0	472.0	DB04299	experimental	Maleic Acid	OC(=O)/C=C\C(=O)O
2196	sp|O15770|GSHR_PLA	P18925	90.8	5.0	459.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2197	sp|O15770|GSHR_PLA	P09622	90.4	43.0	495.0	DB00157	approved; nutraceutical	NADH	NC(=O)C1=CN(C=CC1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n4cnc(c45)c(N)ncn5
2198	sp|O15770|GSHR_PLA	P09622	90.4	43.0	495.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2199	sp|O15770|GSHR_PLA	Q51225	91.2	118.0	574.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2200	sp|O15770|GSHR_PLA	P09063	87.4	9.0	446.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2202	sp|O15770|GSHR_PLA	Q56839	90.6	44.0	497.0	DB03147	approved	Flavin adenine dinucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)n5cnc(c56)c(N)ncn6
2203	sp|O15770|GSHR_PLA	Q56839	90.6	44.0	497.0	DB03163	experimental	2-oxopropyl-CoM	CC(=O)CSCCS(=O)(=O)O
2204	sp|Q8IBP3|ITPA_PLA	Q9BY32	90.91	9.0	189.0	DB04272	approved; nutraceutical; vet_approved	Citric acid	OC(=O)CC(O)(C(=O)O)CC(=O)O
2205	sp|Q8I6U8|GBP_PLAF	Q8I6U8	99.88	1.0	824.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2206	sp|Q8ILQ7|GST_PLAF	Q8MU52	99.53	1.0	211.0	DB00608	approved; investigational; vet_approved	Chloroquine	CCN(CC)CCCC(C)Nc1ccnc(c12)cc(Cl)cc2
2207	sp|Q8ILQ7|GST_PLAF	Q8MU52	99.53	1.0	211.0	DB01942	experimental; investigational	Formic acid	OC=O
2208	sp|Q8ILQ7|GST_PLAF	Q8MU52	99.53	1.0	211.0	DB04132	experimental	S-Hexylglutathione	CCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2209	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2210	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2211	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB00608	approved; investigational; vet_approved	Chloroquine	CCN(CC)CCCC(C)Nc1ccnc(c12)cc(Cl)cc2
2212	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB01834	experimental	(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CS[C@@H]([C@@H]1O)c(cccc2)c2c(c13)cccc3
2213	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB02165	experimental	Zinc trihydroxide	[O]
2214	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB02458	experimental	S-(2,4-dinitrophenyl)glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSc1c(N(=O)=O)cc(N(=O)=O)cc1
2215	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB03314	experimental	5-fluorotryptophan	OC(=O)[C@@H](N)Cc1c[nH]c(c12)ccc(F)c2
2216	sp|Q8ILQ7|GST_PLAF	P09488	93.36	3.0	200.0	DB04187	experimental	(9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CS[C@@H]1[C@@H](O)c(cccc2)c2c(c13)cccc3
2217	sp|Q8ILQ7|GST_PLAF	Q03013	93.84	2.0	200.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2218	sp|Q8ILQ7|GST_PLAF	Q03013	93.84	2.0	200.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2219	sp|Q8ILQ7|GST_PLAF	Q03013	93.84	2.0	200.0	DB03003	experimental	Glutathione sulfonic acid	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCC(=O)O
2220	sp|Q8ILQ7|GST_PLAF	Q03013	93.84	2.0	200.0	DB03032	experimental	S-octylglutathione	CCCCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2221	sp|Q8ILQ7|GST_PLAF	Q03013	93.84	2.0	200.0	DB03597	experimental	gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSCc1ccccc1I
2222	sp|Q8ILQ7|GST_PLAF	Q03013	93.84	2.0	200.0	DB03706	experimental	1-Hydroxy-2-S-glutathionyl-3-para-nitrophenoxy-propane	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CS[C@@H](CO)COc1ccc([N+]([O-])=O)cc1
2223	sp|Q8ILQ7|GST_PLAF	Q03013	93.84	2.0	200.0	DB04132	experimental	S-Hexylglutathione	CCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2224	sp|Q8ILQ7|GST_PLAF	P28161	93.36	3.0	200.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2225	sp|Q8ILQ7|GST_PLAF	P28161	93.36	3.0	200.0	DB02458	experimental	S-(2,4-dinitrophenyl)glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSc1c(N(=O)=O)cc(N(=O)=O)cc1
2226	sp|Q8ILQ7|GST_PLAF	P28161	93.36	3.0	200.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2227	sp|Q8ILQ7|GST_PLAF	P28161	93.36	3.0	200.0	DB04701	experimental	S-Methyl glutathione	OC(=O)CNC(=O)[C@H](CSC)NC(=O)CC[C@H](N)C(=O)O
2229	sp|Q8ILQ7|GST_PLAF	P46439	93.36	3.0	200.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2230	sp|Q8ILQ7|GST_PLAF	P46439	93.36	3.0	200.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2231	sp|Q8ILQ7|GST_PLAF	P21266	93.84	6.0	204.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2232	sp|Q8ILQ7|GST_PLAF	P21266	93.84	6.0	204.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2233	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2234	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB01915	experimental	S-Hydroxycysteine	OC(=O)[C@@H](N)CSO
2235	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB02486	experimental	2-Hydroxyethyl Disulfide	OCCSSCCO
2236	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB02943	experimental	N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine	NCCCC(=O)N[C@H](C(=O)NCC(=O)O)CSCc1ccc(OC)cc1
2237	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB03003	experimental	Glutathione sulfonic acid	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCC(=O)O
2238	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB03602	experimental	S-benzylglutathione	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSCc1ccccc1
2239	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB04132	experimental	S-Hexylglutathione	CCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2240	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB13014	investigational	Hypericin	Oc1cc(C)c2c(c(C)cc3O)c4c3c(=O)c(c(O)cc5O)c6c4c7c2c1c(=O)c(c7c8c56)c(O)cc8O
2241	sp|Q8ILQ7|GST_PLAF	P08263	93.84	1.0	199.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2242	sp|Q8ILQ7|GST_PLAF	P09210	93.84	1.0	199.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2243	sp|Q8ILQ7|GST_PLAF	P09210	93.84	1.0	199.0	DB00608	approved; investigational; vet_approved	Chloroquine	CCN(CC)CCCC(C)Nc1ccnc(c12)cc(Cl)cc2
2244	sp|Q8ILQ7|GST_PLAF	P09210	93.84	1.0	199.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2245	sp|Q8ILQ7|GST_PLAF	Q16772	93.84	1.0	199.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2246	sp|Q8ILQ7|GST_PLAF	Q16772	93.84	1.0	199.0	DB04521	experimental	4-S-Glutathionyl-5-pentyl-tetrahydro-furan-2-ol	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CS[C@H]1C[C@H](O)O[C@@H]1CCCCC
2247	sp|Q8ILQ7|GST_PLAF	Q7RTV2	93.84	1.0	199.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2248	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2249	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB00755	approved; investigational; nutraceutical	Tretinoin	OC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C(C1(C)C)=C(C)CCC1
2250	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB01897	experimental	2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride	O=c1[nH][nH]c(=O)c(c12)cc(cc2)-[n+]3nc(/C=C/c4ccccc4)nn3-c(s5)nc(c56)cccc6
2251	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB07613	experimental	3-phenyl-5-(1H-pyrazol-3-yl)isoxazole	c1c[nH]nc1-c2cc(no2)-c3ccccc3
2252	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB07614	experimental	PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE	c1c[nH]nc1-c2cnc(s2)-c3ccccc3
2253	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB07615	investigational	Tranilast	COc1ccc(cc1OC)/C=C/C(=O)Nc2ccccc2C(=O)O
2254	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB07616	experimental	4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid	Fc1ccc(cc1C)-c2csc(n2)Nc3ccc(C(=O)O)c(O)c3
2255	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB07917	experimental	4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE	n1nn[nH]c1CCCN2CCC(CC2)OC(c3ccccc3)c4ccccc4
2256	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB08313	experimental	Nocodazole	COC(=O)Nc([nH]1)nc(c12)cc(cc2)C(=O)c3cccs3
2257	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB08695	experimental	3-(4-nitrophenyl)-1H-pyrazole	[O-][N+](=O)c1ccc(cc1)-c2n[nH]cc2
2258	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB08790	experimental	1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID	OC(=O)c1cn(nc1)-c2ccccc2
2259	sp|Q8ILQ7|GST_PLAF	O60760	91.94	3.0	197.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2260	sp|Q8ILQ7|GST_PLAF	O15217	93.84	1.0	199.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2261	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2262	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2263	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB00197	approved; investigational; withdrawn	Troglitazone	Cc1c(O)c(C)c(C)c(c12)OC(C)(CC2)COc3ccc(cc3)CC4SC(=O)NC4=O
2264	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB00363	approved	Clozapine	CN1CCN(CC1)C2=Nc(cc(Cl)cc3)c3Nc(c24)cccc4
2265	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB00903	approved; investigational	Etacrynic acid	CCC(=C)C(=O)c1c(Cl)c(Cl)c(cc1)OCC(=O)O
2266	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB01242	approved; investigational; vet_approved	Clomipramine	CN(C)CCCN1c(cccc2)c2CCc(c13)ccc(Cl)c3
2267	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB01834	experimental	(9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CS[C@@H]([C@@H]1O)c(cccc2)c2c(c13)cccc3
2268	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB01915	experimental	S-Hydroxycysteine	OC(=O)[C@@H](N)CSO
2269	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB02633	experimental	Cibacron Blue	c1cccc(c12)C(=O)c3c(C2=O)c(cc(c3N)S(=O)(=O)O)Nc4ccc(c(c4)S(=O)(=O)O)Nc5nc(Cl)nc(n5)Nc6ccccc6S(=O)(=O)O
2270	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB03003	experimental	Glutathione sulfonic acid	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCC(=O)O
2271	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB03619	approved	Deoxycholic acid	C1C[C@@H](O)C[C@H]([C@]12C)CC[C@@H]3[C@@H]2C[C@H](O)[C@@]4(C)[C@H]3CC[C@@H]4[C@H](C)CCC(=O)O
2272	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB03686	experimental	S-(4-nitrobenzyl)glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSCc1ccc([N+]([O-])=O)cc1
2273	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB03814	experimental	2-(N-morpholino)ethanesulfonic acid	OS(=O)(=O)CCN1CCOCC1
2274	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB04132	experimental	S-Hexylglutathione	CCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2275	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB04339	approved; investigational	Carbocisteine	OC(=O)[C@@H](N)CSCC(=O)O
2276	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB04972	investigational	Canfosfamide	c1ccccc1[C@H](C(=O)O)NC(=O)[C@@H](NC(=O)CC[C@H](N)C(=O)O)CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl
2277	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB05460	investigational	Ezatiostat	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c2ccccc2
2278	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB06246	investigational	Exisulind	c1cc(F)cc(c12)C(CC(=O)O)=C(C)/C2=C/c3ccc(cc3)S(=O)(=O)C
2279	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB07849	experimental	S-NONYL-CYSTEINE	OC(=O)[C@@H](N)CSCCCCCCCCC
2280	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB08370	experimental	S-(4-BROMOBENZYL)CYSTEINE	OC(=O)[C@@H](N)CSCc1ccc(Br)cc1
2281	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB11672	approved; experimental; investigational	Curcumin	COc1cc(ccc1O)/C=C/C(=O)CC(=O)/C=C/c2cc(OC)c(O)cc2
2282	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB11831	investigational	Dinitrochlorobenzene	Clc1c(N(=O)=O)cc(N(=O)=O)cc1
2283	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB13014	investigational	Hypericin	Oc1cc(C)c2c(c(C)cc3O)c4c3c(=O)c(c(O)cc5O)c6c4c7c2c1c(=O)c(c7c8c56)c(O)cc8O
2284	sp|Q8ILQ7|GST_PLAF	P09211	91.0	4.0	196.0	DB14635	experimental	Curcumin sulfate	COc1cc(ccc1O)/C=C/C(=O)CC(=O)/C=C/c2ccc(OS(=O)(=O)O)c(c2)OC
2285	sp|Q8ILQ7|GST_PLAF	P78417	91.94	26.0	220.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2286	sp|Q8ILQ7|GST_PLAF	O43708	92.89	4.0	200.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2287	sp|Q8ILQ7|GST_PLAF	O43708	92.89	4.0	200.0	DB04447	experimental	1,4-Dithiothreitol	SC[C@H](O)[C@@H](O)CS
2288	sp|Q8ILQ7|GST_PLAF	O43708	92.89	4.0	200.0	DB08809	approved; investigational	Dichloroacetic acid	OC(=O)C(Cl)Cl
2289	sp|Q8ILQ7|GST_PLAF	O43708	92.89	4.0	200.0	DB09462	approved; investigational	Glycerin	OCC(O)CO
2290	sp|Q8ILQ7|GST_PLAF	Q9H4Y5	91.0	27.0	219.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2291	sp|Q8ILQ7|GST_PLAF	P0CG29	83.89	22.0	199.0	DB04132	experimental	S-Hexylglutathione	CCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2292	sp|Q8ILQ7|GST_PLAF	P0CG29	83.89	22.0	199.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2293	sp|Q8ILQ7|GST_PLAF	P0CG30	83.89	22.0	199.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2294	sp|Q8ILQ7|GST_PLAF	P30711	84.36	22.0	200.0	DB03310	approved; experimental; investigational	Glutathione disulfide	OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(=O)O)CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@H](N)C(=O)O
2295	sp|Q8ILQ7|GST_PLAF	P30711	84.36	22.0	200.0	DB00143	approved; investigational; nutraceutical	Glutathione	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O
2296	sp|Q8ILQ7|GST_PLAF	Q59721	86.73	13.0	196.0	DB07914	experimental	2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid	OC(=O)/C(O)=C/C=C/C(=O)c1ccccc1
2297	sp|Q8ILQ7|GST_PLAF	Q8IDV0	75.83	32.0	192.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2298	sp|Q8ILQ7|GST_PLAF	P0A9D2	85.31	16.0	196.0	DB03003	experimental	Glutathione sulfonic acid	OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCC(=O)O
2299	sp|Q8ILQ7|GST_PLAF	K7YNB3	72.99	17.0	171.0	DB12245	approved; investigational	Triclabendazole	CSc([nH]1)nc(c12)cc(c(Cl)c2)Oc3cccc(Cl)c3Cl
2300	sp|Q8ILQ7|GST_PLAF	A0A384KMD8	85.31	21.0	201.0	DB04272	approved; nutraceutical; vet_approved	Citric acid	OC(=O)CC(O)(C(=O)O)CC(=O)O
2301	sp|Q8ILQ7|GST_PLAF	O00299	77.25	27.0	190.0	DB09130	approved; investigational	Copper	[Cu]
2302	sp|Q8ILQ7|GST_PLAF	O00299	77.25	27.0	190.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2303	sp|Q8IHZ9|KC1_PLAF	Q15418	75.85	60.0	305.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
2304	sp|Q8IHZ9|KC1_PLAF	Q15418	75.85	60.0	305.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2305	sp|Q8IHZ9|KC1_PLAF	Q15418	80.5	414.0	674.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
2306	sp|Q8IHZ9|KC1_PLAF	Q15418	80.5	414.0	674.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2307	sp|Q8IHZ9|KC1_PLAF	P51812	75.85	66.0	311.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
2308	sp|Q8IHZ9|KC1_PLAF	P51812	75.85	66.0	311.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2309	sp|Q8IHZ9|KC1_PLAF	P51812	79.57	416.0	673.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
2310	sp|Q8IHZ9|KC1_PLAF	P51812	79.57	416.0	673.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2311	sp|Q8IHZ9|KC1_PLAF	Q9UK32	80.8	71.0	332.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2312	sp|Q8IHZ9|KC1_PLAF	Q9UK32	80.19	421.0	680.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2313	sp|Q8IHZ9|KC1_PLAF	O75676	78.95	30.0	285.0	DB03247	approved; investigational	Flavin mononucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
2314	sp|Q8IHZ9|KC1_PLAF	O75676	78.33	416.0	669.0	DB03247	approved; investigational	Flavin mononucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
2315	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2316	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB05243	investigational	XL019	 
2317	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB07161	experimental	5-phenyl-1H-indazol-3-amine	Nc1n[nH]c(c12)ccc(c2)-c3ccccc3
2318	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB07162	experimental	4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide	CC(C)(C)NS(=O)(=O)c1ccc(cc1)-c(cc2)cc(c23)c(N)n[nH]3
2319	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB08067	experimental	4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM	C1CC1NC(=O)Nc2c[nH]nc2-c([nH]3)nc(c34)ccc(c4)C[NH+]5CCOCC5
2320	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB08877	approved	Ruxolitinib	C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2321	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2322	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2323	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
2324	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2325	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB12500	approved; investigational	Fedratinib	CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4
2326	sp|Q8IHZ9|KC1_PLAF	O60674	82.97	543.0	811.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2327	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2328	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB05243	investigational	XL019	 
2329	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB07161	experimental	5-phenyl-1H-indazol-3-amine	Nc1n[nH]c(c12)ccc(c2)-c3ccccc3
2330	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB07162	experimental	4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide	CC(C)(C)NS(=O)(=O)c1ccc(cc1)-c(cc2)cc(c23)c(N)n[nH]3
2331	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB08067	experimental	4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM	C1CC1NC(=O)Nc2c[nH]nc2-c([nH]3)nc(c34)ccc(c4)C[NH+]5CCOCC5
2332	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB08877	approved	Ruxolitinib	C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2333	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2334	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2335	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
2336	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2337	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB12500	approved; investigational	Fedratinib	CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4
2338	sp|Q8IHZ9|KC1_PLAF	O60674	86.38	847.0	1126.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2339	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB02375	experimental	Myricetin	Oc(c1)cc(O)c(c12)c(=O)c(O)c(o2)-c3cc(O)c(O)c(O)c3
2340	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2341	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB08877	approved	Ruxolitinib	C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2342	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2343	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2344	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2345	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB12500	approved; investigational	Fedratinib	CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4
2346	sp|Q8IHZ9|KC1_PLAF	P23458	84.83	579.0	853.0	DB15091	approved; investigational	Upadacitinib	FC(F)(F)CNC(=O)N1C[C@@H](CC)[C@H](C1)c2cnc(n23)cnc4c3cc[nH]4
2347	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB02375	experimental	Myricetin	Oc(c1)cc(O)c(c12)c(=O)c(O)c(o2)-c3cc(O)c(O)c(O)c3
2348	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2349	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB08877	approved	Ruxolitinib	C1CCCC1[C@@H](CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2350	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2351	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2352	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2353	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB12500	approved; investigational	Fedratinib	CC(C)(C)NS(=O)(=O)c1cc(ccc1)Nc2nc(ncc2C)Nc3ccc(cc3)OCCN4CCCC4
2354	sp|Q8IHZ9|KC1_PLAF	P23458	85.76	876.0	1153.0	DB15091	approved; investigational	Upadacitinib	FC(F)(F)CNC(=O)N1C[C@@H](CC)[C@H](C1)c2cnc(n23)cnc4c3cc[nH]4
2355	sp|Q8IHZ9|KC1_PLAF	P29597	88.54	587.0	873.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2356	sp|Q8IHZ9|KC1_PLAF	P29597	88.54	587.0	873.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2357	sp|Q8IHZ9|KC1_PLAF	P29597	88.54	587.0	873.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2358	sp|Q8IHZ9|KC1_PLAF	P29597	86.69	897.0	1177.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2359	sp|Q8IHZ9|KC1_PLAF	P29597	86.69	897.0	1177.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2360	sp|Q8IHZ9|KC1_PLAF	P29597	86.69	897.0	1177.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2361	sp|Q8IHZ9|KC1_PLAF	P52333	81.73	519.0	783.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2362	sp|Q8IHZ9|KC1_PLAF	P52333	81.73	519.0	783.0	DB06321	investigational	R-348	CCC(=O)NS(=O)(=O)c1cc(ccc1C)Nc2ncc(F)c(n2)Nc3ccc(cc3)OCC#C
2363	sp|Q8IHZ9|KC1_PLAF	P52333	81.73	519.0	783.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2364	sp|Q8IHZ9|KC1_PLAF	P52333	81.73	519.0	783.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2365	sp|Q8IHZ9|KC1_PLAF	P52333	81.73	519.0	783.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2366	sp|Q8IHZ9|KC1_PLAF	P52333	81.73	519.0	783.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2367	sp|Q8IHZ9|KC1_PLAF	P52333	88.54	821.0	1107.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2368	sp|Q8IHZ9|KC1_PLAF	P52333	88.54	821.0	1107.0	DB06321	investigational	R-348	CCC(=O)NS(=O)(=O)c1cc(ccc1C)Nc2ncc(F)c(n2)Nc3ccc(cc3)OCC#C
2369	sp|Q8IHZ9|KC1_PLAF	P52333	88.54	821.0	1107.0	DB08895	approved; investigational	Tofacitinib	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c2ncnc(c23)[nH]cc3
2370	sp|Q8IHZ9|KC1_PLAF	P52333	88.54	821.0	1107.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2371	sp|Q8IHZ9|KC1_PLAF	P52333	88.54	821.0	1107.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2372	sp|Q8IHZ9|KC1_PLAF	P52333	88.54	821.0	1107.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2373	sp|Q8IHZ9|KC1_PLAF	P49674	98.76	1.0	320.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
2374	sp|Q8IHZ9|KC1_PLAF	P48729	96.28	10.0	321.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2375	sp|Q8IHZ9|KC1_PLAF	P00521	82.66	126.0	393.0	DB02567	experimental	PD173955	CSc1cccc(c1)Nc(n2)ncc(c23)cc(c(=O)n3C)-c4c(Cl)cccc4Cl
2376	sp|Q8IHZ9|KC1_PLAF	P00521	82.66	126.0	393.0	DB03814	experimental	2-(N-morpholino)ethanesulfonic acid	OS(=O)(=O)CCN1CCOCC1
2377	sp|Q8IHZ9|KC1_PLAF	P00521	82.66	126.0	393.0	DB03878	experimental	N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide	c1ccncc1C(=O)Nc2ccc(C)c(c2)Nc3nccc(n3)-c4cccnc4
2378	sp|Q8IHZ9|KC1_PLAF	P00521	82.66	126.0	393.0	DB05489	investigational	ACA 125	 
2379	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
2380	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB00619	approved	Imatinib	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(C)cc3)Nc4nccc(n4)-c5cnccc5
2381	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2382	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB03878	experimental	N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide	c1ccncc1C(=O)Nc2ccc(C)c(c2)Nc3nccc(n3)-c4cccnc4
2383	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB04868	approved; investigational	Nilotinib	Cc1cn(cn1)-c2cc(cc(c2)C(F)(F)F)NC(=O)c3ccc(C)c(c3)Nc4nccc(n4)-c5cnccc5
2384	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB05184	investigational	XL228	 
2385	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
2386	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB07831	experimental	2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	CCCc1ccc(cc1C(F)(F)F)NC(=O)c2ccccc2NCc3c[nH]c(=O)cc3
2387	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB08043	experimental	1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA	FC(F)(F)c1cc(ccc1)NC(=O)Nc2ccc(cc2)Oc3ccncc3
2388	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
2389	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB08339	experimental	PD-166326	Clc1cccc(Cl)c1-c(c(=O)n2C)cc(c23)cnc(n3)Nc4cccc(c4)CO
2390	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB08350	experimental	5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE	COc1ccccc1-c2c[nH]c(c23)ncc(c3)-c4cc(cnc4)C(=O)N(C)C
2391	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB08583	experimental	2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide	CCn1nccc1-c2c[nH]c(c23)ncc(c3)-c4cc(C(=O)N(C)C)c(N)cc4
2392	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2393	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2394	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2395	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
2396	sp|Q8IHZ9|KC1_PLAF	P00519	82.97	240.0	508.0	DB12323	investigational	Radotinib	Cc1cn(cn1)-c2cc(cc(c2)C(F)(F)F)NC(=O)c3ccc(C)c(c3)Nc4nccc(n4)-c5cnccn5
2397	sp|Q8IHZ9|KC1_PLAF	P42685	82.35	232.0	498.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2398	sp|Q8IHZ9|KC1_PLAF	P42685	82.35	232.0	498.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2399	sp|Q8IHZ9|KC1_PLAF	P42685	82.35	232.0	498.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2400	sp|Q8IHZ9|KC1_PLAF	P42685	82.35	232.0	498.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2401	sp|Q8IHZ9|KC1_PLAF	Q13188	91.02	24.0	318.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2402	sp|Q8IHZ9|KC1_PLAF	P42684	82.97	286.0	554.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
2403	sp|Q8IHZ9|KC1_PLAF	P42684	82.97	286.0	554.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2404	sp|Q8IHZ9|KC1_PLAF	P42684	82.97	286.0	554.0	DB05184	investigational	XL228	 
2405	sp|Q8IHZ9|KC1_PLAF	P42684	82.97	286.0	554.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
2406	sp|Q8IHZ9|KC1_PLAF	P42684	82.97	286.0	554.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2407	sp|Q8IHZ9|KC1_PLAF	Q9NYL2	91.64	14.0	310.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2408	sp|Q8IHZ9|KC1_PLAF	Q9NYL2	91.64	14.0	310.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2409	sp|Q8IHZ9|KC1_PLAF	P06241	81.11	269.0	531.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2410	sp|Q8IHZ9|KC1_PLAF	P06241	81.11	269.0	531.0	DB02078	experimental	Triglyme	COCCOCCOCCOC
2411	sp|Q8IHZ9|KC1_PLAF	P06241	81.11	269.0	531.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2412	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2413	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB01678	experimental	RU84687	OP(=O)(O)Oc1c(C=O)cc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2414	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB01866	experimental	RU79256	OC(=O)[C@H](S(=O)(=O)O)c1ccccc1
2415	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB01893	experimental	N6-Benzyl Adenosine-5'-Diphosphate	OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(ncn3)NCc4ccccc4
2416	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB01908	experimental	RU85493	OC(=O)COc1c(P(=O)(O)O)cc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2417	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB01947	experimental	RU78262	OP(=O)(O)Oc1c(C=O)cccc1
2418	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB01962	experimental	Phosphonotyrosine	OC(=O)[C@@H](N)Cc1ccc(cc1)OP(=O)(O)O
2419	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB02175	experimental	Malonic acid	OC(=O)CC(=O)O
2420	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB02336	experimental	RU83876	O=P(O)(O)c1ccc(cc1P(=O)(O)O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2421	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB02432	experimental	RU90395	COC(=O)c1c(C(F)(C(=O)O)C(=O)O)ccc(c1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2422	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB02762	experimental	RU79072	OP(=O)(O)Oc1cccc(c12)ccc(n2)C#N
2423	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB02908	experimental	RU78783	OP(=O)(O)C(P(=O)(O)O)c1ccccc1
2424	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03023	experimental	1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	n1cnc(N)c(c12)c([nH+]n2C(C)(C)C)-c3ccc(Cl)cc3
2425	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03078	experimental	PASBN	O=Cc1ccccc1O[P@@](=O)(O)OCc2ccccc2
2426	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03104	experimental	2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid	OC(=O)Cc1c(C=O)cc(cc1)/C=C(\NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2427	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03114	experimental	PAS219	O=Cc1ccccc1O[P@@](=O)(O)OCC2CCCCC2
2428	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03217	experimental	DPI59	c1cccc(c12)cccc2[C@@H](O)P(=O)(O)O
2429	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03268	experimental	RU82197	O=C(O)c1ccc(cc1C=O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2430	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03298	experimental	Phenylphosphate	OP(=O)(O)Oc1ccccc1
2431	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03306	experimental	RU78300	COc1cccc(C=O)c1OP(=O)(O)O
2432	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03525	experimental	RU79073	OP(=O)(O)Oc(ccc1)c(c12)NCCC2
2433	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03591	experimental	RU82209	OP(=O)(O)C(F)(F)c1ccc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2434	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03628	experimental	ISO24	CCc1ccc(cc1)NC(=O)P(=O)(O)O
2435	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03712	experimental	RU85053	OC(=O)Cc1ccc(cc1C(=O)O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2436	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03828	experimental	RU78299	Cc1cc(C=O)c(c(C=O)c1)OP(=O)(O)O
2437	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB03902	experimental	Oxalic Acid	OC(=O)C(=O)O
2438	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB04080	experimental	RU78191	OC(=O)C(C(=O)O)c1ccccc1
2439	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB04272	approved; nutraceutical; vet_approved	Citric acid	OC(=O)CC(O)(C(=O)O)CC(=O)O
2440	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB04495	experimental	Paratoulene phosphate	OP(=O)(O)Oc1ccc(cc1)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCN(C2=O)Cc3ccc(cc3)-c4ccccc4
2441	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB04739	experimental	4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cccc(c3)Nc4nccc(n4)-c5cnccc5
2442	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
2443	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB05184	investigational	XL228	 
2444	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB06137	investigational	KX-01	c1ccccc1CNC(=O)Cc2ccc(cn2)-c3ccc(cc3)OCCN4CCOCC4
2445	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
2446	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB06882	experimental	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea	Nc1cc(ccc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc(ccc3)c(c34)cccc4
2447	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB06883	experimental	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea	Nc1cc(ccc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc3ccccc3
2448	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB07335	experimental	3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL	n1cnc(N)c(c12)c(nn2C(C)C)-c3cccc(O)c3
2449	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB07662	experimental	PD-168393	Brc1cc(ccc1)Nc(ncn2)c(c23)cc(cc3)NC(=O)C=C
2450	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB07966	experimental	[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile	N#CCc1ccc(cc1)Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
2451	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB08052	experimental	PP-121	[nH]1ccc(c12)cc(cn2)-c3nn(C4CCCC4)c(c35)ncnc5N
2452	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB08053	experimental	1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	COc1c(OC)cc(cc1)-c2nn(C3CCC3)c(c24)ncnc4N
2453	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB08054	experimental	1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine	n1cnc(N)c(c12)c(nn2C(C)C)-c(cc3)cc(c34)cccn4
2454	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB08192	experimental	2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE	CC(C)c1sc(nc1C(=O)O)[C@@H](NC2)Cc(c23)cccc3
2455	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB08462	experimental	N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE	C=CC(=O)Nc(c1)ccc(c12)ncnc2Nc3ccccc3
2456	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB08564	experimental	(2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide	CN(C)C/C=C/C(=O)Nc(c1)ccc(c12)ncnc2Nc3cc(Br)ccc3
2457	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2458	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
2459	sp|Q8IHZ9|KC1_PLAF	P12931	81.11	268.0	530.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2460	sp|Q8IHZ9|KC1_PLAF	P07947	81.11	275.0	537.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2461	sp|Q8IHZ9|KC1_PLAF	P07947	81.11	275.0	537.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2462	sp|Q8IHZ9|KC1_PLAF	Q9Y6E0	91.02	33.0	327.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2463	sp|Q8IHZ9|KC1_PLAF	P54762	83.28	620.0	889.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2464	sp|Q8IHZ9|KC1_PLAF	P07948	81.42	245.0	508.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2465	sp|Q8IHZ9|KC1_PLAF	P07948	81.42	245.0	508.0	DB03023	experimental	1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	n1cnc(N)c(c12)c([nH+]n2C(C)(C)C)-c3ccc(Cl)cc3
2466	sp|Q8IHZ9|KC1_PLAF	P07948	81.42	245.0	508.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
2467	sp|Q8IHZ9|KC1_PLAF	P07948	81.42	245.0	508.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2468	sp|Q8IHZ9|KC1_PLAF	P07948	81.42	245.0	508.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
2469	sp|Q8IHZ9|KC1_PLAF	P07948	81.42	245.0	508.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2470	sp|Q8IHZ9|KC1_PLAF	P63185	77.71	265.0	516.0	DB01773	experimental	4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid	C1CCCCC1CCCN(C)C(=O)[C@H](CCC(=O)O)NC(=O)N(CC(=O)O)Cc2ccc(cc2)OP(=O)(O)O
2471	sp|Q8IHZ9|KC1_PLAF	P00524	77.71	265.0	516.0	DB08434	experimental	2-METHYLCARBAMOYL-3-(4-PHOSPHONOOXY-PHENYL)-CYCLOPROPANECARBOXYLIC ACID	OC(=O)[C@H]1[C@H](C(=O)NC)[C@@H]1c2ccc(cc2)OP(=O)(O)O
2472	sp|Q8IHZ9|KC1_PLAF	P27448	80.5	55.0	315.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2473	sp|Q8IHZ9|KC1_PLAF	P29320	83.28	619.0	888.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2474	sp|Q8IHZ9|KC1_PLAF	P80192	95.67	143.0	452.0	DB08703	experimental	12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one	CC(C)Oc(c1)ccc(c12)c3c(CC2)c4c(c5c3C(=O)N=C5)c6c(n4CCO)cccc6
2475	sp|Q8IHZ9|KC1_PLAF	P80192	95.67	143.0	452.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2476	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2477	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB01830	experimental	AP-22408	O=P(O)(O)c1ccc(cc1P(=O)(O)O)C[C@H](NC(=O)C)C(=O)N[C@H]2CCCCc(c23)cc(c(c3)C(=O)N)OCC4CCCCC4
2478	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
2479	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB03023	experimental	1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	n1cnc(N)c(c12)c([nH+]n2C(C)(C)C)-c3ccc(Cl)cc3
2480	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB04003	experimental	{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid	C1CCCCC1COc2c(C(=O)N)cc(cc2)[C@H](C)NC(=O)[C@@H](NC(=O)C)Cc3cc(P(=O)(O)O)c(cc3)OCC(=O)O
2481	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
2482	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB06925	experimental	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	FC(F)(F)c1cc(ccc1)NC(=O)c2ccc(C)c(c2)-c(c3)ccc(c34)nc(N)nc4
2483	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB07146	experimental	2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE	C1CNCCN1CCNc2ccnc(c23)oc(-c4ccccc4)c3-c5ccccc5
2484	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB07297	experimental	5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE	C1CNCCN1CCNc(ncn2)c(c23)c(-c4ccccc4)c(o3)-c5ccccc5
2485	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB08055	experimental	N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine	Clc1ccccc1Nc2ncc(n(c23)cnc3)-c4ccccc4
2486	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB08056	experimental	N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine	Cc1cccc(C)c1Nc2ncc(n(c23)cnc3)-c4ccccc4
2487	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB08057	experimental	N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine	C[C@H]1CN(CCN1)c(c2)ccc(c23)nc(c4n3cnc4)Nc5c(C)cccc5Cl
2488	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2489	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
2490	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2491	sp|Q8IHZ9|KC1_PLAF	P06239	81.11	243.0	505.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2492	sp|Q8IHZ9|KC1_PLAF	P08631	81.42	260.0	523.0	DB01809	experimental	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	Cc1ccc(cc1)-c2nn(C(C)(C)C)c(c23)ncnc3N
2493	sp|Q8IHZ9|KC1_PLAF	P08631	81.42	260.0	523.0	DB01962	experimental	Phosphonotyrosine	OC(=O)[C@@H](N)Cc1ccc(cc1)OP(=O)(O)O
2494	sp|Q8IHZ9|KC1_PLAF	P08631	81.42	260.0	523.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
2495	sp|Q8IHZ9|KC1_PLAF	P08631	81.42	260.0	523.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
2496	sp|Q8IHZ9|KC1_PLAF	P08631	81.42	260.0	523.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2497	sp|Q8IHZ9|KC1_PLAF	Q96L34	76.78	58.0	306.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2498	sp|Q8IHZ9|KC1_PLAF	P29323	82.66	622.0	889.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
2499	sp|Q8IHZ9|KC1_PLAF	P29323	82.66	622.0	889.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2500	sp|Q8IHZ9|KC1_PLAF	Q7KZI7	76.78	52.0	300.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2501	sp|Q8IHZ9|KC1_PLAF	Q02779	95.05	97.0	404.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2502	sp|Q8IHZ9|KC1_PLAF	Q9Y6M4	96.59	38.0	350.0	DB04751	experimental	Purvalanol A	CC(C)n1cnc(c12)c(nc(n2)N[C@@H](CO)C(C)C)Nc3cccc(Cl)c3
2503	sp|Q8IHZ9|KC1_PLAF	Q9Y6M4	96.59	38.0	350.0	DB07488	experimental	{4-Amino-2-[(4-methoxyphenyl)amino]-1,3-thiazol-5-yl}(4-methoxyphenyl)methanone	COc1ccc(cc1)/N=c2/[nH]c(N)c(s2)C(=O)c3ccc(OC)cc3
2504	sp|Q8IHZ9|KC1_PLAF	Q9Y6M4	96.59	38.0	350.0	DB07489	experimental	4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium	Fc1ccc(cc1)C(=O)c2c(N)[nH+]c(s2)Nc3cc(Cl)ccc3
2505	sp|Q8IHZ9|KC1_PLAF	Q9Y6M4	96.59	38.0	350.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
2506	sp|Q8IHZ9|KC1_PLAF	Q9P0L2	76.78	59.0	307.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2507	sp|Q8IHZ9|KC1_PLAF	P54764	82.97	621.0	889.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2508	sp|Q8IHZ9|KC1_PLAF	P09769	81.11	261.0	523.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2509	sp|Q8IHZ9|KC1_PLAF	P09769	81.11	261.0	523.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2510	sp|Q8IHZ9|KC1_PLAF	P09769	81.11	261.0	523.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2511	sp|Q8IHZ9|KC1_PLAF	Q9HCP0	89.78	39.0	329.0	DB08325	experimental	2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol	CC(C)n1cnc(c12)c(nc(n2)NCCO)Nc3cc(Cl)ccc3
2512	sp|Q8IHZ9|KC1_PLAF	Q15375	82.35	633.0	899.0	DB07970	experimental	5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide	O=C(N)c1cncc(c1)Nc2c(C)ccc(c2)C(=O)Nc3cccc(c3)C(F)(F)F
2513	sp|Q8IHZ9|KC1_PLAF	Q15375	82.35	633.0	899.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2514	sp|Q8IHZ9|KC1_PLAF	Q8IU85	79.88	18.0	276.0	DB08454	experimental	N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE	Cc1cc(n[nH]1)Nc(c(c23)cccc3)nc(n2)-c4ccccc4
2515	sp|Q8IHZ9|KC1_PLAF	Q8IU85	79.88	18.0	276.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2516	sp|Q8IHZ9|KC1_PLAF	P54756	83.9	675.0	946.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2517	sp|Q8IHZ9|KC1_PLAF	P54756	83.9	675.0	946.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2518	sp|Q8IHZ9|KC1_PLAF	Q9P289	87.0	22.0	303.0	DB07853	experimental	2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile	N#CCC1C=CC(C=C1)=Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
2519	sp|Q8IHZ9|KC1_PLAF	Q9P289	87.0	22.0	303.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2520	sp|Q8IHZ9|KC1_PLAF	Q16584	95.36	115.0	423.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2521	sp|Q8IHZ9|KC1_PLAF	Q13882	79.88	188.0	446.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
2522	sp|Q8IHZ9|KC1_PLAF	Q13882	79.88	188.0	446.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2523	sp|Q8IHZ9|KC1_PLAF	Q13882	79.88	188.0	446.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2524	sp|Q8IHZ9|KC1_PLAF	Q16620	86.07	536.0	814.0	DB00321	approved	Amitriptyline	CN(C)CCC=C1c(cccc2)c2CCc(c13)cccc3
2525	sp|Q8IHZ9|KC1_PLAF	Q16620	86.07	536.0	814.0	DB11823	approved; investigational	Esketamine	C1CCCC(=O)[C@@]1(NC)c2ccccc2Cl
2526	sp|Q8IHZ9|KC1_PLAF	Q16620	86.07	536.0	814.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
2527	sp|Q8IHZ9|KC1_PLAF	Q16620	86.07	536.0	814.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2528	sp|Q8IHZ9|KC1_PLAF	Q16620	86.07	536.0	814.0	DB14723	approved; investigational	Larotrectinib	O[C@H]1CCN(C1)C(=O)Nc(cn2)c(n23)nc(cc3)N4CCC[C@@H]4c5c(F)ccc(F)c5
2529	sp|Q8IHZ9|KC1_PLAF	P42680	79.26	369.0	625.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2530	sp|Q8IHZ9|KC1_PLAF	P42680	79.26	369.0	625.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2531	sp|Q8IHZ9|KC1_PLAF	O60285	78.33	49.0	302.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2532	sp|Q8IHZ9|KC1_PLAF	P16591	79.26	561.0	817.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2533	sp|Q8IHZ9|KC1_PLAF	P62344	87.93	50.0	334.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2534	sp|Q8IHZ9|KC1_PLAF	P78368	89.47	41.0	330.0	DB03083	experimental	IC261	COc1cc(OC)c(c(c1)OC)/C=C2/C(=O)Nc(c23)cccc3
2535	sp|Q8IHZ9|KC1_PLAF	P78368	89.47	41.0	330.0	DB03693	experimental	N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide	NCCNS(=O)(=O)c1ccc(Cl)c(c12)ccnc2
2536	sp|Q8IHZ9|KC1_PLAF	P78368	89.47	41.0	330.0	DB04604	experimental	5-iodotubercidin	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cc(I)c(c23)c(N)ncn3
2538	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
2539	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB01109	approved; investigational	Heparin	 
2540	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB02058	experimental	3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone	c1cccc(c12)C(C(=O)N2)Cc3ccc(cc3)N4CCN(C=O)CC4
2541	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB05014	investigational	XL999	 
2542	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB07525	experimental	3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine	COc1cccc(c1)Cc2c[nH]c(c23)nccc3
2543	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB07840	experimental	(E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol	COc1cccc(c1)C(=O)c2c[nH]c(c23)nccc3-c4cc(F)cc(F)c4
2544	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB08577	experimental	3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE	OC(=O)CCc1c([nH]cc1C)/C=C2\C(=O)Nc(c23)cccc3
2545	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2546	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2547	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
2548	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
2549	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2550	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
2551	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
2552	sp|Q8IHZ9|KC1_PLAF	P11362	89.16	476.0	764.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
2553	sp|Q8IHZ9|KC1_PLAF	P07332	80.8	559.0	820.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2554	sp|Q8IHZ9|KC1_PLAF	Q13557	87.93	9.0	293.0	DB07853	experimental	2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile	N#CCC1C=CC(C=C1)=Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
2555	sp|Q8IHZ9|KC1_PLAF	Q13557	87.93	9.0	293.0	DB08039	experimental	(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE	CN(C)S(=O)(=O)c(c1)ccc(c12)NC(=O)C\2=C/c([nH]3)cc(c34)CCCC4
2556	sp|Q8IHZ9|KC1_PLAF	Q13557	87.93	9.0	293.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2557	sp|Q8IHZ9|KC1_PLAF	P29317	81.42	615.0	878.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2558	sp|Q8IHZ9|KC1_PLAF	P29317	81.42	615.0	878.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
2559	sp|Q8IHZ9|KC1_PLAF	P29317	81.42	615.0	878.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2560	sp|Q8IHZ9|KC1_PLAF	P29317	81.42	615.0	878.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2561	sp|Q8IHZ9|KC1_PLAF	Q13555	87.62	9.0	292.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
2562	sp|Q8IHZ9|KC1_PLAF	Q13555	87.62	9.0	292.0	DB08699	experimental	1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	Cc1cc(ccc1)Cc2nn(C(C)(C)C)c(c23)ncnc3N
2563	sp|Q8IHZ9|KC1_PLAF	Q13555	87.62	9.0	292.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2564	sp|Q8IHZ9|KC1_PLAF	O43293	84.21	7.0	279.0	DB04716	experimental	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	CC(C)(C)c([nH]1)nc2c(cc[nH]c3=O)c3c(c4c12)cc(F)cc4
2565	sp|Q8IHZ9|KC1_PLAF	O43293	84.21	7.0	279.0	DB07125	experimental	4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid	CC[C@H](CO)Nc(cc1)nn(c12)c(cn2)-c3ccc(cc3)C(=O)O
2566	sp|Q8IHZ9|KC1_PLAF	O43293	84.21	7.0	279.0	DB07242	experimental	(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile	C1CN(C)CCC12[C@H](C#N)c3c(C(=O)N2)n(C)c4c3ccc(Cl)c4Cl
2567	sp|Q8IHZ9|KC1_PLAF	O43293	84.21	7.0	279.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2568	sp|Q8IHZ9|KC1_PLAF	Q14012	89.16	16.0	304.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2569	sp|Q8IHZ9|KC1_PLAF	Q9NYY3	84.52	77.0	350.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2570	sp|Q8IHZ9|KC1_PLAF	O95747	94.12	14.0	318.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2571	sp|Q8IHZ9|KC1_PLAF	Q96NX5	88.24	18.0	303.0	DB08009	experimental	SU-11652	CCN(CC)CCNC(=O)c1c(C)[nH]c(c1C)/C=C2\C(=O)Nc(c23)ccc(Cl)c3
2572	sp|Q8IHZ9|KC1_PLAF	Q96NX5	88.24	18.0	303.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2573	sp|Q8IHZ9|KC1_PLAF	Q13131	86.38	26.0	305.0	DB00131	approved; investigational; nutraceutical	Adenosine phosphate	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)O
2574	sp|Q8IHZ9|KC1_PLAF	Q13131	86.38	26.0	305.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
2575	sp|Q8IHZ9|KC1_PLAF	Q13131	86.38	26.0	305.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2577	sp|Q8IHZ9|KC1_PLAF	Q13131	86.38	26.0	305.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
2578	sp|Q8IHZ9|KC1_PLAF	Q13131	86.38	26.0	305.0	DB00914	approved; investigational; withdrawn	Phenformin	NC(=N)NC(=N)NCCc1ccccc1
2580	sp|Q8IHZ9|KC1_PLAF	P42681	78.64	270.0	524.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2581	sp|Q8IHZ9|KC1_PLAF	P42681	78.64	270.0	524.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2582	sp|Q8IHZ9|KC1_PLAF	Q08881	78.95	362.0	617.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
2583	sp|Q8IHZ9|KC1_PLAF	Q08881	78.95	362.0	617.0	DB06589	approved	Pazopanib	Cc1n(C)nc(c12)cc(cc2)N(C)c3ccnc(n3)Nc4ccc(C)c(c4)S(=O)(=O)N
2584	sp|Q8IHZ9|KC1_PLAF	Q08881	78.95	362.0	617.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2585	sp|Q8IHZ9|KC1_PLAF	Q08881	78.95	362.0	617.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2586	sp|Q8IHZ9|KC1_PLAF	Q9BYT3	94.74	112.0	418.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2587	sp|Q8IHZ9|KC1_PLAF	O43283	85.45	167.0	443.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2588	sp|Q8IHZ9|KC1_PLAF	O00444	80.8	10.0	271.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2589	sp|Q8IHZ9|KC1_PLAF	Q9UQM7	86.07	8.0	286.0	DB04119	experimental	Hexatantalum Dodecabromide	[Br]
2590	sp|Q8IHZ9|KC1_PLAF	Q9UQM7	86.07	8.0	286.0	DB04447	experimental	1,4-Dithiothreitol	SC[C@H](O)[C@@H](O)CS
2591	sp|Q8IHZ9|KC1_PLAF	Q9UQM7	86.07	8.0	286.0	DB07766	experimental	(2Z,3E)-2,3'-biindole-2',3(1H,1'H)-dione 3-{O-[(3R)-3,4-dihydroxybutyl]oxime}	c1cccc(c12)/C(C(=O)N2)=C(/Nc(c34)cccc4)\C3=N\OCC[C@@H](O)CO
2592	sp|Q8IHZ9|KC1_PLAF	Q9UQM7	86.07	8.0	286.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2593	sp|Q8IHZ9|KC1_PLAF	Q13153	77.71	267.0	518.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2595	sp|Q8IHZ9|KC1_PLAF	Q05397	85.14	419.0	694.0	DB07248	experimental	7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE	COc1c(OC)cc(cc1OC)Nc(n2)ncc(c23)ccn3-c4ccccn4
2596	sp|Q8IHZ9|KC1_PLAF	Q05397	85.14	419.0	694.0	DB07460	experimental	2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE	CNC(=O)c1c(cccc1)Nc2nc(ncc2Cl)Nc3ccc(cc3OC)N4CCOCC4
2597	sp|Q8IHZ9|KC1_PLAF	Q05397	85.14	419.0	694.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2599	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB01041	approved; investigational; withdrawn	Thalidomide	c1cccc(c12)C(=O)N(C2=O)C3CCC(=O)NC3=O
2600	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB01109	approved; investigational	Heparin	 
2601	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB01901	experimental	Sucrosofate	O=S(=O)(O)OC[C@@H](O1)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@]1(COS(=O)(=O)O)O[C@H]2O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O
2602	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB02058	experimental	3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone	c1cccc(c12)C(C(=O)N2)Cc3ccc(cc3)N4CCN(C=O)CC4
2603	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB02491	experimental	4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine	CC(C)(N)c1ccc(cc1)-c2nc(ncc2Cl)Nc3ccc(cc3)CCN4CCOCC4
2604	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2605	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2606	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
2607	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
2610	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2611	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
2612	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
2613	sp|Q8IHZ9|KC1_PLAF	P21802	88.85	479.0	766.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
2614	sp|Q8IHZ9|KC1_PLAF	Q9H093	78.02	47.0	299.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2615	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2616	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07249	experimental	N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine	O1COc(c12)ccc(Cl)c2Nc3ncnc(c34)cc(c(c4)OC)OCCCN5CCCCC5
2617	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07250	experimental	N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE	COc1c(OC)cc(cc1OC)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
2618	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07251	experimental	N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE	COc1c(OC)cc(cc1OC)Nc2ncnc(n2)Nc3cc(Cl)c(OC)cc3
2619	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07252	experimental	3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide	NS(=O)(=O)c1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
2620	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07253	experimental	N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine	CS(=O)(=O)c1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
2621	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07254	experimental	N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE	CS(=O)(=O)Nc1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
2622	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07255	experimental	N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE	O1COc(c12)c(c(Cl)cc2)Nc3nc(ncc3)Nc4cc(ccc4)N5CCOCC5
2623	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB07256	experimental	3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE	NC(=O)c1cc(ccc1)Nc2nc(ccn2)Nc3c(Cl)ccc(c34)OCO4
2624	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB11973	investigational	Tesevatinib	CN(C1)C[C@@H]([C@@H]12)C[C@@H](C2)COc(c(c3)OC)cc(c34)ncnc4Nc5ccc(Cl)c(Cl)c5F
2625	sp|Q8IHZ9|KC1_PLAF	P54760	82.35	616.0	882.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2626	sp|Q8IHZ9|KC1_PLAF	Q14680	81.11	9.0	271.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2627	sp|Q8IHZ9|KC1_PLAF	Q13554	89.78	9.0	299.0	DB07168	experimental	[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile	N#CCc1ccc(cc1)Nc2nc(NC)cc(n2)Nc3n[nH]c(c3)C4CC4
2628	sp|Q8IHZ9|KC1_PLAF	Q13554	89.78	9.0	299.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2629	sp|Q8IHZ9|KC1_PLAF	P51451	81.42	239.0	502.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2630	sp|Q8IHZ9|KC1_PLAF	P51451	81.42	239.0	502.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2631	sp|Q8IHZ9|KC1_PLAF	P57059	76.47	27.0	274.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
2632	sp|Q8IHZ9|KC1_PLAF	P57059	76.47	27.0	274.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2633	sp|Q8IHZ9|KC1_PLAF	Q9NRH2	78.02	13.0	265.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2634	sp|Q8IHZ9|KC1_PLAF	Q8IBS5	85.45	65.0	341.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
2635	sp|Q8IHZ9|KC1_PLAF	O75914	78.33	280.0	533.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2636	sp|Q8IHZ9|KC1_PLAF	P31751	75.54	149.0	393.0	DB07812	experimental	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide	c1ccccc1[C@@H](CN)NC(=O)c2ccc(s2)-c(ccn3)c(c34)cc[nH]4
2637	sp|Q8IHZ9|KC1_PLAF	P31751	75.54	149.0	393.0	DB07859	experimental	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c4c[nH]nc4
2638	sp|Q8IHZ9|KC1_PLAF	P31751	75.54	149.0	393.0	DB07947	experimental	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	Clc1ccc(cc1)COCCNCCNS(=O)(=O)c2cccc(c23)cncc3
2639	sp|Q8IHZ9|KC1_PLAF	P31751	75.54	149.0	393.0	DB08073	experimental	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)-c(c4)ccc(c45)[nH]nc5C
2640	sp|Q8IHZ9|KC1_PLAF	Q9UKE5	93.81	25.0	328.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2642	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB05014	investigational	XL999	 
2643	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB06589	approved	Pazopanib	Cc1n(C)nc(c12)cc(cc2)N(C)c3ccnc(n3)Nc4ccc(C)c(c4)S(=O)(=O)N
2644	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2645	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
2646	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB09079	approved	Nintedanib	COC(=O)c(c1)ccc(c12)/C(C(=O)N2)=C(\c3ccccc3)Nc4ccc(cc4)N(C)C(=O)CN5CCN(C)CC5
2647	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2648	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
2649	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
2650	sp|Q8IHZ9|KC1_PLAF	P22607	88.54	470.0	756.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
2651	sp|Q8IHZ9|KC1_PLAF	Q9H4B4	83.9	57.0	328.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2652	sp|Q8IHZ9|KC1_PLAF	Q8IYT8	82.66	6.0	273.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2653	sp|Q8IHZ9|KC1_PLAF	Q13177	79.57	246.0	503.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2654	sp|Q8IHZ9|KC1_PLAF	P51957	85.14	5.0	280.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2655	sp|Q8IHZ9|KC1_PLAF	Q9C098	87.31	350.0	632.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2656	sp|Q8IHZ9|KC1_PLAF	P51813	79.88	414.0	672.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2657	sp|Q8IHZ9|KC1_PLAF	P51813	79.88	414.0	672.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2658	sp|Q8IHZ9|KC1_PLAF	P53355	91.95	8.0	305.0	DB04069	experimental	5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine	Nc(c1)nnc(c12)c3c(CC2)cccc3
2659	sp|Q8IHZ9|KC1_PLAF	P53355	91.95	8.0	305.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
2660	sp|Q8IHZ9|KC1_PLAF	P53355	91.95	8.0	305.0	DB07444	experimental	6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE	c1cc(C)cc(c12)c3c(n2CCCN)cc(C)c4c3C(=O)NC4=O
2661	sp|Q8IHZ9|KC1_PLAF	P53355	91.95	8.0	305.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2662	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB01919	experimental	Pentanal	CCCCC=O
2663	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB01940	experimental	Balanol Analog 2	Oc1ccc(cc1)C(=O)N[C@@H]2CNCCC[C@H]2OC(=O)c3ccc(cc3)C(=O)c4ccccc4O
2664	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB02155	experimental	3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate	CC[C@H](C)c1c(O)ccc(c1)C(=O)N[C@@H]2CNCCC[C@H]2OC(=O)c3ccc(cc3)C(=O)c4c(O)ccc(c4)OC
2665	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
2666	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB02611	experimental	Balanol Analog 1	Oc1ccc(cc1)C(=O)N[C@@H]2CNCCC[C@H]2OC(=O)c3ccc(O)cc3
2667	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB03374	experimental	3,5-Diiodotyrosine	OC(=O)[C@@H](N)Cc1cc(I)c(O)c(I)c1
2668	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB04098	experimental	Balanol	OC(=O)c1cccc(O)c1C(=O)c2c(O)cc(cc2O)C(=O)O[C@@H]3CCCNC[C@@H]3NC(=O)c4ccc(O)cc4
2669	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
2670	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB04530	experimental	S,S-(2-Hydroxyethyl)Thiocysteine	OC(=O)[C@@H](N)CSSCCO
2671	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB04707	experimental	Hydroxyfasudil	O=c1[nH]ccc(c12)c(ccc2)S(=O)(=O)N3CCCNCC3
2672	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB06959	experimental	(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine	c1cccc(c12)N=CC2C[C@H](N)COc3cncc(c3)-c(cc4)cc(c45)ccnc5
2673	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB06977	experimental	(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine	C1=CC=CC(C12)=C(C=N2)C[C@H](N)COc3cncc(c3)-c(cc4)cc(c45)c[nH]n5
2674	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07107	experimental	(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)/C=C/c4ccncc4
2675	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07124	experimental	(2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	C=1CC=CC(C12)=C(C=N2)C[C@H](N)COc3cncc(c3)C(C=4)=NCC(C45)=NN=C5
2676	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07204	experimental	(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc(cnc3)c(c34)ccc(n4)-c5ccncc5
2677	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07235	experimental	N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE	Clc1ccc(c(Cl)c1)C[C@@H](CN)NC(=O)c2ccc(s2)-c3ccnc(n3)NC
2678	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07458	experimental	3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione	c1cccc(c12)c(c[nH]2)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)CC[C@@H]6CCCN6C
2679	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07583	experimental	(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE	c1cncc(c12)cccc2S(=O)(=O)NC[C@@H]3C[C@H](CN3)OCc4ccc(Cl)cc4
2680	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07854	experimental	N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE	CNCc1ccc(cc1)-c2ncnc(c23)[nH]cn3
2681	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07855	experimental	(S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE	c1ccccc1[C@H](N)c2ccc(cc2)-c(ncn3)c(c34)nc[nH]4
2682	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07856	experimental	6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c(ncn4)c(c45)nc[nH]5
2683	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07857	experimental	(2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine	Clc1ccc(cc1)[C@H](CN)c2ccc(cc2)-c3c[nH]nc3
2684	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07858	experimental	(2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine	Clc1ccc(cc1)[C@@H](CN)c2ccc(cc2)-c3c[nH]nc3
2685	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07859	experimental	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c4c[nH]nc4
2686	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07860	experimental	(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE	Clc1ccc(cc1)[C@H](CN)c2ccccc2
2687	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07876	experimental	(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(C)cnc3
2688	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07947	experimental	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	Clc1ccc(cc1)COCCNCCNS(=O)(=O)c2cccc(c23)cncc3
2689	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07995	experimental	H-89	Brc1ccc(cc1)/C=C/CNCCNS(=O)(=O)c2cccc(c23)cncc3
2690	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07996	experimental	5-(2-methylpiperazine-1-sulfonyl)isoquinoline	CC1CNCCN1S(=O)(=O)c(ccc2)c(c23)ccnc3
2691	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB07997	experimental	N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE	CNCCNS(=O)(=O)c1cccc(c12)cncc2
2692	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08070	experimental	2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE	Cc1n[nH]cc1-c2ccc(cc2)CCN
2693	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08073	experimental	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)-c(c4)ccc(c45)[nH]nc5C
2694	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08113	experimental	3-pyridin-4-yl-1H-indazole	c1cccc(c12)c(n[nH]2)-c3ccncc3
2695	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08114	experimental	5-benzyl-1,3-thiazol-2-amine	Nc1ncc(s1)Cc2ccccc2
2696	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08148	experimental	1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	Clc1ccc(cc1)C2(CN)CCN(CC2)c(ncn3)c(c34)cc[nH]4
2697	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08149	experimental	1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	Clc1ccc(cc1)CC2(CN)CCN(CC2)c(ncn3)c(c34)cc[nH]4
2698	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08150	experimental	4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium	Clc1ccc(cc1)CC2([NH3+])CCN(CC2)c(ncn3)c(c34)cc[nH]4
2699	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08162	investigational	Fasudil	c1cncc(c12)cccc2S(=O)(=O)N3CCCNCC3
2700	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08231	experimental	Myristic acid	CCCCCCCCCCCCCC(=O)O
2701	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08568	experimental	A-674563	Cc1n[nH]c(c12)ccc(c2)-c3cc(cnc3)OC[C@@H](N)Cc4ccccc4
2702	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08569	experimental	3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE	Brc1ccc(cc1)C[C@H](N)COc2cncc(c2)-c(cc3)cc(c34)c(C)n[nH]4
2703	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08756	experimental	Y-27632	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc2ccncc2
2704	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
2705	sp|Q8IHZ9|KC1_PLAF	P17612	91.95	41.0	338.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2706	sp|Q8IHZ9|KC1_PLAF	P22694	81.11	42.0	304.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
2707	sp|Q8IHZ9|KC1_PLAF	P22694	81.11	42.0	304.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2708	sp|Q8IHZ9|KC1_PLAF	O75385	79.26	15.0	271.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2709	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB00144	approved; investigational; nutraceutical	Phosphatidyl serine	CCCC(=O)O[C@H](COC(=O)CC)COP(=O)(O)OC[C@H](N)C(=O)O
2710	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB00163	approved; nutraceutical; vet_approved	Vitamin E	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(O)c(C)c2C
2711	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB05013	approved	Ingenol mebutate	C[C@@H]1C[C@@H](C2(C)C)[C@@H]2[C@H](C3=O)C=C(CO)[C@@H](O)[C@]([C@@]134)(O)[C@H](C(=C4)C)OC(=O)/C(C)=C\C
2712	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB06451	investigational	Aprinocarsen	n1cnc(N)c(c12)ncn2C3CC(O)C(O3)COP(=S)(O)OC4CC(n5ccc(=N)nc5O)OC4COP(=S)(O)OC6CC(n7cc(C)c(O)nc7=O)OC6COP(=S)(O)OC8CC(n9cc(C)c(O)nc9=O)OC8COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(N)ncn3)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2ccc(=N)nc2O)OC1COP(=S)(O)OC1CC(n2cnc(c23)c(O)nc([nH]3)=N)OC1COP(=S)(O)OC1CC(n2ccc(=N)nc2O)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2ccc(=N)nc2O)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(n2cc(C)c(O)nc2=O)OC1COP(=S)(O)OC1CC(OC1CO)n1cnc(c12)c(O)nc([nH]2)=N
2713	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB06595	approved; investigational	Midostaurin	c1ccccc1C(=O)N(C)[C@@H]([C@H]2OC)C[C@@H](O3)n(c4c5n6[C@]23C)c7c(cccc7)c4c8c(CNC8=O)c5c9c6cccc9
2714	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB06641	investigational	Perifosine	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC(CC1)CC[N+]1(C)C
2715	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
2716	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB11752	investigational	Bryostatin 1	 
2717	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB14001	approved; nutraceutical; vet_approved	alpha-Tocopherol succinate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)CCC(=O)O
2718	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB14002	approved; nutraceutical; vet_approved	D-alpha-Tocopherol acetate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)C
2719	sp|Q8IHZ9|KC1_PLAF	P17252	75.54	337.0	581.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
2720	sp|Q8IHZ9|KC1_PLAF	P54646	86.07	15.0	293.0	DB00131	approved; investigational; nutraceutical	Adenosine phosphate	n1cnc(N)c(c12)ncn2[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)O
2721	sp|Q8IHZ9|KC1_PLAF	P54646	86.07	15.0	293.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
2722	sp|Q8IHZ9|KC1_PLAF	P54646	86.07	15.0	293.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2723	sp|Q8IHZ9|KC1_PLAF	O00141	76.47	96.0	343.0	DB03247	approved; investigational	Flavin mononucleotide	O=c1[nH]c(=O)nc(c12)n(c3c(n2)cc(C)c(c3)C)C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O
2724	sp|Q8IHZ9|KC1_PLAF	O00141	76.47	96.0	343.0	DB07837	experimental	[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid	OC(=O)Cc1ccc(cc1)-c2c[nH]c(c23)ncc(c3)-c(c4)ccc(c45)cccc5
2725	sp|Q8IHZ9|KC1_PLAF	O00141	76.47	96.0	343.0	DB08191	experimental	4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid	OC(=O)c1ccc(cc1)-c2c[nH]c(c23)ncc(c3)-c4ccccc4
2726	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
2727	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
2728	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB01645	investigational	Genistein	Oc1ccc(cc1)-c(c2=O)coc(c23)cc(O)cc3O
2729	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB01863	experimental	Inositol 1,3,4,5-Tetrakisphosphate	OP(=O)(O)O[C@@H]1[C@H](O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@@H]([C@H]1O)OP(=O)(O)O
2730	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB02709	investigational	Resveratrol	Oc1ccc(cc1)/C=C/c2cc(O)cc(O)c2
2731	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB05971	investigational	Archexin	 
2732	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
2733	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB06641	investigational	Perifosine	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC(CC1)CC[N+]1(C)C
2734	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB07584	experimental	N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	Cc1nnc([nH]1)-c2ccccc2Nc3ncnc(c34)[nH]cc4
2735	sp|Q8IHZ9|KC1_PLAF	P31749	75.85	147.0	392.0	DB07585	experimental	5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	Clc1c[nH]c(c12)ncnc2N(C3)CCc(c34)[nH]cn4
2736	sp|Q8IHZ9|KC1_PLAF	Q8IVH8	83.59	13.0	283.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2737	sp|Q8IHZ9|KC1_PLAF	P29322	83.28	633.0	902.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2738	sp|Q8IHZ9|KC1_PLAF	Q9NRP7	76.16	2.0	248.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2739	sp|Q8IHZ9|KC1_PLAF	Q06187	79.26	400.0	656.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2740	sp|Q8IHZ9|KC1_PLAF	Q06187	79.26	400.0	656.0	DB01863	experimental	Inositol 1,3,4,5-Tetrakisphosphate	OP(=O)(O)O[C@@H]1[C@H](O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@@H]([C@H]1O)OP(=O)(O)O
2741	sp|Q8IHZ9|KC1_PLAF	Q06187	79.26	400.0	656.0	DB05204	investigational	XL418	 
2742	sp|Q8IHZ9|KC1_PLAF	Q06187	79.26	400.0	656.0	DB09053	approved	Ibrutinib	C=CC(=O)N1C[C@@H](CCC1)n(c(c23)ncnc3N)nc2-c4ccc(cc4)Oc5ccccc5
2743	sp|Q8IHZ9|KC1_PLAF	Q06187	79.26	400.0	656.0	DB11703	approved; investigational	Acalabrutinib	CC#CC(=O)N1CCC[C@H]1c2nc(c(n23)c(N)ncc3)-c4ccc(cc4)C(=O)Nc5ccccn5
2744	sp|Q8IHZ9|KC1_PLAF	Q06187	79.26	400.0	656.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2745	sp|Q8IHZ9|KC1_PLAF	Q06187	79.26	400.0	656.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
2746	sp|Q8IHZ9|KC1_PLAF	P21709	80.8	627.0	888.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2747	sp|Q8IHZ9|KC1_PLAF	Q9Y2K2	76.78	66.0	314.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2748	sp|Q8IHZ9|KC1_PLAF	Q9H0K1	76.78	20.0	268.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2749	sp|Q8IHZ9|KC1_PLAF	Q9UEW8	93.81	60.0	363.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2750	sp|Q8IHZ9|KC1_PLAF	Q12852	83.9	128.0	399.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2752	sp|Q8IHZ9|KC1_PLAF	P22455	87.62	465.0	748.0	DB01109	approved; investigational	Heparin	 
2753	sp|Q8IHZ9|KC1_PLAF	P22455	87.62	465.0	748.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2754	sp|Q8IHZ9|KC1_PLAF	P22455	87.62	465.0	748.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
2755	sp|Q8IHZ9|KC1_PLAF	P22455	87.62	465.0	748.0	DB12147	approved; investigational	Erdafitinib	COc1cc(cc(c1)OC)N(CCNC(C)C)c(c2)ccc(c23)ncc(n3)-c4cn(C)nc4
2756	sp|Q8IHZ9|KC1_PLAF	P22455	87.62	465.0	748.0	DB15102	approved; investigational	Pemigatinib	COc1c(F)c(c(F)c(c1)OC)N(C(=O)N2CC)Cc(c23)cnc4c3cc([nH]4)CN5CCOCC5
2757	sp|Q8IHZ9|KC1_PLAF	Q02763	89.16	822.0	1110.0	DB00415	approved; vet_approved	Ampicillin	O=C(O)[C@H]1C(C)(C)S[C@@H](N12)[C@@H](C2=O)NC(=O)[C@H](N)c3ccccc3
2758	sp|Q8IHZ9|KC1_PLAF	Q02763	89.16	822.0	1110.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
2759	sp|Q8IHZ9|KC1_PLAF	Q02763	89.16	822.0	1110.0	DB08221	experimental	N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE	FC(F)(F)c1cc(ccc1)C(=O)Nc2ccc(C)c(c2)Nc3ncccc3-c4ccncn4
2760	sp|Q8IHZ9|KC1_PLAF	Q02763	89.16	822.0	1110.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2761	sp|Q8IHZ9|KC1_PLAF	Q02763	89.16	822.0	1110.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2762	sp|Q8IHZ9|KC1_PLAF	Q02763	89.16	822.0	1110.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2763	sp|Q8IHZ9|KC1_PLAF	Q02763	89.16	822.0	1110.0	DB14840	approved	Ripretinib	CNc(c1)ncc(c12)cc(c(=O)n2CC)-c3c(Br)cc(F)c(c3)NC(=O)Nc4ccccc4
2764	sp|Q8IHZ9|KC1_PLAF	P41240	78.33	193.0	446.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
2765	sp|Q8IHZ9|KC1_PLAF	P41240	78.33	193.0	446.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
2766	sp|Q8IHZ9|KC1_PLAF	P41240	78.33	193.0	446.0	DB05075	investigational	TG-100801	c1ccccc1C(=O)Oc2ccc(Cl)c(c2)-c(c3)cc(C)c(c34)nc(nn4)Nc5ccc(cc5)OCCN6CCCC6
2767	sp|Q8IHZ9|KC1_PLAF	P41240	78.33	193.0	446.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2768	sp|Q8IHZ9|KC1_PLAF	Q16288	91.02	535.0	829.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
2769	sp|Q8IHZ9|KC1_PLAF	Q16288	91.02	535.0	829.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2770	sp|Q8IHZ9|KC1_PLAF	Q16288	91.02	535.0	829.0	DB14723	approved; investigational	Larotrectinib	O[C@H]1CCN(C1)C(=O)Nc(cn2)c(n23)nc(cc3)N4CCC[C@@H]4c5c(F)ccc(F)c5
2771	sp|Q8IHZ9|KC1_PLAF	Q6P3R8	81.42	2.0	265.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2772	sp|Q8IHZ9|KC1_PLAF	Q9H2G2	91.64	31.0	327.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
2773	sp|Q8IHZ9|KC1_PLAF	Q9H2G2	91.64	31.0	327.0	DB07853	experimental	2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile	N#CCC1C=CC(C=C1)=Nc(nc(c23)cccc3)nc2Nc4n[nH]c(c4)C5CC5
2774	sp|Q8IHZ9|KC1_PLAF	Q9H2G2	91.64	31.0	327.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2775	sp|Q8IHZ9|KC1_PLAF	Q9H3Y6	78.95	228.0	483.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2776	sp|Q8IHZ9|KC1_PLAF	P51956	78.02	2.0	254.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2777	sp|Q8IHZ9|KC1_PLAF	O95819	91.95	25.0	322.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2786	sp|Q8IHZ9|KC1_PLAF	P06213	92.26	1020.0	1318.0	DB03909	experimental	Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate	OP(=O)(O)CP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
2787	sp|Q8IHZ9|KC1_PLAF	P06213	92.26	1020.0	1318.0	DB05115	investigational	NN344	 
2788	sp|Q8IHZ9|KC1_PLAF	P06213	92.26	1020.0	1318.0	DB05120	investigational	AT1391	 
2789	sp|Q8IHZ9|KC1_PLAF	P06213	92.26	1020.0	1318.0	DB08513	experimental	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Cc1cc(ccc1)Nc2nc(ncc2C(=O)N)Nc3ccc(cc3)CC(=O)O
2790	sp|Q8IHZ9|KC1_PLAF	P06213	92.26	1020.0	1318.0	DB09129	approved	Chromic chloride	[Cl-]
2792	sp|Q8IHZ9|KC1_PLAF	P06213	92.26	1020.0	1318.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2793	sp|Q8IHZ9|KC1_PLAF	P06213	92.26	1020.0	1318.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
2795	sp|Q8IHZ9|KC1_PLAF	P04629	86.38	508.0	787.0	DB00321	approved	Amitriptyline	CN(C)CCC=C1c(cccc2)c2CCc(c13)cccc3
2796	sp|Q8IHZ9|KC1_PLAF	P04629	86.38	508.0	787.0	DB00619	approved	Imatinib	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(C)cc3)Nc4nccc(n4)-c5cnccc5
2797	sp|Q8IHZ9|KC1_PLAF	P04629	86.38	508.0	787.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2798	sp|Q8IHZ9|KC1_PLAF	P04629	86.38	508.0	787.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
2799	sp|Q8IHZ9|KC1_PLAF	P04629	86.38	508.0	787.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2801	sp|Q8IHZ9|KC1_PLAF	P04629	86.38	508.0	787.0	DB14723	approved; investigational	Larotrectinib	O[C@H]1CCN(C1)C(=O)Nc(cn2)c(n23)nc(cc3)N4CCC[C@@H]4c5c(F)ccc(F)c5
2802	sp|Q8IHZ9|KC1_PLAF	P53350	80.5	48.0	308.0	DB06897	experimental	3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol	c1ccccc1[C@H](C)Nc(nc2)cc(c23)c(no3)-c4cc(Cl)cc(c4)CCCO
2803	sp|Q8IHZ9|KC1_PLAF	P53350	80.5	48.0	308.0	DB06963	experimental	3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide	c1ccccc1[C@H](C)Nc(nc2)cc(c23)n(nc3C)-c4cccc(c4)CCC(=O)N
2804	sp|Q8IHZ9|KC1_PLAF	P53350	80.5	48.0	308.0	DB07186	experimental	4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE	CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3n[nH]c(c34)cn(c4)C(=O)Cc5cccs5
2805	sp|Q8IHZ9|KC1_PLAF	P53350	80.5	48.0	308.0	DB07789	experimental	1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea	Cc1cc(c(o1)C(F)(F)F)NC(=O)Nc2ncc(s2)CCNc3cc(ncn3)Nc4ncn[nH]4
2806	sp|Q8IHZ9|KC1_PLAF	P53350	80.5	48.0	308.0	DB08059	experimental	Wortmannin	O=C1CC[C@H]([C@@]12C)C3=C([C@@H](C2)OC(=O)C)[C@]4(C)c5c(C3=O)occ5C(=O)O[C@@H]4COC
2807	sp|Q8IHZ9|KC1_PLAF	P53350	80.5	48.0	308.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2808	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
2809	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB05169	investigational	AT9283	 
2810	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB05198	investigational	CYC116	 
2811	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB05220	investigational	Alisertib	OC(=O)c1ccc(cc1OC)Nc(n2)ncc(c23)CN=C(c4c3ccc(Cl)c4)c5c(OC)cccc5F
2812	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB06134	investigational	SNS-314	Clc1cccc(c1)NC(=O)Nc2ncc(s2)CCNc(ncn3)c(c34)scc4
2813	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB06347	investigational	Cenisertib	[C@@H]12C[C@@H](C=C1)[C@H](C(=O)N)[C@@H]2Nc3c(F)cnc(n3)Nc4ccc(c(C)c4)N5CCN(C)CC5
2814	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
2815	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB07186	experimental	4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE	CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3n[nH]c(c34)cn(c4)C(=O)Cc5cccs5
2816	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB07266	experimental	AKI-001	CCN1C(=O)C(C)(C)c(c12)cc3c(c2)c4c([nH]3)c5c(c([nH]n5)C)CCC4
2817	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB07360	experimental	1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea	FC(F)(F)c1cccc(c1)NC(=O)Nc2ncc(s2)CCNc3ncnc(c34)ccs4
2818	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB07362	experimental	1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea	Cn1ncc(c12)ncnc2NCCc3cnc(s3)NC(=O)Nc4cccc(c4)C(F)(F)F
2819	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB07545	experimental	N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE	FC(F)(F)c1cccc(c1)Nc2nc(ncc2)Nc3cc(ccc3)NC(=O)C4CC4
2820	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB07801	experimental	N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide	CCCCNC(=O)c1cccc(c1)NC(=O)CCCCCNc(ncn2)c(c23)nc[nH]3
2821	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB08065	experimental	2-(1H-pyrazol-3-yl)-1H-benzimidazole	c1c[nH]nc1-c([nH]2)nc(c23)cccc3
2822	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB08066	experimental	N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE	c1ccccc1C(=O)Nc2c[nH]nc2-c([nH]3)nc(c34)cccc4
2823	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2824	sp|Q8IHZ9|KC1_PLAF	O14965	80.5	131.0	391.0	DB13061	investigational	MLN8054	OC(=O)c1ccc(cc1)Nc(n2)ncc(c23)CN=C(c4c3ccc(Cl)c4)c5c(F)cccc5F
2825	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
2826	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB01809	experimental	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	Cc1ccc(cc1)-c2nn(C(C)(C)C)c(c23)ncnc3N
2827	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
2828	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB08875	approved; investigational	Cabozantinib	COc(c1)c(OC)cc(c12)nccc2Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5
2829	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
2830	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB08901	approved; investigational	Ponatinib	CN1CCN(CC1)Cc2ccc(cc2C(F)(F)F)NC(=O)c3cc(c(C)cc3)C#Cc4cnc(n45)cccn5
2831	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB09078	approved; investigational	Lenvatinib	COc(c1)c(C(=O)N)cc(c12)c(ccn2)Oc3ccc(c(Cl)c3)NC(=O)NC4CC4
2832	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2833	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB12742	investigational	Amuvatinib	O1COc(c12)ccc(c2)CNC(=S)N3CCN(CC3)c4ncnc(c45)c6c(o5)cccc6
2834	sp|Q8IHZ9|KC1_PLAF	P07949	90.09	722.0	1013.0	DB15685	approved; investigational	Selpercatinib	COc1ncc(cc1)CN(C23)C(C2)CN(C3)c4ccc(cn4)-c5cc(OCC(C)(C)O)cn(c56)ncc6C#N
2835	sp|Q8IHZ9|KC1_PLAF	Q8N568	84.52	390.0	663.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2836	sp|Q8IHZ9|KC1_PLAF	Q04759	75.85	378.0	623.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
2837	sp|Q8IHZ9|KC1_PLAF	Q04759	75.85	378.0	623.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
2838	sp|Q8IHZ9|KC1_PLAF	Q04759	75.85	378.0	623.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
2839	sp|Q8IHZ9|KC1_PLAF	Q04759	75.85	378.0	623.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2840	sp|Q8IHZ9|KC1_PLAF	Q04759	75.85	378.0	623.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
2841	sp|Q8IHZ9|KC1_PLAF	Q9UIK4	88.54	17.0	303.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2842	sp|Q8IHZ9|KC1_PLAF	O15075	80.19	385.0	644.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2843	sp|Q8IHZ9|KC1_PLAF	Q16566	88.24	43.0	328.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
2844	sp|Q8IHZ9|KC1_PLAF	Q16566	88.24	43.0	328.0	DB07676	experimental	3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one	OC[C@@H](O)CCONc1c([nH]c(c12)cccc2)C(C(=O)N=3)=c(c34)cccc4
2845	sp|Q8IHZ9|KC1_PLAF	Q8N4C8	92.26	25.0	323.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2846	sp|Q8IHZ9|KC1_PLAF	O15146	90.4	572.0	864.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2847	sp|Q8IHZ9|KC1_PLAF	Q7L7X3	87.31	26.0	308.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2848	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
2849	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB00163	approved; nutraceutical; vet_approved	Vitamin E	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(O)c(C)c2C
2850	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB01738	experimental	Phosphorylcolamine	NCCOP(=O)(O)O
2851	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
2852	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
2853	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB08862	approved; investigational	Cholecystokinin	 
2854	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB14001	approved; nutraceutical; vet_approved	alpha-Tocopherol succinate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)CCC(=O)O
2855	sp|Q8IHZ9|KC1_PLAF	P05771	75.54	340.0	584.0	DB14002	approved; nutraceutical; vet_approved	D-alpha-Tocopherol acetate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](O1)(C)CCc(c12)c(C)c(c(C)c2C)OC(=O)C
2856	sp|Q8IHZ9|KC1_PLAF	Q14289	82.35	423.0	689.0	DB01097	approved; investigational	Leflunomide	Cc1oncc1C(=O)Nc2ccc(C(F)(F)F)cc2
2857	sp|Q8IHZ9|KC1_PLAF	Q14289	82.35	423.0	689.0	DB01645	investigational	Genistein	Oc1ccc(cc1)-c(c2=O)coc(c23)cc(O)cc3O
2858	sp|Q8IHZ9|KC1_PLAF	Q14289	82.35	423.0	689.0	DB08341	experimental	4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide	CN(C)[C@@H]1CCC[C@H]1Nc2nc(ncc2C(F)(F)F)Nc3ccc(cc3)S(=O)(=O)NC
2859	sp|Q8IHZ9|KC1_PLAF	Q14289	82.35	423.0	689.0	DB11817	approved; investigational	Baricitinib	CCS(=O)(=O)N(C1)CC1(CC#N)n2cc(cn2)-c(ncn3)c(c34)cc[nH]4
2860	sp|Q8IHZ9|KC1_PLAF	Q14289	82.35	423.0	689.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2861	sp|Q8IHZ9|KC1_PLAF	Q02156	76.47	406.0	653.0	DB06064	investigational	KAI-1455	 
2862	sp|Q8IHZ9|KC1_PLAF	Q02156	76.47	406.0	653.0	DB11752	investigational	Bryostatin 1	 
2863	sp|Q8IHZ9|KC1_PLAF	Q02156	76.47	406.0	653.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2864	sp|Q8IHZ9|KC1_PLAF	Q02156	76.47	406.0	653.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
2865	sp|Q8IHZ9|KC1_PLAF	O96017	89.78	216.0	506.0	DB05149	investigational	XL844	 
2866	sp|Q8IHZ9|KC1_PLAF	O96017	89.78	216.0	506.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
2867	sp|Q8IHZ9|KC1_PLAF	O96017	89.78	216.0	506.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2868	sp|Q8IHZ9|KC1_PLAF	O94804	89.78	33.0	323.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2869	sp|Q8IHZ9|KC1_PLAF	Q96BR1	79.88	160.0	418.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2870	sp|Q8IHZ9|KC1_PLAF	Q9UQB9	77.71	39.0	290.0	DB06134	investigational	SNS-314	Clc1cccc(c1)NC(=O)Nc2ncc(s2)CCNc(ncn3)c(c34)scc4
2871	sp|Q8IHZ9|KC1_PLAF	Q9UQB9	77.71	39.0	290.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2872	sp|Q8IHZ9|KC1_PLAF	P35590	87.62	837.0	1120.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2873	sp|Q8IHZ9|KC1_PLAF	Q16816	86.69	15.0	295.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2874	sp|Q8IHZ9|KC1_PLAF	Q9Y4K4	80.19	17.0	276.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2875	sp|Q8IHZ9|KC1_PLAF	Q9H2K8	85.76	27.0	304.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2876	sp|Q8IHZ9|KC1_PLAF	Q99759	79.57	361.0	618.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2877	sp|Q8IHZ9|KC1_PLAF	Q05655	75.85	347.0	592.0	DB04376	experimental	13-Acetylphorbol	OCC(=C1)C[C@](O)(C(=O)C(=C2)C)[C@@H]2[C@@](O)([C@H](C)[C@H]3O)[C@@H]1[C@H](C4(C)C)[C@@]34OC(=O)C
2878	sp|Q8IHZ9|KC1_PLAF	Q05655	75.85	347.0	592.0	DB05013	approved	Ingenol mebutate	C[C@@H]1C[C@@H](C2(C)C)[C@@H]2[C@H](C3=O)C=C(CO)[C@@H](O)[C@]([C@@]134)(O)[C@H](C(=C4)C)OC(=O)/C(C)=C\C
2879	sp|Q8IHZ9|KC1_PLAF	Q05655	75.85	347.0	592.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2880	sp|Q8IHZ9|KC1_PLAF	Q05655	75.85	347.0	592.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
2881	sp|Q8IHZ9|KC1_PLAF	Q07912	82.66	123.0	390.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
2882	sp|Q8IHZ9|KC1_PLAF	Q07912	82.66	123.0	390.0	DB04367	experimental	Debromohymenialdisine	NC1=NC(=O)/C(N1)=C2\CCNC(=O)c(c23)[nH]cc3
2883	sp|Q8IHZ9|KC1_PLAF	Q07912	82.66	123.0	390.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
2884	sp|Q8IHZ9|KC1_PLAF	Q07912	82.66	123.0	390.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
2885	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB01888	experimental	4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide	CN(C)S(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)c(cn3)C(C)C)N[C@H]4CC[C@H](N)CC4
2886	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
2887	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
2888	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02091	experimental	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine	Cc1nc(C)c(s1)-c2nc(N)ncc2
2889	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
2890	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02197	experimental	4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide	NS(=O)(=O)c1ccc(cc1)Nc2nc(ccn2)-c3cnc(n34)cccc4
2891	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02297	experimental	2-Amino-6-Chloropyrazine	Nc1cncc(Cl)n1
2892	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02407	experimental	6-O-Cyclohexylmethyl Guanine	[nH]1cnc(c12)c(nc(n2)N)OCC3CCCCC3
2893	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02538	experimental	N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide	CC(=O)Nc1nc(ccn1)-c2c(C)nc(n23)cccc3
2894	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02603	experimental	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	[nH]1cnc(c12)c(nc(c2)N)OCC3CCCCC3
2895	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02647	experimental	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	c1ccccc1C(=O)Nc2cc(n[nH]2)C3CC3
2896	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
2897	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02833	experimental	[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine	Nc1nc(C)c(s1)-c2nc(ncc2)Nc3cccc(c3)[N+]([O-])=O
2898	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02898	experimental	(5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone	n1c[nH]c(c12)nc(N)nc2OC[C@H]3CCC(=O)N3
2899	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02915	experimental	4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine	Cc1nc(C)c(s1)-c2ccnc(n2)Nc3ccc(C(F)(F)F)cc3
2900	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02950	experimental	Hymenialdisine	O=C1NCC[C@@H]([C@@H](C12)C=C(Br)N=2)C3=NC(N)=NC3=O
2901	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02963	experimental	(5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine	CS(=O)(=O)c1ccc(cc1)Nc2cc(Cl)nc(n23)ccn3
2902	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB02973	experimental	4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide	NS(=O)(=O)c1ccc(cc1)/N=N/C(C(=O)N=2)=c(c23)cc(Br)cc3
2903	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03019	experimental	4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine	Nc1nccc(n1)-c2c(Cl)sc(Cl)c2
2904	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03307	experimental	4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide	Nc1ncnc(c1)Nc2ccc(cc2)S(=O)(=O)N
2905	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03365	experimental	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	COc(c1)c(OC)cc(c12)ncnc2Nc3cc(O)ccc3
2906	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03428	experimental	SU9516	COc(c1)ccc(c12)NC(=O)C\2=C/c3cnc[nH]3
2907	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03490	experimental	3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole	c1cccc(c12)Cc3c2n[nH]c3-c4ccncc4
2908	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
2909	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03583	experimental	(2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one	c1cccc(c12)NC(\[C@@]2(C)O)=C(/C(=O)N3)c(c34)cc(cc4)S(=O)(=O)N5CCC(O)CC5
2910	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03663	experimental	1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol	CC(C)C(=O)COc1nc(N)nc(c12)nc[nH]2
2911	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03737	experimental	4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One	C[C@@H](O)[C@H](N)[C@H](O)C#Cc1c(F)ccc(c12)NC(=O)C\2=C/c3c(OC)cc[nH]3
2912	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB03801	experimental	Lysine Nz-Carboxylic Acid	OC(=O)[C@@H](N)CCCCNC(=O)O
2913	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04006	experimental	[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone	c1ccccc1C(=O)c(c(n2)N)n(c23)cc(cc3)C(=O)c4c(F)cccc4F
2914	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04101	experimental	N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide	Cc1nc(C)c(s1)-c2nc(ncc2)/N=C/NO
2915	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04186	experimental	N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea	C1CC[C@@H](N12)c3c(C2=O)cccc3NC(=O)Nc4ccccn4
2916	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04288	experimental	2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine	C1CCCC1n2cnc(c23)c(NCc4ccccc4)nc(n3)N[C@@H]5CC[C@@H](N)CC5
2917	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04407	experimental	4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol	CNc1nc(C)c(s1)-c2ccnc(n2)Nc3ccc(O)cc3
2918	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04518	experimental	3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol	Cc1nc(C)c(s1)-c2nc(ncc2)Nc3cccc(O)c3
2919	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04607	experimental	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE	NS(=O)(=O)c1ccc(cc1)Nc(n2)cn(c23)cc(cc3)C(=O)c4c(Cl)cccc4Cl
2920	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04662	experimental	OLOMOUCINE II	n1cn(C(C)C)c(c12)nc(N[C@H](CC)CO)nc2NCc3ccccc3O
2921	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB04669	experimental	TRIAZOLOPYRIMIDINE	Brc1cccc(c1)-c(nc([n+]23)nc[nH]3)cc2NCc4ccncc4
2922	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
2923	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
2924	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06844	experimental	4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE	n1csc(c12)c=3c(cc2)=NC(=O)C3CNc4ccc(cc4)S(=O)(=O)Nc5ccccn5
2925	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06888	experimental	(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE	[C@@H]12CN([C@H](C)C1)CCn3[nH]c4c(cccc4c3=O)c5nc6c([nH]c5=O)cccc6O2
2926	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06944	experimental	N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide	C1CC1c2n[nH]c(c2)NC(=O)Cc(cc3)cc(c34)cccc4
2927	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06948	experimental	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	C1CCCCC1COc(c(c23)[nH]cn3)nc(n2)Nc4ccccc4
2928	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06976	experimental	1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA	C1CCN[C@@H]1c2cc(n[nH]2)NC(=O)Nc3cccc(c34)C(=O)N5[C@H]4CCC5
2929	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB06983	experimental	(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol	c1ccccc1-c(nc(n23)c(cn3)CO)cc2NCc4cnccc4
2930	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07024	experimental	2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE	O=S1(=O)CCCN1c(cc(C)c2)c(c23)oc(c(c3=O)O)-c4ccc(O)c(O)c4
2931	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07054	experimental	(2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2ncnc(c2)Nc3c(F)ccc(c3)C(F)(F)F
2932	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07065	experimental	5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine	N#CSc(cn1)c(n12)nc(-c3c(Cl)c(Cl)ccc3)cc2NCc4ccncc4
2933	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07126	experimental	O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE	NS(=O)(=O)c1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
2934	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07137	experimental	(2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide	C1CC1C2=CC(\N=N2)=N/C(=O)[C@@H](C)c3ccc(cc3)N4CCNC4=O
2935	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07163	experimental	5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE	NCCNc1cc(-c2[nH]ccc2)c3C(=O)Nc(c3c14)ccc4F
2936	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07164	experimental	N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	C1CC1Nc2nc(ccn2)-c(cn3)c(n34)cccn4
2937	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07179	experimental	3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide	Cc1ccccc1-c(nc(n23)c(Br)cn3)cc2NCc4c[n+]([O-])ccc4
2938	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07203	experimental	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	Clc1cccc(c1)Nc(n2)nc(c(c23)[nH]cn3)OCC4CCCCC4
2939	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07210	experimental	3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	c1ccccc1-c(nc(n23)c(Br)cn3)cc2NCc4ccncc4
2940	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07220	experimental	N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE	O=S1(=O)CCCN1c(c2)ccc(c23)[nH]nc3NC(=O)Cc4ccc(cc4)N5CCCCC5
2941	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07431	experimental	(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one	O=C1N[C@H](CN)CNc(c12)c3c(s2)ccc(c3)OC
2942	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07471	experimental	5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE	Clc1ccccc1[C@@H](C)Oc2c(C(=O)N)sc(c2)-n3cnc(c34)cc(OC)c(c4)OC
2943	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07493	experimental	5-Bromoindirubin	c1cc(Br)cc(c12)/C(C(=O)N2)=C(C3=O)/Nc(c34)cccc4
2944	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07501	experimental	(2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2ncc(Br)c(n2)Nc3ccccc3
2945	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07504	experimental	(2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2ncc(Br)c(n2)Nc3ccccc3
2946	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07529	experimental	(5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one	N=C1NC(=O)/C(S1)=C\c2ccccn2
2947	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07531	experimental	4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=O)NC3=O
2948	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07533	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE	CNS(=O)(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=N)NC3=O
2949	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07534	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=N)NC3=O
2950	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07538	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1C(F)(F)F)-c2ccc(o2)/C=C3\SC(=N)NC3=O
2951	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07539	experimental	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID	OC(=O)c1ccc(cc1)-c2ccc(o2)/C=C3\SC(=N)NC3=O
2952	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07540	experimental	4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE	O=C1NC(=N)SC\1=C(\C)c2ccc(o2)-c3ccc(cc3)S(=O)(=O)N
2953	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07562	experimental	N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE	CN(C)c1ccc(cc1)Nc2nc(ccn2)-c3c(C)nc(s3)C
2954	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07595	experimental	(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE	Brc1cccc(c1)-c(nc([n+]23)cc[nH]3)cc2NCc4ccncc4
2955	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07606	experimental	6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE	Clc1cc(Cl)cc(Cl)c1-n(nc2CC)c(c23)nc([nH]c3=O)Cc4cc(O)c(O)cc4
2956	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07612	experimental	6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE	CC(C)(C)Nc1nc(C(F)(F)F)nc(c12)ccc(c2)-c3cccc(N)c3
2957	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07618	experimental	2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE	NCC1CCN(CC1)CC(=O)Nc2cccc(c23)c4c(C3=O)c([nH]n4)C5CCCCC5
2958	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07622	experimental	1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA	CN1CCN(CC1)NC(=O)Nc2cccc(c23)c4c(C3=O)c([nH]n4)-c5c(C)nc(s5)C
2959	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07685	experimental	4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)ncn3)OCC4CCCCC4
2960	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07686	experimental	4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)ncn3)NC4CCCCC4
2961	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07687	experimental	4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE	N[C@H]1CC[C@@H](CC1)Nc(nc(n23)ncn3)cc2Nc4ccc(cc4)S(=O)(=O)N
2962	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07688	experimental	4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	NS(=O)(=O)c1ccc(cc1)Nc2cc(nc(n23)ncn3)OC4CCCCC4
2963	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07731	experimental	CAN-508	Nc1n[nH]c(N)c1/N=N/c2ccc(O)cc2
2964	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07750	experimental	(2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2nccc(n2)Nc3c(Cl)ccc(Cl)c3
2965	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07751	experimental	(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2cc(ncn2)Nc3c(F)cccc3F
2966	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07755	experimental	(2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2nccc(n2)Nc3c(Cl)ccc(Cl)c3
2967	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07761	experimental	(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	CN(C)C[C@@H](O)COc1ccc(cc1)Nc2cc(ncn2)Nc3c(F)cccc3F
2968	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07790	experimental	N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE	COCCNS(=O)(=O)c1ccc(cc1)Nc2nc(ccn2)-c3cnc(C)n3C(C)C
2969	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07791	experimental	4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE	CNS(=O)(=O)c1ccc(cc1)Nc2nc(ccn2)-c3cnc(C)n3C4CC4
2970	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07852	experimental	1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID	Cc1nc(C(=O)O)nn1-c2cc(Cl)cc(Cl)c2
2971	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07889	experimental	(2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol	CN(C)C[C@H](O)COc1ccc(cc1)Nc2nccc(n2)-c3c(C)nc(n34)cccc4
2972	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07936	experimental	N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine	CN(C)[C@H]1CCN(C1)C(=O)c2ccc(cc2)Nc3nc(c(F)cn3)-c4cnc(C)n4C(C)C
2973	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB07982	experimental	2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol	CC(C)n1c(C)ncc1-c2nc(ncc2)Nc3ccc(cc3)N4CCN(CC4)C(=O)CO
2974	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08066	experimental	N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE	c1ccccc1C(=O)Nc2c[nH]nc2-c([nH]3)nc(c34)cccc4
2975	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08094	investigational	RO-4584820	COc1ccc(F)c(F)c1C(=O)c2cnc(nc2N)NC3CCN(CC3)S(=O)(=O)C
2976	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08122	experimental	N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide	c1cccc(c12)NC(=O)C\2=C/Nc3ccc(cc3)S(=O)(=O)NC
2977	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08123	experimental	N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide	CNS(=O)(=O)Cc1ccc(cc1)N/N=C2\C(=O)Nc(c23)ccc4c3scn4
2978	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08124	experimental	3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one	c1ncoc1-c(c2)ccc(c23)NC(=O)C\3=C/Nc(cc4)cc(c45)CS(=O)(=O)C5
2979	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08125	experimental	4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide	c1cccc(c12)NC(=O)C\2=C/Nc3ccc(cc3)S(=O)(=O)Nc4nccs4
2980	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08126	experimental	3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole	NC(=N)NS(=O)(=O)c1ccc(cc1)N/C=C2\C(=O)Nc(c23)cccc3
2981	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08132	experimental	5-hydroxynaphthalene-1-sulfonamide	c1ccc(S(=O)(=O)N)c(c12)cccc2O
2982	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08133	experimental	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	NS(=O)(=O)c1ccc(cc1)NC(=O)c2n[nH]c(c23)cccc3
2983	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08134	experimental	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	NS(=O)(=O)c1ccc(cc1)Nc2nc(Cl)cnc2
2984	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08135	experimental	N-phenyl-1H-pyrazole-3-carboxamide	n1[nH]ccc1C(=O)Nc2ccccc2
2985	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08136	experimental	4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide	CC(=O)Nc1c[nH]nc1C(=O)Nc2ccc(F)cc2
2986	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08137	experimental	(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide	Fc1ccc(cc1)NC(=O)c2n[nH]cc2NC(=O)c3ccccc3
2987	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08138	experimental	{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide	Fc1ccc(cc1)NC(=O)c2n[nH]cc2NC(=O)c3c(F)cccc3F
2988	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08139	experimental	5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile	CC(C)Nc1cc(Cl)nc(n12)c(cn2)C#N
2989	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08140	experimental	5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE	N[C@H]1CC[C@@H](CC1)Nc(nc(n23)c(cn3)C#N)cc2NC(C)C
2990	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08141	experimental	4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide	C1CCNC[C@H]1NC(=O)c2n[nH]cc2NC(=O)c3c(F)cccc3F
2991	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08142	investigational	AT-7519	Clc1cccc(Cl)c1C(=O)Nc2c[nH]nc2C(=O)NC3CCNCC3
2992	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08178	experimental	4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	n1ccc(OC)c(c12)c(c[nH]2)-c3nc(N)ncc3
2993	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08182	experimental	4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	CCCOc(ccn1)c(c12)c(c[nH]2)-c3nc(N)ncc3
2994	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08218	experimental	HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM	O=N(=O)c1cccc(c1)/N=C2/N=CCC(=N2)c3cccc(c3)Cn4cncn4
2995	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08219	experimental	4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine	Nc1nc(C)c(s1)C2=N/C(N=CC2)=N\c3ccc(cc3)N4CCOCC4
2996	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08233	experimental	6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE	Oc1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
2997	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08241	experimental	4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE	NC(=O)c1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
2998	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08247	experimental	6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE	CC(C)c([nH]1)nc(c12)c(nc(n2)N)OCC3CCCCC3
2999	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08248	experimental	3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE	NS(=O)(=O)c1cccc(c1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
3000	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08285	experimental	(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol	n1cc(C(C)C)c(n12)nc(N[C@H](CC)CO)nc2NCc3ccccc3
3001	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08309	experimental	3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL	OCCCNCCS(=O)(=O)c1ccc(cc1)Nc(n2)nc(c(c23)nc[nH]3)OCC4CCCCC4
3002	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08312	experimental	6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE	Nc1nc(N)c(N=O)c(n1)OCC2CCCCC2
3003	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08355	experimental	1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid	Cn1nc(C(=O)O)c(c12)CCc3c2nc(nc3)Nc4ccccc4
3004	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08441	experimental	6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE	Brc(c12)cnc(n1)Nc3cccc(c3)S(=O)(=O)NCCCN2
3005	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08463	experimental	(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol	n1cn(C(C)C)c(c12)nc(N[C@H](CC)CO)nc2NCc3ccc(cc3)-c4ccccn4
3006	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08527	experimental	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	O=S(=O)(N)c1ccc(cc1)-n(nc2C(=O)N)c(c23)c4c(cc3)[nH]nc4
3007	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08531	experimental	5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	Clc1cccc(c1Cl)-c(nc(n23)ccn3)cc2NCc4ccncc4
3008	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08532	experimental	6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine	Fc1ccccc1-c(cn(c23)ccn3)nc2NCc4cccnc4
3009	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08533	experimental	3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine	Cc1cnc(n12)c(ncc2)NCc3ccncc3
3010	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08534	experimental	5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	Fc1ccccc1-c(nc(n23)ccn3)cc2NCc4ccncc4
3011	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08535	experimental	3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	c1ccccc1-c(nc(n23)c(Br)cn3)cc2NCc4cccnc4
3012	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08536	experimental	3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine	c1ccccc1-c(cc(n23)c(Br)cn3)cc2NCc4cncnc4
3013	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08537	experimental	3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine	c1ccccc1-c(c2)cc(c(n23)ncc3Br)NCc4cncnc4
3014	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08538	experimental	N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine	Nc1ncc(cn1)CNc2cc(nc(n23)c(cn3)CC)-c4c(F)cccc4F
3015	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08539	experimental	3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine	c1ncccc1CNc2cc(nc(n23)c(cn3)C4CC4)-c5ccccc5
3016	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08572	experimental	4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE	NC(=O)c1ccc(cc1)Nc2nc(c(N=O)c(n2)N)OCC3CCCCC3
3017	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08673	experimental	4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE	CC(C)c1cnc(s1)Nc2ccc(cc2)S(=O)(=O)N
3018	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08677	experimental	N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide	CC(C)c1sc(nc1)NC(=O)Cc2cnccc2
3019	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08694	experimental	Variolin B	Nc1nccc(n1)-c2c(ccnc3N)n3c(c24)nccc4O
3020	sp|Q8IHZ9|KC1_PLAF	P24941	85.45	2.0	278.0	DB08768	experimental	N(6)-dimethylallyladenine	CC(C)=CCNc1ncnc(c12)[nH]cn2
3021	sp|Q8IHZ9|KC1_PLAF	P43405	78.95	375.0	630.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
3022	sp|Q8IHZ9|KC1_PLAF	P43405	78.95	375.0	630.0	DB06834	experimental	N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide	OCC(C)(C)NC(=O)c(cc1)cc(c12)c(cn2C)-c([nH]3)cc(c34)cccn4
3023	sp|Q8IHZ9|KC1_PLAF	P43405	78.95	375.0	630.0	DB07159	experimental; investigational	Tamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(n3)ccc(c34)OC(C)(C)C(=O)N4
3024	sp|Q8IHZ9|KC1_PLAF	P43405	78.95	375.0	630.0	DB07194	experimental	2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide	OC[C@H](C)NC(=O)c1c(C)nc(s1)-c2nc(ncc2)Nc3cc(C)cc(C)c3
3025	sp|Q8IHZ9|KC1_PLAF	P43405	78.95	375.0	630.0	DB08361	experimental	2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide	N[C@H]1CCCC[C@H]1Nc2nc(c(cn2)C(=O)N)Nc3cccc(C)c3
3026	sp|Q8IHZ9|KC1_PLAF	P43405	78.95	375.0	630.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
3027	sp|Q8IHZ9|KC1_PLAF	P43405	78.95	375.0	630.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3028	sp|Q8IHZ9|KC1_PLAF	Q96PY6	80.19	2.0	261.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3029	sp|Q8IHZ9|KC1_PLAF	Q8NEV4	92.57	19.0	318.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3030	sp|Q8IHZ9|KC1_PLAF	Q12851	82.97	13.0	281.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3039	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
3040	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB05023	investigational	ATL1101	 
3041	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB05184	investigational	XL228	 
3042	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB05897	investigational	rhIGFBP-3	 
3043	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB06075	investigational	Linsitinib	C[C@]1(O)C[C@H](C1)c2nc(c(n23)c(N)ncc3)-c(c4)ccc(c45)ccc(n5)-c6ccccc6
3045	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB07156	experimental	(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione	Brc(c1)ccc(c12)C(=O)NC(=O)C\2=C/Nc3ccc(cc3)CN4CCCC4
3046	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB07474	experimental	3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE	c1cncn1-c(cc2C)cc(c23)[nH]c(n3)-c4c(cc[nH]c4=O)NCc5ncccc5
3050	sp|Q8IHZ9|KC1_PLAF	P08069	85.76	996.0	1273.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
3052	sp|Q8IHZ9|KC1_PLAF	P43403	78.64	343.0	597.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
3053	sp|Q8IHZ9|KC1_PLAF	P43403	78.64	343.0	597.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3054	sp|Q8IHZ9|KC1_PLAF	Q16513	76.78	655.0	903.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3055	sp|Q8IHZ9|KC1_PLAF	Q15303	82.66	716.0	983.0	DB08916	approved	Afatinib	CN(C)C/C=C/C(=O)Nc(c1)c(O[C@H]2CCOC2)cc(c13)ncnc3Nc4cc(Cl)c(F)cc4
3056	sp|Q8IHZ9|KC1_PLAF	Q15303	82.66	716.0	983.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3057	sp|Q8IHZ9|KC1_PLAF	Q15303	82.66	716.0	983.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
3058	sp|Q8IHZ9|KC1_PLAF	Q15303	82.66	716.0	983.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
3059	sp|Q8IHZ9|KC1_PLAF	Q32MK0	85.14	517.0	792.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3060	sp|Q8IHZ9|KC1_PLAF	P08922	84.83	1943.0	2217.0	DB11986	approved; investigational	Entrectinib	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4n[nH]c(c45)ccc(c5)Cc6cc(F)cc(F)c6
3061	sp|Q8IHZ9|KC1_PLAF	P08922	84.83	1943.0	2217.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3062	sp|Q8IHZ9|KC1_PLAF	Q8NG66	84.21	25.0	297.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
3063	sp|Q8IHZ9|KC1_PLAF	Q8NG66	84.21	25.0	297.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3064	sp|Q8IHZ9|KC1_PLAF	Q08345	92.57	608.0	907.0	DB00619	approved	Imatinib	CN1CCN(CC1)Cc2ccc(cc2)C(=O)Nc3cc(c(C)cc3)Nc4nccc(n4)-c5cnccc5
3065	sp|Q8IHZ9|KC1_PLAF	Q08345	92.57	608.0	907.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3066	sp|Q8IHZ9|KC1_PLAF	Q56UN5	80.19	1061.0	1320.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3067	sp|Q8IHZ9|KC1_PLAF	Q9UPZ9	71.21	2.0	232.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3068	sp|Q8IHZ9|KC1_PLAF	Q6PHR2	77.09	14.0	263.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3069	sp|Q8IHZ9|KC1_PLAF	Q15746	89.78	1457.0	1747.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3070	sp|Q8IHZ9|KC1_PLAF	Q92772	100.93	2.0	328.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3071	sp|Q8IHZ9|KC1_PLAF	Q9Y2U5	80.5	353.0	613.0	DB06616	approved	Bosutinib	COc1cc(c(Cl)cc1Cl)Nc2c(C#N)cnc(c23)cc(c(c3)OC)OCCCN4CCN(C)CC4
3072	sp|Q8IHZ9|KC1_PLAF	Q9Y2U5	80.5	353.0	613.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3073	sp|Q8IHZ9|KC1_PLAF	Q16832	88.54	563.0	849.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
3074	sp|Q8IHZ9|KC1_PLAF	Q16832	88.54	563.0	849.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3075	sp|Q8IHZ9|KC1_PLAF	Q96GD4	76.47	75.0	322.0	DB04703	approved; investigational	Hesperidin	COc1ccc(cc1O)[C@@H](O2)CC(=O)c(c23)c(O)cc(c3)O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O
3076	sp|Q8IHZ9|KC1_PLAF	Q96GD4	76.47	75.0	322.0	DB05169	investigational	AT9283	 
3077	sp|Q8IHZ9|KC1_PLAF	Q96GD4	76.47	75.0	322.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
3078	sp|Q8IHZ9|KC1_PLAF	Q96GD4	76.47	75.0	322.0	DB07340	experimental	Reversine	C1CCCCC1Nc2nc(nc(c23)[nH]cn3)Nc4ccc(cc4)N5CCOCC5
3079	sp|Q8IHZ9|KC1_PLAF	Q96GD4	76.47	75.0	322.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3080	sp|Q8IHZ9|KC1_PLAF	Q9NQU5	74.92	412.0	654.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3081	sp|Q8IHZ9|KC1_PLAF	O14936	91.02	8.0	302.0	DB01942	experimental; investigational	Formic acid	OC=O
3082	sp|Q8IHZ9|KC1_PLAF	O14936	91.02	8.0	302.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3083	sp|Q8IHZ9|KC1_PLAF	Q9UL54	85.14	27.0	302.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
3084	sp|Q8IHZ9|KC1_PLAF	Q9UL54	85.14	27.0	302.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3085	sp|Q8IHZ9|KC1_PLAF	P05129	76.78	350.0	598.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
3086	sp|Q8IHZ9|KC1_PLAF	P05129	76.78	350.0	598.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3087	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB01782	experimental	Pyrazolanthrone	c1cccc(c12)c3c4c([nH]n3)cccc4C2=O
3088	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB02388	experimental	Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	C1CNCCC1c2n(CCC)c(c(n2)-c3ccc(Cl)c(Cl)c3)-c4ccnc(n4)NC5CCCCC5
3089	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB03084	experimental	Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	CN1CCC(CC1)c2n(CCC)c(c(n2)-c3ccc(Cl)c(Cl)c3)-c4ccnc(n4)NC5CC5
3090	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB03623	experimental	9-(4-Hydroxyphenyl)-2,7-Phenanthroline	Oc1ccc(cc1)-c(cn2)cc(c23)c4c(cc3)ccnc4
3091	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
3092	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB06933	experimental	N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide	CC(C)(C)NS(=O)(=O)c1ccc(cc1)-c(c2)cnc(c23)cccc3Nc4ccccn4
3093	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB07010	experimental	N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE	Clc1cc(ccc1)-c2c[nH]nc2-c3c[nH]c(c3)C(=O)NCc4ccccc4
3094	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB07217	experimental	N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide	Fc1ccccc1C(=O)Nc(s2)c(C#N)c(c23)CCCC3
3095	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08005	experimental	4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide	CCNC(=O)N1CCC(CC1)Nc2nc(c(Cl)cn2)-c3c[nH]c(c34)cccc4
3096	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08010	experimental	(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime	c1ccccc1/C=C/c2cccc(c23)N(C(=O)C\3=N/O)Cc(cc(F)c4)c(c45)OCOC5
3097	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08011	experimental	(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime	Fc(c1)ccc(c12)N(C(=O)C\2=N\O)Cc3cc(F)cc(c34)COCO4
3098	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08015	experimental	(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime	c1ccccc1-c2cccc(c23)N(C(=O)C\3=N/O)Cc4cc(F)cc(c45)COCO5
3099	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08021	experimental	5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide	C#CCN1CCN(CC1)c2c(Cl)cccc2NC(=O)c3ccc(Br)o3
3100	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08023	experimental	N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine	C1CCCCC1N(C)c2nc(ccn2)-c3cnc(n34)cccc4
3101	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08025	experimental	N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE	CO[C@H]1CC[C@@H](CC1)C(=O)Nc2cc(ccn2)-c3cc(ncc3)Nc4ccc(F)cc4
3102	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08026	experimental	2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide	CNC(=O)CN1CCC(CC1)Nc2nc(ccn2)-c3cnc(n34)cccc4
3103	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB08555	experimental	1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline	COc(c(Cl)c1)cc(c12)CCN=C2c3cccc(Br)c3
3104	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3105	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3106	sp|Q8IHZ9|KC1_PLAF	P53779	83.28	58.0	327.0	DB15624	experimental	Halicin	Nc1nnc(s1)Sc2ncc(s2)[N+]([O-])=O
3107	sp|Q8IHZ9|KC1_PLAF	Q9P286	74.61	454.0	695.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3108	sp|Q8IHZ9|KC1_PLAF	Q59EB3	82.04	401.0	666.0	DB08111	experimental	4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol	Oc1ccc(cc1)Cc2nnc(n23)ccc(n3)-c4ccccc4
3109	sp|Q8IHZ9|KC1_PLAF	P53778	76.78	22.0	270.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
3110	sp|Q8IHZ9|KC1_PLAF	P53778	76.78	22.0	270.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
3111	sp|Q8IHZ9|KC1_PLAF	P53778	76.78	22.0	270.0	DB05157	investigational	KC706	 
3112	sp|Q8IHZ9|KC1_PLAF	P53778	76.78	22.0	270.0	DB05403	investigational	CEP-1347	COOC(=O)[C@H]1C[C@H](O2)n(c3c4n5[C@]12C)c6c(cc(cc6)CSCC)c3c7c(CNC7=O)c4c8c5ccc(c8)CSCC
3113	sp|Q8IHZ9|KC1_PLAF	P53778	76.78	22.0	270.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3114	sp|Q8IHZ9|KC1_PLAF	Q15139	80.19	586.0	845.0	DB11752	investigational	Bryostatin 1	 
3115	sp|Q8IHZ9|KC1_PLAF	Q15139	80.19	586.0	845.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3116	sp|Q8IHZ9|KC1_PLAF	Q86YV6	81.42	108.0	371.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3117	sp|Q8IHZ9|KC1_PLAF	P30530	84.52	535.0	808.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3118	sp|Q8IHZ9|KC1_PLAF	P30530	84.52	535.0	808.0	DB12141	approved; investigational	Gilteritinib	C1COCCC1Nc2c(CC)nc(C(=O)N)c(n2)Nc3ccc(c(c3)OC)N4CCC(CC4)N5CCN(C)CC5
3119	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB02152	experimental	K-252a	COC(=O)[C@@]1(O)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
3120	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB06314	investigational	SGX-523	Cn1cc(cn1)-c(cc2)nn(c23)c(nn3)Sc(c4)ccc(c45)nccc5
3121	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB06896	experimental	1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide	Fc1ccc(cc1)-n2cccc(c2=O)C(=O)Nc3ccc(c(F)c3)Oc4ccnc(c45)[nH]cc5
3122	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB06995	experimental	N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide	Nc1nccc(c1)Oc2c(F)cc(cc2)NC(=O)NC(=O)Cc3ccc(F)cc3
3123	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB06997	experimental	2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide	Fc1ccc(cc1)CC(=O)NC(=O)Nc2cc(F)c(cc2)Oc3ccnc(c34)[nH]cc4
3124	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB07369	experimental	N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide	Clc1cccc(c1)N(C)S(=O)(=O)c(cc2)cc(c2=3)=C(C(N3)=O)Cc4c(C)c(C)c(C)[nH]4
3125	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB07969	experimental	3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol	CN1CCN(CC1)c(cn2)nc(c23)c(cc(c3)C(F)(F)F)-c4cc(O)ccc4
3126	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB08079	investigational	AMG-208	COc(cc1)cc(c12)nccc2OCc3nnc(n34)ccc(n4)-c5ccccc5
3127	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB08791	experimental	1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE	NC(=O)c(c1)cnc(c12)ccn2S(=O)(=O)c3ccccc3[N+]([O-])=O
3128	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB08865	approved	Crizotinib	Clc1c(F)ccc(Cl)c1[C@@H](C)Oc2cc(cnc2N)-c3cn(nc3)C4CCNCC4
3129	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB08875	approved; investigational	Cabozantinib	COc(c1)c(OC)cc(c12)nccc2Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5
3130	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB11791	approved; investigational	Capmatinib	CNC(=O)c1c(F)cc(cc1)-c(cn2)nn(c23)c(cn3)Cc(cc4)cc(c45)cccn5
3131	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3132	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB12200	investigational	Tivantinib	c1cccc(c12)[nH]cc2[C@H]3[C@@H](C(=O)NC3=O)c4cn5CCCc(c5c46)ccc6
3133	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
3134	sp|Q8IHZ9|KC1_PLAF	P08581	82.04	1079.0	1344.0	DB12742	investigational	Amuvatinib	O1COc(c12)ccc(c2)CNC(=S)N3CCN(CC3)c4ncnc(c45)c6c(o5)cccc6
3135	sp|Q8IHZ9|KC1_PLAF	Q92918	79.26	14.0	270.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3136	sp|Q8IHZ9|KC1_PLAF	Q9UEE5	92.57	64.0	363.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3137	sp|Q8IHZ9|KC1_PLAF	P51955	85.76	5.0	282.0	DB07180	experimental	5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide	CNC(=O)c1c(C)[nH]c(c1C)/C=C2\C(=O)Nc(c23)ccc(Cl)c3
3138	sp|Q8IHZ9|KC1_PLAF	P51955	85.76	5.0	282.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3139	sp|Q8IHZ9|KC1_PLAF	Q16512	76.16	613.0	859.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3140	sp|Q8IHZ9|KC1_PLAF	Q07785	71.83	2.0	234.0	DB02519	experimental	Indirubin-5-sulphonate	OS(=O)(=O)c(cc1)cc(c12)/C(C(=O)N2)=C(C3=O)/Nc(c34)cccc4
3141	sp|Q8IHZ9|KC1_PLAF	Q07785	71.83	2.0	234.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
3143	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB00281	approved; vet_approved	Lidocaine	CCN(CC)CC(=O)Nc1c(C)cccc1C
3144	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB00317	approved; investigational	Gefitinib	C1COCCN1CCCOc(c(c2)OC)cc(c23)c(ncn3)Nc4cc(Cl)c(F)cc4
3145	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB00530	approved; investigational	Erlotinib	COCCOc(c1)c(OCCOC)cc(c12)ncnc2Nc3cc(C#C)ccc3
3146	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB01259	approved; investigational	Lapatinib	CS(=O)(=O)CCNCc1ccc(o1)-c(cc2)cc(c23)c(ncn3)Nc4cc(Cl)c(cc4)OCc5cc(F)ccc5
3148	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3151	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB05294	approved	Vandetanib	CN1CCC(CC1)COc(c(c2)OC)cc(c23)ncnc3Nc4c(F)cc(Br)cc4
3152	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB05374	investigational	Rindopepimut	 
3153	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB05424	investigational	Canertinib	Fc1c(Cl)cc(cc1)Nc2ncnc(c23)cc(c(c3)NC(=O)C=C)OCCCN4CCOCC4
3154	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB05524	investigational	Pelitinib	CN(C)C/C=C/C(=O)Nc(c1)c(OCC)cc(c12)ncc(C#N)c2Nc3cc(Cl)c(F)cc3
3155	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB05944	investigational	Varlitinib	C[C@@H]1COC(=N1)Nc(c2)ccc(c23)ncnc3Nc4ccc(c(Cl)c4)OCc5nccs5
3156	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB06021	investigational	AV-412	CN1CCN(CC1)C(C)(C)C#Cc(c2)c(NC(=O)C=C)cc(c23)c(ncn3)Nc4ccc(F)c(Cl)c4
3157	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB07602	experimental	S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE	OC(=O)[C@@H](N)CSCCC(=O)Nc(cc1)cc(c12)c(ncn2)Nc3ccccc3
3158	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB07662	experimental	PD-168393	Brc1cc(ccc1)Nc(ncn2)c(c23)cc(cc3)NC(=O)C=C
3159	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB08916	approved	Afatinib	CN(C)C/C=C/C(=O)Nc(c1)c(O[C@H]2CCOC2)cc(c13)ncnc3Nc4cc(Cl)c(F)cc4
3160	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB09330	approved	Osimertinib	CN(C)CCN(C)c1cc(OC)c(cc1NC(=O)C=C)Nc2nccc(n2)-c3cn(C)c(c34)cccc4
3164	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB11737	experimental; investigational	Icotinib	C#Cc1cccc(c1)Nc2ncnc(c23)cc4c(c3)OCCOCCOCCO4
3165	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB11828	approved; investigational	Neratinib	CN(C)C/C=C/C(=O)Nc(c(c1)OCC)cc(c12)c(c(cn2)C#N)Nc3ccc(c(Cl)c3)OCc4ccccn4
3166	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB11963	approved; investigational	Dacomitinib	C1CCCCN1C/C=C/C(=O)Nc(c(c2)OC)cc(c23)c(ncn3)Nc4cc(Cl)c(F)cc4
3167	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3169	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
3170	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB13164	investigational	Olmutinib	CN1CCN(CC1)c2ccc(cc2)Nc(n3)nc(c(c34)scc4)Oc5cccc(c5)NC(=O)C=C
3171	sp|Q8IHZ9|KC1_PLAF	P00533	82.97	709.0	977.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
3172	sp|Q8IHZ9|KC1_PLAF	P42679	78.64	234.0	488.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3173	sp|Q8IHZ9|KC1_PLAF	P45984	82.66	20.0	287.0	DB07020	experimental	N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide	c1ccoc1C(=O)Nc2cc(ccc2)-c3n[nH]c(c34)ccc(c4)-c5n[nH]cn5
3174	sp|Q8IHZ9|KC1_PLAF	P45984	82.66	20.0	287.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3175	sp|Q8IHZ9|KC1_PLAF	P45984	82.66	20.0	287.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3176	sp|Q8IHZ9|KC1_PLAF	P45984	82.66	20.0	287.0	DB15624	experimental	Halicin	Nc1nnc(s1)Sc2ncc(s2)[N+]([O-])=O
3177	sp|Q8IHZ9|KC1_PLAF	Q8WU08	77.71	21.0	272.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3178	sp|Q8IHZ9|KC1_PLAF	Q8IY84	76.16	74.0	320.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3179	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
3180	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB01782	experimental	Pyrazolanthrone	c1cccc(c12)c3c4c([nH]n3)cccc4C2=O
3181	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB07218	experimental	6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE	Cn1nc(C)c(c12)c(=O)c3c(n2O)ccc(Cl)c3
3182	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB07268	experimental	2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE	NC(=O)c1ccccc1Nc2nc(ncc2)Nc3cc(O)ccc3
3183	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB07272	experimental	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	CCOc1nc(cc(N)c1C#N)NC(=O)Cc2cc(OC)c(Br)cc2OC
3184	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB07276	experimental	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	CCOc1nc(ccc1C#N)C(=O)NCc2cc(OC)ccc2OC
3185	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB07845	experimental	2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide	CS(=O)(=O)Cc1cc(OC)c(cc1)Nc(nc(c23)[nH]cc3)nc2Nc4cccc(F)c4C(=O)N
3186	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3187	sp|Q8IHZ9|KC1_PLAF	P45983	84.21	20.0	292.0	DB15624	experimental	Halicin	Nc1nnc(s1)Sc2ncc(s2)[N+]([O-])=O
3188	sp|Q8IHZ9|KC1_PLAF	Q13464	82.66	73.0	340.0	DB04707	experimental	Hydroxyfasudil	O=c1[nH]ccc(c12)c(ccc2)S(=O)(=O)N3CCCNCC3
3189	sp|Q8IHZ9|KC1_PLAF	Q13464	82.66	73.0	340.0	DB07876	experimental	(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(C)cnc3
3190	sp|Q8IHZ9|KC1_PLAF	Q13464	82.66	73.0	340.0	DB08162	investigational	Fasudil	c1cncc(c12)cccc2S(=O)(=O)N3CCCNCC3
3191	sp|Q8IHZ9|KC1_PLAF	Q13464	82.66	73.0	340.0	DB08756	experimental	Y-27632	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc2ccncc2
3192	sp|Q8IHZ9|KC1_PLAF	Q13464	82.66	73.0	340.0	DB13165	experimental	Ripasudil	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(F)cnc3
3193	sp|Q8IHZ9|KC1_PLAF	Q13464	82.66	73.0	340.0	DB13931	approved	Netarsudil	Cc1cc(C)c(cc1)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc(c3)ccc(c34)cncc4
3194	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
3195	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB01064	approved; investigational	Isoprenaline	CC(C)NCC(O)c1cc(O)c(O)cc1
3196	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
3197	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
3198	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
3199	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
3200	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB04338	experimental	SB220025	Nc1nccc(n1)-c2c(-c3ccc(F)cc3)ncn2C4CCNCC4
3201	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
3202	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB06641	investigational	Perifosine	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC(CC1)CC[N+]1(C)C
3203	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB06877	experimental	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	CN(C)C(=O)c1cc(c[nH]1)-c2n[nH]cc2-c3ccccc3
3204	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB07010	experimental	N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE	Clc1cc(ccc1)-c2c[nH]nc2-c3c[nH]c(c3)C(=O)NCc4ccccc4
3205	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB07264	experimental	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Fc1ccc(cc1Cl)[C@@H](CO)NC(=O)c2cc(c[nH]2)-c3n[nH]cc3-c4cccc(Cl)c4
3206	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB07788	experimental	(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE	Oc1cc(OC)cc(c12)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@@H](C)OC2=O
3207	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB07794	experimental	5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE	Nc1n[nH]c(c12)nnc(c2)-c(c(n34)cccc4)c(n3)-c5ccccc5
3208	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB07905	experimental	(1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione	Oc1cc(OC)cc(c12)[C@@H]3[C@H](O3)C[C@H](O)[C@H](O)C(=O)\C=C\C[C@H](C)OC2=O
3209	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB08513	experimental	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Cc1cc(ccc1)Nc2nc(ncc2C(=O)N)Nc3ccc(cc3)CC(=O)O
3210	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB08521	experimental	4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine	C[S@@](=O)c1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4
3211	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB11120	approved; experimental	Turpentine	 
3212	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB13930	investigational	Ulixertinib	Clc1cccc(c1)[C@@H](CO)NC(=O)c2cc(c[nH]2)-c3cc(ncc3Cl)NC(C)C
3213	sp|Q8IHZ9|KC1_PLAF	P28482	75.85	20.0	265.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3214	sp|Q8IHZ9|KC1_PLAF	P41743	78.33	252.0	505.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
3215	sp|Q8IHZ9|KC1_PLAF	P41743	78.33	252.0	505.0	DB03777	experimental	Bisindolylmaleimide I	CN(C)CCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
3216	sp|Q8IHZ9|KC1_PLAF	P41743	78.33	252.0	505.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3217	sp|Q8IHZ9|KC1_PLAF	Q16644	89.78	37.0	327.0	DB07728	experimental	2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	Fc1ccccc1-c2cc(ccn2)-c([nH]3)cc(c34)C(=O)NCC4
3218	sp|Q8IHZ9|KC1_PLAF	Q16644	89.78	37.0	327.0	DB08358	experimental	2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	O=C1NCCc(c12)[nH]c(c2)-c3cc(ncc3)-c(cn4)cc(c45)cccc5
3219	sp|Q8IHZ9|KC1_PLAF	Q6ZN16	76.47	657.0	904.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3220	sp|Q8IHZ9|KC1_PLAF	P49137	89.16	61.0	349.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
3221	sp|Q8IHZ9|KC1_PLAF	P49137	89.16	61.0	349.0	DB07234	experimental	3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione	c1ccccc1[C@@H](C)Nc2c(c(=O)c2=O)Nc3ccncc3
3222	sp|Q8IHZ9|KC1_PLAF	P49137	89.16	61.0	349.0	DB07406	experimental	(4R)-N-[4-({[2-(DIMETHYLAMINO)ETHYL]AMINO}CARBONYL)-1,3-THIAZOL-2-YL]-4-METHYL-1-OXO-2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLINE-6-CARBOXAMIDE	C[C@H]1CNC(=O)c(c12)[nH]c3c2cc(cc3)C(=O)Nc4nc(cs4)C(=O)NCCN(C)C
3223	sp|Q8IHZ9|KC1_PLAF	P49137	89.16	61.0	349.0	DB07430	experimental	(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one	O=C1N[C@H](C)CNc(c12)c3c(s2)ccc4c3ccc(n4)-c5cnc(C)cc5
3224	sp|Q8IHZ9|KC1_PLAF	P49137	89.16	61.0	349.0	DB07431	experimental	(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one	O=C1N[C@H](CN)CNc(c12)c3c(s2)ccc(c3)OC
3225	sp|Q8IHZ9|KC1_PLAF	P49137	89.16	61.0	349.0	DB07728	experimental	2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	Fc1ccccc1-c2cc(ccn2)-c([nH]3)cc(c34)C(=O)NCC4
3226	sp|Q8IHZ9|KC1_PLAF	P49137	89.16	61.0	349.0	DB08358	experimental	2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	O=C1NCCc(c12)[nH]c(c2)-c3cc(ncc3)-c(cn4)cc(c45)cccc5
3227	sp|Q8IHZ9|KC1_PLAF	Q06418	85.76	515.0	792.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3228	sp|Q8IHZ9|KC1_PLAF	P04049	85.76	350.0	627.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
3230	sp|Q8IHZ9|KC1_PLAF	P04049	85.76	350.0	627.0	DB05190	investigational	XL281	 
3231	sp|Q8IHZ9|KC1_PLAF	P04049	85.76	350.0	627.0	DB05268	investigational	iCo-007	 
3232	sp|Q8IHZ9|KC1_PLAF	P04049	85.76	350.0	627.0	DB08862	approved; investigational	Cholecystokinin	 
3233	sp|Q8IHZ9|KC1_PLAF	P04049	85.76	350.0	627.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
3234	sp|Q8IHZ9|KC1_PLAF	P04049	85.76	350.0	627.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
3235	sp|Q8IHZ9|KC1_PLAF	P04049	85.76	350.0	627.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3236	sp|Q8IHZ9|KC1_PLAF	Q05513	78.02	250.0	502.0	DB00675	approved	Tamoxifen	c1ccccc1/C(CC)=C(/c2ccccc2)c3ccc(cc3)OCCN(C)C
3237	sp|Q8IHZ9|KC1_PLAF	O96013	74.92	326.0	568.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3238	sp|Q8IHZ9|KC1_PLAF	Q9H1R3	86.38	287.0	566.0	DB04825	approved; withdrawn	Prenylamine	c1ccccc1CC(C)NCCC(c2ccccc2)c3ccccc3
3239	sp|Q8IHZ9|KC1_PLAF	Q9H1R3	86.38	287.0	566.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3240	sp|Q8IHZ9|KC1_PLAF	Q9Y6R4	80.19	1338.0	1597.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3241	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB00398	approved; investigational	Sorafenib	CNC(=O)c1nccc(c1)Oc2ccc(cc2)NC(=O)Nc3cc(C(F)(F)F)c(Cl)cc3
3242	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB05190	investigational	XL281	 
3243	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB05984	investigational	RAF-265	FC(F)(F)c1ccc(cc1)Nc(n2C)nc(c23)cc(cc3)Oc4ccnc(c4)-c5ncc([nH]5)C(F)(F)F
3244	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB06999	experimental	PLX-4720	CCCS(=O)(=O)Nc1ccc(F)c(c1F)C(=O)c2c[nH]c(c23)ncc(Cl)c3
3245	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB07000	experimental	N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide	CCS(=O)(=O)Nc1ccc(F)c(c1F)C(=O)c2c[nH]c(c23)ncc(c3)-c4cnccc4
3246	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB08553	experimental	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime	O/N=C1\CCc(c12)cc(cc2)-c3cn(C4CCNCC4)nc3-c5ccncc5
3247	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB08881	approved	Vemurafenib	CCCS(=O)(=O)Nc1c(F)c(c(F)cc1)C(=O)c2c[nH]c(c23)ncc(c3)-c4ccc(Cl)cc4
3248	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
3249	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
3250	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB11718	approved; investigational	Encorafenib	COC(=O)N[C@@H](C)CNc1nccc(n1)-c2cn(C(C)C)nc2-c3cc(Cl)cc(c3F)NS(=O)(=O)C
3251	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3252	sp|Q8IHZ9|KC1_PLAF	P15056	81.42	456.0	719.0	DB14840	approved	Ripretinib	CNc(c1)ncc(c12)cc(c(=O)n2CC)-c3c(Br)cc(F)c(c3)NC(=O)Nc4ccccc4
3253	sp|Q8IHZ9|KC1_PLAF	Q8TD08	71.52	7.0	238.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3254	sp|Q8IHZ9|KC1_PLAF	Q8TD08	71.52	7.0	238.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
3255	sp|Q8IHZ9|KC1_PLAF	Q8TD08	71.52	7.0	238.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3256	sp|Q8IHZ9|KC1_PLAF	Q13237	77.71	452.0	703.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3257	sp|Q8IHZ9|KC1_PLAF	Q04912	80.5	1085.0	1345.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3258	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
3259	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB00605	approved; investigational	Sulindac	c1cc(F)cc(c12)C(CC(=O)O)=C(C)/C2=C/c3ccc(cc3)S(=O)C
3260	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB01169	approved; investigational	Arsenic trioxide	O=[As]O[As]=O
3261	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
3262	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB04604	experimental	5-iodotubercidin	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cc(I)c(c23)c(N)ncn3
3263	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
3264	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB08862	approved; investigational	Cholecystokinin	 
3265	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB13930	investigational	Ulixertinib	Clc1cccc(c1)[C@@H](CO)NC(=O)c2cc(c[nH]2)-c3cc(ncc3Cl)NC(C)C
3266	sp|Q8IHZ9|KC1_PLAF	P27361	76.47	37.0	284.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3268	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB01259	approved; investigational	Lapatinib	CS(=O)(=O)CCNCc1ccc(o1)-c(cc2)cc(c23)c(ncn3)Nc4cc(Cl)c(cc4)OCc5cc(F)ccc5
3271	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB05944	investigational	Varlitinib	C[C@@H]1COC(=N1)Nc(c2)ccc(c23)ncnc3Nc4ccc(c(Cl)c4)OCc5nccs5
3272	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB06021	investigational	AV-412	CN1CCN(CC1)C(C)(C)C#Cc(c2)c(NC(=O)C=C)cc(c23)c(ncn3)Nc4ccc(F)c(Cl)c4
3274	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB08916	approved	Afatinib	CN(C)C/C=C/C(=O)Nc(c1)c(O[C@H]2CCOC2)cc(c13)ncnc3Nc4cc(Cl)c(F)cc4
3275	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB11652	approved; investigational	Tucatinib	CC1(C)N=C(OC1)Nc(c2)ccc(c23)ncnc3Nc4cc(C)c(cc4)Oc(cc5)cc(n56)ncn6
3276	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB11973	investigational	Tesevatinib	CN(C1)C[C@@H]([C@@H]12)C[C@@H](C2)COc(c(c3)OC)cc(c34)ncnc4Nc5ccc(Cl)c(Cl)c5F
3277	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3278	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
3279	sp|Q8IHZ9|KC1_PLAF	P04626	82.35	717.0	983.0	DB15035	approved; investigational	Zanubrutinib	C=CC(=O)N1CCC(CC1)[C@@H]2CCNc(n23)c(C(=O)N)c(n3)-c4ccc(cc4)Oc5ccccc5
3280	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB01254	approved; investigational	Dasatinib	OCCN1CCN(CC1)c2nc(C)nc(c2)Nc3ncc(s3)C(=O)Nc4c(C)cccc4Cl
3281	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB01761	experimental	4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine	c1ccccc1[C@H](C)Nc2nc(ccn2)-c3c(-c4cccc(c4)C(F)(F)F)nc(n3C)C5CCNCC5
3282	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB01807	experimental	N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea	c1ccccc1-n2nc(C(C)(C)C)cc2NC(=O)Nc3ccc(Cl)cc3
3283	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB01948	experimental	1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One	c1cc(F)cc(F)c1-c2cc(C3CCNCC3)cc(c24)N(C(=O)CC4)c5c(Cl)cccc5Cl
3284	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB01953	experimental	Inhibitor of P38 Kinase	c1cccc(c12)[nH]cc2CCc3ccncc3
3285	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB01988	experimental	6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine	c1ccccc1C[C@H]2CN(CCN2)c3nnc(c(c3)-c4ccncc4)-c(cc5)cc(c56)cccc6
3286	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB02195	experimental	3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine	c1cnccc1-c(n(O)c(c23)cccn3)c2-c4ccc(F)cc4
3287	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB02277	experimental	1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea	Cn1nc(C(C)(C)C)cc1NC(=O)Nc2ccc(Cl)cc2
3288	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB02352	experimental	3-(Benzyloxy)Pyridin-2-Amine	Nc1ncccc1OCc2ccccc2
3289	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB02873	experimental	1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One	C1CNCCN1c(c2)cc(-c(c(F)c3)ccc3F)c(c24)CNC(=O)N4c5c(Cl)cccc5Cl
3290	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB02984	experimental	4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline	COc(c1)c(OC)cc(c12)ncnc2Nc3cc(SC)ccc3
3291	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB03044	investigational	Doramapimod	Cc1ccc(cc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc3ccc(c(c34)cccc4)OCCN5CCOCC5
3292	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB03110	experimental	2-Chlorophenol	Oc1ccccc1Cl
3293	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB03980	experimental	4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole	Fc1ccc(cc1)-c2c(n(cn2)CC3CC3)-c4ccnc(n4)N
3294	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB04338	experimental	SB220025	Nc1nccc(n1)-c2c(-c3ccc(F)cc3)ncn2C4CCNCC4
3295	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB04632	experimental	4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE	Oc1ccccc1CNC2CCN(CC2)S(=O)(=O)Nc3cc(ccc3)Oc4ccc(F)cc4
3296	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB04797	experimental	Triazolopyridine	CC(C)c1nnc(n12)ccc(c2)-c3c(nco3)-c4ccc(F)cc4
3297	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB05157	investigational	KC706	 
3298	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB05412	investigational	Talmapimod	CN(C)C(=O)C(=O)c1cn(C)c(c12)cc(Cl)c(c2)C(=O)N3C[C@H](C)N(C[C@H]3C)Cc4ccc(F)cc4
3299	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB05470	investigational	VX-702	Fc1cccc(F)c1N(C(=O)N)c2ccc(C(=O)N)c(n2)-c3ccc(F)cc3F
3300	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB06518	investigational	R-1487	C1COCCC1Nc(n2)ncc(c23)cc(c(=O)n3C)Oc4ccc(F)cc4F
3301	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB06882	experimental	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea	Nc1cc(ccc1)-n2nc(C(C)(C)C)cc2NC(=O)Nc(ccc3)c(c34)cccc4
3302	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB06940	experimental	N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide	CCNC(=O)c(c1C)cn(c12)ncnc2Nc3cc(ccc3C)C(=O)NOC
3303	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB06991	experimental	N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide	CC[C@@H](C)Nc1ncc(s1)C(=O)Nc2c(C)ccc(c2)C(=O)NC
3304	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07138	investigational	Neflamapimod	Fc1cc(F)c(cc1)Sc(cc2)nn(c23)cnc(=O)c3-c4c(Cl)cccc4Cl
3305	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07307	experimental	N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide	Cc1ccccc1-c2nncc(c23)cc(cc3)-c4c(C)ccc(c4)C(=O)NC5CC5
3306	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07459	experimental	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	n1ccccc1CNC(=O)c2ccc(cc2)Oc3ccccc3
3307	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07607	experimental	4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE	C[S@@](=O)c1ccc(cc1)-c2nc(-c3ccncc3)c([nH]2)-c4cc(I)ccc4
3308	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07811	experimental	N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide	Cc1nnc(o1)-c2ccc(c(C)c2)-c3cc(ccc3C)C(=O)NC4CC4
3309	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07829	experimental	4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE	Fc1ccc(cc1)-c2n[nH]cc2-c3ccncc3
3310	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07832	experimental	4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde	Oc1ccc(C)c(c1)Nc2ccnc(c23)cc(cc3)-c4csc(n4)C=O
3311	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07833	experimental	N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide	Cc1nnc(o1)-c2ccc(C)c(c2)-c3ccc(cc3)C(=O)Nc4cc(C#N)ccc4
3312	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07834	experimental	N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide	Cc1nnc(o1)-c2ccc(C)c(c2)-c3ccc(cc3)C(=O)NCC4CC4
3313	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07835	experimental	N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide	C1CC1NC(=O)c2ccc(C)c(c2)-c3ccc(cc3)C(=O)NCC4CC4
3314	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07941	investigational	PH-797804	CNC(=O)c1ccc(C)c(c1)-n2c(C)cc(c(Br)c2=O)OCc3c(F)cc(F)cc3
3315	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07942	experimental	2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine	Fc1ccc(cc1)-c2c[nH]nc2-c3cc(F)ncc3
3316	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB07943	investigational	SD-0006	OCC(=O)N1CCC(CC1)c2n[nH]c(c2-c3ccncn3)-c4ccc(Cl)cc4
3317	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08064	experimental	N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA	CC(C)(C)c1n[nH]c(c1)NC(=O)Nc2ccc(Cl)c(c2)COc3cccnc3
3318	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08068	experimental	N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-	C1COCCN1[C@@H]2C[C@@H](F)C=C(C2)C(=O)Nc3ccc(Cl)c(c3)COc4cnccc4
3319	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08091	experimental	3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE	C1COCCN1c2cc(F)cc(c2)C(=O)Nc(c3)ccc(c34)[nH]cc4CCc5ccncc5
3320	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08092	experimental	3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide	C1COCCN1c2cc(F)cc(c2)C(=O)Nc(c3)ccc(c34)[nH]cc4
3321	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08093	experimental	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	Nc1ncccc1OCc2cccc(c23)cccc3
3322	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08095	experimental	3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA	CC(C)(O)[C@H](C)Nc1nccc(n1)N(c2ccc(OC)cc2)C(=O)Nc3ccccc3Cl
3323	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08096	experimental	8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM	Clc1ccccc1Nc(n2CC)nc(c23)cnc(n3)Nc4c(F)cccc4F
3324	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08097	experimental	2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE	Fc1ccccc1Nc(n2C(C)C)nc(c23)cnc(n3)Oc4c(F)cccc4F
3325	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08242	experimental	N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide	CNC(=O)c1cc(c(C)cc1)Nc(ncn2)c(c23)cnn3-c4ccccc4
3326	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08349	experimental	N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide	Fc1ccc(c(F)c1)-n(nc2)c(c23)n(C)c(=O)cc3Nc4c(C)ccc(c4)C(=O)NC5CC5
3327	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08351	experimental	N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide	C1CC1NC(=O)c2ccc(C)c(c2)-c(cc3)cc(c34)cnc(n4)NCCN5CCOCC5
3328	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08352	experimental	6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine	CC(C)Nc(s1)nc(c12)ccc(c2)-c3c(nco3)-c4ccccc4F
3329	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08395	experimental	2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE	CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c3ccnc(n3)Oc4ccccc4O
3330	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08423	experimental	[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE	Fc1ccc(cc1)-n2ncc(c2N)C(=O)c3cc(ccc3)OC4CCNCC4
3331	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08424	experimental	[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE	OC[C@H](O)COc1cc(ccc1)C(=O)c2c(N)n(nc2)-c3ccc(F)cc3
3332	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08521	experimental	4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine	C[S@@](=O)c1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4
3333	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08522	experimental	4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE	Fc1ccc(cc1)-c2c(n(cn2)CC3CC3)-c4ccncc4
3334	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB08730	experimental	3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE	C1COCCN1c2cc(F)cc(c2)C(=O)Nc(c3)ccc(c34)ccn4CCc5ccncc5
3335	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3336	sp|Q8IHZ9|KC1_PLAF	Q16539	75.85	19.0	264.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3337	sp|Q8IHZ9|KC1_PLAF	Q12866	84.21	588.0	860.0	DB08325	experimental	2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol	CC(C)n1cnc(c12)c(nc(n2)NCCO)Nc3cc(Cl)ccc3
3338	sp|Q8IHZ9|KC1_PLAF	Q12866	84.21	588.0	860.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3339	sp|Q8IHZ9|KC1_PLAF	O15264	89.16	23.0	311.0	DB05157	investigational	KC706	 
3340	sp|Q8IHZ9|KC1_PLAF	O15264	89.16	23.0	311.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3341	sp|Q8IHZ9|KC1_PLAF	O15264	89.16	23.0	311.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3342	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB00482	approved; investigational	Celecoxib	Cc1ccc(cc1)-c2cc(C(F)(F)F)nn2-c3ccc(cc3)S(=O)(=O)N
3343	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB01863	experimental	Inositol 1,3,4,5-Tetrakisphosphate	OP(=O)(O)O[C@@H]1[C@H](O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@@H]([C@H]1O)OP(=O)(O)O
3344	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB01933	experimental; investigational	7-Hydroxystaurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c([C@@H](O)NC7=O)c4c8c5cccc8
3345	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB01946	experimental	Bisindolylmaleimide VIII	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(CCCN)c(c45)cccc5
3346	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
3347	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB03777	experimental	Bisindolylmaleimide I	CN(C)CCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
3348	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
3349	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB06932	experimental	10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine	COc(c1)c(OC)cc(c12)ncc3c2c4c(nc3N)c(C)c(N)cc4
3350	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB07033	experimental	5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE	c1cc[nH]c1[C@H](C)C(C(=O)N=2)=c(c23)cc(O)cc3
3351	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB07132	experimental	1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA	c1cc[nH]c1[C@H](C)C(C(=O)N=2)=c(c23)cc(cc3)NC(=O)N
3352	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB07300	experimental	2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine	COCCOc(c1)c(OC)cc(c12)c3c(cn2)c(N)nc(c3)-n4ccnc4
3353	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB07456	experimental	3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione	c1cccc(c12)c(c[nH]2)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)CC[C@H]6CCCN6C
3354	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB07457	experimental	3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE	NCCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
3355	sp|Q8IHZ9|KC1_PLAF	O15530	77.71	79.0	330.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3356	sp|Q8IHZ9|KC1_PLAF	Q86UE8	86.38	457.0	736.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3357	sp|Q8IHZ9|KC1_PLAF	Q9BXA7	79.88	11.0	269.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3358	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
3359	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
3360	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB02950	experimental	Hymenialdisine	O=C1NCC[C@@H]([C@@H](C12)C=C(Br)N=2)C3=NC(N)=NC3=O
3361	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB03428	experimental	SU9516	COc(c1)ccc(c12)NC(=O)C\2=C/c3cnc[nH]3
3362	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3363	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB04014	experimental	Alsterpaullone	[O-][N+](=O)c(cc1)cc(c12)c3c([nH]2)c4c(NC(=O)C3)cccc4
3364	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
3365	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB08142	investigational	AT-7519	Clc1cccc(Cl)c1C(=O)Nc2c[nH]nc2C(=O)NC3CCNCC3
3366	sp|Q8IHZ9|KC1_PLAF	P06493	72.45	2.0	236.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3367	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3368	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB08865	approved	Crizotinib	Clc1c(F)ccc(Cl)c1[C@@H](C)Oc2cc(cnc2N)-c3cn(nc3)C4CCNCC4
3369	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB09063	approved	Ceritinib	C1CNCCC1c2cc(OC(C)C)c(cc2C)Nc3ncc(Cl)/c([nH]3)=N\c4ccccc4S(=O)(=O)C(C)C
3370	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB11363	approved; investigational	Alectinib	C1COCCN1C2CCN(CC2)c(c3)c(CC)cc(c34)C(=O)c5c(C4(C)C)[nH]c6c5ccc(c6)C#N
3371	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3372	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB12130	approved; investigational	Lorlatinib	Fc(c1)ccc(c12)C(=O)N(C)Cc3c(c(C#N)n(n3)C)c4cc(O[C@@H]2C)c(N)nc4
3373	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB12141	approved; investigational	Gilteritinib	C1COCCC1Nc2c(CC)nc(C(=O)N)c(n2)Nc3ccc(c(c3)OC)N4CCC(CC4)N5CCN(C)CC5
3374	sp|Q8IHZ9|KC1_PLAF	Q9UM73	86.69	1113.0	1393.0	DB12267	approved; investigational	Brigatinib	CN1CCN(CC1)C2CCN(CC2)c3cc(OC)c(cc3)Nc4ncc(Cl)c(n4)Nc5ccccc5P(=O)(C)C
3375	sp|Q8IHZ9|KC1_PLAF	P14616	85.14	977.0	1252.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3376	sp|Q8IHZ9|KC1_PLAF	O75116	82.04	89.0	354.0	DB08162	investigational	Fasudil	c1cncc(c12)cccc2S(=O)(=O)N3CCCNCC3
3377	sp|Q8IHZ9|KC1_PLAF	O75116	82.04	89.0	354.0	DB08756	experimental	Y-27632	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc2ccncc2
3378	sp|Q8IHZ9|KC1_PLAF	O75116	82.04	89.0	354.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3379	sp|Q8IHZ9|KC1_PLAF	O75116	82.04	89.0	354.0	DB13165	experimental	Ripasudil	C[C@H]1CNCCCN1S(=O)(=O)c(ccc2)c(c23)c(F)cnc3
3380	sp|Q8IHZ9|KC1_PLAF	O75116	82.04	89.0	354.0	DB13931	approved	Netarsudil	Cc1cc(C)c(cc1)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc(c3)ccc(c34)cncc4
3381	sp|Q8IHZ9|KC1_PLAF	Q00535	70.59	2.0	230.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
3382	sp|Q8IHZ9|KC1_PLAF	Q00535	70.59	2.0	230.0	DB02116	experimental	Olomoucine	OCCNc(n1)nc(c(c12)ncn2C)NCc3ccccc3
3383	sp|Q8IHZ9|KC1_PLAF	Q00535	70.59	2.0	230.0	DB02950	experimental	Hymenialdisine	O=C1NCC[C@@H]([C@@H](C12)C=C(Br)N=2)C3=NC(N)=NC3=O
3384	sp|Q8IHZ9|KC1_PLAF	Q00535	70.59	2.0	230.0	DB03428	experimental	SU9516	COc(c1)ccc(c12)NC(=O)C\2=C/c3cnc[nH]3
3385	sp|Q8IHZ9|KC1_PLAF	Q00535	70.59	2.0	230.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3386	sp|Q8IHZ9|KC1_PLAF	Q00535	70.59	2.0	230.0	DB04014	experimental	Alsterpaullone	[O-][N+](=O)c(cc1)cc(c12)c3c([nH]2)c4c(NC(=O)C3)cccc4
3387	sp|Q8IHZ9|KC1_PLAF	Q00535	70.59	2.0	230.0	DB07364	experimental	6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE	n1ccnc(c12)[nH]c(c2CCCC)-c3ccc(O)cc3
3388	sp|Q8IHZ9|KC1_PLAF	Q96RR4	86.07	163.0	441.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3389	sp|Q8IHZ9|KC1_PLAF	Q13233	81.42	1241.0	1504.0	DB06061	investigational	AZD-8330	OCCONC(=O)c1cc(C)c(=O)n(C)c1Nc2ccc(I)cc2F
3390	sp|Q8IHZ9|KC1_PLAF	Q13233	81.42	1241.0	1504.0	DB11967	approved; investigational	Binimetinib	OCCONC(=O)c(c1)c(c(F)c(c12)ncn2C)Nc3ccc(Br)cc3F
3391	sp|Q8IHZ9|KC1_PLAF	Q13233	81.42	1241.0	1504.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3392	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB05149	investigational	XL844	 
3393	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
3394	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB06852	experimental	CHIR-124	c1cc(Cl)cc(c12)c(N[C@H](CN34)C(CC3)CC4)c(c(=O)[nH]2)-c([nH]5)nc(c56)cccc6
3395	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB06876	experimental	N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE	CN1CCN(CC1)c2ccc(cc2)-c(cn3)cc(c34)c(c[nH]4)NC(=O)c5cnccc5
3396	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07025	experimental	3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE	NCC1CCN(CC1)Cc(cc2)cc(c23)cc([nH]3)-c(c(=O)[nH]4)cc(c45)cccc5
3397	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07034	experimental	2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID	OC(=O)COc(c1)ccc(c12)c3c(C2=NO)cc(cc3)OCC(=O)O
3398	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07037	experimental	(2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL	NC[C@H](O)CNc(ccc1[N+]([O-])=O)c(c12)nccc2
3399	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07038	experimental	2-(cyclohexylamino)benzoic acid	OC(=O)c1ccccc1NC2CCCCC2
3400	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07075	experimental	3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE	NCC1CCN(CC1)Cc(cc2)cc(c23)cc([nH]3)-c4n[nH]c(c45)cc(C#N)cc5
3401	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07078	experimental	(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE	COc1cc(ccc1O)-c(cc2)cc(c23)NC(=O)C\3=C/c4ccc[nH]4
3402	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07158	experimental	5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE	c1cccc(c12)c3c(c(C)n[nH]3)c(=O)n2CC
3403	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07213	experimental	(5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL	OCc1n[nH]nc1-c(cc2)cc(c23)[nH]nc3-c([nH]4)cc(c45)cc(cc5)CN6CCCCC6
3404	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07228	experimental	1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA	CN(C)C[C@H](C)Oc1cncc(n1)NC(=O)Nc2c(OC)ccc(Cl)c2
3405	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07243	experimental	(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE	[C@@H]12CC[C@@H](N1C)C[C@@H](C2)OC(=O)c3c[nH]c(c34)nccc4
3406	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07311	experimental	18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE	c1cc(Cl)cc(c12)NC(=O)Nc3cncc(n3)OCCCCCO2
3407	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07314	experimental	1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA	COc1cc(OC)c(cc1Cl)NC(=O)Nc2ncc(C#N)nc2
3408	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07320	experimental	4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID	C[C@H]1CC[C@H](CC1)NCc(cc2)cc(c23)Cc4c3[nH]nc4-c5ccc(cc5)C(=O)O
3409	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07336	experimental	4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL	COc1cc(ccc1O)-c(cc2)cc(c23)[nH]nc3-c([nH]4)nc(c45)cccc5
3410	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07647	experimental	(2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL	C[C@@H](O)CNc(ncn1)c(c12)c(-c3ccccc3)c([nH]2)-c4ccccc4
3411	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07648	experimental	(2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL	OC[C@H](O)CNc(ncn1)c(c12)c(-c3ccccc3)c([nH]2)-c4ccccc4
3412	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07653	experimental	N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE	OC(=O)CNc1ncnc(c12)oc(-c3ccccc3)c2-c4ccccc4
3413	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07654	experimental	(5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC	OCCN(C)c1ncnc(c12)oc(-c3ccccc3)c2-c4ccccc4
3414	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07655	experimental	3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE	OCCNc1ncnc(c12)[nH]c(-c3ccccc3)c2-c4ccccc4
3415	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB07959	experimental	3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE	c1cccc(c12)c(n[nH]2)-c([nH]3)nc(c34)cccc4
3416	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08392	experimental	2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL	COc1ccc(cc1)-c(c(c23)c(ncn3)NCCO)c(o2)-c4ccc(cc4)OC
3417	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08393	experimental	2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL	OCCNc1ncnc(c12)oc(-c3ccccc3)c2-c4ccccc4
3418	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08683	experimental	REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE	c1cccc(c12)n3c4c2c5c(C(=O)NC5=O)c6c7c(cccc7)n(c46)[C@H]8O[C@@H]3CC8
3419	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08774	experimental	1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine	NC[C@H]1CN(CCO1)c2c(cnc(c23)[nH]nc3)-c4ccccc4
3420	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08776	experimental	N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE	CC(=O)Nc(s1)nc(c12)CCCNC2=O
3421	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08777	experimental	5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE	O=c1[nH]cnc(c12)sc3c2CCCC3
3422	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08778	experimental	[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone	CC(C)(C)Nc1nc(N)c(s1)C(=O)c2ccccc2
3423	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08779	experimental	2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol	CSc1nc(O)c([nH]1)Cc2cccs2
3424	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08780	experimental	6-MORPHOLIN-4-YL-9H-PURINE	C1COCCN1c(ncn2)c(c23)nc[nH]3
3425	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB08781	experimental	1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE	NC[C@H]1CN(CCO1)c2c(Br)cnc(c23)[nH]nc3
3426	sp|Q8IHZ9|KC1_PLAF	O14757	79.88	3.0	261.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3427	sp|Q8IHZ9|KC1_PLAF	Q9HBH9	88.85	78.0	365.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3428	sp|Q8IHZ9|KC1_PLAF	O94768	89.47	35.0	324.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
3429	sp|Q8IHZ9|KC1_PLAF	O94768	89.47	35.0	324.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3430	sp|Q8IHZ9|KC1_PLAF	P53667	82.35	341.0	607.0	DB08912	approved; investigational	Dabrafenib	Nc1nccc(n1)-c2sc(C(C)(C)C)nc2-c3c(F)c(ccc3)NS(=O)(=O)c4c(F)cccc4F
3431	sp|Q8IHZ9|KC1_PLAF	P53667	82.35	341.0	607.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3432	sp|Q8IHZ9|KC1_PLAF	Q13164	77.71	49.0	300.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3433	sp|Q8IHZ9|KC1_PLAF	Q13164	77.71	49.0	300.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
3434	sp|Q8IHZ9|KC1_PLAF	Q13164	77.71	49.0	300.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3435	sp|Q8IHZ9|KC1_PLAF	Q15759	74.92	20.0	262.0	DB05157	investigational	KC706	 
3436	sp|Q8IHZ9|KC1_PLAF	Q15759	74.92	20.0	262.0	DB08896	approved	Regorafenib	CNC(=O)c1cc(ccn1)Oc2cc(F)c(cc2)NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F
3437	sp|Q8IHZ9|KC1_PLAF	Q15759	74.92	20.0	262.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3438	sp|Q8IHZ9|KC1_PLAF	Q8TD19	78.33	51.0	304.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3439	sp|Q8IHZ9|KC1_PLAF	P10398	81.73	309.0	573.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3440	sp|Q8IHZ9|KC1_PLAF	Q00537	70.28	190.0	417.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3441	sp|Q8IHZ9|KC1_PLAF	P29376	86.38	509.0	788.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3442	sp|Q8IHZ9|KC1_PLAF	Q9UKI8	86.38	451.0	730.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3443	sp|Q8IHZ9|KC1_PLAF	P50613	71.83	9.0	241.0	DB02482	experimental	Phosphonothreonine	OC(=O)[C@H](N)[C@H](C)OP(=O)(O)O
3444	sp|Q8IHZ9|KC1_PLAF	P50613	71.83	9.0	241.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3445	sp|Q8IHZ9|KC1_PLAF	P50613	71.83	9.0	241.0	DB05969	investigational	SNS-032	CC(C)(C)c1cnc(o1)CSc2cnc(s2)NC(=O)C3CCNCC3
3446	sp|Q8IHZ9|KC1_PLAF	P50613	71.83	9.0	241.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
3447	sp|Q8IHZ9|KC1_PLAF	Q8N5S9	86.07	126.0	404.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3448	sp|Q8IHZ9|KC1_PLAF	Q9Y2H1	84.83	88.0	362.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3449	sp|Q8IHZ9|KC1_PLAF	Q00534	71.83	8.0	240.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3450	sp|Q8IHZ9|KC1_PLAF	Q00534	71.83	8.0	240.0	DB07379	experimental	(2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol	n1cn(C(C)C)c(c12)nc(N[C@H](CO)C(C)C)nc2Nc3cc(Cl)cc(N)c3
3451	sp|Q8IHZ9|KC1_PLAF	Q00534	71.83	8.0	240.0	DB07795	experimental	Fisetin	c1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
3452	sp|Q8IHZ9|KC1_PLAF	Q00534	71.83	8.0	240.0	DB09073	approved; investigational	Palbociclib	C1CCCC1n2c(=O)c(C(=O)C)c(C)c(c23)cnc(n3)Nc4ncc(cc4)N5CCNCC5
3453	sp|Q8IHZ9|KC1_PLAF	Q00534	71.83	8.0	240.0	DB11730	approved; investigational	Ribociclib	C1CCCC1n2c(C(=O)N(C)C)cc(c23)cnc(n3)Nc4ccc(cn4)N5CCNCC5
3454	sp|Q8IHZ9|KC1_PLAF	Q00534	71.83	8.0	240.0	DB12001	approved; investigational	Abemaciclib	CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(F)c(n3)-c(c4)cc(F)c(c45)nc(C)n5C(C)C
3455	sp|Q8IHZ9|KC1_PLAF	Q6DT37	78.02	68.0	320.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3456	sp|Q8IHZ9|KC1_PLAF	Q9Y2H9	81.42	371.0	634.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3457	sp|Q8IHZ9|KC1_PLAF	Q13546	91.33	16.0	311.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3458	sp|Q8IHZ9|KC1_PLAF	O95382	76.47	653.0	900.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3459	sp|Q8IHZ9|KC1_PLAF	Q15208	84.83	87.0	361.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3460	sp|Q8IHZ9|KC1_PLAF	O14578	79.88	94.0	352.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3461	sp|Q8IHZ9|KC1_PLAF	P35626	77.09	188.0	437.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3462	sp|Q8IHZ9|KC1_PLAF	P53671	83.59	334.0	604.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3463	sp|Q8IHZ9|KC1_PLAF	Q59H18	81.11	462.0	724.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3464	sp|Q8IHZ9|KC1_PLAF	P50750	76.78	17.0	265.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3465	sp|Q8IHZ9|KC1_PLAF	P50750	76.78	17.0	265.0	DB06195	investigational	Seliciclib	CC(C)n1cnc(c12)c(nc(n2)N[C@H](CC)CO)NCc3ccccc3
3466	sp|Q8IHZ9|KC1_PLAF	Q9NWZ3	82.97	190.0	458.0	DB08590	experimental	1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE	CC(C)(C)C(=O)Oc(c1)ccc(c12)n(CCCO)c(n2)NC(=O)c3cc([N+]([O-])=O)ccc3
3467	sp|Q8IHZ9|KC1_PLAF	Q9NWZ3	82.97	190.0	458.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3468	sp|Q8IHZ9|KC1_PLAF	Q09013	77.4	68.0	318.0	DB01946	experimental	Bisindolylmaleimide VIII	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(CCCN)c(c45)cccc5
3469	sp|Q8IHZ9|KC1_PLAF	Q9BQI3	76.16	379.0	625.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3470	sp|Q8IHZ9|KC1_PLAF	Q13163	79.88	163.0	421.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3471	sp|Q8IHZ9|KC1_PLAF	Q8IW41	89.47	22.0	311.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3472	sp|Q8IHZ9|KC1_PLAF	P25098	77.09	188.0	437.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3473	sp|Q8IHZ9|KC1_PLAF	P9WI81	79.88	7.0	265.0	DB02930	experimental	Adenosine 5'-[gamma-thio]triphosphate	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=S)(O)O
3474	sp|Q8IHZ9|KC1_PLAF	P9WI81	79.88	7.0	265.0	DB03909	experimental	Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate	OP(=O)(O)CP(=O)(O)OP(=O)(O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)c(N)ncn3
3475	sp|Q8IHZ9|KC1_PLAF	P9WI81	79.88	7.0	265.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3476	sp|Q8IHZ9|KC1_PLAF	Q96Q40	70.9	100.0	329.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3477	sp|Q8IHZ9|KC1_PLAF	Q96Q40	70.9	100.0	329.0	DB06486	investigational	Enzastaurin	c1cccc(c12)c(cn2C)C3=C(C(=O)NC3=O)c4cn(c(c45)cccc5)C6CCN(CC6)Cc7ccccn7
3478	sp|Q8IHZ9|KC1_PLAF	Q96Q40	70.9	100.0	329.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3479	sp|Q8IHZ9|KC1_PLAF	P33981	81.42	524.0	787.0	DB01782	experimental	Pyrazolanthrone	c1cccc(c12)c3c4c([nH]n3)cccc4C2=O
3480	sp|Q8IHZ9|KC1_PLAF	P33981	81.42	524.0	787.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3481	sp|Q8IHZ9|KC1_PLAF	P33981	81.42	524.0	787.0	DB15498	experimental	BOS172722	Cn1cnnc1-c2cc(OCC)c(cc2)Nc(n3)ncc(c34)cc(C)nc4NCC(C)(C)C
3482	sp|Q8IHZ9|KC1_PLAF	P11802	72.76	3.0	238.0	DB02733	experimental	Purvalanol	n1cn(C(C)C)c(c12)nc(N[C@@H](CO)C(C)C)nc2Nc3ccc(C(=O)O)c(Cl)c3
3483	sp|Q8IHZ9|KC1_PLAF	P11802	72.76	3.0	238.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3484	sp|Q8IHZ9|KC1_PLAF	P11802	72.76	3.0	238.0	DB09073	approved; investigational	Palbociclib	C1CCCC1n2c(=O)c(C(=O)C)c(C)c(c23)cnc(n3)Nc4ncc(cc4)N5CCNCC5
3485	sp|Q8IHZ9|KC1_PLAF	P11802	72.76	3.0	238.0	DB11730	approved; investigational	Ribociclib	C1CCCC1n2c(C(=O)N(C)C)cc(c23)cnc(n3)Nc4ccc(cn4)N5CCNCC5
3486	sp|Q8IHZ9|KC1_PLAF	P11802	72.76	3.0	238.0	DB12001	approved; investigational	Abemaciclib	CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(F)c(n3)-c(c4)cc(F)c(c45)nc(C)n5C(C)C
3487	sp|Q8IHZ9|KC1_PLAF	P11802	72.76	3.0	238.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3488	sp|Q8IHZ9|KC1_PLAF	Q15569	81.11	55.0	317.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3489	sp|Q8IHZ9|KC1_PLAF	Q52WX2	84.21	48.0	320.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3490	sp|Q8IHZ9|KC1_PLAF	P19525	86.69	260.0	540.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3491	sp|Q8IHZ9|KC1_PLAF	P46734	81.42	62.0	325.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3492	sp|Q8IHZ9|KC1_PLAF	P21860	81.42	707.0	970.0	DB11652	approved; investigational	Tucatinib	CC1(C)N=C(OC1)Nc(c2)ccc(c23)ncnc3Nc4cc(C)c(cc4)Oc(cc5)cc(n56)ncn6
3493	sp|Q8IHZ9|KC1_PLAF	Q16659	71.83	16.0	248.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
3494	sp|Q8IHZ9|KC1_PLAF	Q16659	71.83	16.0	248.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3495	sp|Q8IHZ9|KC1_PLAF	O00238	93.19	198.0	499.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3496	sp|Q8IHZ9|KC1_PLAF	P52564	80.5	51.0	311.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3497	sp|Q8IHZ9|KC1_PLAF	O14976	87.93	40.0	324.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3498	sp|Q8IHZ9|KC1_PLAF	P36897	93.5	199.0	501.0	DB03921	experimental	4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline	n1ccccc1-c2n[nH]cc2-c(ccn3)c(c34)cccc4
3499	sp|Q8IHZ9|KC1_PLAF	P36897	93.5	199.0	501.0	DB04434	experimental	Naphthyridine Inhibitor	Cc1cccc(n1)C2=C(CNN2)c(n3)ccc(c34)nccc4
3500	sp|Q8IHZ9|KC1_PLAF	P36897	93.5	199.0	501.0	DB04480	experimental	3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole	C1CCn(c12)nc(-c(nc3C)ccc3)c2-c4ccc(F)cc4
3501	sp|Q8IHZ9|KC1_PLAF	P36897	93.5	199.0	501.0	DB07152	experimental	N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide	Fc1ccc(nc1C)-c2nc(NC(=O)C)[nH]c2-c(c3)ccc(c34)nccn4
3502	sp|Q8IHZ9|KC1_PLAF	P36897	93.5	199.0	501.0	DB07267	experimental	2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine	Cc1cccc(n1)-c(n2)nc(c(c23)cccc3)Nc4ccncc4
3503	sp|Q8IHZ9|KC1_PLAF	P36897	93.5	199.0	501.0	DB08450	experimental	N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine	Cc1cccc(n1)-c(n2)nc(c(c23)cccc3)Nc(c4)ccc(c45)[nH]nc5
3504	sp|Q8IHZ9|KC1_PLAF	P36897	93.5	199.0	501.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3505	sp|Q8IHZ9|KC1_PLAF	P31152	79.88	18.0	276.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3506	sp|Q8IHZ9|KC1_PLAF	P31152	79.88	18.0	276.0	DB00945	approved; vet_approved	Acetylsalicylic acid	CC(=O)Oc1ccccc1C(=O)O
3507	sp|Q8IHZ9|KC1_PLAF	P31152	79.88	18.0	276.0	DB01017	approved; investigational	Minocycline	O=C1C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]([C@@]12O)C[C@H]3C(=C2O)C(=O)c4c(C3)c(N(C)C)ccc4O
3508	sp|Q8IHZ9|KC1_PLAF	Q8NFD2	79.26	27.0	283.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3509	sp|Q8IHZ9|KC1_PLAF	P49840	80.19	118.0	377.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3511	sp|Q8IHZ9|KC1_PLAF	Q13627	70.28	155.0	382.0	DB07608	experimental	N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide	Clc1cccc(c1)[C@H](CCN)C(=O)Nc(c2)ccc(c23)[nH]nc3NC(=O)c4ccccc4
3512	sp|Q8IHZ9|KC1_PLAF	Q13627	70.28	155.0	382.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3513	sp|Q8IHZ9|KC1_PLAF	O15111	73.07	15.0	251.0	DB00233	approved	Aminosalicylic acid	Nc1cc(O)c(cc1)C(=O)O
3514	sp|Q8IHZ9|KC1_PLAF	O15111	73.07	15.0	251.0	DB00244	approved	Mesalazine	Nc1cc(C(=O)O)c(O)cc1
3515	sp|Q8IHZ9|KC1_PLAF	O15111	73.07	15.0	251.0	DB00795	approved	Sulfasalazine	OC(=O)c1cc(ccc1O)/N=N/c2ccc(cc2)S(=O)(=O)Nc3ncccc3
3516	sp|Q8IHZ9|KC1_PLAF	O15111	73.07	15.0	251.0	DB06151	approved; investigational	Acetylcysteine	CC(=O)N[C@@H](CS)C(=O)O
3517	sp|Q8IHZ9|KC1_PLAF	P57078	79.26	21.0	277.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3518	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB01356	experimental	Lithium cation	[Li+]
3519	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB01772	experimental	3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione	OC[C@@H](O)CNc1cccc(c1)C2=C(C(=O)NC2=O)c3cn(C)c(c34)ccc(F)c4
3520	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB01793	experimental	SB-409513	OC(=O)c1cc(ccc1Cl)NC2=C(C(=O)NC2=O)c3cc(Cl)ccc3
3521	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB01950	experimental	AR-AO-14418	COc1ccc(cc1)CNC(=O)Nc2ncc(s2)[N+]([O-])=O
3522	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
3523	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB02052	experimental	Indirubin-3'-monoxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cccc4
3524	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB03444	experimental	6-bromoindirubin-3'-oxime	c1cccc(c12)NC(\C\2=N\O)=C3/C(=O)Nc(c34)cc(Br)cc4
3525	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB04014	experimental	Alsterpaullone	[O-][N+](=O)c(cc1)cc(c12)c3c([nH]2)c4c(NC(=O)C3)cccc4
3526	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
3527	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07014	experimental	2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole	COc1c(F)cc(cc1)CSc2nnc(o2)-c(cc3)cc(c34)OCO4
3528	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07058	experimental	5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione	COc1ccc(cc1)-n2cnc(c23)ccc(c3)-c4n[nH]c(=S)o4
3529	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07149	experimental	(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one	FCC[C@H]1CNC(=O)c(c12)cc([nH]2)-c3nc(N)ncc3
3530	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07584	experimental	N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	Cc1nnc([nH]1)-c2ccccc2Nc3ncnc(c34)[nH]cc4
3531	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07585	experimental	5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	Clc1c[nH]c(c12)ncnc2N(C3)CCc(c34)[nH]cn4
3532	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07676	experimental	3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one	OC[C@@H](O)CCONc1c([nH]c(c12)cccc2)C(C(=O)N=3)=c(c34)cccc4
3533	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07812	experimental	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide	c1ccccc1[C@@H](CN)NC(=O)c2ccc(s2)-c(ccn3)c(c34)cc[nH]4
3534	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07859	experimental	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)-c4c[nH]nc4
3535	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB07947	experimental	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	Clc1ccc(cc1)COCCNCCNS(=O)(=O)c2cccc(c23)cncc3
3536	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB08073	experimental	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	c1cccc(c12)[nH]cc2C[C@H](N)COc3cncc(c3)-c(c4)ccc(c45)[nH]nc5C
3537	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3538	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB12129	investigational; withdrawn	Tideglusib	c1cccc(c12)c(ccc2)-n3sc(=O)n(c3=O)Cc4ccccc4
3539	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB14507	approved	Lithium citrate	[O-]C(=O)CC(O)(C([O-])=O)CC([O-])=O
3540	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB14508	experimental	Lithium succinate	[O-]C(=O)CCC([O-])=O
3541	sp|Q8IHZ9|KC1_PLAF	P49841	78.33	55.0	308.0	DB14509	approved	Lithium carbonate	[O-]C([O-])=O
3542	sp|Q8IHZ9|KC1_PLAF	Q9Y463	70.59	107.0	335.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3543	sp|Q8IHZ9|KC1_PLAF	Q13470	82.66	119.0	386.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3544	sp|Q8IHZ9|KC1_PLAF	Q04771	91.64	202.0	498.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3545	sp|Q8IHZ9|KC1_PLAF	Q04771	91.64	202.0	498.0	DB08597	experimental	Dorsomorphin	C1CCCCN1CCOc2ccc(cc2)-c(cn3)cn(c34)ncc4-c5ccncc5
3546	sp|Q8IHZ9|KC1_PLAF	Q04771	91.64	202.0	498.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3547	sp|Q8IHZ9|KC1_PLAF	P49759	73.37	158.0	395.0	DB04367	experimental	Debromohymenialdisine	NC1=NC(=O)/C(N1)=C2\CCNC(=O)c(c23)[nH]cc3
3548	sp|Q8IHZ9|KC1_PLAF	P49759	73.37	158.0	395.0	DB06376	investigational	CHGN111	 
3549	sp|Q8IHZ9|KC1_PLAF	P49759	73.37	158.0	395.0	DB08691	experimental	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate	CCOC(=O)c(n1C)c(/C(C#N)=C\N)c(c12)ccc(Cl)c2Cl
3550	sp|Q8IHZ9|KC1_PLAF	P49759	73.37	158.0	395.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3551	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB01754	experimental	3,4-Dihydroxy-1-Methylquinolin-2(1h)-One	Cn1c(=O)c(O)c(O)c(c12)cccc2
3552	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB02010	experimental	Staurosporine	CO[C@@H]1[C@H](NC)C[C@@H](O2)n(c3c4n5[C@]12C)c6c(cccc6)c3c7c(CNC7=O)c4c8c5cccc8
3553	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB02656	experimental	LY-294002	C1COCCN1c(cc2=O)oc(c23)c(ccc3)-c4ccccc4
3554	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB03366	experimental; investigational	Imidazole	[nH]1ccnc1
3555	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB03650	experimental	(3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One	Oc1ccc(cc1)/N=C2\C(=O)Nc(c23)cccc3
3556	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB03777	experimental	Bisindolylmaleimide I	CN(C)CCCn1cc(c(c12)cccc2)C3=C(C(=O)NC3=O)c4c[nH]c(c45)cccc5
3557	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
3558	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
3559	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB04522	experimental	Dexfosfoserine	OC(=O)[C@@H](N)COP(=O)(O)O
3560	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB04530	experimental	S,S-(2-Hydroxyethyl)Thiocysteine	OC(=O)[C@@H](N)CSSCCO
3561	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB04715	experimental	IMIDAZOPYRIDAZIN 1	CC(=O)c1cccc(c1)-c2cnc(n23)ccc(n3)NCC4CC4
3562	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB07151	experimental	4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one	Oc1ccc(cc1C)C2=NC(=O)N=C(C2)c3ccccc3
3563	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB07242	experimental	(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile	C1CN(C)CCC12[C@H](C#N)c3c(C(=O)N2)n(C)c4c3ccc(Cl)c4Cl
3564	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB07524	experimental	N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine	c1ccccc1Nc2c[nH]c(c23)nccc3
3565	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB08022	experimental	(2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile	c1cccc(c12)nc(s2)[C@H](C#N)c3nc(ncc3)NCCc4cccnc4
3566	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB08166	experimental	(4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile	C1CNCCC12[C@H](C#N)c3c(C(=O)N2)n(C)c4c3ccc(Cl)c4
3567	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB08230	experimental	Tricetin	Oc(c1)cc(O)c(c12)c(=O)cc(o2)-c3cc(O)c(O)c(O)c3
3568	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB08705	experimental	6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE	Brc1ccc(O)c(c1)-c2cc(c(C#N)c(=O)[nH]2)-c3ccccc3
3569	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB08707	experimental	4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine	Nc1nccc(n1)-c(cc2)cc(c23)c(on3)-c4ccc(Cl)cc4
3570	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB08708	experimental	N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine	FC(F)(F)c1cccc(c1)-c2nnc(n23)ccc(n3)NC4CCCCC4
3571	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB08709	experimental	2,3-diphenyl-1H-indole-7-carboxylic acid	O=C(O)c1cccc(c12)c(-c3ccccc3)c([nH]2)-c4ccccc4
3572	sp|Q8IHZ9|KC1_PLAF	P11309	78.02	125.0	377.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3573	sp|Q8IHZ9|KC1_PLAF	O75716	85.45	17.0	293.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3574	sp|Q8IHZ9|KC1_PLAF	Q8TDR2	71.21	300.0	530.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3575	sp|Q8IHZ9|KC1_PLAF	O15197	78.02	670.0	922.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3576	sp|Q8IHZ9|KC1_PLAF	Q86V86	78.33	35.0	288.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3577	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3578	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB01765	experimental	(5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid	c1cccc(c12)n3c(c2CC(=O)O)[nH]c(=O)c4c3cccc4
3579	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB02170	experimental	1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One	Oc1ccc([N+]([O-])=O)c(c12)oc3c(c2=O)c(O)ccc3
3580	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB02709	investigational	Resveratrol	Oc1ccc(cc1)/C=C/c2cc(O)cc(O)c2
3581	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB03035	experimental	1,8-Di-Hydroxy-4-Nitro-Anthraquinone	Oc1cccc(c12)C(=O)c3c(C2=O)c(O)ccc3[N+]([O-])=O
3582	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB03127	experimental	Benzamidine	NC(=[NH2+])c1ccccc1
3583	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB03924	experimental	5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone	Nc1ccc(N)c(c12)C(=O)c3c(C2=O)c(O)ccc3O
3584	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB04216	experimental; investigational	Quercetin	Oc1cc(O)cc(c12)oc(c(c2=O)O)-c3ccc(O)c(O)c3
3585	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB04395	experimental	Phosphoaminophosphonic Acid-Adenylate Ester	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@H]([C@H](O)[C@H]3O)CO[P@@](=O)(O)O[P@](=O)(O)NP(=O)(O)O
3586	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB04462	experimental	Tetrabromo-2-Benzotriazole	n1[nH]nc(c12)c(Br)c(Br)c(Br)c2Br
3587	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB04719	experimental	DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE	CN(C)c([nH]1)nc(c12)c(Br)c(Br)c(Br)c2Br
3588	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB04720	experimental	S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE	CSc([nH]1)nc(c12)c(Br)c(Br)c(Br)c2Br
3589	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB04721	experimental	N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE	CN1CCn(c12)c3c(n2)c(Br)c(Br)c(Br)c3Br
3590	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB07715	investigational	Emodin	Cc(c1)cc(O)c(c12)C(=O)c3c(C2=O)cc(O)cc3O
3591	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB07802	experimental	3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE	Cc1c(Br)c(=O)oc(c12)c(Br)c(O)cc2
3592	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08338	experimental	19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one	O=C(N1)CCCCc2cnn(c(n3)NC4CC4)c2nc3Nc(c5)cccc15
3593	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08340	experimental	N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE	c1ccccc1Nc(nc(n23)ccn3)nc2Nc4ccccc4
3594	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08345	experimental	4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	c1nc[nH]c1CCNc2nc(nc(n23)c(cn3)C#N)Nc4ccccc4
3595	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08353	experimental	2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	c1ccccc1Nc2nc(nc(n23)c(cn3)C#N)NCC4CCCCC4
3596	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08354	experimental	2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	Clc1ccc(cc1)CNc(nc(n23)c(cn3)C#N)nc2Nc4ccccc4
3597	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08360	experimental	2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE	CCN1CCN(CC1)c(nc(n23)c(cn3)C#N)nc2Nc4ccccc4
3598	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08362	experimental	N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE	CC(=O)Nc1cccc(c1)Nc(nc(n23)c(cn3)C#N)nc2Nc4ccccc4
3599	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08473	experimental	Dichlororibofuranosylbenzimidazole	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc(c23)cc(Cl)c(Cl)c3
3600	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08660	experimental	Quinalizarin	Oc1ccc(O)c(c12)C(=O)c3c(C2=O)ccc(O)c3O
3601	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB08846	investigational	Ellagic acid	Oc(c1)c(O)c(c2c13)oc(=O)c4c2c(oc3=O)c(O)c(c4)O
3602	sp|Q8IHZ9|KC1_PLAF	P68400	75.85	35.0	280.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3603	sp|Q8IHZ9|KC1_PLAF	P36896	92.88	201.0	501.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3604	sp|Q8IHZ9|KC1_PLAF	P36896	92.88	201.0	501.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3605	sp|Q8IHZ9|KC1_PLAF	Q9HAZ1	73.68	156.0	394.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3606	sp|Q8IHZ9|KC1_PLAF	P37023	92.88	196.0	496.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3607	sp|Q8IHZ9|KC1_PLAF	O43353	85.76	20.0	297.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3608	sp|Q8IHZ9|KC1_PLAF	P49336	76.16	24.0	270.0	DB03496	experimental; investigational	Alvocidib	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c(c23)c(=O)cc(o3)-c4ccccc4Cl
3609	sp|Q8IHZ9|KC1_PLAF	Q2M2I8	84.21	44.0	316.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3610	sp|Q8IHZ9|KC1_PLAF	Q99640	76.78	106.0	354.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3611	sp|Q8IHZ9|KC1_PLAF	Q14164	73.07	5.0	241.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3612	sp|Q8IHZ9|KC1_PLAF	Q5S007	77.4	1884.0	2134.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3613	sp|Q8IHZ9|KC1_PLAF	P49760	73.37	160.0	397.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3614	sp|Q8IHZ9|KC1_PLAF	Q9UHD2	74.3	3.0	243.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3615	sp|Q8IHZ9|KC1_PLAF	Q13523	70.59	684.0	912.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3616	sp|Q8IHZ9|KC1_PLAF	Q9NSY1	81.73	49.0	313.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3619	sp|Q8IHZ9|KC1_PLAF	P37173	92.88	245.0	545.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3620	sp|Q8IHZ9|KC1_PLAF	P49761	73.68	300.0	538.0	DB07664	experimental	K-00546	O=S(=O)(N)c1ccc(cc1)Nc2nc(N)n(n2)C(=S)Nc3c(F)cccc3F
3621	sp|Q8IHZ9|KC1_PLAF	P49761	73.68	300.0	538.0	DB08691	experimental	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate	CCOC(=O)c(n1C)c(/C(C#N)=C\N)c(c12)ccc(Cl)c2Cl
3622	sp|Q8IHZ9|KC1_PLAF	P49761	73.68	300.0	538.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3623	sp|Q8IHZ9|KC1_PLAF	P20594	86.07	544.0	822.0	DB01613	approved; experimental; investigational	Erythrityl tetranitrate	[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O
3626	sp|Q8IHZ9|KC1_PLAF	P51617	71.21	209.0	439.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3627	sp|Q8IHZ9|KC1_PLAF	Q9Y616	89.16	162.0	450.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3628	sp|Q8IHZ9|KC1_PLAF	P16066	90.4	551.0	843.0	DB00325	approved; investigational	Nitroprusside	O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N
3629	sp|Q8IHZ9|KC1_PLAF	P16066	90.4	551.0	843.0	DB00727	approved; investigational	Nitroglycerin	[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O
3630	sp|Q8IHZ9|KC1_PLAF	P16066	90.4	551.0	843.0	DB00883	approved; investigational	Isosorbide dinitrate	[O-][N+](=O)O[C@H]1CO[C@@H]([C@@H]12)[C@@H](CO2)O[N+]([O-])=O
3631	sp|Q8IHZ9|KC1_PLAF	P16066	90.4	551.0	843.0	DB01612	approved	Amyl Nitrite	CCCCCON=O
3632	sp|Q8IHZ9|KC1_PLAF	P16066	90.4	551.0	843.0	DB01613	approved; experimental; investigational	Erythrityl tetranitrate	[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O
3634	sp|Q8IHZ9|KC1_PLAF	P16066	90.4	551.0	843.0	DB05034	investigational	Ularitide	O=C1NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)O)Cc3ccc(O)cc3)CSSC[C@@H](C(=O)N[C@@H](Cc4ccccc4)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@H]1[C@@H](C)CC)CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]5CCCN5C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O
3635	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB04608	experimental	9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE	c1cc(O)cc(c12)c3c([nH]2)cc(c4c3C(=O)NC4=O)-c5ccccc5
3636	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB07006	experimental	9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE	COc1ccccc1-c2cc(c3c(c24)C(=O)NC4=O)n(CCCO)c5c3cc(O)cc5
3637	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB07226	experimental	N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE	Clc1ccccc1-c2cc(c3c(c24)C(=O)NC4=O)[nH]c5c3cc(cc5)NC=O
3638	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB07257	experimental	4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione	OCCc(cn1C)c(c12)c3c(C(=O)NC3=O)c(c2)-c4ccccc4Cl
3639	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB07265	experimental	3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID	Oc(c1)ccc(c12)n(CCC(=O)O)c3c2c4c(C(=O)NC4=O)c(c3)-c5ccccc5
3640	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB08365	experimental	8-bromo-4-(2-chlorophenyl)-N-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide	OCCNC(=O)c(c1Br)n(C)c(c12)cc(c3c2C(=O)NC3=O)-c4c(Cl)cccc4
3641	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB11740	investigational	MK-1775	CN1CCN(CC1)c2ccc(cc2)Nc(n3)ncc(c34)c(=O)n(CC=C)n4-c5nc(C(C)(C)O)ccc5
3642	sp|Q8IHZ9|KC1_PLAF	P30291	98.45	291.0	609.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3643	sp|Q8IHZ9|KC1_PLAF	O75460	80.8	573.0	834.0	DB07382	experimental	N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine	C1CC1c2n[nH]c(c2)Nc3ccnc(n3)Nc(cc4)cc(c45)nc[nH]5
3644	sp|Q8IHZ9|KC1_PLAF	O75460	80.8	573.0	834.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3646	sp|Q8IHZ9|KC1_PLAF	Q13873	97.83	201.0	517.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3647	sp|Q8IHZ9|KC1_PLAF	P25092	84.83	506.0	780.0	DB08890	approved	Linaclotide	Oc1ccc(cc1)C[C@@H](C(=O)O)NC(=O)[C@H](CSSC[C@H]23)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N2)Cc5ccc(O)cc5)NC(=O)[C@@H](N)CSSC[C@H](NC3=O)C(=O)N[C@@H](CC(=O)N)C(=O)N6[C@@H](CCC6)C(=O)N[C@@H](C)C(=O)N4
3648	sp|Q8IHZ9|KC1_PLAF	P0C264	81.73	39.0	303.0	DB12010	approved; investigational	Fostamatinib	COc1c(OC)cc(cc1OC)Nc2ncc(F)c(n2)Nc(cc3)nc(c34)N(C(=O)C(O4)(C)C)COP(=O)(O)O
3649	sp|Q8IHZ9|KC1_PLAF	Q16671	95.98	203.0	513.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3650	sp|Q7KQM4|PLM1_PLA	Q7KQM4	99.78	1.0	452.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
3651	sp|Q7KQM4|PLM1_PLA	P46925	100.0	1.0	453.0	DB01218	approved	Halofantrine	CCCCN(CCCC)CCC(O)c(c1)c(ccc(c2)C(F)(F)F)c2c(c13)cc(Cl)cc3Cl
3652	sp|Q7KQM4|PLM1_PLA	P46925	100.0	1.0	453.0	DB02505	experimental	N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)	CCCCCc1ccc(cc1)C(=O)N(C2CCN(CC2)Cc3ncc[nH]3)Cc4ccc(cc4)-c5ccc(cc5)CC(=O)OC
3653	sp|Q7KQM4|PLM1_PLA	P46925	100.0	1.0	453.0	DB03063	experimental	N-[(2S,3S)-4-[2-[(5S)-3a,4,5,6,7,7a-Hexahydro-1,3-benzodioxol-5-yl]ethyl-[3-(1,3-dioxoisoindol-2-yl)propanoyl]amino]-3-hydroxy-1-phenylbutan-2-yl]-3,5-dimethoxy-4-phenylmethoxybenzamide	c1ccccc1COc2c(OC)cc(cc2OC)C(=O)N[C@@H](Cc3ccccc3)[C@@H](O)CN(CC[C@@H](C4)CCC(C45)OCO5)C(=O)CCN(C6=O)C(=O)c(c67)cccc7
3654	sp|Q7KQM4|PLM1_PLA	P46925	100.0	1.0	453.0	DB04373	experimental	4-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide	Nc1cc(ccc1)C(=O)N[C@@H](CC(C)C)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)COc3c(C)cccc3C
3655	sp|Q7KQM4|PLM1_PLA	P46925	100.0	1.0	453.0	DB04378	experimental	3-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide	Nc1ccc(cc1)C(=O)N[C@@H](CC(C)C)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)COc3c(C)cccc3C
3656	sp|Q7KQM4|PLM1_PLA	P46925	100.0	1.0	453.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
3657	sp|Q7KQM4|PLM1_PLA	Q8IM16	98.89	1.0	448.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
3658	sp|Q7KQM4|PLM1_PLA	Q8IM15	99.34	1.0	450.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
3659	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB00212	experimental	Remikiren	c1ccccc1C[C@H](CS(=O)(=O)C(C)(C)C)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H]([C@@H](O)[C@@H](O)C3CC3)CC4CCCCC4
3660	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB00350	approved; investigational	Minoxidil	[O-][n+]1c(N)nc(cc1N)N2CCCCC2
3661	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB00722	approved; investigational	Lisinopril	OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N[C@H](C(=O)O)CCc2ccccc2
3662	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB01844	experimental	N,N-dimethylformamide	CN(C)C=O
3663	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB02296	experimental	Isoamyl alcohol	CC(C)CCO
3664	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB02803	experimental	3-Phenyl-1,2-Propandiol	OC[C@@H](O)Cc1ccccc1
3665	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB03024	experimental	2-Methyl-3-(2-Aminothiazolo)Propanal	O=C[C@@H](C)Cc1csc(n1)N
3666	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB03395	experimental	Enalkiren	COc1ccc(cc1)C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H]([C@@H](O)[C@@H](O)CC(C)C)CC3CCCCC3
3667	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB03736	experimental	2-Cyclopropylmethylenepropanal	O=C[C@@H](C)CC1CC1
3668	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB03968	experimental	1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine	CC1(C)N(C)C(=O)CC1
3669	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB04379	experimental	N-Methyl-N-(Methylbenzyl)Formamide	O=CN(C)[C@@H](C)c1ccccc1
3670	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB04387	experimental	1-Hydroxy-2-Amino-3-Cyclohexylpropane	OC[C@@H](N)CC1CCCCC1
3671	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB05203	investigational	SPP1148	 
3672	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB06899	experimental	N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE	CCc1nc(N)nc(N)c1-c(c2)ccc(c23)SC(C)(C)C(=O)N3CCNC(=O)C
3673	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB06967	experimental	6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE	CCc1nc(N)nc(N)c1-c(cc2)cc(c23)n(CCCOC)c4c3cccc4
3674	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB07059	experimental	N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE	CCc1nc(N)nc(N)c1-c(cc2)cc(c23)N(C(=O)C(O3)(C)C)CCNC(=O)C
3675	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB07113	experimental	(2S)-6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2-(3,5-DIFLUOROPHENYL)-4-(3-METHOXYPROPYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE	COCCCN1C(=O)[C@H](c(cc2F)cc(F)c2)Oc(c13)ccc(c3)-c4c(N)nc(N)nc4CC
3676	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB07174	experimental	6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-4-(3-METHOXYPROPYL)-2,2-DIMETHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE	Nc1nc(CC)c(c(n1)N)-c(c2)ccc(c23)OC(C)(C)C(=O)N3CCCOC
3677	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB07244	experimental	5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE	Nc1nc(CC)c(c(n1)N)-c2ccc(cc2)NCc3cc(F)cc(F)c3
3678	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB08099	experimental	6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine	c1ccccc1[C@@H](N2CCCOC)CCc(c23)ccc(c3)-c4c(N)nc(N)nc4CC
3679	sp|Q7KQM4|PLM1_PLA	P00797	75.44	65.0	406.0	DB09026	approved; investigational	Aliskiren	COCCCOc1c(OC)ccc(c1)C[C@H](C(C)C)C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N
3680	sp|Q7KQM4|PLM1_PLA	P0DJD9	71.46	63.0	386.0	DB00364	approved	Sucralfate	O[Al](O)OS(=O)(=O)OC[C@@H](O1)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@]1(COS(=O)(=O)O[Al](O)O)O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O
3682	sp|Q7KQM4|PLM1_PLA	P07339	75.0	71.0	410.0	DB02216	experimental	S-Methylcysteine	CSC[C@H](N)C(=O)O
3683	sp|Q7KQM4|PLM1_PLA	P07339	75.0	71.0	410.0	DB03028	experimental	1h-Benoximidazole-2-Carboxylic Acid	OC(=O)c([nH]1)nc(c12)cccc2
3684	sp|Q7KQM4|PLM1_PLA	P07339	75.0	71.0	410.0	DB03096	experimental	2-Morpholinoethylamine	NCCN1CCOCC1
3685	sp|Q7KQM4|PLM1_PLA	P07339	75.0	71.0	410.0	DB07542	experimental	5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID	CC(C)C[C@@H](C(=O)O)C[C@H](O)[C@@H](N)CC1CCCCC1
3686	sp|Q7KQM4|PLM1_PLA	P07339	75.0	71.0	410.0	DB08740	experimental	CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE	CC(C)C[C@H](O)[C@H](O)[C@@H](N)CC1CCCCC1
3687	sp|Q7KQM4|PLM1_PLA	P0DJ06	72.35	60.0	387.0	DB03090	experimental	Ethylaminobenzylmethylcarbonyl Group	CCCC[C@@H](C(=O)O)N1CCN[C@@H](C1=O)Cc2ccccc2
3688	sp|Q7KQM4|PLM1_PLA	P0DJ06	72.35	60.0	387.0	DB03241	experimental	1-Amino-1-Carbonyl Pentane	O=C[C@@H](N)CCCC
3689	sp|Q7KQM4|PLM1_PLA	P0DJ06	72.35	60.0	387.0	DB03659	experimental	Butylamine	CCCCN
3690	sp|Q7KQM4|PLM1_PLA	P0DJ06	72.35	60.0	387.0	DB04387	experimental	1-Hydroxy-2-Amino-3-Cyclohexylpropane	OC[C@@H](N)CC1CCCCC1
3691	sp|Q7KQM4|PLM1_PLA	P0DJ06	72.35	60.0	387.0	DB04451	experimental	4-Methylpiperazin-1-Yl Carbonyl Group	CN1CCN(CC1)C(=O)O
3692	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB02378	experimental	MMI-175	c1ccccc1CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H]2CC(=O)NCCCCCCOC(=O)N[C@@H](C(C)C)C(=O)N2
3693	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB06073	investigational	CTS-21166	 
3694	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB06930	experimental	N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide	NC(=N)NC(=O)Cn1c(-c2ccccc2)ccc1-c3ccccc3
3695	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07019	experimental	N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE	C1C[C@H](C)CCc(ccc2)cc2C[C@@](C)(N)C(=O)OCc(c3)cc(nc13)N(C)S(=O)(=O)C
3696	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07089	experimental	N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide	CCCOc1ccc(cc1)-c2csc(c2CC(=O)NC(N)=N)-c3ccccc3Cl
3697	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07110	experimental	4-(4-FLUOROBENZYL)PIPERIDINE	Fc1ccc(cc1)CC2CCNCC2
3698	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07175	experimental	N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide	CS(=O)(=O)Nc1cc(ccc1C)Nc2cc(ncn2)-c3ccccc3
3699	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07206	experimental	6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE	Nc1nc(ccc1)CCc(c2)ccc(c23)cc[nH]3
3700	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07245	experimental	6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE	COc1cccc(c1)-c2cc(ccc2)CCc3cccc(n3)N
3701	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07281	experimental	N~3~-BENZYLPYRIDINE-2,3-DIAMINE	Nc1ncccc1NCc2ccccc2
3702	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07284	experimental	N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE	Nc1ncccc1NCc2cccc(c2)-c3cnccc3
3703	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07303	experimental	N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE	COc1cncc(c1)-c2cc(ccc2)CNc3cccnc3N
3704	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07345	experimental	4-(2-aminoethyl)-2-cyclohexylphenol	NCCc1ccc(O)c(c1)C2CCCCC2
3705	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07346	experimental	4-(2-aminoethyl)-2-ethylphenol	CCc1cc(CCN)ccc1O
3706	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07415	experimental	4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine	COc1c(F)cc(cc1)[C@@H](c2c[nH]c(n2)N)Cc3cc([N+]([O-])=O)ccc3OC
3707	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07519	experimental	(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one	COc1cc(ccc1)-c2cc(ccc2)CC[C@]3(C)CC(=O)N(C)C(=N3)N
3708	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07535	experimental	2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one	Nc1nc(cc(=O)[nH]1)CCc(cc2)cc(c23)[nH]cc3
3709	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07573	experimental	(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol	C1COCCN1C[C@H](O)COc2c(C)ccc(C)c2
3710	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07734	experimental	N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide	SCCCC(=O)NC1CCN(CC1)Cc2ccccc2
3711	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07735	experimental	N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide	COc1cccc(OC)c1CN2CCC(CC2)NC(=O)CCCS
3712	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07736	experimental	(2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide	SCCNC(=O)[C@@H]1CN(CCN1)Cc2ccc(F)cc2
3713	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07737	experimental	(2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide	SCCCNC(=O)[C@@H]1CN(CCN1)Cc2ccc(F)cc2
3714	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07738	experimental	N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide	COc1c(OC)c(cc(Br)c1)CN2CCC(CC2)NC(=O)CCCS
3715	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07874	experimental	(6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one	COc1cc(ccc1)-c2cc(ccc2)[C@]3(C)CC(=O)N(C)C(=N3)N
3716	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07993	experimental	N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE	Nc1ncccc1NCc2cccc(c2)-c(cc3)cc(c34)[nH]cc4
3717	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB07994	experimental	N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE	Nc1ncccc1NCc2c(OCc3ncccc3)ccc(c2)-c(cc4)cc(c45)[nH]cc5
3718	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB08749	experimental	3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE	C1CCCCC1N(C)C(=O)CCN(C(=N2)N)Cc(c23)cc(cc3)C(=O)c4ccccc4
3719	sp|Q7KQM4|PLM1_PLA	P56817	76.99	70.0	418.0	DB12285	investigational	Verubecestat	CN1C(N)=N[C@@](C)(CS1(=O)=O)c2cc(ccc2F)NC(=O)c3ccc(F)cn3
3720	sp|Q8IDQ0|LIPA_PLA	O43766	72.05	70.0	369.0	DB00166	approved; investigational; nutraceutical	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1
3721	sp|Q8I1T8|ASNA_PLA	O43681	71.5	16.0	287.0	DB00171	investigational; nutraceutical	ATP	Nc1ncnc(c12)n(cn2)[C@@H]3O[C@@H]([C@@H](O)[C@H]3O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
3722	sp|C0H4X5|DRE2_PLA	C0H4X5	99.62	1.0	266.0	DB11638	experimental; investigational	Artenimol	[C@]123[C@H]4CC[C@@H](C)[C@@H]1CC[C@@](C)(OO2)O[C@H]3OC(O)[C@@H]4C
3723	sp|Q8IKG4|DXR_PLAF	P45568	75.41	3.0	371.0	DB02496	experimental	1-Deoxy-D-xylulose 5-phosphate	CC(=O)[C@@H](O)[C@H](O)COP(=O)(O)O
3724	sp|Q8IKG4|DXR_PLAF	P45568	75.41	3.0	371.0	DB02948	experimental; investigational	Fosmidomycin	O=CN(O)CCCP(=O)(O)O
3725	sp|Q8IKG4|DXR_PLAF	P45568	75.41	3.0	371.0	DB03649	experimental	[{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate	OP(=O)(O)C(P(=O)(O)O)Nc1ccc(Cl)cn1
